BEFORE THE

INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

REGULAR MEETING

LOCATION: HILTON SAN DIEGO AIRPORT

HARBOR ISLAND MARINA BALLROOM

1960 HARBOR ISLAND DRIVE SAN DIEGO, CALIFORNIA

DATE: WEDNESDAY, OCTOBER 3, 2007

9:30 A.M.

REPORTER: BETH C. DRAIN, CSR

CSR. NO. 7152

BRS FILE NO.: 77062

I N D E X

ITEM DI	ESCRIPTION	PAGE NO
CALL TO ORDER		3
ROLL CALL		5
PUBLIC COMMENT	RE HUNTOINGTON'S DISEASE	7
CONSENT ITEMS		11
CHAIRMAN'S REPO	ORT	12
PRESIDENT'S REP	PORT	16
ACTION ITEMS:		
	OF AMENDMENTS TO GRANTS POLICY REGARDING FACILITIES:	46
CONSIDERATION O	OF CONCEPT FOR DISEASE WARDS.	73
CONSIDERATION CLINES AWARDS.	OF CONCEPT FOR NEW CELL	111
	OF GRANTS MANAGEMENT SYSTEM ERVICES PROVIDER.	98
CONSIDERATION C SUBCOMMITTEE OF	F CREATION OF FINANCE THE ICOC	119
CLOSED SESSION		
REPORT FROM CLO	SED SESSION	NONE
DISCUSSION ITEM	1S	
SUMMARY OF THE AND CONTRACT CL	2006-07 ADMINISTRATIVE BUDGET OSE-OUT.	125
UPDATE ON CSU D	OTSCUSSTONS.	132

PUBLIC COMMENT	144
ADJOURNMENT	147

1	SAN DIEGO, CALIFORNIA; WEDNESDAY, OCTOBER 3D, 2007
2	9:30 A.M.
3	
4	CHAIRMAN KLEIN: WELCOME, EVERYONE. IN THE
5	LAND OF THE BECAUSE OF THE WATER AND THE GORGEOUS
6	SUNSHINE, WE'RE HAPPY TO BE BACK HERE IN SAN DIEGO. WE
7	HAVE THE PRIVILEGE OF BEING BACK HERE WITH A NEW BOARD
8	MEMBER, DR. MARSHA CHANDLER. SHOULD WE GIVE HER A ROUND
9	OF APPLAUSE.
10	(APPLAUSE.)
11	CHAIRMAN KLEIN: WE HAD AN OUTSTANDING
12	SPOTLIGHT THIS MORNING I LEARNED IN THE PROCEEDINGS
13	NOT TO USE THE WORD "INCREDIBLE" PREPARED BY WITH
14	THE HELP OF LYNN HARWELL OF MY STAFF IN COORDINATION WITH
15	OUR EMINENT BOARD MEMBER DR. JANET WRIGHT. AND OUR
16	FOCUS, OF COURSE, WAS ON HEART DISEASE AND STEM CELL
17	RESEARCH.
18	WE HAD THE PRIVILEGE OF HAVING DR. ANTHONY
19	DEMERIA AND DR. MARK MERCOLA SPEAK, AND I WOULD MENTION
20	TO YOU THAT DR. DEMARIA LAST WEEK MADE THE GREAT STEP
21	FORWARD AS A LEADER OF UC SAN DIEGO IN OPENING THE NEW
22	VASCULAR CENTER AT UC SAN DIEGO, ANOTHER TREMENDOUS
23	ADVANCE FOR MEDICAL RESEARCH.
24	WE HAVE A CHALLENGING SCHEDULE TODAY, BUT WE
25	HOPE TO MOVE EXPEDITIOUSLY THROUGH IT. AND WE HAVE SOME

1	EXTRAORDINARILY EXCITING NEW CONCEPT PLANS FOR PROGRAMS
2	IN THE DEVELOPMENT OF THE SCIENCE TEAM THAT THE SCIENCE
3	STAFF WILL GO THROUGH.
4	TO BEGIN TODAY'S MEETING, WE HAD A SPECIAL
5	REQUEST FROM THE HUNTINGTON DISEASE PATIENT ORGANIZATIONS
6	HERE IN SAN DIEGO TO MAKE A SPECIAL PRESENTATION TO THE
7	BOARD FOR FIVE MINUTES. WHAT I'D LIKE TO DO, THOUGH, IS
8	HAVE THE PLEDGE OF ALLEGIANCE WITH MELISSA KING LEADING
9	US IN THAT PLEDGE AND THE ROLL CALL. MELISSA.
LO	MS. KING: PLEASE STAND IF YOU ARE ABLE. THE
L1	FLAG IS AT THE FRONT OF THE ROOM.
L2	CHAIRMAN KLEIN: FOR THE HUNTINGTON DISEASE
L3	PATIENT ADVOCATES ORGANIZATION, IF KEN SERBIN WILL BE
L4	READY RIGHT AFTER THE ROLL CALL TO IMMEDIATELY PRESENT.
L5	(THE PLEDGE OF ALLEGIANCE.)
L6	MS. KING: DAVID MEYER FOR RICARDO AZZIZ.
L7	DR. MEYER: HERE.
L8	MS. KING: ROBERT PRICE FOR ROBERT BIRGENEAU.
L9	DR. PRICE: HERE.
20	MS. KING: DAVID BRENNER.
21	DR. BRENNER: HERE.
22	MS. KING: SUSAN BRYANT.
23	DR. BRYANT: HERE.
24	MS. KING: MARSHA CHANDLER.

DR. CHANDLER: HERE.

1 MS. KING: MARCY FEIT. ALEXANDRA LEVINE FOR 2 MICHAEL FRIEDMAN. 3 DR. LEVINE: HERE. 4 MS. KING: MICHAEL GOLDBERG. 5 MR. GOLDBERG: HERE. 6 MS. KING: BRIAN HENDERSON. 7 DR. HENDERSON: HERE. 8 MS. KING: DAVID KESSLER. BOB KLEIN. 9 CHAIRMAN KLEIN: HERE. 10 MS. KING: SHERRY LANSING. 11 MS. LANSING: HERE. 12 MS. KING: GERALD LEVEY. DR. LEVY: HERE. 13 14 MS. KING: MICHAEL LEVY FOR TED LOVE. 15 DR. LEVY: HERE. 16 MS. KING: TINA NOVA. ED PENHOET. PHIL PIZZO. 17 DR. PIZZO: HERE. 18 MS. KING: CLAIRE POMEROY. 19 DR. POMEROY: HERE. 20 MS. KING: FRANCISCO PRIETO. 21 DR. PRIETO: HERE. 22 MS. KING: JOHN REED. DUANE ROTH. 23 MR. ROTH: HERE. 24 MS. KING: JOAN SAMUELSON. DAVID 25 SERRANO-SEWELL.

1	MR. SERRANO-SEWELL: HERE.
2	MS. KING: JEFF SHEEHY. JONATHAN SHESTACK.
3	OSWALD STEWARD.
4	DR. STEWARD: HERE.
5	MS. KING: JANET WRIGHT.
6	DR. WRIGHT: HERE.
7	WE DO HAVE A QUORUM.
8	CHAIRMAN KLEIN: THANK YOU. KEN, AS A LEADER
9	OF THE HUNTINGTON DISEASE SOCIETY OF AMERICA,
10	REPRESENTING SAN DIEGO, WOULD YOU ADVANCE YOUR
11	PRESENTATION, PLEASE?
12	MR. SERBIN: I WANT TO INTRODUCE BILL JOHNSTON
13	AND RAMONA JOHNSTON. BILL IS THE PRESIDENT OF THE SAN
14	DIEGO CHAPTER OF THE HUNTINGTON'S DISEASE SOCIETY OF
15	AMERICA.
16	MR. JOHNSTON: THANK YOU VERY MUCH FOR GIVING
17	US A FEW MINUTES OF YOUR TIME, AND I'LL TRY TO BE
18	EXPEDITIOUS FOR YOUR MEETING HERE.
19	I WANTED TO BRING MY WIFE WITH ME TODAY,
20	RAMONA, WHO WE'VE BEEN KNOWN EACH OTHER SINCE HIGH
21	SCHOOL, AND IT'S REALLY THE REASON THAT I'M HERE AND THAT
22	THERE'S SEVERAL OTHER PEOPLE HERE REPRESENTING THE
23	HUNTINGTON'S DISEASE SOCIETY.
24	I KNOW YOU ARE GOING TO HEAR A PRESENTATION ON

7

25 HD IN DECEMBER AS WELL. I BELIEVE IT'S A SPOTLIGHT

- 1 YOU'VE AFFORDED OUR ORGANIZATION. I APPRECIATE THAT VERY
- 2 MUCH. THANK YOU. BUT I THINK IT'S JUST FIVE MINUTES OF
- 3 YOUR TIME TO GIVE YOU AN IDEA OF HD, THE PROJECTS THAT WE
- 4 HAVE GOING, AND THE OPTIMISM THAT WE FEEL IN OUR
- 5 ORGANIZATION, AND THE WAYS THAT YOUR ORGANIZATION CAN, WE
- 6 FEEL, PLAY A ROLE IN FINDING A CURE FOR HD.
- 7 LIKE KEN SAID, I'M THE PRESIDENT OF THE HDSA
- 8 HERE IN SAN DIEGO. I JOINED THE ORGANIZATION -- REALLY I
- 9 BECAME A PART OF IT, IT BECAME PART OF MY LIFE WHEN MY
- 10 WIFE WAS DIAGNOSED IN 1999, ABOUT EIGHT YEARS AGO, WITH
- 11 HUNTINGTON'S DISEASE. WE HAVE TWO CHILDREN WHO ARE AT
- 12 RISK. KIDS OF AN HD PATIENT OR A PARENT HAVE A 50-50
- 13 CHANCE OF INHERITING THE DISEASE. IT'S A GENETIC
- 14 NEUROLOGICAL DISEASE. AND I APOLOGIZE IF -- I KNOW I'M
- 15 PROBABLY SPEAKING WAY UNDER YOUR LEVEL, BUT THIS IS ALL
- 16 INFORMATION I'M SURE YOU'RE WELL AWARE OF.
- 17 BUT WHEN SHE -- WE MET IN HIGH SCHOOL. SHE
- 18 GRADUATED FROM COLLEGE SUMMA CUM LAUDE, WENT ON TO BECOME
- 19 AN EXTRAORDINARY TEACHER. AND THIS IS -- SINCE HD HAS
- TAKEN OVER HER LIFE, IT HAS NOW BECOME MY LIFE, AND SO WE
- 21 ARE IN THE -- WE ARE FACED WITH THE TASK OF FINDING A
- 22 CURE FOR HD.
- SO IN MY OTHER JOB, MY OTHER LIFE, I'M THE PR
- 24 DIRECTOR FOR THE SAN DIEGO CHARGERS. SO, AGAIN, THIS
- 25 IS -- I'M SPEAKING IN A LANGUAGE OR YOU GUYS PROBABLY

- 1 SPEAK IN A LANGUAGE MUCH OVER MY HEAD, SO I'LL TRY TO DO
- THE BEST I CAN HERE. BUT I'LL TRY TO SHARE WITH YOU THE
- 3 INFORMATION THAT I HAVE ABOUT HD THAT'S CONVINCED ME THAT
- 4 RESEARCH PROJECTS -- THAT OUR RESEARCH PROJECTS DESERVE
- 5 YOUR ATTENTION OR SHOULD BE CONSIDERED HIGHLY FOR YOUR
- 6 ATTENTION.
- 7 FIRST, AS YOU KNOW, ABOUT 20 YEARS AGO, I
- 8 BELIEVE IT WAS, THE GENE THAT CAUSES HUNTINGTON DISEASE
- 9 WAS DISCOVERED, WHICH WAS A HUGE, HUGE STEP AHEAD FOR OUR
- 10 ORGANIZATION AND FOR THE SEARCH FOR A TREATMENT OR A
- 11 CURE. ONCE YOU FOUND THE GENE, THAT GIVES THE
- 12 RESEARCHERS AND SCIENTISTS A HUGE STEP AHEAD OR AT LEAST
- 13 A HUGE FOCUS ON WHAT THEY'RE DOING.
- 14 AND WITH THAT, THERE NOW IS A DEFINITIVE TEST
- 15 TO DETERMINE IF SOMEONE HAS HD, WHICH IS THE SAME TEST
- 16 THAT MY WIFE TOOK, SAME TEST THAT --
- 17 MS. JOHNSTON: OUR SON.
- 18 MR. JOHNSTON: -- OUR SON TOOK. AND THANKS TO
- 19 GOD HE WAS NEGATIVE. OUR DAUGHTER IS 19 AND HAS CHOSEN
- 20 NOT TO BE TESTED AT THIS POINT YET. BUT IT'S ALSO THE
- 21 SAME TEST THAT SHARON SHAEFFER HAS TAKEN, AND SHE WAS
- 22 POSITIVE IN THE TEST. SHE HAS A DAUGHTER HERE, ALEXA,
- 23 WHO IS AN AMAZING LITTLE GIRL AND REPRESENTATIVE OF OUR
- ORGANIZATION. SHE IS LIKE MY DAUGHTER, 50-50 CHANCE OF
- 25 INHERITING THE DISEASE.

1	SO WE HAVE WITH THAT TEST NOW, THEY HAVE THE
2	FOCUS WHICH WE FEEL THAT WITH HD, THE RESEARCH THAT CAN
3	BE DONE ON HD OR TO CURE HD CAN BENEFIT DISEASES LIKE
4	PARKINSON'S AND ALZHEIMER'S AND SEVERAL OTHERS THAT DON'T
5	HAVE HAVEN'T DISCOVERED THAT INITIAL CAUSE, THAT
6	SINGLE MUTATION THAT CAUSES THE DISEASE. SO THAT'S WHY
7	WE FEEL THAT OUR DISEASE CAN BE A ROSETTA STONE, SO TO
8	SPEAK, FOR OTHER DISEASES. AND IT CAN LEAD TO A
9	TREATMENT AND A CURE WITH THE RIGHT FUNDING AND WITH THE
10	RIGHT STEM CELL RESEARCH AVAILABILITY.
11	IT IS, LIKE I SAID, A PART OF OUR LIFE, AND WE
12	FEEL THAT WITH YOUR SUPPORT, YOUR KNOWLEDGE OF WHAT THE
13	HUNTINGTON'S DISEASE COMMUNITY IS GOING THROUGH, AND
14	THERE ARE THOUSANDS OF PEOPLE IN CALIFORNIA, 3,000 IS THE
15	ESTIMATE, 30,000 IN THE UNITED STATES JUST KNOWN, ANOTHER
16	200,000 WHO ARE AT RISK OF INHERITING THE DISEASE, THAT
17	IT CAN MAKE A HUGE DIFFERENCE IN SO MANY LIVES.
18	THEY HAVE IN A LAB IN CANADA. IT IS OUR
19	UNDERSTANDING AND THEIR UNDERSTANDING THEY HAVE CURED THE
20	DISEASE IN MICE MODELS. AND WITH YOUR SUPPORT, IT IS OUR
21	BELIEF AND RESEARCHERS' BELIEF THAT STEM CELLS, HUMAN
22	EMBRYONIC STEM CELLS, AND HUMAN MODELS, PRODUCE HUMAN
23	MODELS WHICH CAN THEN TAKE THE NEXT STEP FOR THIS
24	RESEARCH. SO WE FEEL THAT OUR RESEARCH PROJECTS, AND
25	MANY OF THOSE ARE SOME OF THE GREATEST AROUND, ARE IN

Т	CALIFORNIA, CAN TAKE THAT NEXT STEP AND TO CORE THE
2	DISEASE THAT AFFECTS OUR FAMILIES.
3	IF YOU'RE IN SAN DIEGO THERE ARE RESEARCH
4	PROJECTS, HERE IN IRVINE, L.A., SAN FRANCISCO, THERE ARE
5	SOME OF THE BEST FROM OUR ORGANIZATIONS THAT ARE DOING
6	RESEARCH TO CURE THIS DISEASE. THERE ARE TWO
7	ORGANIZATIONS THAT ARE HEADQUARTERED IN CALIFORNIA, THE
8	HEREDITARY DISEASE FOUNDATION AND THE CURE HUNTINGTON'S
9	DISEASE INITIATIVE ARE ALSO HERE IN CALIFORNIA.
10	SO, AGAIN, I APPRECIATE THE TIME THAT YOU'VE
11	GIVEN US ON BEHALF OF MY WIFE, AND THAT'S WHY I'M HERE,
12	AND ON BEHALF OF OUR FAMILIES WHO ARE HERE AND OTHER
13	PEOPLE WHO ARE AFFECTED BY THIS DISEASE. THERE ARE
14	THOUSANDS OF PEOPLE OUT THERE THAT WE FEEL CAN BENEFIT
15	FROM THE OPPORTUNITY THAT YOU CAN PROVIDE THE RESEARCHERS
16	THAT ARE DOING WORK WITH HUNTINGTON'S DISEASE RESEARCH.
17	THANK YOU FOR LISTENING. IF YOU HAVE ANY QUESTIONS.
18	(APPLAUSE.)
19	CHAIRMAN KLEIN: THANK YOU VERY MUCH FOR YOUR
20	ADVOCACY AND YOUR PRESENTATION. WE'RE GOING TO LOOK
21	FORWARD TO YOUR SPOTLIGHT PRESENTATION. AND IT MAKES A
22	GREAT DIFFERENCE TO HEAR YOUR MESSAGE PERSONALLY.
23	MR. JOHNSTON: THANK YOU VERY MUCH.
24	(APPLAUSE.)
25	CHAIRMAN KLEIN: WE NEED TO MOVE TO AGENDA ITEM

- 1 NO. 4, WHICH IS THE CONSENT CALENDAR. IT'S JUST ONE ITEM
- 2 THIS TIME BEHIND TAB 4 IN YOUR BINDERS. IT'S
- 3 CONSIDERATION OF THE ICOC MEETING MINUTES FROM JUNE, TWO
- 4 FROM JULY, AND ONE FROM AUGUST. THE BOARD HAS BEEN VERY
- 5 BUSY. IS THERE A MOTION TO APPROVE THESE MINUTES?
- 6 MR. SERRANO-SEWELL: SO MOVED.
- 7 DR. WRIGHT: SECOND.
- 8 CHAIRMAN KLEIN: MOVED AND SECONDED. MOVED BY
- 9 DAVID SERRANO-SEWELL. SECONDED BY DR. WRIGHT. IS THERE
- 10 DISCUSSION? SEEING NO DISCUSSION, I WOULD CALL THE
- 11 QUESTION. ALL IN FAVOR. OPPOSED? MOTION PASSES.
- 12 I WOULD LIKE TO GO ON TO THE AGENDA ITEM NO. 5,
- 13 THE CHAIRMAN'S REPORT AT THIS TIME.
- 14 TODAY IS ANOTHER HISTORIC DAY FOR PROPOSITION
- 15 71. CALIFORNIA'S INSTITUTE FOR REGENERATIVE MEDICINE IS
- 16 TRAILBLAZING ON THE FRONTIER OF MEDICAL FUNDING. THE
- 17 PRICING STARTS TODAY FOR \$250 MILLION OF STEM CELL
- 18 RESEARCH AND CURES BONDS. FIRST TIME IN THE HISTORY OF
- 19 THIS NATION OR OF THE WORLD, TO OUR KNOWLEDGE, LONG-TERM
- 20 STATE GOVERNMENT BONDS OR GOVERNMENT BONDS ARE BEING USED
- 21 TO FINANCE INTELLECTUAL CAPITAL, THE INTELLECTUAL CAPITAL
- 22 HOPEFULLY THAT WILL DRIVE THE 21ST CENTURY JUST AS THE
- 23 FINANCING OF PHYSICAL CAPITAL, BRIDGES, ROADS, HARBORS,
- 24 DROVE THE PROSPERITY OF THE 19TH AND 20TH CENTURIES.
- 25 I WOULD CALL TO EVERYONE'S ATTENTION THAT THE

1	ROCKEFFLLER	TNSTTTUTF	DEMONSTRATES	THAT	THE	MODEL
_		TI301TI01		111/71		

- 2 FUNCTION, THE MODEL LEADERSHIP FUNCTION OF THIS INSTITUTE
- 3 HAS HAD A TREMENDOUS EFFECT IN THIS COUNTRY WITH \$3
- 4 BILLION IN INITIATIVES FROM OTHER STATES FOLLOWING THE
- 5 CALIFORNIA MODEL AND RELYING PRINCIPALLY ON BONDS TO
- 6 FINANCE THE LONG-TERM BENEFITS FOR THE SOCIETY OF THE
- 7 INTELLECTUAL CAPITAL.
- THE THEORY BEHIND THE FUNDING IS, OF COURSE,
- 9 THAT THE INTELLECTUAL BREAKTHROUGHS THAT OCCUR IN MEDICAL
- 10 SCIENCE WILL BENEFIT GENERATIONS, THAT IT IS
- 11 INAPPROPRIATE TO TAX THE CURRENT GENERATION FOR THE
- 12 BENEFITS OF MANY GENERATIONS; AND BY SPREADING THE COST,
- AMORTIZING IT OVER LONG-TERM BONDS, YOU HAVE THE ABILITY
- 14 TO RAISE MORE FUNDS UP FRONT TO ADVANCE SCIENCE AT A MUCH
- 15 FASTER PACE THAN AN APPROACH TRADITIONALLY TAKEN WITH
- 16 YEAR-TO-YEAR APPROPRIATIONS.
- 17 IT IS ALSO CRITICAL TO NOTE THAT BY USING
- 18 LONG-TERM BONDS AND FOCUSING ON THIS AS INTELLECTUAL
- 19 CAPITAL AND NOT AN OPERATING COST OF GOVERNMENT, THAT
- 20 RESEARCH IS NO LONGER COMPETING AT THE STATE LEVEL WITH
- THE YEAR-TO-YEAR DEMANDS OF A HEALTH SYSTEM, WHICH ARE IN
- 22 MANY CASES DESPERATE. COUNTY HOSPITALS NEED THOSE
- 23 APPROPRIATIONS. THE CLINICS NEED THOSE APPROPRIATIONS.
- 24 BY HAVING LONG-TERM BONDS, A CAPITAL INSTRUMENT, FINANCE
- THIS RESEARCH, WE ARE NO LONGER CONTESTING OR FIGHTING

1 OVER THE SAME FUNDS BECAUSE, IN FACT, THEY'R
--

- 2 DIFFERENT KIND OF EXPENDITURES. SO THE CAPITAL STRUCTURE
- 3 HERE IS ALIGNED WITH THE NATURE OF THE EXPENDITURE, WHICH
- 4 IS ONE OF INVESTMENT, NOT AN OPERATING COST.
- I WOULD POINT OUT AS WELL THAT AS THIS SPREADS
- 6 ACROSS THE COUNTRY, WE SEE ANOTHER LEVEL OF FUNDING BEING
- 7 RAISED EVEN TO THE LEVEL OF POTENTIALLY MATCHING
- 8 CALIFORNIA'S INVESTMENT EVEN THOUGH ON A NARROWER SCALE.
- 9 GOVERNOR PERRY IS NOW SEEKING \$3 BILLION FOR CANCER STEM
- 10 CELL RESEARCH IN TEXAS. OF COURSE, THEY'VE NARROWED
- 11 THEIR SCOPE BECAUSE THEY'RE AVOIDING THE POLITICAL
- 12 QUESTION ABOUT ADDRESSING THE WHOLE RANGE OF STEM CELLS,
- 13 BUT I WOULD LIKE TO DISTINGUISH WHAT THEY'RE DOING FROM
- 14 WHAT WE ARE DOING HERE IN CALIFORNIA BECAUSE ON A
- 15 HISTORICAL BASIS THE BENEFITS OF AN INVESTMENT IN MEDICAL
- 16 RESEARCH HAS BEEN MOST PRODUCTIVE BY, IN FACT -- I'D LIKE
- 17 TO POINT OUT THAT IN TEXAS BY FOCUSING ON ONE DISEASE
- 18 AREA, THEY ARE DEPARTING FROM THE CALIFORNIA APPROACH OF
- 19 ADDRESSING THE ENTIRE SPECTRUM OF MEDICINE.
- 20 HISTORICALLY THE NIH HAS BEEN VERY EFFECTIVE,
- 21 BUT IT HAS ADDRESSED A PORTFOLIO OF MEDICINE. SEVERAL
- 22 YEARS AGO THERE WAS A MAJOR INVESTMENT, THAT I'VE ALLUDED
- 23 TO BEFORE, FOR PANCREATIC CANCER. THERE WAS NO BENEFIT
- 24 FOR PANCREATIC CANCER, BUT THERE WAS A GREAT DISCOVERY
- 25 FOR JUVENILE DIABETES. IT IS IMPORTANT TO NOTE THAT WE

Т	HAVE AN ORGANIC RELATIONSHIP IN OUR SPECIRUM AND SCOPE OF
2	SUBJECT MATTER IN CALIFORNIA IN THAT WE CAN FOLLOW THE
3	BEST SCIENCE AND THE LEADS, WHETHER THEY ARE IN CANCER,
4	HEART DISEASE, DIABETES, ALS, ALZHEIMER'S. WE ARE NOT
5	TIED TO A SINGLE AREA OF RESEARCH. FORTUNATELY, CANCER
6	IS A BROAD TARGET AND THERE IS THE BENEFIT WITH THAT
7	BROAD TARGET OF HAVING A SUBSTANTIAL SCOPE TO RESEARCH
8	FUNDING, BUT THEY MIGHT FIND THAT IF THEIR CANCER
9	RESEARCH LEADS TO GREAT BREAKTHROUGHS FOR HEART DISEASE
10	OR ALZHEIMER'S, THEY MAY HAVE TO SHIP THE RESEARCH
11	REQUEST TO CALIFORNIA.
12	IT IS ALSO IMPORTANT TO NOTE AS A MATTER OF OUR
13	SCIENTIFIC LEGACY ON THIS DAY WHEN \$250 MILLION OF BONDS
14	ARE BEING PRICED THAT CALIFORNIA LED THE EFFORT WITH
15	RECOMBINANT DNA. THIS IS THE CALIFORNIA LEGACY. IT WAS
16	THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO AND CITY OF
17	HOPE THAT CREATED THE FIRST COMMERCIAL PRODUCT FROM THAT
18	RESEARCH, ARTIFICIAL HUMAN INSULIN. AND, IN FACT, LED,
19	THEN, IN THE NEXT DECADE TO A HUNDRED CRITICAL HEART AND
20	CANCER DRUGS THAT HAVE SAVED MILLIONS OF LIVES.
21	WE HOPE THAT WE ARE AT LEAST PARTIALLY AS
22	SUCCESSFUL, ALTHOUGH DR. PAUL BERG, WHO RECEIVED THE
23	NOBEL PRIZE FOR RECOMBINANT DNA, AS DID DR. BALTIMORE,
24	BOTH MEMBERS OF THIS BOARD AT DIFFERENT TIMES, HAVE SAID

ON OCCASION THAT THE POTENTIAL OF STEM CELL RESEARCH MAY,

2	FINALLY,	THERE'S A	SPECIAL	MESSAGE	FROM	OUR	NEW

IN FACT, BE MUCH BROADER THAN FROM RECOMBINANT DNA.

- 3 PRESIDENT, DR. ALAN TROUNSON, FROM AUSTRALIA. IN TALKING
- 4 WITH HIM LAST NIGHT, HE WANTED THE BOARD TO KNOW THAT HE
- 5 HAS TREMENDOUS APPRECIATION FOR THE COMMUNICATIONS
- 6 BETWEEN THIS BOARD AND HIS OFFICE AND IN PARTICULAR FOR
- 7 THE TREMENDOUS JOB THAT OUR INTERIM PRESIDENT, DR.
- 8 RICHARD MURPHY, IS DOING IN REALLY LIFTING THIS
- 9 ORGANIZATION TO THE NEXT LEVEL OF DEVELOPMENT FOR THE
- 10 IMPLEMENTATION OF OUR MISSION. HE TELLS ME THAT HE IS
- 11 EXCITED, HE IS THRILLED WITH THE CONSTANT COMMUNICATION
- 12 AND UPDATES FROM DR. MURPHY, AND THE PARTNERSHIP IN WHICH
- OUR MISSION IS BEING ADVANCED BY THIS TREMENDOUS DUAL
- 14 TEAM THAT WE HAVE.

- 15 I WOULD LIKE AT THIS TIME, THEREFORE, TO GO TO
- 16 DR. MURPHY, AND I THINK IT WOULD BE APPROPRIATE FOR SOME
- 17 APPLAUSE FOR HIS PERFORMANCE.
- 18 (APPLAUSE.)
- DR. MURPHY: THANK YOU VERY MUCH AND THANK YOU,
- 20 CHAIRMAN KLEIN. FIRST, LET ME THANK ALL THE MEMBERS OF
- 21 THE ICOC FOR GIVING ME THE PRIVILEGE TO SERVE AS INTERIM
- 22 PRESIDENT. I ACCEPTED YOUR VERY KIND OFFER BECAUSE I
- 23 THINK THIS IS A VERY IMPORTANT TIME IN THE HISTORY OF
- 24 CIRM. WE HAVE BYPASSED ALL OF THE LEGAL HURDLES THAT
- 25 FACED US, AND NOW WE ARE REALLY READY TO RELEASE THE

1	MONEY THAT WILL BE NECESSARY TO DO THE RESEARCH THAT
2	CALIFORNIANS REQUESTED OF US. AND I'M VERY HAPPY TO SIT
3	ON THIS SIDE OF THE ICOC TABLE TO HELP IN THAT PROCESS,
4	HAVING SERVED FOR THREE YEARS ON THAT SIDE OF THE TABLE.
5	I'M REMINDED OF BILL GATES' COMMENTS TO A
6	GRADUATING CLASS OF STUDENTS. HE ONCE SAID, "ALWAYS BE
7	NICE TO NERDS BECAUSE YOU COULD BE WORKING FOR THEM."
8	YOU ARE NOT NERDS, BUT I HOPE I WAS NICE TO YOU.
9	I WOULD LIKE VERY BRIEFLY TO PRESENT TO YOU
10	FOUR GOALS THAT I HAVE OVER THE BRIEF TIME I'M GOING TO
11	BE SERVING AS INTERIM PRESIDENT. THOSE GOALS ARE TO
12	TRANSITION THE PRESIDENCY FOR DR. TROUNSON, TO IMPROVE
13	OPERATIONS, TO PROMOTE OUR SCIENTIFIC PROGRAMS, AND TO
14	EXPAND OUR PUBLIC OUTREACH.
15	WITH RESPECT TO THE FIRST GOAL, TRANSITIONING
16	THE PRESIDENCY, I HAD HOPED THAT MY EFFORTS WOULD ALLOW
17	US TO ATTRACT A GOOD PRESIDENT AND THAT I COULD HELP IN
18	THE TRANSITION TO THAT PERSON. JUST FOR HISTORICAL
19	PURPOSES, I SHOULD TELL THE ICOC THAT I BEGAN WORKING ON
20	SEPTEMBER 6TH, WHICH WAS A THURSDAY, I CONTINUED ON THE
21	7TH, AND THEN I WAS AWAY THE NEXT WEEK ON A COMMITMENT
22	THAT I HAD IN CANADA, COMMITMENT THAT I HAD MADE PREVIOUS
23	TO TAKING THIS POSITION. ABOUT MIDWEEK ON MY TRIP I GOT
24	A CALL FROM CHAIRMAN KLEIN SAYING THAT DR. TROUNSON HAD

BEEN IDENTIFIED AS AN EXCELLENT CANDIDATE, THAT HE

	1	ACCEPTED	THE	TERMS	OF	THE	APPOINTMENT,	AND	THAT	HIS
--	---	----------	-----	-------	----	-----	--------------	-----	------	-----

- 2 APPOINTMENT WOULD BE RATIFIED OR DISCUSSED BY THE ICOC ON
- 3 FRIDAY. BY THE TIME I RETURNED AND GOT OFF THE PLANE,
- 4 THE VOTE HAD BEEN TAKEN AND THE ANNOUNCEMENT HAD BEEN
- 5 MADE.
- 6 I CONGRATULATE THE ICOC FOR THIS EXCELLENT
- 7 CHOICE, BUT I ALSO WANT TO MAKE CERTAIN THAT IN THE
- 8 EUPHORIA SURROUNDING DR. TROUNSON'S APPOINTMENT, THE
- 9 VALUE OF MY LEADERSHIP IN THAT PROCESS NOT BE FORGOTTEN.
- 10 AS BOB SAID, ALAN AND I HAVE VISITED, AND HE AND I HAVE
- 11 BEEN IN CONSTANT COMMUNICATION ABOUT HOW WE SHOULD WORK
- 12 TOGETHER; AND I THINK I AGREE WITH YOU, YOU MADE A SUPERB
- 13 CHOICE.
- 14 IT'S CLEAR THAT ALAN AND I SHARE THE SAME GOALS
- 15 FOR THE INSTITUTE AND THAT WE HAVE THE SAME SENSE AS TO
- 16 HOW WE SHOULD PROCEED TO ACHIEVE THE INSTITUTE'S MISSION.
- 17 AND SINCE THOSE MEETINGS, AS BOB SAID, WE HAVE SHARED IN
- 18 NUMEROUS E-MAILS, AND THE DECISIONS WE ARE MAKING WITH
- 19 BOB'S INPUT GO TOWARDS COMMON ENDS. SHARED
- 20 DECISION-MAKING WILL BE A VERY IMPORTANT ASPECT OF MY
- 21 PRESIDENCY TO ALLOW ALAN TO SEAMLESSLY INTEGRATE INTO THE
- 22 INSTITUTE AND ALSO TO GET HIM OFF TO A RUNNING START WHEN
- 23 HE ARRIVES.
- 24 IT'S ALSO IMPORTANT FOR THE ICOC AND THE CIRM
- 25 STAFF TO KNOW THAT THE SHARED DECISIONS WE ARE MAKING NOW

1 WILL BE CONSISTENT WITH ALAN'S FUTURE PLANS AND PROGR

- 2 I.E., WHEN ALAN COMES, IT WILL NOT BE A BIG SHIFT.
- 3 HOPEFULLY WE WILL ALL HAVE BEEN WORKING TOGETHER SO THAT
- 4 WHEN HE ARRIVES, IT WILL BE BUSINESS AS USUAL.
- THE OTHER GOAL, MY SECOND GOAL, WAS TO IMPROVE
- 6 OPERATIONS. TO UNDERSTAND HOW THE INSTITUTE WORKS
- 7 INTERNALLY, I'VE MET ONE ON ONE WITH EVERYONE IN THE
- 8 INSTITUTE OVER THE LAST SEVERAL WEEKS, WHICH WAS AN
- 9 ABSOLUTE PLEASURE. WHAT I LEARNED IS THAT CIRM STAFF ARE
- 10 SMART, DEDICATED, SUPPORTIVE VERY MUCH OF CIRM'S MISSION.
- 11 AND I VERY MUCH ENJOYED LEARNING ABOUT THEIR HOPES AND
- 12 DREAMS FOR THE INSTITUTE AND ABOUT THEIR OWN GOALS. I
- 13 LEARNED HOW OUR SCIENTIFIC PEOPLE HAVE ACCOMPLISHED SO
- 14 MUCH IN SUPPORTING THE PROGRAMS WE HAVE FUNDED, GOING
- 15 THROUGH VERY DIFFICULT STEPS OF PROGRAM DESIGN, SEEKING
- 16 PUBLIC INPUT, PUTTING OUT RFA'S, ACCEPTING AND PROCESSING
- 17 APPLICATIONS, ORGANIZING PEER REVIEW, PREPARING GRANT
- 18 SUMMARIES, AND BEING METICULOUS ABOUT ENSURING THAT ALL
- 19 THE ADMINISTRATIVE REQUIREMENTS THAT ARE NECESSARY ARE
- 20 MET BEFORE MONEY FLOWS.
- THE ADMINISTRATIVE GROUP HAS CREATED MECHANISMS
- 22 TO ENSURE THAT INSTITUTE OPERATIONS ARE CONSISTENT WITH
- 23 STATE POLICIES, BUT AT THE SAME TIME CAN SUPPORT THE
- 24 EVERCHANGING NEEDS OF A FUNDING AGENCY THAT REQUIRES
- 25 FLEXIBILITY TO MEET THE INSTITUTE'S SCIENTIFIC MISSION.

1	AND THE CHAIR'S OFFICE HAS TAKEN ON THE
2	ADMINISTRATIVE TASKS THAT ARE NECESSARY FOR SERVING THE
3	NEEDS OF THE ICOC, FOR ISSUING BONDS, AS YOU HEARD ABOUT,
4	AND FOR MUCH OF THE INTERNATIONAL OUTREACH THAT'S
5	ESSENTIAL TO PROVIDE LEADERSHIP IN STEM CELL RESEARCH
6	AROUND THE WORLD.
7	IN SUMMARY, THE INSTITUTE IS OPERATIONALLY
8	HEALTHY AND DOING ITS JOBS WELL. THANKS GO TO BOB, ZACH,
9	ARLENE, LORI, AND OTHERS IN LEADERSHIP POSITIONS FOR OUR
10	ORGANIZATIONAL SUCCESS.
11	NOW, I HAVE ASKED MANY OF THE PEOPLE AT CIRM
12	OVER THE NEXT ICOC MEETINGS TO MEET WITH THE ICOC
13	DIRECTLY BECAUSE THEY ARE THE EXPERTS IN THE POLICIES AND
14	ADVANCES THAT CIRM IS MAKING, THEY ARE THE PEOPLE WHO YOU
15	WILL MEET AND I KNOW WILL ENJOY, AND I KNOW THAT THEY
16	WILL ENJOY MEETING YOU. IT'S IMPORTANT TO ME THAT THE
17	ICOC GET TO KNOW CIRM STAFF DIRECTLY; AND I'M SURE WHEN
18	YOU DO THAT, YOU WILL BE AS PLEASED AS I AM WITH THE
19	QUALITY OF WHO YOU ARE DEALING WITH.
20	THAT SAID, THERE ARE STILL IMPROVEMENTS THAT
21	NEED TO BE PUT IN PLACE OVER THE NEXT SEVERAL MONTHS.
22	AND THESE INCLUDE CHANGING ORGANIZATIONAL STRUCTURE. WE
23	NEED TO ASSESS THE ORGANIZATIONAL STRUCTURE OF THE
24	INSTITUTE TO BE CERTAIN WE HAVE THE APPROPRIATE WORKING
25	AND EMPLOYEE REPORTING RELATIONSHIPS. I WILL BE

	1	RECOMMENDING	CHANGES	ΙN	THE	ORGANIZATIONAL	CHART	TH⊅
--	---	--------------	---------	----	-----	----------------	-------	-----

- 2 HOPEFULLY WILL MAKE THE INSTITUTE MOVE MORE SMOOTHLY,
- 3 INCLUDING HAVING HUMAN RESOURCES REPORT TO THE PRESIDENT,
- 4 GRANTS MANAGEMENT REPORT TO FINANCE. AND THE CHAIRMAN'S
- 5 OFFICE REPORT TO THE CHAIR AND THROUGH THE CHAIR TO THE
- 6 PRESIDENT. THERE MAY BE OTHER CHANGES AS WELL THAT WILL
- 7 REQUIRE A FRESH LOOK AT MANY OF THE POLICIES THAT EXIST
- 8 AT THE INSTITUTE AND THAT MAY NEED REEXAMINATION AS WELL.
- 9 AND I'M THINKING ABOUT WORK FLOW MECHANISMS, ETC.
- 10 WE ALSO NEED TO BEGIN THE HIRING OF ADDITIONAL
- 11 PEOPLE TO FULFILL CIRM'S SCIENTIFIC MISSION. RECALL THAT
- 12 WE HAVE A MAXIMUM OF 50 EMPLOYEES WITH 26 NOW ON STAFF.
- 13 MANY OF THESE PEOPLE HAVE CARRIED OUT THEIR
- 14 RESPONSIBILITIES BECAUSE OF HEROIC EFFORTS AND LONG
- 15 HOURS, WELL BEYOND WHAT ANY OF US WOULD EXPECT OF OUR
- 16 EMPLOYEES IN A WORKING DAY. I FEAR EMPLOYEE BURNOUT
- 17 UNLESS WE BRING INTO THE INSTITUTE THOSE ADDITIONAL
- 18 PEOPLE THAT WE NEED. CURRENTLY WE HAVE NEEDS FOR AT
- 19 LEAST FIVE PEOPLE ON THE SCIENTIFIC STAFF. INCLUDING A
- 20 HIGH LEVEL REPLACEMENT FOR ARLENE CHIU. ARLENE CAN NEVER
- 21 BE REPLACED, BUT WE NEED TO TRY IT. WE NEED AT LEAST
- 22 FOUR PEOPLE ON OUR ADMINISTRATIVE STAFF. THE CHAIR'S
- 23 OFFICE MAY NEED ADDITIONAL PEOPLE FOR ADMINISTRATIVE
- 24 MATTERS ASSOCIATED WITH THE ICOC, BOND SALES, AND
- 25 GOVERNMENT RELATIONS. AND FINALLY, DR. TROUNSON AND I

1	HAVF	DTSCUSSED	THE	POTENTIAL	NFFD	FOR A	000	ONCF	HF

- 2 ARRIVES ON SCENE. AND I THINK THAT IS VERY MUCH IN THE
- 3 INTEREST OF CIRM.
- 4 SOME OF THESE RECRUITMENTS ARE COMPLETE. IN
- 5 FACT, THREE OF THE SCIENTIFIC PEOPLE HAVE BEEN IDENTIFIED
- 6 AND OTHERS ARE IN VARIOUS STAGES OF BEING PROCESSED. WE
- 7 ALSO NEED TO RETAIN THE STAFF WE HAVE, AND WE NEED TO
- 8 TAKE A FRESH LOOK AT THE SALARIES WE PAY CIRM'S EMPLOYEES
- 9 AND THE GRADE LEVELS THEY OCCUPY. WE ARE CURRENTLY DOING
- 10 A SALARY COMPARISON WITH MERCER ASSOCIATES AND SHOULD BE
- 11 ABLE TO ADVISE THE GOVERNANCE COMMITTEE AND THEN THE ICOC
- 12 ON SALARY AND ORGANIZATIONAL CHALLENGES -- CHANGES AT OUR
- 13 NEXT MEETING.
- 14 FINALLY, WE NEED TO PLAN FOR THE FUTURE.
- 15 PROPOSITION 71 IS NOW THREE YEARS OLD, AND WE SHOULD USE
- 16 ITS ORIGINAL VISION, WHICH WAS ADMIRABLE, AS THE
- 17 FOUNDATION ABOUT THINKING ABOUT THE FUTURE OF THE
- 18 ORGANIZATION. ONE OF THE NEEDS I HEARD IN MY INTERVIEWS
- 19 WITH THE STAFF WAS THE NEED TO CONSIDER CIRM'S FUTURE AND
- 20 HOW WE WILL ADAPT TO ADVANCES IN THE STEM CELL FIELD. TO
- 21 DO THAT, WE NEED TO GIVE OUR TIME -- OUR STAFF TIME TO
- 22 THINK AND TO EXPOSE THEM TO OUTSIDE PEOPLE AND INFLUENCES
- 23 SO THAT THEY WILL CONTINUE TO ADVISE US HOW TO IMPROVE
- 24 THE INSTITUTE. WE NEED TO BENEFIT NOT ONLY FROM THEIR
- DAILY WORK, BUT WE ALSO NEED TO BENEFIT FROM THEIR

1	EXPERIENCE.	THE	KNOWI FDGF	THFY	GENERATE	ΤN	THE	COURSE	ΩF
_			KINOWELDGE			T 1.4		COUNSE	\sim 1

- THEIR WORK, AND FROM THEIR CONSTANT OBSERVATIONS OF
- 3 PROGRESS IN THE STEM CELL FIELD, WHICH WILL LEAD US IN
- 4 NEW DIRECTIONS.
- 5 THIRDLY, WE WANTED TO PROMOTE SCIENTIFIC
- 6 PROGRAMS. AND HERE IT TURNS OUT THAT MY EFFORTS WILL NOT
- 7 BE NECESSARY BECAUSE THE STAFF HAVE ALREADY DONE THAT
- 8 RESPONSIBILITY WELL AND HAVE THE RESPONSIBILITY WELL IN
- 9 HAND. WE ARE CURRENTLY IN THE MIDST OF PROGRAMS FOR
- 10 MAJOR FACILITIES AND NEW INVESTIGATORS, AND RFA'S ARE
- 11 BEING PREPARED FOR DISEASE-RELATED RESEARCH GROUPS AND
- 12 NEW CELL LINES. IN MY VIEW, IMPLEMENTING FOR ALL OF
- 13 THESE PROGRAMS THE RFA'S, THE GRANT PROCESSES, AND THE
- 14 HEAVY ADMINISTRATIVE LOADS THAT WILL SURROUND THOSE
- 15 INITIATIVES WILL PUT OUR STAFF AT FULL CAPACITY. AND TO
- 16 INCREASE THEIR RESPONSIBILITIES AT LEAST IN THE NEAR TERM
- 17 IS UNWISE. AND YOU WILL BE HEARING ABOUT THE CURRENT
- 18 PROGRAMS AND FUTURE PROGRAMS FROM ARLENE.
- 19 NOW. ONE OF THE NECESSITIES FOR ENSURING THAT
- 20 WE PROCESS THE ENORMOUS AMOUNT OF PEER REVIEW ASSOCIATED
- 21 PAPER THAT COMES WITH ALL OF THESE PROGRAMS IS AN
- 22 EFFICIENT AND EFFECTIVE WAY TO IMPLEMENT OUR GRANTS
- 23 MANAGEMENT SYSTEM. AND TODAY WE WILL BE MAKING A
- 24 RECOMMENDATION TO YOU FOR THE PURCHASE OF A GRANTS
- 25 MANAGEMENT PROGRAM AND COMPUTER WARE THAT WILL ALLOW THAT

1	TO HAPPEN, AND THAT PURCHASE IS ESSENTIAL FOR OUR FUTURE.
2	AND FINALLY, WHAT WE WANT TO DO IS EXPAND
3	PUBLIC OUTREACH. CIRM HAS GONE THROUGH SOME VERY
4	INTERESTING TIMES, MUCH OF WHICH HAS BEEN DOMINATED BY
5	OUR LEGAL CHALLENGES. HOWEVER, THE TIDE HAS TURNED. WE
6	ARE FUNDING OUR TRAINEES AND PRINCIPAL INVESTIGATORS, AND
7	NEW KNOWLEDGE ABOUT STEM CELLS IS BEGINNING TO EMERGE
8	FROM CIRM-SPONSORED PROGRAMS. IT'S TIME FOR CIRM TO
9	EXPAND ITS PUBLIC OUTREACH TO TELL CALIFORNIANS ABOUT OUR
10	SUCCESSES, TO EDUCATE THEM BETTER ON STEM CELL BIOLOGY,
11	AND TO SHARE THE PROGRESS WE ARE MAKING IN STEM CELL
12	RESEARCH.
13	AND YOU WILL HEAR ABOUT TWO STUDENT MEETINGS
14	THAT WERE HELD RECENTLY WITH STUDENT TRAINEES FROM THE
15	NORTH AND SOUTH OF THE STATE IN WHICH THESE YOUNG PEOPLE
16	ARE NOW BEGINNING TO PRODUCE THE RESULTS THAT WE'RE
17	FUNDING THEM TO DO. AND YOU HAVE ASSOCIATED WITH YOUR
18	MATERIALS TODAY SUMMARY BOOKS OF THE ABSTRACTS OF THEIR
19	PROGRESS.
20	WE ALSO NEED TO UPDATE THE MANY ORGANIZATIONS
21	THAT SUPPORTED PROPOSITION 71 ON OUR PROGRESS AND TO
22	CONVINCE THEM THAT THEY MADE A GOOD DECISION IN
23	SUPPORTING US. NOW, DALE CARLSON, HEAD OF PUBLIC
24	INFORMATION AT CIRM, HAS ANNOUNCED THAT HE HAS DECIDED TO
25	LEAVE CIRM TO CONTINUE HIS CAREER IN THE PRIVATE SECTOR.

1	DALE HAS PROVIDED SERVICE TO CIRM UNDER VERY DIFFICULT
2	CIRCUMSTANCES WHEN OUR LEGAL ACTIVITIES SLOWED DOWN OUR
3	PROGRESS. IN MY SHORT TIME WORKING WITH DALE, I CAME TO
4	ENJOY HIM, AND I KNOW YOU WILL BE WISHING HIM WELL ALSO.
5	TO REPLACE DALE AND TO MOVE FORWARD, WE NEED TO
6	CONSIDER EXPANDING OUR PUBLIC OUTREACH PROGRAM THROUGH
7	PROBABLY THE ENGAGEMENT OF AN OUTSIDE FIRM WORKING WITH
8	AN INTERNAL PUBLIC RELATIONS COORDINATOR. ALAN AND BOB
9	AGREE WITH THIS APPROACH, AND WE WILL BEGIN TO SEARCH FOR
LO	A FIRM THAT IS STRONG IN MEDICAL AFFAIRS AND JOURNALISM
L1	AND HAS GOOD RELATIONS WITH GOVERNMENT. BOB AND I WILL
L2	BE DISCUSSING THIS ISSUE WITH ALAN AND COMING BACK TO YOU
L3	FOR INPUT AND WITH A RECOMMENDATION.
L4	IN MY VIEW WHAT WE NEED TO DO IS TO PROVIDE
L5	PUBLIC EDUCATION INFORMATION AND UPDATING TO THE PUBLIC.
L6	WE NEED TO INFORM THE PUBLIC, GOVERNMENT, PATIENTS, AND
L7	THEIR FAMILIES, AND THE PATIENT ADVOCATES TO WHOM OUR
L8	WORK IS SO IMPORTANT. WE ALSO NEED TO RECOGNIZE THAT WE
L9	ARE PLAYING ON MANY STAGES WHICH INCLUDE THE STATE AND
20	LOCAL LEVELS, NATIONAL INTERESTS AND INTERNATIONAL
21	AUDIENCE AS WELL.
22	SO, MR. CHAIRMAN, WITH THAT STATEMENT, I WOULD
23	LIKE TO TERMINATE MY COMMENTS. AND I'M VERY HAPPY,

25

BEFORE WE MOVE ON IN THE PRESIDENT'S REPORT, TO ANSWER

ANY QUESTIONS THAT THE MEMBERS MAY HAVE.

24

1	CHAIRMAN KLEIN: THANK YOU VERY MUCH, DR.
2	MURPHY. IT HAS BEEN AN INSPIRATION AND A TREMENDOUS LIFT
3	OF THE MORALE AS THE STAFF HAS SEEN THAT WE'RE GOING TO
4	HAVE STRONG LEADERSHIP ALL THE WAY TO WHEN DR. TROUNSON
5	GETS HERE AND THE OVERLAPPING LEADERSHIP FOR A COUPLE OF
6	MONTHS AS DR. MURPHY SETTLES INTO THIS NEW POSITION TO
7	HAVE TWO STRONG LEADERS AT OUR INSTITUTION WITH THEIR
8	TREMENDOUS BACKGROUND OF INFORMATION. YOUR INCREDIBLE
9	HISTORY WITH THIS BOARD AND GUIDANCE IN THE EARLY STAGES
10	OF PUTTING TOGETHER THE INITIATIVE, WE HAVE A TEAM THAT'S
11	IRREPLACEABLE. SO WE ARE DEEPLY APPRECIATIVE.
12	ARE THERE QUESTIONS FROM THE BOARD? SHERRY
13	LANSING.
14	MS. LANSING: THIS ISN'T A QUESTION. I JUST
15	REALLY WANT TO REITERATE ON BEHALF OF ALL THE BOARD
16	MEMBERS, IT WAS AN HONOR WHEN YOU WERE ON THE BOARD, AND
17	I THINK I SPEAK FOR ALL OF US IN SAYING THE FACT THAT YOU
18	WOULD STEP IN IN THIS TRANSITORY POSITION WAS SO
19	WONDERFUL, AND WE WERE ALL SO EXCITED ABOUT IT. AND NOW
20	I THINK I SPEAK FOR ALL OF US IN SAYING WHAT YOU JUST
21	PRESENTED TO US SHOWS YOUR PASSION, YOUR COMMITMENT, YOUR
22	EXTRAORDINARY INTELLIGENCE, AND ORGANIZATIONAL ABILITY.
23	AND I THINK I SPEAK FOR ALL OF US IN SAYING THAT THANK
24	YOU, THANK YOU, THANK YOU, AND YOUR LEADERSHIP IS JUST
25	EXTRAORDINARY. SO THANK YOU FROM ALL OF US.

1	(APPLAUSE.)
2	CHAIRMAN KLEIN: DAVID.
3	MR. SERRANO-SEWELL: THANK YOU. DR. MURPHY, I
4	JUST WANTED TO ADD AND SHARE WITH YOU AS PART OF YOUR
5	REPORT AND SHARE WITH MY COLLEAGUES AS WELL, AND I THINK
6	IT DOES SPEAK TO ONE OF THE GOALS THAT YOU'VE SET, AND
7	THAT IS EXPANDING PUBLIC OUTREACH. A COUPLE OF WEEKS AGO
8	I HAD THE OPPORTUNITY TO BE IN LOS ANGELES WITH OUR
9	GENERAL COUNSEL, TAMAR PACHTER, AT THE CALIFORNIA
10	MINORITY COUNSEL'S ASSOCIATION ANNUAL EVENT. THAT IS AN
11	ASSOCIATION THAT IS A LEGAL ASSOCIATION THAT HAS BEEN
12	AROUND A LONG TIME. IT'S PRIMARILY COMPRISED OF LAWYERS
13	OF COLOR AND SMALLER LAW FIRMS. AND WHAT IT IS IS AN
14	OPPORTUNITY FOR THE LARGER LAW FIRMS TO MEET WITH SMALLER
15	BOUTIQUE FIRMS AND SORT OF INTERACT AND SEE WHERE THERE
16	MIGHT BE OPPORTUNITIES TO WORK TOGETHER.
17	THERE WERE A COUPLE OF STATE AGENCIES THERE.
18	WE WERE ONE OF THEM IN ADDITION TO SOME LOCAL
19	MUNICIPALITIES. IT WAS DULY NOTED BY EVERYBODY THERE,
20	AND I THOUGHT IT WAS A VERY PRODUCTIVE MEETING. AND I
21	ALSO WANTED TO THANK TAMAR FOR ATTENDING IT.
22	CHAIRMAN KLEIN: DR. LEVEY.
23	DR. LEVEY: RICHARD, AGAIN, LET ME ADD MY
24	THANKS FOR WHAT YOU'VE DONE, WHICH IS TERRIFIC. AND I
25	JUST WANTED TO ASK ONE QUESTION. WHEN YOU WERE TALKING

1	A D ∩IIT	EVEDVONE	WHO	NEEDED	TO DE	LITDED	\4/LI A T ! C	VALID	EADIV
L	ABUUT	EVERYONE	WHU	NEEDED	IU BE	HIKEU.	WHAI S	YUUK	EAKLY

- 2 ASSESSMENT OF HOW WELL STOCKED OUR GRANT REVIEW PANELS
- 3 ARE? HOW MANY NEW REVIEWERS DO YOU THINK WE NEED?
- 4 DR. MURPHY: WELL, THAT IS AN ONGOING PROBLEM,
- 5 JERRY. THE PROBLEM IS WE HAVE A SOLID GROUP OF PRIMARY
- 6 REVIEWERS, BUT THEY CANNOT ALWAYS BE AT THE MEETINGS. SO
- 7 WHAT THE STAFF HAS DONE VERY -- IN A VERY EXCELLENT WAY
- 8 IS IDENTIFIED AD HOC REVIEWERS WHO CAN CONTRIBUTE TO THE
- 9 PROCESS WHO -- AND THEY HAVE BEEN ABLE TO MAKE THE QUORUM
- 10 FOR EVERY ONE OF OUR GRANT COMPETITIONS.
- 11 BUT I THINK ONE OF THE THINGS WE NEED TO DO IS
- 12 INCREASE THE STABLE OF VERY QUALIFIED REVIEWERS WHO ARE
- 13 AVAILABLE TO CIRM, ESPECIALLY AS THE NEW PROGRAMS COME
- 14 IN. AND FRANKLY, WE'RE JUST NOT GOING TO BE ABLE TO GET
- 15 THE SAME PEOPLE COMING TO CALIFORNIA FOR EVERY ONE OF THE
- 16 REVIEWS.
- 17 ONE OF THE THINGS THAT ALAN AND I HAVE TALKED
- 18 ABOUT IS MY OWN EXPERIENCE. HAVING BEEN IN CANADA FOR 14
- 19 YEARS OPENS UP A WHOLE NEW BEVY OF POSSIBILITIES TO BRING
- 20 IN CANADIANS INTO THE SYSTEM. ALAN CERTAINLY WITH HIS
- 21 EXPERTISE IN STEM CELLS IS CAPABLE OF DOING THAT ALL
- 22 AROUND THE WORLD. AND I THINK, WORKING WITH THE
- 23 SCIENTIFIC STAFF, WE NEED TO INCREASE THE NUMBER OF
- 24 REVIEWERS WHO ARE AVAILABLE TO US SO WE CAN ENSURE THAT
- 25 FOR EVERY ONE OF THE COMPETITIONS WE HAVE, AT LEAST THE

1	MINIMUM NUMBER THAT WE NEED.
2	CHAIRMAN KLEIN: THANK YOU.
3	DR. HENDERSON: WE DISCUSSED BRIEFLY AT A
4	MEETING A POSSIBILITY OF TRYING MORE VIDEOCONFERENCING TO
5	KEEP THE BEST REVIEWERS ENGAGED, EVEN THOUGH THEY DON'T
6	NECESSARILY WANT TO TRAVEL ALL THE WAY TO CALIFORNIA.
7	AND I THINK IT'S SOMETHING TO PUT NEAR THE TOP OF THE
8	LIST BECAUSE I THINK WE REALLY DO NEED THE BEST PEOPLE.
9	AND THE TENDENCY WILL BE FOR THAT TO CHANGE AS PEOPLE GET
10	FATIGUED, JUST LIKE STAFF. HOW DO WE KEEP THEM ENGAGED?
11	MAKE IT AS EASY AS POSSIBLE FOR THEM BY BEING AS FLEXIBLE
12	AS WE CAN BE.
13	DR. MURPHY: BRIAN, WE AGREE WITH THAT. AND IT
14	TURNS OUT I'VE LEARNED FROM BOB THAT AT&T PARK RIGHT
15	ACROSS FROM CIRM HEADQUARTERS HAS A VERY ELABORATE
16	TELECONFERENCE FACILITY WHICH IS AVAILABLE TO US. AND
17	WE'VE ALSO ASKED DENNIS BUTLER AT CIRM TO DO TWO THINGS.
18	ONE IS TO MAKE CERTAIN THAT THE CIRM HEADQUARTERS IS
19	GOING TO BE FULLY CAPABLE FOR WI-FI SO THAT WE CAN HAVE
20	PEOPLE COMING IN AND BEING VERY COMFORTABLE AT CIRM
21	HEADQUARTERS USING THEIR OWN COMPUTER EQUIPMENT, BUT ALSO
22	UPDATING THE CIRM HEADQUARTERS SO IT WILL HAVE
23	TELECONFERENCING FACILITIES AS WELL, SPEAKING VERY MUCH
24	TO WHAT YOU'VE JUST SUGGESTED.
25	CHAIRMAN KLEIN: ALL RIGHT. ADDITIONAL BOARD

- 2 COMMENT.
- 3 MR. SIMPSON: ACTUALLY IT MIGHT BE MORE
- 4 APPROPRIATE AFTER THE UPDATES.
- 5 CHAIRMAN KLEIN: ALL RIGHT. GREAT. WE
- 6 WILL --
- 7 DR. MURPHY: MR. CHAIRMAN, TO COMPLETE THE
- 8 PRESIDENT'S REPORT, I'VE ASKED GIL SAMBRANO TO SUMMARIZE
- 9 WHAT HAS HAPPENED WITH THE TRAINING PROGRAMS, AMY LEWIS
- 10 WILL GIVE ICOC AN UPDATE ON THE NUMBER OF GRANTS WE HAVE
- 11 AWARDED AND PAID OUT, AND ARLENE WILL TALK ABOUT THE
- 12 CURRENT AND FUTURE RFA'S, AND THEN WE WILL OPEN UP FOR
- 13 QUESTIONS.
- DR. SAMBRANO: THANK YOU, DR. MURPHY. I AM
- 15 VERY PLEASED TO BRING TO YOU TODAY A REPORT ON THE ANNUAL
- 16 CIRM SCHOLAR'S MEETING. AS YOU WILL RECALL, IN APRIL OF
- 17 2006, THE CIRM AWARDED TRAINING GRANTS TO 16 CALIFORNIA
- 18 NONPROFIT AND ACADEMIC INSTITUTIONS TO FOSTER TRAINING OF
- 19 PREDOCTORAL, POSTDOCTORAL, AND CLINICAL TRAINEES ALL IN
- 20 STEM CELL RESEARCH. THIS WAS THE FIRST INITIATIVE OF THE
- 21 CIRM, IT WAS THE FIRST REVIEW BY OUR GRANTS WORKING
- 22 GROUP, AND IT WAS THE FIRST APPROVAL OF APPLICATIONS BY
- 23 THIS BOARD.
- 24 EACH OF THE GRANTEE INSTITUTIONS BRINGS UNIQUE
- 25 STRENGTHS AND AREAS OF SPECIALIZATION IN STEM CELL

1	RESEARCH TRAINING, AND OVERALL THE PROGRAM CAN SUPPORT UP
2	TO 170 TRAINEES PER YEAR.
3	SO THIS SEPTEMBER WE HELD THE FIRST ANNUAL CIRM
4	SCHOLAR'S MEETING. AND THE PURPOSE OF THIS MEETING WAS
5	TO OFFER TRAINEES THE OPPORTUNITY TO PRESENT THEIR
6	PRELIMINARY DATA, TO ENGAGE IN SCIENTIFIC DISCUSSION, AND
7	EXCHANGE IDEAS. IT WAS AN OCCASION FOR THEM TO MEET WITH
8	PEERS AND MENTORS ACROSS DIFFERENT INSTITUTIONS AND TO
9	SHARE AND DISCOVER WHAT OTHERS ARE WORKING ON. FOR THE
10	CIRM IT WAS AN OPPORTUNITY TO SEE FIRSTHAND THE PRODUCT
11	OF OUR TRAINING PROGRAM.
12	NOW, BECAUSE WE HAVE A LARGE NUMBER OF
13	TRAINEES, ASSOCIATED MENTORS AND PROGRAM DIRECTORS, WE
14	HAD ACTUALLY JUST A LITTLE OVER 200 PEOPLE REGISTER FOR
15	THIS MEETING. AND IN ADDITION, TO REDUCE TRAVEL, WE SET
16	UP TWO MEETINGS, ONE IN NORTHERN CALIFORNIA AND ONE IN
17	SOUTHERN CALIFORNIA, AS SHOWN ON THE SLIDE. THE NORTHERN
18	CALIFORNIA MEETING TOOK PLACE SEPTEMBER 11TH AT UC SAN
19	FRANCISCO MISSION BAY CAMPUS, AND THE SOUTHERN CALIFORNIA
20	COHORT MET JUST LAST WEEK AT THE UCI CAMPUS.
21	NOW, BOTH MEETINGS FEATURED THE SAME OVERALL
22	AGENDA THAT INCLUDED SHORT TALKS THAT WERE GIVEN BY ONE
23	SELECTED TRAINEE FROM EACH OF THE INSTITUTIONS. AND
24	THOSE PHOTOS THAT YOU ARE SEEING HERE ARE ACTUALLY FROM
25	THE NORTHERN CALIFORNIA MEETING, SO THESE ARE ACTUALLY
	21

- 1 TAKEN FROM THE MEETINGS. THERE WAS ALSO A POSTER SESSION
- 2 AT EACH IN WHICH TRAINEES HAD THE OPPORTUNITY TO DISPLAY
- 3 AND DISCUSS RESEARCH ON A ONE-TO-ONE BASIS. THERE WERE
- 4 ABOUT 115 ABSTRACTS OVERALL, AND THOSE ARE SHOWN AND
- 5 AVAILABLE IN THIS BOOK THAT WAS JUST PASSED AROUND A
- 6 LITTLE EARLIER.
- 7 THE SCHOLARS ALSO HAD THE OPPORTUNITY TO LEAD
- 8 AND PARTICIPATE IN DISCUSSION GROUPS ON VARIED SELECTED
- 9 TOPICS THAT INCLUDED THINGS LIKE TRANSLATIONAL
- 10 CHALLENGES, DIRECTED DIFFERENTIATION, AND CAREER
- 11 TRANSITIONS. AND THIS LAST PHOTO WAS IN ONE OF THE
- 12 POSTERS PRESENTED BY THE TRAINEES; AND AS YOU CAN SEE,
- 13 THEY ARE ALREADY LOOKING TO THE FUTURE OF THE CIRM
- 14 SCHOLARS.
- 15 SO LET ME JUST SAY THAT, IN CLOSING, WE REALLY
- 16 LEARNED A GREAT DEAL FROM THESE MEETINGS. IN PARTICULAR
- 17 IT REINFORCED THE FACT THAT THERE IS GREAT VALUE IN
- 18 HOLDING SUCH MEETINGS. NOT ONLY WAS IT IMPRESSIVE TO SEE
- 19 THE QUALITY PRESENTATIONS AND THE ENTHUSIASTIC
- 20 PARTICIPATION OF THE TRAINEES, BUT I THINK WE TOOK A GOOD
- 21 FIRST STEP TOWARDS DEVELOPING A NETWORK AND A COMMUNITY
- 22 OF SCIENTISTS IN STEM CELL RESEARCH. FOR THE TRAINEES
- 23 THIS WAS A FIRST TIME IN MEETING MANY OTHERS AT OTHER
- 24 INSTITUTIONS, SO I THINK THEY BENEFITED A LOT. I THINK
- 25 THIS HAS ALSO GOTTEN US TO THINK ABOUT HOLDING AN ANNUAL

1	MEETING FOR ALL CIRM INVESTIGATORS IN THE NEAR FUTURE,
2	SOMETHING THAT, AGAIN, WOULD HELP CREATE AND MAINTAIN A
3	COMMUNITY OF SCIENTISTS TO SYNERGIZE THEIR EFFORTS.
4	THANK YOU. I THINK AMY WILL BE SPEAKING NEXT.
5	MS. LEWIS: GOOD MORNING. I'M PLEASED TO
6	PROVIDE TO YOU AND TO THE PUBLIC A COMPILATION OF THE
7	CIRM'S AWARDS AND APPLICATIONS APPROVED FOR FUNDING. YOU
8	SHOULD HAVE A COPY AT YOUR PLACE OF THIS DOCUMENT. THERE
9	ARE SEVERAL COPIES AT THE BACK TABLE FOR THE PUBLIC TO
10	VIEW HERE AT THE MEETING. PLEASE NOTE THAT THIS IS AN
11	ADVANCE DRAFT COPY, AND WE WILL MAKE THE FINAL COPY
12	AVAILABLE TO YOU AND TO THE PUBLIC IN A FEW WEEKS AFTER
13	IT IS PRODUCED.
14	THE PUBLICATION INCLUDES FUNDING DATA AND
15	PUBLIC ABSTRACTS FOR ALL OF THE AWARDS AND APPROVED
16	APPLICATIONS AS OF AUGUST 2007. SO THIS BOOKLET IS
17	ORGANIZED INTO THREE CHAPTERS. THE FIRST CHAPTER COVERS
18	THE CIRM TRAINING GRANT AWARDS, THE TRAINEES THAT GIL
19	JUST REFERENCED. THOSE ARE ORGANIZED ALPHABETICALLY BY
20	INSTITUTION. THE SECOND CHAPTER, THE LEON J. THAL SEED
21	GRANTS AND COMPREHENSIVE RESEARCH GRANTS, ARE ORGANIZED
22	BY SPECIFIC INJURIES AND DISEASES AND THEN BY TYPES OF
23	RESEARCH. AND FINALLY, CHAPTER 3 COVERS THE SHARED
24	RESEARCH LABORATORIES AND TECHNIQUES COURSES, ALSO
25	ORGANIZED ALPHABETICALLY BY INSTITUTION.

1	I'D LIKE NOW TO TAKE JUST A MOMENT TO UPDATE
2	YOU ON THE PROGRESS OF THE GRANT AWARDS FOR THE SEED,
3	COMPREHENSIVE, AND SHARED LABS PROGRAMS.
4	MANY OF YOU MAY REMEMBER THE SLIDE THAT DR.
5	CHIU USED AT THE JUNE ICOC MEETING TO SUMMARIZE THE
6	GRANTS ADMINISTRATION PROCESS. FOR THE THREE PROGRAMS I
7	JUST MENTIONED, WE ARE CURRENTLY IN STAGES 4 AND 5,
8	PRE-AWARD REVIEW AND AWARD ACCEPTANCE.
9	AS A QUICK REMINDER, IN STAGE 4, PRE-AWARD
10	REVIEW, EACH APPLICATION IS CAREFULLY REVIEWED BY CIRM
11	GRANTS MANAGEMENT AND SCIENTIFIC STAFF FOR COMPLIANCE
12	WITH THE GRANTS ADMINISTRATION POLICY AND CONDITIONS OF
13	THE RFA ON ISSUES SUCH AS ELIGIBILITY, BUDGET, AND PUBLIC
14	POLICY ASSURANCES. THOSE ASSURANCES ARE THE SCRO, OR
15	STEM CELL RESEARCH OVERSIGHT COMMITTEE, APPROVAL FOR WORK
16	WITH HUMAN EMBRYONIC STEM CELLS, ALSO APPROVAL FOR WORK
17	WITH HUMAN SUBJECTS, AND APPROVAL FOR WORK WITH
18	VERTEBRATE ANIMALS.
19	AT THIS STAGE THE APPLICANT IS ASKED TO PROVIDE
20	TO CIRM PROVIDE CIRM WITH THE REQUIRED ASSURANCES AND
21	CERTIFICATIONS AS THEY APPLY TO THE RESEARCH PROPOSED.
22	WE DEPEND ON THE APPLICANTS TO PROVIDE US WITH THE
23	REQUIRED AND APPROPRIATE MATERIAL IN ORDER TO MOVE
24	FORWARD WITH ISSUING THE NOTICE OF GRANT AWARD. WHEN ALL
25	THE MATERIALS HAVE BEEN RECEIVED AND ALL REQUIREMENTS

1	MET, WE MOVE ON TO STAGE 5. THAT'S AWARD ACCEPTANCE.
2	CIRM SENDS OUT A NOTICE OF GRANT AWARD STATING
3	THE TERMS AND CONDITIONS OF THE AWARD. WHEN THE NOTICE
4	OF GRANT AWARD IS SIGNED AND RETURNED TO US BY THE
5	APPLICANT, WE NOTIFY THE STATE CONTROLLER, WHO ISSUES
6	CHECKS OR WARRANTS, AS THE STATE CALLS THEM, TO GRANTEES.
7	AT THE END OF STAGE 5, AN APPLICATION BECOMES A GRANT.
8	JUST A LITTLE BIT MORE DETAIL ON OUR NEXT
9	SLIDE, I HOPE. SO EARLIER THIS YEAR THE ICOC APPROVED
10	THE FUNDING OF 74 SEED APPLICATIONS, 29 COMPREHENSIVE
11	RESEARCH APPLICATIONS, AND 17 SHARED LABS APPLICATIONS
12	FOR A TOTAL OF 120 APPLICATIONS APPROVED FOR FUNDING.
13	SINCE THEN WE'VE BEEN WORKING HARD ON STAGE 4 AND STAGE 5
14	OF THE GRANTS ADMINISTRATION PROCESS WITH EACH APPLICANT,
15	MANY OF WHOM ARE NEW AT THIS AND UNFAMILIAR WITH OUR
16	CONDITIONS AND PROCESSES. WE'VE ALSO AUGMENTED OUR
17	GRANTS MANAGEMENT OFFICE, UP FROM ONE TO THREE STAFF.
18	YOU WILL NOTE THAT THERE ARE 33 APPLICATIONS
19	TOTAL IN THE FIRST COLUMN WITH DOCUMENTS PENDING. FOR
20	THESE APPLICATIONS WE AWAIT FINAL REQUIRED DOCUMENTATION
21	NECESSARY TO ISSUE A NOTICE OF GRANT AWARD, AND A HANDFUL
22	OF THOSE ARE FOR CASES WHERE A PRINCIPAL INVESTIGATOR HAS
23	REQUESTED TO DEFER THE START DATE OF THE AWARD.
24	WE HAVE SUCCESSFULLY ENTERED STAGE 5 WITH ABOUT
25	75 PERCENT OF THE APPROVED APPLICATIONS, ISSUING 87 AWARD

NOTICES BETWEEN AUGUST 1ST AND OCTOBER 1ST.

2	FINALLY, HERE'S A QUICK VISUAL SUMMARY OF THE
3	CURRENTLY FUNDED CIRM PROGRAMS WHICH FALL INTO THREE
4	MAJOR AREAS. FIRST, CIRM IS TRAINING NEW PEOPLE THROUGH
5	THE TRAINING GRANTS PROGRAM, PREPARING EXCEPTIONAL
6	PREDOCTORAL, POSTDOCTORAL, AND CLINICAL FELLOWS FOR
7	CAREERS IN STEM CELL RESEARCH, AND ALSO AS PART OF THE
8	SHARED LABS PROGRAMS, THROUGH THE TECHNIQUES COURSES,
9	PROVIDING HANDS-ON TRAINING FOR WORK WITH HUMAN EMBRYONIC
10	STEM CELLS FOR SCIENTISTS AND TECHNICAL STAFF.
11	CIRM IS SUPPORTING TALENTED INVESTIGATORS
12	WORKING ON BOTH GROUNDBREAKING CONCEPTS AND APPROACHES
13	AND MATURE ONGOING STUDIES IN THE SEED AND COMPREHENSIVE
14	RESEARCH GRANT PROGRAMS, AND CIRM IS FUNDING DEDICATED
15	LABORATORY SPACE AND EQUIPMENT THAT IS FREE OF FEDERAL
16	FUNDING THROUGH THE SHARED RESEARCH LABORATORY GRANT
17	PROGRAM.
18	AS YOU CAN SEE, THE ICOC HAS APPROVED MORE THAN
19	208 MILLION FOR RESEARCH AND FACILITIES FUNDING AT 23
20	CALIFORNIA INSTITUTIONS. THANK YOU VERY MUCH FOR YOUR
21	TIME AND ATTENTION. I BELIEVE DR. CHIU IS NEXT.
22	DR. CHIU: WITH THE LITIGATION BEHIND US AND IN
23	ANTICIPATION OF THE SALE OF BONDS, I'D TODAY LIKE TO
24	SUMMARIZE FOR THE BOARD OUR CURRENT INITIATIVES AND
25	PRESENT TO YOU PRELIMINARY PLANS FOR FUTURE INITIATIVES

1	WITH 2007 AND 2008.
2	SO FOR CURRENT INITIATIVES, WHICH YOU'VE
3	ALREADY SEEN, WE HAVE TWO THAT ARE POSTED, THE NEW
4	FACULTY AWARD WHERE THE BOARD APPROVED THE CONCEPT IN
5	JUNE, AND WE EXPECT TO BRING THE RESULTS FOR BOARD REVIEW
6	AND APPROVAL IN DECEMBER OF THIS YEAR. THE MAJOR
7	FACILITIES AWARDS, YOU APPROVED THE CONCEPT IN AUGUST OF
8	THIS YEAR, AND WE ANTICIPATE FINAL ICOC REVIEW AND
9	APPROVAL IN APRIL OF '08.
10	WE HAVE NEW INITIATIVES, TWO MORE NEW
11	INITIATIVES PLANNED FOR 2007. AND STAFF WILL BE
12	PRESENTING THESE IN MORE DETAIL IN AGENDA ITEMS 8 AND 9
13	THAT WILL FOLLOW. I JUST WANT TO POINT OUT THAT THE
14	DISEASE TEAM PLANNING GRANTS AND THE NEW PLURIPOTENT
15	HUMAN CELL LINES PROGRAM, WE EXPECT, WITH YOUR APPROVAL
16	TODAY, WE EXPECT THE RFA'S TO BE POSTED IN THE FALL OF

17 THIS YEAR FOR REVIEW TO TAKE PLACE IN THE WINTER AND TO

18 COME FOR YOUR APPROVAL ON THE INDIVIDUAL APPLICATIONS IN

19 THE SPRING OF '08.

20 SO AS YOU HAVE SEEN, FOR 2007 OUR PLATE IS NOW

21 VERY FULL. HOWEVER, WE DO ENVISION MORE INITIATIVES

22 COMING DOWN THE PIKE FOR 2008. NOW, I WANT TO WARN YOU

23 THE BIG WORD "DRAFT." THESE ARE JUST PRELIMINARY PLANS

24 AND ARE MEANT TO BE VERY FLEXIBLE. THE TIMING AND EXACT

25 NATURE OF EACH INITIATIVE MAY CHANGE DEPENDING ON NEW

1	PI ANS	MADE	RY	THE	TNTFRTM	PRESIDENT	AND	THE	NFW	PRESTDENT
			-		TIM LIVE 1	1 1/22776111	\neg		14 - 77	1 1/2277711

- 2 AS WELL AS ON CIRCUMSTANCES SUCH AS REVIEWER AVAILABILITY
- 3 AND STAFF RESOURCES. AND, OF COURSE, BEFORE EACH
- 4 INITIATIVE IS FINALIZED AND LAUNCHED, IT WILL BE BROUGHT
- 5 BEFORE THE BOARD FOR CONCEPT APPROVAL.
- 6 SO FUTURE INITIATIVES CAN BE CLASSIFIED UNDER
- 7 FOUR CATEGORIES. UNDER BASIC DISCOVERY RESEARCH, WE
- 8 PROPOSE SEVERAL POSSIBILITIES, NOT ALL OF WHICH MIGHT BE
- 9 PUT UP FOR 2008. AND THESE ARE BIOLOGY OF STEM CELLS,
- 10 TOOLS AND REAGENTS, EGG AND EMBRYO RESEARCH, AND TISSUE
- 11 ENGINEERING, EACH OF WHICH IS MORE FULLY DESCRIBED IN THE
- 12 SCIENTIFIC STRATEGIC PLAN.
- 13 UNDER TRANSLATIONAL RESEARCH, WE ENVISION TWO
- 14 IMPORTANT INITIATIVES, AN RFA FOR STAGE 1 TRANSLATIONAL
- 15 OR PRECLINICAL RESEARCH AND A MAJOR DISEASE TEAM GRANT
- 16 PROGRAM TO BE LAUNCHED LATE IN 2008. AND PAT OLSON WILL
- 17 BE TALKING MORE ABOUT THIS PROGRAM IN A FEW MINUTES.
- 18 TWO OTHER AREAS. TRAINING PROGRAMS, OUR
- 19 CURRENT TRAINING PROGRAM THAT YOU HEARD A LITTLE BIT
- 20 ABOUT RUNS FOR THREE YEARS, BUT WILL EXPIRE AT THE END OF
- 21 MARCH IN 2009. WE WOULD LIKE TO RENEW IT UNDER TRAINING
- 22 PROGRAM II. IN ADDITION, WE HOPE TO INITIATE A TECHNICAL
- 23 TRAINING PROGRAM SPECIFICALLY TO EXTEND THE SKILLS OF
- 24 TECHNICAL STAFF IN STEM CELL RESEARCH.
- AND FINALLY, CORES AND FACILITIES. WE

1	ANTICIPATE	ΔN	TNTTTATTVF	TΩ	SUPPORT	CRTTTCAL	CORFS	AND
_		\neg			2011011		COILES	\neg

- 2 SERVICES SUCH AS STEM CELL BANKING AND TRAINING AND OTHER
- 3 IMPORTANT RESOURCES SOMETIME NEXT YEAR. TO CARRY OUT ALL
- 4 THESE AMBITIOUS PLANS WILL REQUIRE STAFFING UP THE
- 5 SCIENCE OFFICE, WHICH IS ALREADY WORKING FLAT OUT TO MEET
- 6 THIS YEAR'S GOALS. AND I THANK YOU FOR YOUR ATTENTION.
- 7 (APPLAUSE.)
- 8 DR. MURPHY: MR. CHAIRMAN, THAT IS THE
- 9 PRESIDENT'S REPORT, AND I'M HAPPY TO OPEN THE FLOOR TO
- 10 QUESTIONS FROM THE ICOC FOR ANY OF OUR STAFF.
- 11 CHAIRMAN KLEIN: THANK YOU VERY MUCH. IT'S A
- 12 VERY IMPRESSIVE REPORT AND VERY INSPIRING. MEMBERS OF
- 13 THE BOARD? DR. PRIETO.
- DR. PRIETO: I WONDER IF YOU COULD GIVE US SOME
- 15 IDEA HOW MUCH HAS ACTUALLY HAS GONE OUT OF THE APPROVED
- 16 GRANTS. WHAT HAVE WE ACTUALLY FUNDED AND WRITTEN CHECKS
- 17 FOR?
- 18 DR. MURPHY: I THINK AMY CAN.
- 19 MS. LEWIS: 75 PERCENT.
- 20 DR. MURPHY: 75 PERCENT OF YEAR ONE GRANTS HAVE
- 21 NOW GONE OUT. MONEY HAS FLOWED.
- DR. PRICE: THAT INCLUDES THE SEED GRANTS YEAR
- 23 ONE WHEN YOU SAY YEAR ONE?
- DR. MURPHY: FOR ALL THREE PROGRAMS.
- 25 CHAIRMAN KLEIN: OKAY. DR. PIZZO.

1	DR. PIZZO: I WAS VERY PLEASED TO HEAR ALL THE
2	REPORTS, OF COURSE. THE ONE ON THE TRAINING GRANTS AND
3	THE SCHOLARS IS, OF COURSE, OF INCREDIBLE IMPORTANCE TO
4	ALL OF US. TWO THINGS, ONE JUST VERY PRACTICAL. I KNOW
5	THAT YOU NEEDED TO DIVIDE THEM INTO A NORTH-SOUTH
6	CORRIDOR FOR THE FIRST PASS. I THINK OBVIOUSLY IT WILL
7	BE GREAT GOING FORWARD TO MIX UP OUR COMMUNITIES SO THAT
8	WE DON'T HAVE A UNNATURAL DIVIDE.
9	THE OTHER IS THAT IT MAY BE VERY WORTHWHILE
10	THINKING ABOUT A GATHERING OF THE PROGRAM DIRECTORS FROM
11	THOSE TRAINING GRANTS AS WELL TO SHARE THEIR EXPERIENCES,
12	WHAT'S WORKING, WHAT'S NOT WORKING IN MENTORING AND
13	GUIDING THESE EXTRAORDINARY YOUNG FUTURE TALENTS SO THAT
14	WE CAN OPTIMIZE THIS, NOT ONLY FOR THE CURRENT TRAINEES,
15	BUT ALSO AS TO HOW IT MIGHT APPLY TO FUTURE ONES AS WELL.
16	DR. MURPHY: I THINK THAT'S AN EXCELLENT
17	SUGGESTION.
18	CHAIRMAN KLEIN: THANK YOU. ADDITIONAL BOARD
19	COMMENTS?
20	DR. MURPHY: EXCUSE ME, BOB. I THINK GIL HAS A
21	COMMENT.
22	DR. SAMBRANO: I JUST WANTED TO REPLY. I THINK
23	THOSE ARE TWO VERY GOOD POINTS, AND I JUST WANT TO NOTE
24	THAT WE ACTUALLY DID HAVE A MEETING OF THE PROGRAM

DIRECTORS LAST YEAR. AND THAT WAS ACTUALLY VERY

25

_										
7	PRODUCTIVE.	TT	COT	EVERYBODY	\sim	THE	$C \wedge M =$	$D \wedge C \Gamma$	TNI	TEDMO
1	PRUDUCITVE.	_ I I	GUL	EVEKTOUDT	UN	1 11 12	SAME	PAGE	TIN	LEKIVIS

- 2 OF WHAT THEY NEEDED TO DO WITH TRAINING PROGRAMS AND ALSO
- 3 A SHARE OF IDEAS OF HOW THEY CAN DO IT IN THE FUTURE.
- 4 I THINK THE TRAINING MEETINGS THAT WE HAD AS
- 5 WELL WAS ANOTHER OPPORTUNITY FOR THE PROGRAM DIRECTORS TO
- 6 COME TOGETHER, AND THEY NOTED THAT THAT WAS AN IMPORTANT
- 7 ASPECT OF HAVING SUCH MEETINGS.
- 8 AND THEN TO YOUR OTHER POINT, AGAIN BRINGING
- 9 TOGETHER ALL THE TRAINEES IN A SINGLE MEETING WAS BROUGHT
- 10 UP BY SEVERAL, AND SO THAT'S SOMETHING THAT WE ARE GOING
- 11 TO THINK ABOUT POSSIBLY FOR NEXT YEAR.
- 12 DR. PIZZO: IT WOULD BE GOOD. IF YOU CAN JUST
- 13 GET THEM ALTOGETHER, IT BECOMES A BIG MEETING, MIXING
- 14 THEM UP SO THAT THEY HAVE AN OPPORTUNITY TO SHARE MORE
- 15 BROADLY WOULD BE WORTHWHILE.
- DR. SAMBRANO: THANK YOU.
- DR. MURPHY: MR. CHAIRMAN, MAY I JUST ADD ONE
- 18 THING?
- 19 CHAIRMAN KLEIN: ABSOLUTELY.
- DR. MURPHY: JUST TO PUT A LITTLE FACE ON THE
- 21 TRAINING PROGRAM. I WAS AT THE IRVINE MEETING. AND
- 22 GOING AROUND THE POSTERS, AND I ENDED UP TALKING WITH TWO
- 23 YOUNG WOMEN, BOTH OF WHOM WERE SURGICAL RESIDENTS AT L.A.
- 24 CHILDREN'S HOSPITAL. ONE WAS A -- PRESENTED A POSTER
- THAT SHE WAS DOING ON THE STEM CELLS OF CANCER, AND THE

T OIH	EK UNE	PRESENTED	А	POSTER	SHE	WAS	DOTING	UN	IHE	SIEM
-------	--------	-----------	---	--------	-----	-----	--------	----	-----	------

- 2 CELLS IN THE GUT. AND AFTER HEARING THEIR SCIENCE, I
- 3 THEN SAID WHAT ARE YOUR CAREER PLANS? IN BOTH CASES
- 4 THESE TWO YOUNG LADIES, BOTH NOW AT THE END OF THEIR
- 5 TRAINING AS SURGEONS, WERE SPENDING THREE YEARS DOING THE
- 6 CELL BIOLOGY OF STEM CELLS. AND BOTH HAD MADE THE
- 7 DECISION THAT THEY NOW WANTED TO BE ACADEMIC PHYSICIANS.
- 8 SO I THINK THAT THAT'S THE IMPACT THAT CIRM
- 9 PROGRAMS ARE HAVING, WHICH I THINK, IF NOTHING ELSE EVER
- 10 HAPPENED TO ME, THAT'S WORTH THE PROGRAM RIGHT THERE.
- 11 CHAIRMAN KLEIN: DR. BRENNER.
- DR. BRENNER: ACTUALLY THAT'S SORT OF MY
- 13 QUESTION. I THINK IT'S VERY IMPORTANT IF WE DOCUMENT THE
- 14 FOLLOW-UP SO IT'S NOT BASED ON TESTIMONIALS, WE KNOW
- 15 ACTUALLY WHERE THEY ARE ONE YEAR, TWO YEARS, THREE YEARS
- 16 OF OUR TRAINEES. I THINK THAT'S VERY IMPORTANT TO
- 17 VALIDATE THE PROGRAM.
- DR. MURPHY: THAT'S A GREAT IDEA, DAVID.
- 19 CHAIRMAN KLEIN: THAT'S A SUPERB IDEA. IT
- 20 WOULD BE VERY HELPFUL IN OUR OVERSIGHT HEARINGS TO REALLY
- 21 PROVIDE THAT DATA.
- 22 ADDITIONAL BOARD COMMENTS? DR. HENDERSON.
- DR. HENDERSON: YEAH. I DON'T KNOW HOW
- 24 FEASIBLE IT IS IN THE SCHOLARS MEETING, BUT IF THERE'S A
- 25 WAY TO WORK IN PARTICIPATION FROM SOME SENIOR SCIENTISTS

	1	IN THE	DIFFERENT	ACADEMIC	INSTITUTIONS	JUST	WITHIN	TH!
--	---	--------	-----------	----------	--------------	------	--------	-----

- 2 STATE AS SORT OF VISITING FELLOWS OR SOMETHING WHO CAN,
- 3 LIKE YOU, GO AROUND AND INTERACT WITH DIFFERENT TRAINEES
- 4 FROM DIFFERENT INSTITUTIONS TO SORT OF BROADEN THE
- 5 TRAINEE'S EXPOSURE TO THE WEALTH OF SCIENTIFIC EXPERTISE
- 6 WE HAVE IN THIS STATE. SORT OF ALONG THE MARQUIS
- 7 SCHOLARS MEETING MODEL, BUT MAYBE NOT THAT ELABORATE, BUT
- 8 I'M SURE MANY OF US WOULD BE WILLING TO DO THIS, AND IT
- 9 MIGHT JUST ADD SOME MORE DEPTH TO THE EXPERIENCE FOR THE
- 10 SCHOLARS.
- DR. MURPHY: EXCELLENT.
- 12 CHAIRMAN KLEIN: DUANE ROTH.
- MR. ROTH: SO I REALLY APPRECIATE THE COMMENTS
- 14 YOU ALL MADE ABOUT THE NEED TO GET THE STAFF THAT'S
- 15 NECESSARY TO KEEP THE MOMENTUM GOING. AND I REALLY WANT
- 16 TO ENCOURAGE THAT. I THINK, YOU KNOW, WE'VE BEEN THROUGH
- 17 SO MUCH WITH THE LITIGATION AND THE DELAYS, AND NOW THAT
- 18 WE'RE THERE, I HOPE WE DON'T LET INTERNAL LACK OF
- 19 RESOURCES, WHETHER IT BE REVIEWERS OR STAFFERS, SLOW US
- 20 DOWN. AND EVEN THE TEMPTATION TO WAIT TILL THE NEW
- 21 PRESIDENT ARRIVES, I THINK, WOULD BE A MISTAKE. WE
- 22 SHOULD KEEP MOVING AND MAKE SURE THAT WE AREN'T THE
- 23 LIMITING STEP TO GET THE MONEY AND GRANTS ISSUED.
- DR. MURPHY: AGREED.
- CHAIRMAN KLEIN: OKAY. I'D ALSO LIKE TO

1	RECOUNT	Α	SHORT	STORY	FOR	ALL	OF	THOSE	ON	THE	BOARD	AND

- 2 THOSE WHO HAVE SAT THROUGH PEER REVIEW SESSIONS AND
- 3 WATCHED DR. CHIU LEAD THOSE REVIEW SESSIONS SEAMLESSLY.
- 4 THERE'S SOME BACKGROUND THAT YOU SHOULD KNOW BECAUSE
- 5 WE'VE ACCOMPLISHED A TREMENDOUS AMOUNT EVEN UNDER THE
- 6 THREAT OF LITIGATION HERE. IT TOOK A REAL DRIVING
- 7 INSPIRATION TO GET THOSE PEER REVIEW SESSIONS COMPLETED
- 8 AND THE SCIENCE MOVING FORWARD.
- 9 SO WE WERE -- DR. MURPHY AND I WERE AT A DINNER
- 10 WITH DR. TROUNSON, AND DR. CHIU WAS THERE, AND WE
- 11 RECOUNTED THAT DURING THE CAMPAIGN FOR PROPOSITION 71,
- 12 WHEN OTHERS THOUGHT THAT IT MIGHT NOT PASS, THERE WAS A
- 13 GREAT INSPIRED SCIENTIST AT THE NIH, DR. ARLENE CHIU.
- 14 AND SHE CALLED THE CAMPAIGN OFFICE DURING THE CAMPAIGN
- 15 AND SHE SAID, "YOU KNOW, WHEN THIS PASSES," NOT IF, "WHEN
- 16 THIS PASSES, YOU SHOULD HIRE ME. I CAN GET IT DONE."
- 17 (APPLAUSE.)
- 18 CHAIRMAN KLEIN: SO HER SPIRIT AND HER
- 19 COMMITMENT, I THINK, ARE ALWAYS THERE. SHE WAS PART OF
- 20 THE BIRTH OF THIS ORGANIZATION AND IS COMMITTED TO
- 21 CONTINUE TO ADVISE US AS WE MATURE. BUT IT'S THAT
- 22 DRIVING SPIRIT EVEN WHEN OTHERS WERE DOUBTING THE
- 23 POSSIBILITY THAT HAS MADE THIS SUCH AN ENERGETIC DYNAMIC
- 24 AND DELIVERING INSTITUTION.
- I BELIEVE THAT WE HAVE A PUBLIC COMMENT AT THIS

1	TIME. JOHN SIMPSON.
2	MR. SIMPSON: JOHN SIMPSON FROM THE FOUNDATION
3	FOR TAXPAYER AND CONSUMER RIGHTS. THREE VERY QUICK
4	ITEMS, TWO OF THEM ARE MAYBE HOUSEKEEPING. YOU MAY HAVE
5	NOTED THAT DON REED IS NOT HERE, AND HE ASKED ME TO NOTE
6	THAT, IN CASE YOU HADN'T NOTED IT, BECAUSE EVEN THOUGH
7	HE'S AN AMAZING FELLOW AND TREMENDOUSLY COMMITTED, HE
8	CANNOT BE IN TWO PLACES AT ONCE. HE IS AT THE STEM CELL
9	SUMMIT IN BOSTON AND SENDS HIS REGRETS, AND HE ASKED ME
10	TO PLEASE DO THAT.
11	THE SECOND THING, I ONCE SPENT A YEAR IN
12	IRELAND TEACHING AND LEARNED THAT ENGLISH IS SPOKEN IN
13	MANY DIFFERENT WAYS AROUND THE WORLD. AND I HAVE
14	ACQUIRED FOR THE STAFF A WORD BOOK OF AUSTRALIAN IDIOM,
15	AUSSIE SLANG, NO WORRIES. SHE'S APPLES. AND I THINK
16	THIS MIGHT HELP AS YOU DEAL WITH ALAN TROUNSON. SO I
17	GIVE THIS TO THE PRESIDENT, AND THE ICOC CAN PERHAPS DRAW
18	ON THAT RESOURCE.
19	(APPLAUSE.)
20	MR. SIMPSON: THE SERIOUS POINT I WANTED TO
21	MAKE ON THE AWARDS THAT WERE ANNOUNCED IN THE REVIEW. IT
22	SEEMS TO ME THAT THE FACT THAT 33 ARE STILL PENDING IS A

VERY GOOD THING IN A SENSE BECAUSE IT SHOWS THAT THE

24 PROCEDURES ARE BEING FOLLOWED AND YOU ARE VETTING THINGS

25 VERY CAREFULLY, AND THAT'S VERY IMPORTANT. BUT I WOULD

- 1 ASK A FURTHER QUESTION ABOUT THOSE, AND MAYBE IT'S HERE
- 2 AND I DIDN'T HEAR IT. ARE THERE ANY THAT YOU HAVE
- 3 CONCLUDED WILL NOT PASS MUSTER AND WILL ULTIMATELY BE
- 4 TURNED DOWN?
- 5 CHAIRMAN KLEIN: WE ACTUALLY HAVE AN
- 6 ADMINISTRATIVE ITEM THAT'S GOING TO COME UP ON, AND THERE
- 7 WILL BE A REPORT ON THAT VERY SPECIFICALLY. SO WHEN WE
- 8 GET TO THAT REPORT, WE'RE GOING TO COVER IT.
- 9 MR. SIMPSON: THAT WILL BE VERY APPROPRIATE.
- 10 THANK YOU.
- 11 CHAIRMAN KLEIN: THANK YOU. SO AT THIS TIME
- 12 I'D LIKE TO ASK DR. MURPHY IF IT'S APPROPRIATE THAT WE
- 13 CAN MOVE TO AGENDA ITEM 7, CONSIDERATION OF AMENDMENTS TO
- 14 GRANTS ADMINISTRATION POLICY REGARDING FACILITIES. THIS
- 15 ITEM IS IN TWO PARTS, BOTH FOUND BEHIND TAB 7 IN YOUR
- 16 BINDERS. PART A IS THE FACILITIES PORTION OF THE GAP
- 17 RECOMMENDED BY THE FACILITIES WORKING GROUP THAT WILL BE
- 18 PRESENTED LATER BY RICK KELLER, AND PART B WILL BE
- 19 PRESENTED BY DR. MURPHY. DR. MURPHY, IT'S YOUR PLEASURE.
- DR. MURPHY: MR. CHAIRMAN, THAT IS THE
- 21 INTRODUCTION I WAS GOING TO GIVE. SO LET ME INTRODUCE TO
- 22 YOU RICK KELLER, WHO HAS BEEN RESPONSIBLE FOR THE ONGOING
- 23 ACTIVITIES OF THE FACILITIES WORKING GROUP.
- DR. POMEROY: BOB, IN TERMS OF CLARIFICATION,
- 25 IS THIS THE DISCUSSION ITEM FROM WHICH MANY OF US HAVE TO

1	RECUSE	OURSELVES?
	NECOSE	CONSELVES.

- 2 CHAIRMAN KLEIN: LET ME HAVE COUNSEL ADDRESS
- 3 THIS. FIRST TAMAR PACHTER AND THEN IF I COULD ALSO HAVE
- 4 JAMES HARRISON MAKE A COMMENT.
- 5 MS. PACHTER: DR. POMEROY, THIS ITEM IS BEING
- 6 PRESENTED IN TWO PARTS, 7 A AND 7 B. THE MEMBERS OF THE
- 7 ICOC HAVE NO KNOWN CONFLICTS OF INTEREST WITH RESPECT TO
- 8 ITEM 7 A; HOWEVER, WE HAVE IDENTIFIED POTENTIAL CONFLICTS
- 9 OF INTEREST WITH RESPECT TO ITEM 7 B, WHICH WILL AFFECT,
- 10 MAY AFFECT, EXISTING CONTRACTS AT INSTITUTIONS WITH WHICH
- 11 SOME OF YOU ARE AFFILIATED.
- 12 SO WITH RESPECT TO ITEM A, THERE IS NO
- 13 RESTRICTION THAT WE ARE AWARE OF ON DISCUSSION OR VOTING.
- 14 THERE ARE RESTRICTIONS WITH RESPECT TO ITEM 7 B.
- 15 CHAIRMAN KLEIN: AND MR. HARRISON, COULD YOU
- 16 PUT THIS 7 B DISCUSSION IN CONTEXT?
- 17 MR. HARRISON: SURE. FIRST OF ALL, AS YOU
- 18 KNOW, THERE IS AN EXCEPTION IN PROPOSITION 71 THAT
- 19 PERMITS THE BOARD TO PARTICIPATE IN DECISIONS WITH
- 20 RESPECT TO STANDARDS OF GENERAL APPLICATION WITHOUT
- 21 RESPECT TO POTENTIAL CONFLICTS OF INTEREST. AND AS YOU
- 22 ALSO KNOW, AND AS THE COURT OF APPEAL RECOGNIZED, ONE OF
- THE REASONS THAT PROPOSITION 71 WAS STRUCTURED AS IT WAS
- 24 WAS IN ORDER TO DRAW UPON THE EXPERTISE OF PEOPLE WHO
- 25 COME FROM INSTITUTIONS THAT HAVE MANAGED SCIENTIFIC AND

1	MEDICAL GRANTS AND THAT ARE EXPERIENCED IN THIS AREA.
2	SO IN THE PAST YOU HAVE PARTICIPATED IN ALL
3	DECISIONS WITH RESPECT TO STANDARDS ON A PROSPECTIVE
4	BASIS. HERE, WITH RESPECT TO ITEM 7 B, THERE ARE A
5	COUPLE OF DISTINCTIONS. ONE IS THAT LETTERS OF INTENT
6	HAVE ALREADY BEEN SUBMITTED FOR THE MAJOR FACILITIES
7	GRANTS. THE SECOND IS THAT THIS PARTICULAR DECISION
8	WOULD AFFECT EXISTING GRANTS.
9	SO FOR THOSE OF YOU WHO COME FROM INSTITUTIONS
10	THAT HAVE ALREADY RECEIVED RESEARCH GRANT AWARDS, THIS
11	DECISION MAY HAVE AN IMPACT ON THOSE AWARDS. SO
12	NOTWITHSTANDING THE EXCEPTION, WE BELIEVE THAT IN THIS
13	PARTICULAR CIRCUMSTANCE THAT IT WOULD BE ADVISABLE FOR
14	THOSE MEMBERS WHO COME FROM INSTITUTIONS WHO HAVE
15	SUBMITTED LOI'S OR THAT INTEND TO APPLY FOR A MAJOR
16	FACILITIES GRANT AND THAT HAVE EXISTING RESEARCH GRANTS
17	RECUSE THEMSELVES FROM PARTICIPATING IN THE DECISION.
18	AND THAT'S OUT OF AN ABUNDANCE OF CAUTION, AGAIN, TO
19	MAINTAIN PUBLIC TRUST AND TRANSPARENCY.
20	CHAIRMAN KLEIN: AND THIS ADVICE IS BASED ON
21	THIS VERY SPECIFIC FACT. IT'S NOT MEANT TO ESTABLISH ANY
22	BROAD PRECEDENT. IT IS NARROWLY LIMITED TO THESE VERY
23	SPECIFIC FACTS, BUT THANK YOU. DR. POMEROY. DR. PIZZO.
24	DR. PIZZO:NOT BEING INVOLVED IN THE
25	DISCUSSION, I UNDERSTAND THE WHOLE, BUT NOT THE

1	DISCUSSION EITHER?
2	MR. HARRISON: THAT'S CORRECT. IT APPLIES TO
3	BOTH.
4	CHAIRMAN KLEIN: ON PART B.
5	DR. BRYANT: WILL THAT LEAVE A QUORUM?
6	CHAIRMAN KLEIN: YES. IN WRITING THE
7	INITIATIVE, THE RULES WERE SET UP SO THAT THE QUORUM
8	AUTOMATICALLY ADJUSTS SO THAT WHENEVER INDIVIDUALS ARE
9	RECUSED, THE QUORUM ADJUSTS FOR EXCLUDING THOSE THAT ARE
10	RECUSED. THERE WERE GREAT LEGAL MINDS THAT WERE PROVIDED
11	AS SUPPORT FOR THAT. BUT I WILL TELL YOU THAT IT'S ALSO
12	IN AN AREA WE HAD SOME CONCERN BECAUSE THERE WERE
13	CANDIDATES RUNNING IN THAT ELECTION WHO WERE NOT
14	SUPPORTIVE OF STEM CELL RESEARCH. IT WOULD ADJUST IF
15	THERE IS AT ANY TIME A CONSTITUTIONAL OFFICER WHO DOES
16	NOT MAKE THE APPOINTMENTS. IT ALSO THEN ADJUSTS FOR
17	VACANT SEATS. RICK KELLER.
18	MR. KELLER: GOOD MORNING. TODAY YOU'RE GOING
19	TO CONSIDER THE GRANTS ADMINISTRATION POLICY OR GAP WHICH
20	PROVIDES GUIDANCE TO APPLICANTS AND GRANTEES ABOUT THE
21	POLICIES AND RULES THAT WILL APPLY TO CIRM GRANTS. YOU
22	HAVE PREVIOUSLY APPROVED SEVEN CHAPTERS WITHIN THE GAP,
23	AND TODAY YOU WILL BE CONSIDERING, AS MENTIONED, CHAPTER

PRESENTING THE REVISIONS TO CHAPTER 5.

25

8 OF THE MAJOR FACILITIES, AND LATER DR. MURPHY WILL BE

1	SO WHERE DO THESE RULES ORIGINATE FROM? WELL,
2	FIRST OF ALL, THERE'S BASICALLY THREE AREAS. THERE ARE
3	PROVISIONS WITHIN PROPOSITION 71 THAT ARE SPECIFIC
4	REQUIREMENTS THAT WE MUST INCORPORATE INTO THE
5	ADMINISTRATIVE LAW FOR APPLICANTS AND GRANTEES TO BE
6	AWARE OF.
7	SECONDLY, YOU HAVE COMMISSIONED OR PROPOSITION
8	71, RATHER, COMMISSIONS THE FACILITIES WORKING GROUP TO
9	"MAKE RECOMMENDATIONS TO THE ICOC ON INTERIM AND FINAL
10	CRITERIA REQUIREMENTS AND STANDARDS FOR APPLICATIONS FOR
11	AND THE AWARDING OF GRANTS AND LOANS FOR BUILDINGS,
12	BUILDING LEASES, AND CAPITAL EQUIPMENT." SO THIS PUTS
13	THE FACILITIES WORKING GROUP IN A POSITION OF
14	RECOMMENDING TO YOU SPECIFIC POLICIES THAT ARE
15	DISCRETIONARY TO YOU.
16	AND THEN THIRDLY, THERE IS ALSO THE STAFF OR
17	CIRM PRESIDENT'S RECOMMENDATIONS AS WILL BE PRESENTED
18	LATER BY DR. MURPHY.
19	LET ME GO THROUGH THE SPECIFIC AREAS HERE THAT
20	I JUST REVIEWED. WITH RESPECT TO THE PROVISIONS APPLYING
21	TO PROPOSITION 71, YOU WILL SEE THAT IT CALLS FOR
22	SPECIFIC REQUIREMENTS RELATED TO BEING NONPROFIT, THAT A
23	GOAL BE ESTABLISHED FOR CALIFORNIA SUPPLIERS THAT WORKERS
24	BE PAID PREVAILING WAGE, THAT FACILITIES HAVE A

20-PERCENT MATCHING REQUIREMENT FROM THE INSTITUTION, AND

25

	1	THAT	THERE	BE	A P	RIORITY	CONSIDERATION	FOR	PROJECTS	THA
--	---	------	-------	----	-----	---------	---------------	-----	----------	-----

- 2 ARE COMPLETED WITHIN TWO YEARS.
- THE RECOMMENDATIONS FROM YOUR FACILITIES
- 4 WORKING GROUP, WHICH MET YESTERDAY, IS WHAT I REVIEW NOW.
- I WANT TO MAKE SURE THAT YOU'RE AWARE OF THE FACT THAT,
- 6 IN ADDITION TO THE MATERIAL THAT YOU RECEIVED IN YOUR
- 7 PACKET IN SECTION 7, THERE IS ALSO AN ADDENDUM REFLECTING
- 8 CHANGES THAT WERE ADOPTED YESTERDAY BY THE FACILITIES
- 9 WORKING GROUP IN THE FRONT LEAF OF THE BINDER AND SHOULD
- 10 BE TITLED AS SUCH. SO AGENDA ITEM 7 A AMENDMENT.
- 11 THE REQUIREMENTS THAT HAVE BEEN ESTABLISHED BY
- 12 THE -- RECOMMENDED, RATHER, BY THE FACILITIES WORKING
- 13 GROUP CONSIST OF MATCHING FUNDS BEING LIMITED TO CASH
- 14 CONTRIBUTIONS TO THE PROJECT. AND THIS LEADS TO REALLY A
- 15 CONCEPT OF PROJECT LEVERAGE, AND I'LL GET INTO MORE
- 16 DETAIL ABOUT PROJECT LEVERAGE LATER. BUT IT BASICALLY IS
- 17 UNDER -- IT ESTABLISHES THE NOTION THAT ALL THE
- 18 CONTRIBUTIONS TO THE PROJECT THAT ARE BEYOND THE
- 19 20-PERCENT CASH MATCH WILL BE CONSIDERED PROJECT LEVERAGE
- 20 AND BE CONSIDERED IN THE EVALUATION OF PROPOSALS.
- THERE'S ALSO A PROVISION THAT ESTABLISHES SPACE
- 22 WILL BE USED FOR STEM CELL RESEARCH FOR AT LEAST TEN
- 23 YEARS, AND THIS IS SECTION F. IT WAS MODIFIED FOR
- 24 CLARITY AND TO GIVE SOME FLEXIBILITY IN THE VERSION THAT
- 25 WAS ADOPTED LAST NIGHT.

1

1	IN ADDITION, BY VIRTUE OF THE SUBSTANTIAL
2	INVESTMENT BY THE STATE OF CALIFORNIA IN THESE
3	FACILITIES, THE FACILITIES WORKING GROUP RECOMMENDS A
4	PROVISION TO ENSURE THAT CIRM RECEIVES RECOGNITION IN THE
5	NAMING OF THESE FACILITIES AND IS ABLE TO PARTICIPATE IN
6	CEREMONIES CONCERNING THESE FACILITIES. AND THAT ALSO IS
7	A SUBJECT OF SECTION F REVISIONS.
8	SOME OF THE OTHER ISSUES RECOMMENDED BY THE
9	FACILITIES WORKING GROUP, IF THE TWO-YEAR PREFERENCE THAT
10	WAS NOTED IN PROP 71 IS REQUESTED, A PRIORITY
11	CONSIDERATION, THERE WILL HAVE TO BE SOME PENALTY
12	ASSESSED IN THE EVENT THAT COMPLETION IS NOT ACCOMPLISHED
13	AS STATED IN THE APPLICATION. SO WE HAVE INCLUDED A
14	PROVISION TO DEAL WITH THAT.
15	AND THEN THERE ARE ISSUES ABOUT HOW PAYMENTS
16	WILL BE MADE TO THE INDIVIDUAL GRANTEES, AND THERE'S
17	TECHNICAL AND FINANCIAL ISSUES ASSOCIATED WITH OUR
18	ABILITY TO REQUEST PROGRESS REPORTS AND TO CONDUCT
19	POSTAUDITS.
20	ONCE THE GAP REVISIONS ARE APPROVED BY THE
21	ICOC, THEY ARE ADOPTED INTO CALIFORNIA CODE OF
22	REGULATIONS. BEFORE I GO TO THE FINAL, I WANT TO MAKE
23	SURE THAT I SAID I WAS GOING TO REVIEW SOMEWHAT THE
24	CALCULATION OF LEVERAGE. WE WANTED TO MAKE SURE YOU HAD
25	A FIRM UNDERSTANDING OF THIS.

1	SO JUST IN TWO SLIDES I WANT TO EXPLAIN A
2	THEORETICAL EXAMPLE. IN THIS CASE, IF THE CONSTRUCTION
3	COSTS WERE TO BE \$65 MILLION AND FUNDS THAT WERE BUDGETED
4	FOR FEES AND ADMINISTRATION 11, EQUIPMENT 14 MILLION WITH
5	A CONTINGENCY OF 5, THERE WOULD BE A TOTAL PROJECT COST
6	OF \$95 MILLION. WE WOULD THEN PROCEED TO CALCULATE THE
7	LEVERAGE ASSOCIATED WITH THIS BUDGET FOR THE FACILITY.
8	AND THAT CALCULATION WOULD TAKE THE 95 MILLION AND SAY
9	PRESUMING THAT CIRM WAS FUNDING 40 MILLION OF THE 95,
LO	THERE WOULD HAVE TO BE MATCHING FUNDS OF 8 MILLION,
L1	LEAVING LEVERAGE FUNDS OF 47 MILLION.
L2	THERE'S A PROVISION RECOMMENDED BY THE
L3	FACILITIES WORKING GROUP THAT SAYS THAT THE AMOUNT OF
L4	LEVERAGE, HOWEVER, SHOULD NOT INCLUDE AN EXCESSIVE AMOUNT
L5	FOR DESIGN FEES WHERE INSTITUTIONS SPEND WHERE IN THEIR
L6	JUDGMENT THEY MAY BE SPENDING TOO MUCH MONEY ON THE
L7	ADMINISTRATION OR DESIGN FEES OF A FACILITY. SO THEY
L8	HAVE LIMITED OR RECOMMENDED IN THE PROVISIONS FOR YOU TO
L9	APPROVE THAT THE ADMINISTRATIVE FEES BE LIMITED TO 10
20	PERCENT OF THE CONSTRUCTION AMOUNT, EXCLUDING AMOUNTS
21	BUDGETED FOR STRUCTURAL ENGINEERING OR SEISMIC SAFETY
22	CONSIDERATIONS IN THE FEES.
23	SO IN THIS LITTLE CALCULATION, THE FEES ARE 11,
24	I'M ASSUMING THAT THE EXCLUDED AMOUNT IS 2 MILLION,
25	LEAVING THE BUDGET PROPOSAL AT 9 MILLION. WHEN WE LOOK

- 1 BACK AT THE CONSTRUCTION COSTS OF 65 MILLION, 10 PERCENT
- 2 OF THAT WOULD ALLOW 6.5 MILLION, SO THERE'S AN ADJUSTMENT
- 3 HERE IN THE LEVERAGE CALCULATION TO SAY THAT 2.5 MILLION
- 4 OF BUDGETED FEES AND ADMINISTRATION WILL NOT BE
- 5 CONSIDERED, SO THE NET LEVERAGE IS 44.5 MILLION, WHICH IS
- 6 ESSENTIALLY THAT WHICH CIRM IS RECOGNIZING OVER AND ABOVE
- 7 THE MATCHING FUNDS.
- 8 IF WE EXPRESS THAT AS A RATIO BETWEEN THE
- 9 AMOUNT OF FUNDS PROVIDED IN THE LEVERAGE BY THE APPLICANT
- 10 AND THE AMOUNT OF FUNDS PROVIDED BY CIRM, THEN THAT WOULD
- 11 BE A 1.11-TO-1 RATIO HERE. SO IT JUST CAME OUT THAT WAY
- 12 IN THE EXAMPLE.
- 13 CHAIRMAN KLEIN: AND, RICK, JUST SO EVERYONE
- 14 UNDERSTANDS, FOR THE BENEFIT OF CALIFORNIA TAXPAYERS AND
- 15 PATIENTS, OUR GROSS LEVERAGE IS REALLY APPROXIMATELY 130
- 16 PERCENT BECAUSE YOU WOULD ADD BACK THE MATCHING FUNDS AS
- 17 WELL TO GET TO GROSS LEVERAGE. SO NET LEVERAGE IS
- 18 CONSIDERED AFTER THE MANDATORY 20 PERCENT, AND THE GROSS
- 19 LEVERAGE, YOU WOULD ADD IT BACK.
- DR. LEVEY: CAN WE GET THIS ON A PIECE OF PAPER
- 21 SO WE CAN MAYBE TRY TO RATIONALIZE THROUGH ALL OF THIS?
- 22 NOT THAT IT --
- MR. KELLER: THIS PARTICULAR EXAMPLE? ALL OF
- 24 OUR SLIDE DECKS ARE POSTED ON THE INTERNET AFTER THE
- 25 MEETING, AND SO WE WILL MAKE SURE THAT THAT'S AVAILABLE

	1	TO ANYONE	WHO WANTS	TO TAKE A	LOOK AT IT.	AND WE HAVE
--	---	-----------	-----------	-----------	-------------	-------------

- 2 SHORT EXAMPLE OF IT IN THE APPENDIX.
- 3 DR. PIZZO: MR. CHAIRMAN.
- 4 CHAIRMAN KLEIN: YES, DR. PIZZO.
- DR. PIZZO: THANK YOU FOR THAT PRESENTATION. I
- 6 HAVE THREE OR SO QUESTIONS THAT ARE JUST CLARIFICATIONS,
- 7 I HOPE. THE FIRST IS WITH REGARD TO MATCHING FUNDS,
- 8 WHICH I THINK SOME DEFINITION ABOUT WOULD BE HELPFUL.
- 9 I'M INTERPRETING THIS AS EITHER FUNDS THAT COME FROM
- 10 PHILANTHROPY OR FROM INSTITUTIONAL MATCH IN SOME WAYS.
- 11 SO YOU'RE TALKING ABOUT INSTITUTIONAL RESOURCES. IS THAT
- 12 CORRECT?
- MR. KELLER: YES. THE MATCHING FUNDS ARE
- 14 INTENDED TO BE A CASH CONTRIBUTION TO THE PROJECT.
- DR. PIZZO: SO THEN I WANT TO FURTHER, THEN,
- 16 CLARIFY THE ISSUE OF THE CASH CONTRIBUTION. AND, AGAIN,
- 17 THIS MAY BE JUST A NUANCE QUESTION. THINKING ABOUT HOW
- 18 VARIOUS INSTITUTIONS DO THIS, I'LL SPEAK SPECIFICALLY,
- 19 WHEN ONE GETS A LARGE CAPITAL GIFT, FOR EXAMPLE, IT'S
- 20 OFTEN PAID AS A PLEDGE OVER A NUMBER OF YEARS. SO WHEN
- 21 WE'LL THINK ABOUT EITHER DOES THE PLEDGE COUNT OR IS IT A
- 22 MATTER OF BACKSTOPPING THE PLEDGE THAT YOU'RE LOOKING AT?
- 23 IS THAT --
- MR. KELLER: OUR APPROACH TO THIS IS TO REQUEST
- 25 AS PART OF THE APPLICATION A FUNDS FLOW STATEMENT OR

1

DRAW-DOWN SCHEDULE.

2	DR. PIZZO: OKAY.
3	MR. KELLER: SO THAT WE CAN UNDERSTAND THE FLOW
4	OF FUNDS, BUT OUR PRESUMPTION IS THAT
5	DR. PIZZO: BECAUSE THAT'S HOW WE WOULD TAKE
6	CARE OF IT INSTITUTIONALLY.
7	THE SECOND IS WITH REGARD TO THE ISSUE OF
8	CEREMONIES IN NAMING OPPORTUNITIES. OBVIOUSLY THIS IS
9	VERY IMPORTANT, AND I THINK VERY APPROPRIATE FOR THERE TO
10	BE RECOGNITION THESE FACILITIES. BUT I WANT TO ALSO
11	UNDERSTAND A LITTLE BIT FURTHER WHAT THAT MEANS IN TERMS
12	OF HOW WE HANDLE NAMING OPPORTUNITIES. SO THAT'S GOING
13	TO VARY DEPENDING UPON THE INSTITUTION.
14	IN OUR OWN INSTITUTION, NAMING OPPORTUNITIES
15	ARE USUALLY SET AT ABOUT HALF THE COST OF THE BUILDING.
16	SO, YOU KNOW, IN THIS EXAMPLE IT WOULD BE, YOU KNOW,
17	POTENTIALLY A \$50 MILLION OPPORTUNITY, SO TO SPEAK.
18	WE'RE OUT RAISING MONEY FOR BUILDINGS, ALL OF
19	US IN DIFFERENT WAYS, AND WE'RE SEEKING OFTEN NAMING
20	DONORS FOR THEM. SO I THINK UNDERSTANDING HOW THAT'S
21	GOING TO APPLY SO THAT WE CAN MERGE THESE IN A WAY THAT
22	WILL ALLOW US TO GET THESE NAMING GIFTS, BUT ALSO PROVIDE
23	VALUE TO THE STATE FOR ITS CONTRIBUTIONS WILL BE
24	IMPORTANT AS WELL. HAS THE COMMITTEE THOUGHT THROUGH
25	THAT ISSUE AS WELL?

- 1 MR. SERRANO-SEWELL: PHIL, DID YOU HAVE A
- 2 CHANCE TO LOOK AT THE -- THERE WAS A DISCUSSION LAST
- 3 NIGHT ON THAT VERY ISSUE.
- 4 DR. PIZZO: OKAY.
- 5 MR. SERRANO-SEWELL: AND THIS LANGUAGE FOR
- 6 SECTION G 2 HAD TO BE MASSAGED A LITTLE BIT.
- 7 DR. PIZZO: OKAY. LET ME JUST --
- 8 MR. SERRANO-SEWELL: IT WAS AN ISSUE THAT DUANE
- 9 ROTH AND OTHER MEMBERS OF THE PUBLIC HAD RAISED, AND LAST
- 10 NIGHT MR. KELLER AND DR. MURPHY WORKED ON THIS REVISED
- 11 LANGUAGE. AND I HOPE IT ADDRESSES THE BALANCE THAT NEEDS
- 12 TO HAPPEN BETWEEN THE CIRM CONTRIBUTION AND ANY
- 13 THIRD-PARTY DONORS YOU MIGHT GET. I HOPE THIS CAPTURES,
- 14 YOU KNOW, THE BALANCING THAT NEEDS TO HAPPEN.
- DR. PIZZO: IT'S A DIFFICULT BALANCING ACT, AS
- 16 YOU KNOW.
- 17 MR. SERRANO-SEWELL: I DON'T THINK ANYONE
- 18 INTENDS TO INTERFERE WITH AN INSTITUTION'S OBJECTIVES IN
- 19 RAISING MONEY AND THE SORT OF THINGS THAT ANY GIVEN
- 20 INSTITUTION NEEDS TO DO, BUT I THINK COMMON SENSE SHOULD
- 21 PREVAIL IN THIS ONE, YOU KNOW.
- DR. PIZZO: RIGHT. RIGHT.
- MR. SERRANO-SEWELL: AND IF THERE ARE ANY
- 24 QUESTIONS, AN INSTITUTION CAN SUBMIT IT TO THE
- 25 PRESIDENT'S OFFICE --

1	DR. PIZZO: THAT'S FINE. AND I AGREE WITH
2	THAT.
3	MR. SERRANO-SEWELL: TO GET IT RESOLVED.
4	DR. PIZZO: SO I HAVE ONE LAST QUESTION, THEN
5	I'LL PASS THE MICROPHONE, WHICH IS WITH REGARD TO THE
6	TIME TO COMPLETION. AND MAYBE THIS IS COVERED BY THE
7	STATEMENT THAT IT WOULD HAVE A PRESIDENTIAL REVIEW.
8	CLEARLY WE ALL WANT TO GET THESE FACILITIES COMPLETED
9	RAPIDLY AND ON TIME, BUT THERE IS A SCALING EFFECT AS
10	WELL, COMPLETING A SMALL FACILITY AS COMPARED TO A VERY
11	LARGE ONE, YOU KNOW, BY DEFINITION MAY TAKE MORE TIME.
12	AND THE SECOND IS I'M A LITTLE CONCERNED ABOUT
13	THE RECOMMENDATION THAT WE USE EXPEDITED SUPPLY LINKS AND
14	THE LIKE BECAUSE THOSE ARE GOING TO BE MORE EXPENSIVE.
15	AND WE ALL RECOGNIZE HOW HARD IT IS TO BRING RESOURCES TO
16	COMPLETING A FACILITY, AND I THINK WE WANT TO BALANCE THE
17	COST, YOU KNOW, OVER THE TOTAL COST VERSUS THE WAY WE
18	GENERATE THE FUNDS TO PAY FOR THOSE TOTAL COSTS.
19	SO CLEARLY OUR GOAL IS THE SAME AS YOURS. WE
20	WANT THESE TO BE UP AS RAPIDLY AS POSSIBLE. I'D HATE TO
21	SEE AN ADDITIONAL ESCALATOR GO INTO THE TOTAL COST OF THE
22	BUILDINGS BECAUSE WE WERE USING A LOT OF OVERTIME AND
23	RELATED ACTIVITIES BECAUSE THAT JUST MAKES THE FUNDING OF
24	THE PROJECT ALL THE MORE DIFFICULT IN THE LONG RUN.
25	MR. KELLER: MY RESPONSE IS I THINK THE TWO ARE

- 1 VERY INTERRELATED, BUT I THINK THE GOVERNING ISSUE HERE
- 2 IS THAT PROPOSITION 71 ESTABLISHES A RESPONSIBILITY THAT
- 3 THERE IS AN URGENCY, AND THAT PROJECTS THAT WILL BE
- 4 COMPLETED WITHIN TWO YEARS WILL RECEIVE PRIORITY. NOW,
- 5 THAT DOESN'T MEAN THAT OTHERS CAN'T COMPETE BECAUSE, AS
- 6 YOU SAY, I THINK IT'S IMPORTANT TO STRIKE A BALANCE
- 7 BETWEEN THAT WHICH CAN BE ACHIEVED AND THE COST
- 8 ASSOCIATED WITH THAT ON A REASONABLE BASIS OR
- 9 INSTITUTIONAL BASIS.
- 10 AND SO I VERY MUCH THINK IT DEPENDS UPON THE
- 11 APPLICANT TO TAKE RESPONSIBILITY FOR WHAT THAT BALANCE IS
- 12 RATHER THAN CIRM BASICALLY MANDATING IT. SO I AGREE WITH
- 13 YOUR PHILOSOPHY. I THINK IT'S PERMITTED WITHIN THE
- 14 LANGUAGE.
- DR. PIZZO: THE LANGUAGE THAT I SEE, AT LEAST
- 16 ON -- IN THE RELEVANT SECTION IS AT THE COMPLETION OF THE
- 17 PROJECT, THE PRESIDENT OF THE CIRM WILL REVIEW ANY DELAYS
- 18 AND MAY ASSESS PENALTY IF THE PRESIDENT IN HIS OR HER
- 19 SOLE DISCRETION DETERMINES THAT THE GRANTEE DID NOT USE
- 20 BEST EFFORTS TO COMPLETE THE PROJECT, ETC., ETC. SO, YOU
- 21 KNOW, IT SEEMS TO ME THAT THAT OFFERS AT LEAST SOME
- 22 SUBJECTIVE EVALUATION BECAUSE WE WANT THESE THINGS TO GO
- 23 AS RAPIDLY AS POSSIBLE, BUT ANYONE, ALL OF US HAVE BEEN
- 24 INVOLVED IN BUILDING PROJECTS AND KNOW THE LIABILITIES
- 25 ASSOCIATED WITH THAT.

1	CHAIRMAN KLEIN: THIS SPECIFIC QUESTION WAS
2	RAISED IN THE FACILITIES COMMITTEE, AND DAVID, AS THE
3	VICE CHAIR, IF YOU WILL PLEASE CORRECT IF YOU THINK THIS
4	IS NOT A FULL SUMMARY, FULL, BUT TERSE SUMMARY OF THOSE
5	THOUGHTS. ONE IS THAT THERE IS A PRIORITY FOR BUILDINGS
6	TO BE COMPLETED WITHIN TWO YEARS. IT'S NOT TWO YEARS
7	FROM THE DATE THE BOARD ACTS. IT'S TWO YEARS FROM NOTICE
8	OF GRANT AWARD. SO IF THE BOARD WERE TO ACT IN APRIL,
9	FOR EXAMPLE, AND THE GRANT AWARD WERE JULY, IT'S TWO
10	YEARS FROM THAT CLOCK.
11	NOW, IN THE APPLICATION THERE'S A REQUEST TO
12	SUBMIT A CRITICAL PATH CHART. IF, IN FACT, THE
13	INSTITUTION SUBMITS AND SAYS TWO YEARS FROM THE NOTICE OF
14	GRANT AWARD, ABOUT TWO YEARS AND FOUR MONTHS FROM THE
15	DATE OF THE BOARD APPROVAL, WE'RE GOING TO BE COMPLETE,
16	SO WE WANT A PRIORITY AND WE WANT POINTS FOR THAT, THEN
17	THEY'RE GOING TO BE GENERALLY HELD FORCE MAJEURE
18	EXCEPTION, ETC., FOR CLAIMING THOSE POINTS. AND THAT'S
19	THE CONTEXT.
20	IF THEY SAY IT'S GOING TO TAKE US THREE YEARS,
21	THEY'LL BE HELD ACCOUNTABLE FOR THREE YEARS. SO THEY'RE
22	HELD ACCOUNTABLE FOR THEIR REPRESENTATIONS, KNOWING THAT
23	THERE'S A PRIORITY FOR THOSE THAT ARE TWO YEARS FROM
24	GRANT AWARD.
25	DR. PIZZO: BUT I'M THINKING I THINK THAT

60

1	THAT'S	HELPFUL,	RUT	YOU	KNOW	TF	YOU'	'RF	WORKTNG	ΟN	Δ
_	IIIAI 3	HILLFFUL,	BUI,	100	INIOW .	T L	100	Γ	MOUNTING	OIN	$\overline{}$

- 2 BUILDING THAT IS SMALLER VERSUS VERY LARGE, YOU KNOW,
- 3 THAT HAS AN IMPACT UPON HOW FAST YOU CAN GET IT DONE. SO
- 4 GOING FROM ARCHITECTURAL DESIGN, I MEAN THERE'S ALL THESE
- 5 ELEMENTS THAT WE ALL UNDERSTAND, YOU KNOW, THROUGH THE
- 6 SITE APPROVALS AND THE LIKE TO ACTUAL CONSTRUCTION DATE
- 7 WILL BE INFLUENCED BY THE MAGNITUDE OR SIZE OF THE
- 8 BUILDING.
- 9 IS THERE SOME WAY OF THINKING ABOUT THAT SO
- 10 THAT THERE IS SOME ACCOMMODATION TO THAT?
- 11 CHAIRMAN KLEIN: I THINK THE BOTTOM LINE IS GET
- 12 A HIGHER SCIENCE SCORE BECAUSE THIS IS ALL -- THIS ALL
- 13 GETS BALANCED IN THE RECOMMENDATIONS, BUT BASICALLY THE
- 14 INITIATIVE IS QUITE SPECIFIC TO GIVE A PRIORITY FOR THOSE
- 15 COMPLETED WITHIN TWO YEARS BECAUSE OF THE NECESSITY OF
- 16 GETTING THIS CAPACITY ONLINE. SO AN ENTITY MAY HAVE
- 17 HIGHER LEVERAGE, IT MAY HAVE A HIGHER SCIENCE SCORE, IT
- 18 MAY HAVE A NUMBER OF CONTRIBUTORS TO BEING COMPETITIVE
- 19 EVEN THOUGH IT'S NOT MEETING THE TWO YEARS.
- 20 BUT I WOULD ALSO SUGGEST THAT THE -- IF YOU
- 21 LOOK AT THE CHINESE STEEL MARKETS AND PROJECT THE DEMAND
- 22 LEVELS --
- DR. PIZZO: I KNOW. I UNDERSTAND. THE PRICES
- 24 ARE ONLY GOING UP. I KNOW. WE'RE RESERVING STILL FOR
- 25 OTHER PROJECTS RIGHT NOW. I UNDERSTAND THE PROBLEM, BUT

- 1 I'M JUST REALLY TRYING TO BE VERY SORT OF THOUGHTFULLY
- 2 PRACTICAL ABOUT THIS SO THAT WE DON'T GET BOXED IN.
- 3 MAYBE IT'S SORT OF THE A PERSONALITY AND YOU LIKE TO GET
- 4 THE BEST IN EVERY SCORE, NOT JUST ONE, TO ACCOMMODATE,
- 5 BUT I DO THINK THIS IS AN IMPORTANT ISSUE AND I HOPE
- 6 THERE WILL BE CONSIDERATION.
- 7 CHAIRMAN KLEIN: I'D LIKE TO CALL ON THE VICE
- 8 CHAIR, AND THEN WE HAVE TWO COMMENTS.
- 9 MR. SERRANO-SEWELL: I'D DEFER MY COMMENTS.
- 10 CHAIRMAN KLEIN: THEN DR. CHANDLER HAS A
- 11 COMMENT. SO DAVID SERRANO-SEWELL IS HOLDING HIS
- 12 COMMENTS. DR. CHANDLER HAS BEEN VERY PATIENT. DR.
- 13 CHANDLER.
- 14 DR. CHANDLER: ACTUALLY WHAT I'D LIKE TO DO IS
- 15 GO BACK TO THE QUESTION ON THE MATCHING. I'M NOT SURE
- 16 THAT I UNDERSTOOD, BUT I THOUGHT THAT YOU'VE SAID THAT
- 17 MONEY COULD BE PLEDGED. IRREVOCABLE PLEDGES WERE
- 18 ACCEPTABLE, WHICH I THINK IS IMPORTANT WHEN IT'S A FAIRLY
- 19 LARGE CHUNK OF MONEY. THAT BEING SAID THOUGH, I DIDN'T
- 20 UNDERSTAND HOW THAT FITS WITH THE IDEA THAT THE MATCHING
- 21 MONEY HAS TO BE SPENT FIRST BEFORE THE CIRM MONEY COMES
- 22 IN.
- MR. SERRANO-SEWELL: WHAT'S UNCLEAR ABOUT THAT?
- DR. CHANDLER: WHAT'S UNCLEAR ABOUT IT IS
- 25 YOU'RE ASKING ME IS THAT IF IT'S A -- UNLESS THE

- 1 ORGANIZATION IS GOING TO DO IT, BUT IF SOMEONE SAYS WE'RE
- 2 GOING TO GIVE IT TO YOU OVER THREE YEARS, AND WE'RE GOING
- 3 TO GIVE YOU 20 MILLION OVER THREE YEARS OR WHATEVER --
- 4 MR. SERRANO-SEWELL: CASH FLOW STATEMENT IN THE
- 5 APPLICATION.
- 6 MR. KELLER: AND THAT WOULD BE A BACKSTOP
- 7 CIRCUMSTANCE THAT YOU JUST DESCRIBED.
- 8 DR. CHANDLER: AND SO IT WOULD HAVE TO BE THAT
- 9 ESSENTIALLY, THEN, THE INSTITUTION WOULD HAVE TO DO THE
- 10 BACKSTOP?
- MR. KELLER: RIGHT. BUT I GUESS I WAS MAKING A
- 12 DISTINCTION BETWEEN HAVING CASH THE FIRST DAY OF THE
- 13 PROJECT APPROVAL VERSUS THE CASH AS IT'S NEEDED BASED ON
- 14 A FUNDS FLOW STATEMENT OF PROGRESS PAYMENTS. IF YOU HAD
- 15 A THREE-YEAR GIFT, THEN CLEARLY IF THAT ISN'T GOING TO
- 16 PROVIDE THE CASH, THEN THERE'S GOING TO BE A BACKSTOP
- 17 SOURCE.
- DR. CHANDLER: SO YOU HAVE TO BE ABLE TO DO
- 19 THAT THEN?
- DR. PIZZO: I THINK, IN FACT, I'M SURE THIS IS
- 21 TRUE AT EVERY INSTITUTION, BUT WE WOULD NOT BE ALLOWED TO
- 22 START A PROJECT UNLESS WE HAD A CASH FLOW MODEL THAT
- 23 SHOWED EVERYTHING WAS THERE WHEN THE PROJECT STARTED. SO
- 24 I'M SURE THAT'S GOING TO BE A PRACTICAL ISSUE FOR ALL OF
- 25 US.

1	MR. KELLER: AND ONE OTHER POINT I WANTED TO
2	CLARIFY ABOUT DR. PIZZO'S COMMENT ABOUT THE PREFERENCE OR
3	THE PRIORITY. IT MIGHT BE IMPORTANT TO KEEP IN MIND THAT
4	THE WAY WE'VE STRUCTURED THE RFA, THAT THERE ARE THREE
5	TIERS OF FUNDING, THREE TIERS, THE XYZ, THE XY AND THE
6	YZ'S, AND THE X, Y, OR Z'S. AND SO EACH OF THOSE WILL
7	COMPETE AS AN INDIVIDUAL STRATA, IF YOU WILL. SO SOMEONE
8	WHO'S GOT A SMALL \$5 MILLION PROJECT THAT COULD POSSIBLY
9	COULD GET DONE IN TWO YEARS IS NOT COMPETING WITH THE
10	LARGER PROJECTS.
11	CHAIRMAN KLEIN: I HAVE
12	DR. BRYANT: I CHANGED MY MIND.
13	CHAIRMAN KLEIN: DUANE ROTH.
14	MR. ROTH: I JUST WANTED TO FOLLOW UP BECAUSE I
15	SUSPECT WHAT YOU ARE GOING TO GET IS EVERYBODY IS GOING
16	TO SUBMIT A TWO-YEAR PLAN. AND I THINK WHAT DR. PIZZO IS
17	SAYING IS THAT IT'S LIKELY THAT THOSE BIG FACILITIES ARE
18	GOING TO GO BEYOND THAT TWO-YEAR PLAN. AND SO I'M
19	COMFORTABLE THAT THE PRESIDENT CAN USE DISCRETION HERE,
20	AND I WANT TO MAKE SURE THAT'S THE INTENT OF THE WAY IT'S
21	WRITTEN IS THAT UNDERSTANDING THAT THERE WILL BE
22	CONSIDERATION FOR OVERRUNS. I DOUBT THAT YOU ARE GOING
23	TO GET ANYBODY THAT SAYS IT'S GOING TO BE FOUR YEARS TO
24	GET THE BUILDING UP BECAUSE THEY'RE GOING TO WANT THOSE
25	POINTS.

MR. KELLER: I THINK THE SENTIMENT OF THE

1

2	FACILITIES WORKING GROUP, AFTER MORE THAN TEN HOURS OF
3	PUBLIC MEETINGS AND DISCOURSE ABOUT THE MAJOR FACILITIES
4	GRANT, WAS THAT IF PRIORITY WAS GOING TO BE PROVIDED,
5	THERE HAD TO BE A MECHANISM TO HOLD THOSE FOLKS WHO
6	REQUESTED IT ACCOUNTABLE FOR THE SCHEDULE THAT THEY
7	SUBMIT, OR ELSE IT WOULD JUST BE MEANINGLESS IN TERMS OF
8	PROVIDING THE PRIORITY. SO I THINK THE LANGUAGE WAS
9	INTENDED TO AT LEAST SAY THERE IS A PENALTY, BUT CLEARLY
10	IF IT'S DELAYS THAT ARE UNAVOIDABLE, THE PRESIDENT CAN
11	MAKE A JUDGMENT.
12	CHAIRMAN KLEIN: THERE'S THE OTHER POINT AS
13	WELL THAT IF YOU'RE COMPETING IN A CATEGORY WITH VERY
14	LARGE FACILITIES, NONE OF WHICH CAN GET DONE WITHIN TWO
15	YEARS, THEY'RE COMPETING IN A CATEGORY WHERE YOU'RE ALL
16	PROPOSING THREE YEARS OR SOMETHING, BUT IF YOU'RE
17	COMPETING IN A CATEGORY THAT CAN GET DONE IN TWO YEARS,
18	IF YOU DON'T HAVE THAT PRIORITY, YOU'VE GOT A
19	DISADVANTAGE.
20	MR. ROTH: BUT MY POINT IS I DOUBT THAT YOU'RE
21	GOING TO SEE ANYBODY WITH A THREE-YEAR PROGRAM IF IT
22	COUNTS. DON'T YOU EXPECT THAT ALL OF THEM WILL COME IN
23	WITHIN THE DEADLINE?
24	CHAIRMAN KLEIN: I WOULD HOPE THAT AS MANY AS
25	CAN LEGITIMATELY CREATE AN AGGRESSIVE PROGRAM FOR

1	CONSTRUCTION W	TII. AND	THOSE	THAT	FACE	THE	RFAI TTTFS	THAT

- 2 THEY CAN'T DELIVER IN THAT TIME PERIOD WILL FACE UP TO
- 3 THAT REALITY IN THEIR SCHEDULE THEY PROPOSE. BUT
- 4 CERTAINLY FOLLOWING THE INITIATIVE, WE WOULD ENCOURAGE
- 5 AND THE SYSTEM ENCOURAGES INDIVIDUAL INSTITUTIONS TO
- 6 CREATE A PROGRAM FOR FAST-TRACK CONSTRUCTION.
- 7 ADDITIONAL COMMENTS? YES, DR. STEWARD.
- 8 DR. STEWARD: THIS IS ACTUALLY WITH REGARD TO
- 9 SECTION F.
- 10 CHAIRMAN KLEIN: IS YOUR MICROPHONE ON THERE?
- DR. STEWARD: NO. 6. THIS IS WITH REGARD TO
- 12 SECTION F, AND I HAVE A QUESTION AND A COMMENT, I GUESS,
- 13 ABOUT THE LANGUAGE. THE PART OF THE THING THAT PROP 71
- 14 IS MEANT TO OVERCOME IS THE ARTIFICIAL
- 15 COMPARTMENTALIZATION OF STEM CELL ACTIVITIES BASED ON
- 16 FEDERAL REGULATIONS. AND SAYING THAT THESE FACILITIES
- 17 ARE INTENDED TO HAVE AS ACTIVITIES FUNDED BY CIRM COULD
- 18 BE INTERPRETED AS --
- 19 MR. KELLER: ARE YOU WORKING FROM THE ADDENDUM?
- DR. STEWARD: NO.
- MR. KELLER: SO THAT VERY POINT, DR. STEWARD,
- 22 WAS EXACTLY THE POINT THAT WE ADDRESSED IN THE ADDENDUM,
- 23 WHICH IS TO MAKE IT BROAD AND TO UNDERSTAND THAT IT'S NOT
- JUST CIRM-FUNDED, BUT OTHER SOURCES.
- DR. STEWARD: I THINK THAT SOLVES IT. LET ME

- 1 THINK ABOUT IT. 2 CHAIRMAN KLEIN: ALL RIGHT. WE HAD A VERY GOOD 3 DISCUSSION OF THESE POINTS. DR. HENDERSON. 4 DR. HENDERSON: DO WE NEED APPROVAL OF THIS? 5 CHAIRMAN KLEIN: WE NEED APPROVAL OF THIS. 6 DR. HENDERSON: I SO MOVE. 7 CHAIRMAN KLEIN: MOVED AND IS THERE A SECOND? 8 MR. ROTH: SECOND. 9 CHAIRMAN KLEIN: SECOND BY DUANE ROTH. I'D 10 LIKE TO ASK IF THERE'S PUBLIC COMMENT. SEEING NO PUBLIC 11 COMMENT, CALL THE QUESTION. ALL IN FAVOR. OPPOSED? 12 MOTION PASSES. 13 IF WE COULD PROCEED, DR. MURPHY, TO PART B. 14 MS. PACHTER: MR. CHAIR. 15 CHAIRMAN KLEIN: YES. 16 MS. PACHTER: FOR THE BENEFIT OF THOSE MEMBERS 17 WHO ARE RECUSED, I'D JUST LIKE TO LIST THE MEMBERS WHO 18 MAY PARTICIPATE IN THE DISCUSSION AND VOTING ON ITEM 7 B, 19 WHICH DR. MURPHY IS ABOUT TO PRODUCE, SO EVERYBODY IS 20 CLEAR.
- 21 CHAIRMAN KLEIN: IF YOU WOULD PROCEED.
- MS. PACHTER: MICHAEL GOLDBERG, DR. LEVY, NOT
- DR. LEVEY, TINA NOVA IS NOT HERE, DR. PRIETO, DUANE ROTH,
- 24 DAVID SERRANO-SEWELL, JON SHESTACK IS NOT HERE, AND
- 25 DR. WRIGHT, AND BOB KLEIN.

Т.	CHAIRMAN KLEIN. ALL KIGHI. DR. MURPHY.
2	DR. MURPHY: MR. CHAIRMAN, I LOOK FORWARD TO
3	SPEAKING TO A VERY SMALL GROUP OF ICOC MEMBERS. THIS
4	ITEM 7 B IS NOW PART OF CHAPTER 5 OF THE GRANT WORKING
5	GROUP'S RECOMMENDATIONS. AND THIS IS A VERY THE WHOLE
6	THING IS VERY DIFFICULT, AND I JUST WANT TO THANK DAVID
7	AND THE OTHER MEMBERS OF THE GRANTS WORKING GROUP FOR
8	REALLY A HEROIC EFFORT IN PUTTING THESE REGULATIONS
9	TOGETHER.
10	THE REGULATION WE'RE GOING TO BE TALKING ABOUT
11	IS IN YOUR BINDER. IT'S THE LAST PAGE IN 7 B. AND WHAT
12	THIS PAGE DEALS WITH IS THE RECOMMENDATIONS WE ARE MAKING
13	THAT ENSURE THAT RESEARCH INSTITUTES THAT ARE FUNDED WITH
14	CIRM MONEY WILL BE PAID ONCE FOR THE COST OF DOING THAT
15	RESEARCH, BUT WILL NOT BE PAID TWICE.
16	IF WE LOOK AT SLIDE ONE, UNDER PROPOSITION 71
17	AND THE GAP, THE CIRM WILL PAY FACILITIES DIRECT COSTS
18	AND IT PAYS THESE COSTS IN TWO WAYS, WHAT WE CALL
19	FACILITIES DIRECT A, WHICH PAYS FOR OPERATIONS,
20	MAINTENANCE, AND LIBRARY COSTS, AND FACILITIES DIRECT B,
21	WHICH PAYS FOR THE COSTS OF SPACE UTILIZATION.
22	NOW, THE PROPOSAL IN FRONT OF YOU DOES NOT
23	AFFECT FACILITIES A, OPERATIONS, MAINTENANCE, LIBRARIES.
24	IN FACT, THOSE PAYMENTS ARE DICTATED BY THE OVERHEAD
25	PAYMENTS THAT ARE ALREADY NEGOTIATED WITH NIH. WHAT THIS

1 POLICY DOES IS AFFECT FACILITIES DIRECT B, WHICH
--

- 2 COST OF SPACE UTILIZATION.
- NOW, WHAT THIS MEASURE DOES IS IT SETS THE
- 4 STANDARDS FOR THOSE INSTITUTIONS THAT ARE AWARDED A
- 5 FACILITIES B -- SORRY -- ARE AWARDED A MAJOR FACILITIES
- 6 GRANT. NOW, THE NEXT SLIDE WILL SHOW YOU THAT IN
- 7 PARAGRAPH 1 OF THE PAGE BEFORE YOU, THAT PARAGRAPH
- 8 INDICATES THAT COSTS FUNDED BY A CIRM FACILITIES OR
- 9 INFRASTRUCTURE GRANT OR BY ANOTHER RESEARCH GRANT FROM
- 10 ANY SOURCE ARE NOT FACILITIES COSTS TO BE PART OF THE
- 11 CIRM RESEARCH GRANT. SO THAT IF FACILITIES MONIES ARE
- 12 ALREADY BEING PROVIDED FROM CIRM OR ANYONE ELSE, CIRM
- 13 WILL NOT COVER THOSE COSTS AGAIN.
- 14 IN THE NEXT PARAGRAPH, PARAGRAPH 2, IT TELLS
- 15 YOU THAT THE CIRM FACILITY CAN ONLY BE USED FOR STEM CELL
- 16 RESEARCH, AND WE TALK ABOUT THAT IN A BROAD SENSE BECAUSE
- 17 WE RECOGNIZE THAT THERE WILL BE OTHER DISCIPLINES THAT
- 18 WILL GO INTO DOING THE KIND OF STEM CELL RESEARCH WE NEED
- 19 TO DO. AND IT ALSO INDICATES THAT INSTITUTIONS THAT
- 20 RECEIVE A MAJOR FACILITIES GRANT MUST LOCATE THEIR CIRM
- 21 RESEARCH-FUNDED ACTIVITIES IN THE CIRM-FUNDED FACILITIES
- 22 AS DESCRIBED IN THEIR APPLICATIONS.
- NOW, THAT DOES NOT MEAN THAT AN INVESTIGATOR
- 24 CAN'T WORK IN AN ALREADY ESTABLISHED LAB ON A CIRM-FUNDED
- 25 GRANT. WE ENCOURAGE THAT. BUT IF YOU DESCRIBE IN YOUR

1 — APPLICATION THAT THERE IS GOING TO BE A C		APPLICATION T	THAT THERI	F TS	GOTNG TO	BF A	A CTRM-FUNDF	٠D
---	--	---------------	------------	------	----------	------	--------------	----

- 2 RESEARCHER IN THAT BUILDING WITH CIRM FUNDING, YOU NEED
- 3 TO DO THAT. SO WE DON'T WANT PEOPLE TO SAY THIS
- 4 SCIENTIST IS GOING TO BE IN THE BUILDING IN THE
- 5 APPLICATION; AND THEN WHEN THE BUILDING IS FUNDED, WE
- 6 FIND OUT THAT THAT PERSON IS NOT IN THE BUILDING.
- 7 CHAIRMAN KLEIN: DR. MURPHY, BEFORE GOING ON,
- 8 SINCE THAT'S SO IMPORTANT, MAYBE WE CAN JUST REEMPHASIZE
- 9 THAT. AGAIN, IF SOMEONE HAS PROPOSED A GRANT AND THAT
- 10 GRANT IS PROPOSED TO BE TAKING PLACE IN SOME OTHER
- 11 BUILDING, THAT IS ACCEPTABLE. BUT IN THE COMPETITION FOR
- 12 THE FACILITIES AWARD, IF THAT INSTITUTION PROPOSES THAT
- 13 THAT SPECIFIC RESEARCH WILL TAKE PLACE IN THIS BUILDING,
- 14 THEN THEY HAVE MADE A REPRESENTATION THAT THEY NEED TO
- 15 FOLLOW THROUGH ON. RIGHT? OKAY.
- 16 DR. MURPHY: IN PARAGRAPH 3, WHAT THAT
- 17 PARAGRAPH INDICATES IS THAT THOSE CIRM-FUNDED RESEARCH
- 18 GRANTS THAT ARE LOCATED IN A CIRM-FUNDED FACILITY WILL
- 19 NOT BE REIMBURSED FOR FACILITIES B COSTS. THEY WILL NOT
- 20 RECEIVE THAT FUNDING, ALTHOUGH THEY WILL CONTINUE TO
- 21 RECEIVE FACILITIES A COSTS. SO THIS ONLY AFFECTS THE B
- 22 COSTS.
- AND FINALLY, IN SLIDE 5 OR THE NEXT SLIDE,
- 24 PARAGRAPH 4 INDICATES THAT REIMBURSEMENT OF FACILITIES
- 25 PART B COSTS WILL RESUME WHEN THE SUM OF THE PART B COSTS

- 1 THAT ARE NOT REIMBURSED TO AN INSTITUTION AS JUST
- 2 DESCRIBED EQUALS THE AMOUNT FUNDED BY THE MAJOR
- 3 FACILITIES GRANT PLUS THE COST OF FUNDS. AND ONCE THIS
- 4 THRESHOLD IS PASSED; I.E., THE MONEY IS PAID BACK, IN
- 5 ESSENCE, THEN FACILITIES PART B COSTS WILL BE FULLY
- 6 REIMBURSED TO INSTITUTIONS THAT RECEIVE A MAJOR
- 7 FACILITIES GRANT.
- 8 SO THIS IS JUST DURING THAT PERIOD WHEN THOSE
- 9 MONIES WOULD NOT HAVE -- ARE NOT PAID TO THEM. ONCE THAT
- 10 CIRM CONTRIBUTION IS ACCOUNTED FOR, THEN FACILITIES B
- 11 COSTS WOULD BE REIMBURSED.
- MR. CHAIRMAN, I RECOMMEND THIS PROPOSAL FOR THE
- 13 ICOC'S CONSIDERATION, AND WE ARE HAPPY TO ANSWER ANY
- 14 QUESTIONS THAT MAY ARISE. DAVID.
- MR. SERRANO-SEWELL: DR. MURPHY, IT'S MY --
- 16 THIS IS A VERY COMPLICATED ISSUE, BUT IT'S MY
- 17 UNDERSTANDING THAT YOU WORKED ON THIS AND YOU LED A
- 18 DISCUSSION WITH OUR VICE CHAIRMAN, DR. PENHOET, OUR
- 19 CHAIRMAN, MR. KLEIN, AND THERE WAS A FOURTH PERSON. WHO
- 20 AM I FORGETTING?
- DR. MURPHY: DR. TROUNSON WAS INVOLVED.
- MR. SERRANO-SEWELL: YES, OF COURSE. DR.
- 23 TROUNSON, OUR INCOMING PRESIDENT. THANK YOU. IN
- 24 CRAFTING THIS LANGUAGE. SO IT NOT ONLY COMES WITH YOUR
- 25 STRONG RECOMMENDATION, BUT HAD THE INPUT FROM YOUR

- 1 TRUSTED COLLEAGUES AND INCOMING PRESIDENT. IF THERE'S NO
- OTHER QUESTIONS, I'LL MAKE THE MOTION TO APPROVE IT.
- 3 CHAIRMAN KLEIN: SO DAVID SERRANO-SEWELL, IF
- 4 YOU COULD MAKE A MOTION.
- 5 MR. SERRANO-SEWELL: SURE. I MOVE TO APPROVE
- 6 THE AMENDMENTS TO CHAPTER 7, SECTION H, PARAGRAPH 4 OF
- 7 THE GRANTS ADMINISTRATION POLICY FOR ACADEMIC AND
- 8 NONPROFIT INSTITUTIONS.
- 9 DR. WRIGHT: SECOND.
- 10 CHAIRMAN KLEIN: SECOND BY DR. WRIGHT. IS
- 11 THERE DISCUSSION BY THE BOARD? IS THERE DISCUSSION BY
- 12 THE PUBLIC? I THINK THAT WE NEED A ROLL CALL VOTE HERE
- 13 BECAUSE WE HAVE -- WE WANT TO VERIFY A COPY OF THE VOTE
- 14 SO THAT WE CAN CONFIRM THE MEMBERS WHO VOTED.
- MS. KING: MICHAEL GOLDBERG.
- MR. GOLDBERG: YES.
- 17 MS. KING: BOB KLEIN.
- 18 CHAIRMAN KLEIN: YES.
- 19 MS. KING: MICHAEL LEVY.
- DR. LEVY: YES.
- 21 MS. KING: FRANCISCO PRIETO.
- DR. PRIETO: YES.
- MS. KING: DUANE ROTH.
- MR. ROTH: YES.
- MS. KING: JANET WRIGHT.

1	DR. WRIGHT: YES.
2	MS. KING: DAVID SERRANO-SEWELL.
3	MR. SERRANO-SEWELL: YES.
4	THAT MOTION CARRIES.
5	CHAIRMAN KLEIN: THAT MOTION CARRIES, AND I
6	BELIEVE THAT DR. PENHOET WAS NOT CONSULTED ON THIS
7	LANGUAGE WE HAVE BEFORE US BECAUSE HE DID NOT PARTICIPATE
8	IN THAT DISCUSSION JUST FOR THE RECORD. SO THE OTHER
9	MEMBERS ALL DID PARTICIPATE.
10	I WOULD LIKE TO GO ON TO ITEM 8, BUT I'M GOING
11	TO GIVE THE DEDICATED BOARD AND PUBLIC A FIVE-MINUTE
12	BREAK HERE.
13	(A RECESS WAS TAKEN.)
14	CHAIRMAN KLEIN: ALL RIGHT. WE WILL CONVENE
15	HERE FOR ITEM NO. 8. MY UNDERSTANDING IS DR. PATRICIA
16	OLSON IS GOING TO GUIDE US IN WHAT IS AN EXTRAORDINARY
17	FIRST STEP ON A MAJOR INITIATIVE OF THIS BODY, ONE THAT
18	IS EXTREMELY EXCITING WITH INCREDIBLE POTENTIAL FOR THIS
19	INSTITUTION AND THE RESEARCH BEING CONDUCTED. DR.
20	PATRICIA OLSON.
21	MS. OLSON: THANK YOU, MR. CHAIRMAN. BOARD
22	MEMBERS, MEMBERS OF THE PUBLIC, TODAY I'D LIKE TO UPDATE
23	YOU ON THE DISEASE TEAM INITIATIVE. THIS IS AGENDA ITEM
24	NO. 8. AND I AM SPEAKING ON BEHALF OF DR. BETTINA
25	STEFFEN, WHO IS LEADING THIS INITIATIVE, BUT WAS UNABLE

TO BRING US HERE TODAY OR BE WITH US TODAY.

1

2	EARLIER TODAY DR. CHIU PRESENTED TO YOU AN
3	OUTLINE OF THE SCIENTIFIC PROGRAMS FOR THE UPCOMING YEAR.
4	AMONG THESE ARE THOSE WHICH MARK OUR ENTRY INTO A NEW
5	EXCITING PHASE. WE ARE BEGINNING TO FUND PROGRAMS THAT
6	WILL HELP BRING STEM CELL THERAPIES TO THE CLINIC. ONE
7	OF THESE PROGRAMS IS THE DISEASE TEAM INITIATIVE.
8	THE DIAGRAM YOU HAVE IN FRONT OF YOU ON THE
9	SCREEN REPRESENTS THE PATH THAT A TYPICAL THERAPY WOULD
10	TAKE FROM DISCOVERY FORWARD INTO CLINICAL TRIALS.
11	UNDERNEATH YOU SEE WHERE WE CONTEMPLATE THE
12	SCOPE OF THE DISEASE TEAM INITIATIVE. TODAY WE WOULD
13	LIKE TO ASK FOR YOUR APPROVAL FOR THE CONCEPT OF A
14	DISEASE TEAM PLANNING GRANT. THE DISEASE TEAM INITIATIVE
15	HAS THREE PARTS. IT HAS A WORKSHOP THAT WAS HELD IN JULY
16	OF THIS YEAR. IT INCLUDES A PLANNING GRANT, THE CONCEPT
17	OF WHICH WE'RE BRINGING FOR YOUR CONSIDERATION TODAY, AND
18	IT HAS THE ACTUAL DISEASE TEAM GRANT, WHICH WE ANTICIPATE
19	IN THE FALL OF NEXT YEAR.
20	THE PURPOSE OF THE WORKSHOP WAS TO ASSEMBLE
21	RESEARCHERS AND REPRESENTATIVES OF OTHER FUNDING AGENCIES
22	WHO HAVE HAD EXPERIENCE WITH TEAM-BASED PROJECTS AND HAVE
23	THEM TALK TO US ABOUT WHAT WORKS AND PERHAPS, MORE
24	IMPORTANTLY, WHAT HASN'T WORKED. WE ASKED ABOUT SCOPE,
25	RESOURCES, FUNDING OF EFFECTIVE TEAMS, PROGRAM

1	MANAGEMENT,	AND	THE	STRENGTHS	AND	WEAKNESSES	OF	THESE

- 2 APPROACHES. WE PRESENTED THE FINDINGS FROM THE WORKSHOP
- 3 TO OUR GRANTS WORKING GROUP IN A PUBLIC MEETING THAT WAS
- 4 HELD ON SEPTEMBER 19TH AND RECEIVED ADDITIONAL INPUT FROM
- 5 THEM AS WELL.
- 6 A COPY OF THE DRAFT WORKSHOP REPORT SUMMARIZING
- 7 THE FINDINGS OF THE WORKSHOP AS WELL AS INCLUDING AN
- 8 APPENDIX WITH COMMENTS FROM THE WORKING GROUP HAS BEEN
- 9 PROVIDED TO YOU. SO YOU SHOULD HAVE THAT. THERE ARE
- 10 COPIES AVAILABLE FOR MEMBERS OF THE PUBLIC ON BOTH THE
- 11 TABLE IN HERE AND THE TABLE OUTSIDE. AND WE WILL BE
- 12 PUBLISHING A FINAL REPORT ON THE WEB WITHIN THE NEXT FEW
- WEEKS.
- 14 MOVING ON TO THE PLANNING GRANT, THE PURPOSE OF
- 15 THIS IS TO ALLOW POTENTIAL TEAMS TO ASSEMBLE AND TO
- 16 PREPARE A COMPREHENSIVE RESEARCH PROPOSAL. FINALLY, WE
- 17 DO ANTICIPATE A MULTIYEAR DISEASE TEAM GRANT IN THE FALL
- 18 OF NEXT YEAR. THESE WOULD BE THE LARGE GRANTS.
- 19 THERE ARE THREE REASONS THAT WE ARE LAUNCHING
- 20 THE DISEASE TEAM INITIATIVE. THIS PROGRAM WILL HELP THE
- 21 INSTITUTE ACHIEVE ITS GOAL OF DEVELOPING STEM CELL-BASED
- 22 THERAPIES BY MOVING CANDIDATES TOWARDS THE CLINIC.
- 23 TRANSLATING DISCOVERIES INTO CLINICALLY VIABLE THERAPIES
- 24 IS REALLY VERY DIFFICULT, AND THIS INITIATIVE WILL
- 25 EXPLORE NEW METHODS FOR INTEGRATING AN ORGANIZING

1	MULTIDISCIPLINARY	TFAMS	FINALLY.	TT	ALLOWS	THE	USF	ΩF
_	MOLITOTOCTLETINALI	ILAMO.	I TINALLI,		ALLUWS	1111	UJL	O1

- 2 INNOVATIVE RESEARCH MODELS THAT INCLUDE ACTIVE MANAGEMENT
- 3 AND DEFINE MILESTONES AS PART OF A COMPREHENSIVE RESEARCH
- 4 PLAN.
- 5 WHAT ARE THE BENEFITS THAT WE SEE ACCRUING FROM
- 6 A DISEASE TEAM PLANNING GRANT? I WOULD NOTE THAT THIS
- 7 PROGRAM DIFFERS FROM THE TRADITIONAL SINGLE INVESTIGATOR,
- 8 PRINCIPAL INVESTIGATOR, FUNDED PI GRANTS THAT WE HAVE
- 9 DONE SO FAR. SO BECAUSE OF THIS, WE ARE RECOMMENDING
- 10 APPROVAL OF A PLANNING GRANT TO ALLOW FOR TEAM FORMATION
- 11 AND PROPOSAL DEVELOPMENT IN ANTICIPATION OF THE ACTUAL
- 12 DISEASE TEAM GRANTS. WE BELIEVE THAT THE PLANNING GRANT
- 13 WILL ENRICH THE POOL OF APPLICATIONS FOR DISEASE TEAM
- 14 GRANTS.
- 15 THE PLANNING GRANT AWARD WILL PROVIDE SUPPORT
- 16 FOR UP TO SIX MONTHS FOR PLANNING AND PROPOSAL
- 17 DEVELOPMENT. WHAT WE WOULD HOPE IS THAT THE TEAM LEADER
- 18 WOULD USE THAT TIME TO IDENTIFY AND RECRUIT A TEAM AND
- 19 THAT THAT TEAM WOULD BE INVOLVED IN THE DEVELOPMENT OF
- THE CONTENT OF THE PROPOSAL, ADMINISTRATION, AND
- 21 MANAGEMENT OF THE TEAM.
- THE DISEASE TEAM INITIATIVE AND THE PLANNING
- 23 GRANT WILL SUPPORT THE FULL SPECTRUM OF STEM CELL TYPES
- 24 AND DISEASES, SO WE ARE NOT IMPOSING ANY LIMITATIONS IN
- 25 THIS REGARD.

1	THE ACTUAL CONCEPT THAT WE BRING FOR YOUR
2	CONSIDERATION IS THAT WE WOULD FUND SIX-MONTH PLANNING
3	AWARDS FOR UP TO 20 TEAMS AT A TOTAL COST OF 50,000 PER
4	AWARD. I WOULD NOTE THAT THIS IS A DIRECT PROJECT COST
5	ONLY AWARD. THERE WILL BE NO INDIRECT COSTS INCLUDED,
6	AND NO FACILITIES COSTS WILL BE PART OF THIS.
7	WE ESTIMATE THAT THE TOTAL COST OF THE PROGRAM
8	WILL BE UP TO \$1 MILLION. THE DRAFT TIMETABLE THAT WE
9	HAVE PROPOSED AND THAT I THINK WAS ALLUDED TO BY ARLENE
10	AS WELL IS WE ANTICIPATE THE RELEASE OF THE RFA FOR THE
11	PLANNING GRANTS IN THE NEXT MONTH, IN NOVEMBER. WE
12	ANTICIPATE REVIEW OF APPLICATIONS IN WINTER OF 2008, AND
13	WE ANTICIPATE COMING TO YOU FOR APPROVAL FOR FUNDING IN
14	THE SPRING OF 2008.
15	FINALLY, AS NOTED, WE DO ANTICIPATE A CALL FOR
16	APPLICATIONS FOR THE DISEASE TEAM GRANT ITSELF IN 2008.
17	FINALLY, I WOULD LIKE TO SAY THAT THE DISEASE TEAM
18	INITIATIVE IS ONE OF SEVERAL INITIATIVES THAT HAVE BEEN
19	OUTLINED IN THE SCIENTIFIC STRATEGIC PLAN FOR ACTUALLY
20	MOVING RESEARCH FROM DISCOVERY TO CLINICAL TESTING. AS
21	YOU SEE HERE, THIS IS THE ANTICIPATED SCOPE OF THE
22	DISEASE TEAM. OTHER INITIATIVES ARE OUTLINED HERE AND
23	HOW THEY MAP ON THE SPECTRUM OF CLINICAL DEVELOPMENT.
24	YOU'VE ALREADY HEARD FROM DR. CHIU THAT WE ANTICIPATE
25	MOVING FORWARD WITH THE TRANSLATIONAL RESEARCH INITIATIVE

- 1 THIS YEAR, AND I THINK I SPEAK FOR MYSELF AS WELL AS ALL
- 2 MEMBERS OF SCIENCE TEAM THAT WE WOULD LOOK FORWARD TO
- 3 BRINGING OTHER INITIATIVES FORWARD TO YOU IN THE FUTURE.
- 4 THANK YOU FOR YOUR CONSIDERATION.
- 5 CHAIRMAN KLEIN: THANK YOU, DR. OLSON. I THINK
- 6 FOR PURPOSES OF THE TRANSCRIPT, THE PEER REVIEW IS WINTER
- 7 OF 2007 VERSUS 2008.
- 8 MS. OLSON: WELL, IT'S LIKELY TO BE ACTUALLY
- 9 PROBABLY IN JANUARY OR FEBRUARY.
- 10 CHAIRMAN KLEIN: RIGHT. OKAY. VERY GOOD
- 11 CLARIFICATION. APPRECIATE THAT. VERY GOOD
- 12 CLARIFICATION.
- SO WITH THAT, ARE THERE QUESTIONS OF DR. OLSON?
- 14 DAVID SERRANO-SEWELL.
- MR. SERRANO-SEWELL: YOU'RE REQUESTING APPROVAL
- 16 FOR THE DISEASE TEAM PLANNING AWARDS, WHICH I SUPPORT,
- 17 BUT THEN YOU MENTIONED THE NEXT PHASE WOULD BE THE
- 18 DISEASE TEAMS GRANTS?
- 19 MS. OLSON: THE ACTUAL GRANTS TO FUND THE WORK
- 20 OF THE DISEASE TEAMS.
- 21 CHAIRMAN KLEIN: THAT WILL BE A SEPARATE.
- MS. OLSON: YES.
- MR. SERRANO-SEWELL: AN ENTITY ISN'T PRECLUDED
- 24 IF THEY DON'T GET THE DISEASE TEAM PLANNING AWARD.
- MS. OLSON: THAT IS CORRECT. THANK YOU FOR

- 1 THAT CLARIFICATION. IF YOU DO NOT APPLY FOR AND RECEIVE
- 2 A PLANNING GRANT, THAT DOES NOT PRECLUDE YOUR
- 3 PARTICIPATING IN THE COMPETITION FOR THE DISEASE TEAM
- 4 GRANTS.
- DR. LEVEY: I WAS PLEASED TO SEE BEFORE THAT
- 6 THERE'S A PLAN FOR A MAJOR INITIATIVE WITH REGARD TO
- 7 CORES. AND I THINK IF WE GO AHEAD WITH THIS DISEASE
- 8 TEAM, IN FACT, YOU MIGHT EVEN WANT TO DO THAT BEFORE YOU
- 9 ACTUALLY HAD THE FULL DECISIONS FOR THE DISEASE TEAMS
- 10 BECAUSE DISEASE TEAMS, IF YOU HAD MULTIPLE TEAMS ON THE
- 11 UNIVERSITY OR LIKE WE'D LIKE TO DO PROBABLY ACROSS
- 12 UNIVERSITY LINES AND BRING POOLS OF GROUPS TOGETHER, IT
- 13 EVEN PUTS GREATER STRESS ON HAVING CORE FACILITIES. SO
- 14 YOU MIGHT WANT TO THINK ABOUT THE TIMING OF THESE AND HOW
- 15 MUCH YOU WANT TO PUT INTO THE CORE -- HOW MUCH WE WANT TO
- 16 PUT INTO THE CORE FACILITIES GRANTS.
- 17 MS. OLSON: I BELIEVE IT IS OUR INTENT, AS
- 18 OUTLINED IN DR. CHIU'S PLAN, TO, IN FACT, MOVE FORWARD
- 19 WITH CORES AS WELL. HOWEVER, I GUESS THEY'RE GOING TO BE
- 20 MOVING FORWARD SIMULTANEOUSLY, AND WE'LL PROBABLY HAVE TO
- 21 RELY TO SOME EXTENT ON RESOURCES ALREADY EXISTING;
- 22 ALTHOUGH AS TIME GOES ON, CERTAINLY THOSE CORES THAT WE
- 23 HOPE TO BRING FORTH WILL CONTRIBUTE TO THEM AS WELL.
- 24 CHAIRMAN KLEIN: DR. PIZZO.
- 25 DR. PIZZO: I'D LIKE TO FOLLOW UP ON JERRY

1	LEVEY'S COMMENT.	IN MANY	LARGE PRO	GRAM PROJECTS,	CORES
---	------------------	---------	-----------	----------------	-------

- 2 ARE OFTEN EMBEDDED INTO THE PROJECTS THEMSELVES. AND IT
- 3 MAY BE A DIFFERENT WAY OF THINKING ABOUT THIS, AND I
- 4 DON'T KNOW WHETHER THERE'S TIME TO DO THAT, BUT THAT
- 5 COULD MAKE A TREMENDOUS DIFFERENCE BECAUSE IN THE ABSENCE
- 6 OF ADDRESSING CORE FACILITIES, WHEN WE'RE LOOKING AT
- 7 DISEASE-BASED PROJECT RESEARCH, WE MISS, I THINK, AN
- 8 IMPORTANT NEED. SO I WOULD MAKE THE REQUEST THAT WE
- 9 THINK ABOUT THIS AND THINK ABOUT WHETHER OR NOT CORES
- 10 COULD BECOME PART OF THE DISEASE-BASED PROCESS ITSELF.
- 11 CHAIRMAN KLEIN: CERTAINLY WE HAVE THE
- 12 OPPORTUNITY WHEN THE PLANNING GRANTS, WHICH IS WHAT WE'RE
- 13 FOCUSED ON TODAY, PROGRESS TO GET FEEDBACK IN REAL-TIME
- 14 FROM THOSE INSTITUTIONS WITH PLANNING GRANTS THAT MIGHT
- 15 CONTRIBUTE TO OUR CONSIDERATION OF CORES BEFORE THE
- 16 DISEASE TEAM GRANTS ARE MADE.
- 17 DR. PIZZO: WELL, NO, I REALLY MEAN SOMETHING
- 18 DIFFERENT. I THINK THAT, YOU KNOW, IF YOU ARE APPLYING
- 19 FOR A COMPREHENSIVE CANCER CENTER PROGRAM OR SOMETHING OF
- THE LIKE AS A MAJOR PROJECT GRANT, WHICH DOES BUILD TEAMS
- 21 IN AN INTERDISCIPLINARY WAY, THERE IS OFTEN CORES AS PART
- 22 OF THAT JUST SORT OF BUILT INTO THE GRANT ITSELF, AND IT
- 23 JUST MAY OBVIATE THIS CHALLENGE.
- DR. CHIU: MAY I RESPOND TO THAT?
- DR. PIZZO: PLEASE. BY ALL MEANS.

1	DR	CHIU:	WΕ	DO	NOT	KNOW	WHAT	KTND	ΩF	DISEASE
_	DIV.	CHILD:	₩.	טט	1101	ININOW	VV I I/~ I	KTIND	OI.	DISLASE

- 2 TEAMS WILL ARISE AND THE NEEDS OF EACH OR ANY OF THE
- 3 DISEASE TEAMS, SO IT WOULD BE UP TO WRITING OF THE
- 4 PROPOSAL OF THE BIG MULTIYEAR DISEASE TEAM GRANT TO STATE
- 5 WHAT THEIR NEEDS ARE AT WHAT STAGE AND HOW THESE
- 6 INTEGRATE. HOWEVER, I DO NOT ALSO WANT TO DEPEND ON
- 7 THOSE FOR THE CORES. AND WHAT WE ENVISION AND WILL BRING
- 8 BEFORE YOU IS THAT CORES AND SERVICES ARE A SEPARATE RFA
- 9 FROM THE DISEASE TEAMS.
- 10 DR. PIZZO: RIGHT. AND I RESPECT THAT AND I
- 11 THINK THAT THAT SHOULD BE THE CASE. I WAS JUST LOOKING
- 12 AT A WAY OF FACILITATING SOME OF THE CORE DEVELOPMENT AS
- 13 PART OF THIS EFFORT SINCE I DON'T KNOW THE SEQUENCING OF
- 14 THE LATTER.
- 15 CHAIRMAN KLEIN: OKAY. DR. MEYER.
- 16 DR. MEYER: I HAVE ACTUALLY TWO SEPARATE
- 17 ISSUES, ONE MORE SPECIFIC AND ONE MORE GENERAL. WHEN
- 18 YOU'RE TALKING ABOUT TEAMS, IT BEGS THE QUESTION ABOUT
- 19 PI'S. AND NOW NIH HAS MULTIPLE PI'S. IS THIS GOING TO
- 20 BE SOMETHING THAT IS GOING TO BE PART OF THIS RFA, THAT
- 21 THERE WILL BE MULTIPLE PI'S ELIGIBLE?
- MS. OLSON: THAT IS NOT HOW WE'RE CONTEMPLATING
- 23 IT AT THE MOMENT. BUT LET ME JUST SAY MY EXPERIENCE WITH
- 24 TEAM-BASED RESEARCH IS THERE IS USUALLY A PROJECT LEADER,
- 25 NOT A PI IN THE SENSE THAT ACADEMIC INSTITUTIONS ARE USED

- 1 TO THINKING ABOUT A PI. BUT THE ROLE OF THE PROJECT
- 2 LEADER IS ALMOST, CALL IT, A HIGH LEVEL MANAGER, MAKE
- 3 SURE THAT BRINGS TOGETHER THE RIGHT PEOPLE, IS A DRIVING
- 4 FORCE. CALL THEM A LEADER AMONG EQUALS, HIM OR HER A
- 5 LEADER AMONG EQUALS BECAUSE THAT -- AND I THINK WHEN
- 6 YOU -- BECAUSE THE EXPECTATION HERE IS THAT FOR A DISEASE
- 7 TEAM, YOU WILL NEED MULTIPLE KINDS OF EXPERTISE, YOU WILL
- 8 NEED PI EQUIVALENTS IN DIFFERENT AREAS.
- 9 SO I TAKE IT UNDER CONSIDERATION, BUT, YOU
- 10 KNOW, WE CRINGE IN TERMS OF ADMINISTRATION AS TO HOW WE
- 11 WOULD MOVE FORWARD WITH THAT PARTICULAR MODEL.
- DR. MEYER: AND MY SECOND QUESTION IS MORE
- 13 GENERAL. AND BOB, IF YOU WANT TO TAKE THIS UP MAYBE
- 14 LATER, THAT'S FINE. BUT I GET BACK TO AN ISSUE THAT I
- 15 RAISED WITH ZACH AND WITH ARLENE, POSSIBLY ALSO WITH BOB,
- 16 AND THAT'S THE ISSUE OF ELIGIBILITY OF HIGHLY QUALIFIED
- 17 PEOPLE WHO HAVE FULL-TIME LABORATORIES IN A CALIFORNIA
- 18 INSTITUTION, BUT THEMSELVES ARE JOINTLY APPOINTED AT
- 19 ANOTHER INSTITUTION OUTSIDE OF CALIFORNIA.
- 20 WHAT I WAS TOLD, AND I THINK IT MADE A LOT OF
- 21 SENSE AT THE TIME, WAS THAT, WELL, WE DON'T REALLY WANT
- 22 TO HAVE THIS BE AN ISSUE WITH THE COURT CASES GOING ON;
- 23 AND THAT ONCE WE HAVE THE MONEY AND THE BONDS ARE SOLD
- 24 AND SO ON, THAT WE WOULD MOVE TOWARD A DIRECTION OF
- 25 MAKING ELIGIBILITY BASED ON WHERE THE LABORATORY IS

1 LOCATED AND THE INSTITUTION AS OPPOSED TO WHER	Τ.	SED TO WHERE	THE P.	Т
--	----	--------------	--------	---

- 2 SPENDS THEIR TIME.
- 3 SO MY QUESTION, THEN, IS BECAUSE THIS IS A
- 4 PI-BASED RFA, NOT LIKE THE FACILITIES ONE, WHICH, YOU
- 5 KNOW, YOU CAN ARGUE, BUT THIS IS MUCH MORE RESEARCH
- 6 ORIENTED, ARE WE NOW, BECAUSE THERE'S NOTHING SPECIFIC
- 7 HERE, ACCEPTING APPLICATIONS FROM INSTITUTIONS WHERE THE
- 8 PI IS, LET'S SAY FOR THE SAKE OF ARGUMENT, 50-PERCENT
- 9 TIME AT THAT INSTITUTION, BUT HAS A HUNDRED PERCENT TIME
- 10 RESEARCH ENTERPRISE GOING ON AT THAT INSTITUTION?
- 11 CHAIRMAN KLEIN: SO IF I CAN UNDERSTAND, VERY
- 12 SPECIFICALLY, IF THERE IS AN APPROPRIATE ALLOCATION OF
- 13 TIME TO THE RESEARCH BEING DONE IN CALIFORNIA, AND WE
- 14 WOULD BE PAYING FOR THE TIME BEING SPENT IN CALIFORNIA
- 15 AND THE STAFF IN CALIFORNIA IN THE FUTURE GRANTS,
- 16 INCLUDING THOSE THAT WE'RE CONTEMPLATING HERE, CAN WE, IN
- 17 FACT, CAPTURE THE OPPORTUNITY TO HAVE THOSE GREAT MINDS
- 18 THAT ARE PARTITIONING THEIR TIME TO CALIFORNIA? AND DR.
- 19 OLSON, IF I COULD CALL ON DR. CHIU BECAUSE IT HAS
- 20 PREVIOUSLY BEEN DIRECTED AT DR. CHIU, AND THEN ON YOU
- 21 AGAIN.
- DR. CHIU: I THINK YOU BRING UP AN EXCELLENT
- 23 POINT BECAUSE THE GOAL OF THESE DISEASE TEAMS IS TO GET
- 24 IT TO WORK AND TO GET IT TO A FINAL PRODUCT READY FOR
- 25 CLINIC. ONE OF THE THINGS WE LEARNED AND YOU WILL SEE IN

1	YOUR	DRAFT	OF	THE	WORKSHOP	TS	THAT	LEADERSHIP	TS	KFY.
_	1001		\sim 1		WONSING		111/71			11

- 2 AND WE WANT TO CAPTURE THE BEST LEADERS THAT WOULD BRING
- 3 THE PROJECT TO FRUITION.
- 4 THE SECOND THING ABOUT THESE DISEASE TEAMS THAT
- 5 DR. OLSON POINTED TO IS THAT THEY'RE GOING TO BE
- 6 MILESTONE DRIVEN. AND SHOULD THEY AT ANY POINT NOT NEED
- 7 THE MILESTONES, THEY WILL END. SO, THEREFORE, WE ARE NOT
- 8 SO WORRIED ABOUT WHO IS GOING TO BE LEADING AS LONG AS
- 9 THE LEADER IS EFFECTIVE AND WILL GET THE PROJECTS DONE
- 10 AND THAT THE WORK WILL BE DONE IN CALIFORNIA BECAUSE WE
- 11 CAN ONLY FUND WORK THAT'S DONE IN CALIFORNIA.
- DR. MEYER: SO IN OTHER WORDS, AND I WILL STOP
- 13 BEAT ON THIS HORSE AFTER I SAY THIS, IT'S BEEN, FROM WHAT
- 14 I HAVE HEARD, AND THIS IS HEARSAY, IS THAT UP UNTIL THIS
- 15 POINT, THE REVIEW COMMITTEES, THE STUDY SECTIONS THAT
- 16 HAVE BEEN REVIEWING GRANTS, HAVE MADE AN ISSUE OUT OF
- 17 THIS AND HAVE NEGATIVELY COMMENTED ON THE POTENTIAL OF
- 18 THESE CERTAIN GRANTS BECAUSE OF WHAT I BRING UP; I.E.,
- 19 THE PART-TIME NATURE. I'M HAPPY TO HEAR THAT THAT'S NOT
- 20 TRUE.
- MS. OLSON: I THINK IT WAS BASED ON THE
- 22 ELIGIBILITY CRITERIA FOR THE RFA'S AND THE APPLICATIONS
- 23 THAT WE HAVE PUT OUT -- THAT WE PUT OUT. SO IT'S THE
- 24 ELIGIBILITY CRITERIA THAT THE REVIEWERS WERE REACTING TO.
- DR. MEYER: PERFECT.

1	CHAIRMAN KLEIN: AND AS I UNDERSTAND THE
2	COMMENTS AND PRIOR DISCUSSIONS AT EXECUTIVE COMMITTEE,
3	DR. CHIU OR DR. OLSON PARTICIPATED IN, THAT THERE IS THE
4	INTENT TO CAPTURE THESE BRILLIANT SCIENTISTS WHO ARE
5	PREPARED TO MAKE A PART-TIME COMMITMENT TO CALIFORNIA,
6	PAYING FOR THE TIME THEY SPEND IN CALIFORNIA AS A PART OF
7	A TEAM THAT WOULD APPROACH THESE VERY COMPLICATED ISSUES.
8	AND, DR. MURPHY, IS THAT CONSISTENT WITH THE POLICY THAT
9	YOU ARE LOOKING AT?
10	DR. MURPHY: YES.
11	CHAIRMAN KLEIN: SO DR. POMEROY.
12	DR. POMEROY: CAN YOU JUST CLARIFY FOR ME ON
13	THESE GRANTS, ARE THESE AIMED AT ACADEMIC INSTITUTIONS,
14	INDUSTRY, AND HOW ABOUT ACADEMIC-INDUSTRY PARTNERSHIPS
15	BECAUSE WE'RE REALLY TALKING ABOUT TRYING TO BRING THESE
16	THERAPIES TO CLINICAL TESTING AND MARKET. SO WHAT DID
17	YOU ENVISION FOR THESE TEAMS?
18	MS. OLSON: CERTAINLY BY THE TIME OF THE
19	DISEASE TEAM GRANTS, WE WOULD EXPECT TO HAVE THEM OPEN TO
20	BOTH ACADEMIC AND FOR-PROFIT IN WHATEVER COLLABORATION,
21	YOU KNOW, YOU CHOOSE TO COME UP WITH. FOR THE PLANNING
22	GRANTS, I THINK WE'RE STILL FINALIZING OUR GRANTS
23	ADMINISTRATION POLICY FOR FOR-PROFITS, SO WE HAVEN'T
24	TOTALLY COME TO TERMS YET WITH WHO'S GOING TO BE ELIGIBLE
25	FOR THOSE, BUT WE'RE LEANING TOWARDS THE NONPROFIT ONLY.

1	CHAIRMAN KLEIN: AND LET ME ASK THE FOLLOW-ON
2	QUESTION TO THAT. IF THE NONPROFITS ARE ELIGIBLE FOR
3	THESE PLANNING GRANTS, THAT DOESN'T NECESSARILY PRECLUDE
4	THEM FROM HAVING FOR-PROFIT SCIENTISTS AS A PART OF THE
5	TEAM. IS THAT A CORRECT STATEMENT?
6	MS. OLSON: THAT IS A CORRECT STATEMENT.
7	CHAIRMAN KLEIN: DR. PRIETO AND THEN DUANE
8	ROTH.
9	DR. PRIETO: JUST A COMMENT REALLY. I THINK
10	THE STRENGTH OF THIS APPROACH IS THAT IT ALLOWS
11	INVESTIGATORS TO PUT TIME DEVOTE TIME AND RESOURCES TO
12	ADDRESSING EXACTLY THESE QUESTIONS AS THEY THINK ABOUT
13	WHAT A DISEASE TEAM WILL LOOK LIKE AND HOW THEY WILL PUT
14	IT TOGETHER AND ALLOWS THEM TO DO THAT WITH SPECIFICALLY
15	SET ASIDE TIME AND RESOURCES THAT WE'RE GIVING THEM. I'M
16	VERY EXCITED ABOUT THIS PROPOSAL BECAUSE THIS REALLY IS,
17	I THINK, WHAT I SIGNED ON FOR, TO, YOU KNOW, DRIVE US TO
18	THE CLINIC AND TO CURES FOR DISEASES. AND I THINK THIS
19	IS A VERY DIRECT STEP IN THAT DIRECTION. AND IF IT'S NOT
20	TOO EARLY, I'D LIKE TO MAKE A MOTION FOR APPROVAL.
21	CHAIRMAN KLEIN: THERE IS WE CAN CONTINUE
22	DEBATE WITH A MOTION, SO YOUR MOTION WOULD BE IN ORDER IF
23	YOU WOULD LIKE TO MAKE A MOTION FOR APPROVAL.
24	DR. PRIETO: I WOULD.
25	CHAIRMAN KLEIN: IS THERE A SECOND?

1	MS. LANSING: SECOND.
2	CHAIRMAN KLEIN: SECOND BY SHERRY LANSING. AND
3	WE HAVE A COMMENT BY DUANE ROTH.
4	MR. ROTH: I WANTED TO MAKE THE MOTION AS WELL,
5	BUT WHAT I REALLY WANTED TO ADD TO IT IS THAT I WOULD
6	LIKE CONSIDERATION TO THE COMMENTS THAT HAVE BEEN MADE BY
7	DR. PIZZO ABOUT CORES, THE CONCEPT OF INCLUDING INDUSTRY
8	SO THAT YOU GET SOME REALLY GOOD FEEDBACK HERE ABOUT WHAT
9	THE ULTIMATE GRANT SHOULD LOOK LIKE.
10	CHAIRMAN KLEIN: AND DR. PRICE.
11	DR. PRICE: YOU VERY RAPIDLY SAID SOMETHING
12	ABOUT INDIRECT COST RECOVERY, SO COULD YOU REPEAT IT, AND
13	COULD YOU GIVE US THE RATIONALE?
14	MS. OLSON: THESE ARE PLANNING GRANTS. WE WERE
15	NOT PLANNING ON INCLUDING ANYTHING IN AN INDIRECT COST.
16	WE DID NOT SEE THAT IT WOULD BE USING LAB FACILITIES OR
17	ANYTHING LIKE THAT.
18	DR. PRICE: OFFICE FACILITIES. I'M SERIOUS.
19	WELL, I HAVE A QUESTION FOR SUE BRYANT, A VCR IN THE UC
20	SYSTEM. I'M JUST WONDERING WHETHER THESE GRANTS COULD BE
21	PROCESSED THROUGH THE UC SYSTEM IF THEY'RE ZERO COST
22	RECOVERY.
23	DR. BRYANT: I'M SURE
24	DR POMEROV: I'D LIKE TO CLARIEV THAT HE

87

POLICY IS THAT WE HAVE TO APPLY THE INDIRECT RATES UNLESS

25

$1 - WE \ GET \ A \ SPECIFIC \ REVIEW \ AND \ WAIVER. \ AND \ SO \ THE$: UC	SO THE	AND	WAIVER.	AND	REVIEW	SPECIFIC	Α	GET	WE	1
---	------	--------	-----	---------	-----	--------	----------	---	-----	----	---

- 2 INSTITUTIONS APPLYING, AND THERE'S PROBABLY SOMETHING
- 3 COMPARABLE AT THE OTHER INSTITUTIONS THAT MIGHT BE
- 4 APPLYING, WOULD HAVE TO GO THROUGH THEIR INTERNAL
- 5 PROCESSES, I WOULD PRESUME, IN ORDER TO DOCUMENT THAT.
- 6 DR. PRICE: I DON'T THINK THAT THIS WILL MEET
- 7 THOSE CRITERIA, SO WE'LL HAVE TO GET AN EXCEPTION TO THE
- 8 CRITERIA. AND BOARD OF REGENTS IS NOT ALLOWING US TO
- 9 HAVE EXCEPTIONS. NOW I'M BEING FACETIOUS.
- 10 MS. LANSING: BOARD OF REGENTS IS FLEXIBLE.
- 11 CHAIRMAN KLEIN: SO SHERRY LANSING.
- 12 MS. LANSING: I JUST AS A MEMBER OF THE CIRM
- 13 BOARD AND AS A REGENT, I AM EXTREMELY SUPPORTIVE OF THIS
- 14 BECAUSE WHAT I THINK THIS IS IS WE'VE BEEN TALKING ABOUT
- 15 INTERDISCIPLINARY APPROACH AND TAKING IT FROM THE
- 16 ABSTRACT INTO THE CLINICAL AND INTO EVENTUALLY CURES.
- 17 AND THIS IS EXACTLY, THOUGH DR. PIZZO INFORMS ME THAT
- 18 THERE HAVE BEEN THINGS LIKE THIS BEFORE, AS A LAYPERSON I
- 19 DON'T HEAR A LOT ABOUT IT, SO I HAVE TO SAY THAT I'M GLAD
- 20 WE'RE AT LEAST AT THE FOREFRONT OF THIS. AND I THINK
- 21 IT'S EVERYTHING THAT OUR GROUP HAS BEEN TALKING ABOUT IN
- 22 TERMS OF SHARED INFORMATION, IN TERMS OF BEING
- 23 INNOVATIVE, IN TERMS OF CROSSING DISCIPLINES. SO I JUST
- 24 THINK IT'S EXTRAORDINARY, SO AS A PATIENT ADVOCATE I
- 25 THANK YOU.

1		CHAIRMAN	KLEIN:	AND I	WOULD	LIKE	TO	SAY	THAT	
_	•	_								

- WE'RE VERY APPRECIATIVE TO HAVE THE RICHNESS OF THE
- 3 REPRESENTATION ON THIS BOARD THAT WE CAN INTERFACE SO
- 4 MANY DIFFERENT LEVELS OF INPUT INTO THIS GRANT SYSTEM.
- 5 DR. PIZZO.
- DR. PIZZO: I'LL FOREGO. THANK YOU.
- 7 CHAIRMAN KLEIN: OKAY.
- 8 DR. BRYANT: COULD I JUST FOLLOW UP? I DO
- 9 BELIEVE IT WOULD BE POSSIBLE. I WANT TO JUST RETURN TO
- 10 THAT, BUT THERE ARE COSTS ASSOCIATED WITH BRINGING MONEY
- 11 IN AND ACCOUNTING FOR IT AND ALL OF THAT, SO IT'S NOT
- 12 THAT THERE AREN'T -- THE LAB ISN'T THE ONLY THING THAT
- 13 GETS PAID. SO I WOULD PREFER IF WE COULD HAVE A REDUCED,
- 14 BUT STILL APPROPRIATE INDIRECT RATE.
- 15 DR. PIZZO: SO NOW THAT SUE HAS MADE THAT
- 16 COMMENT, MAYBE I WILL ALSO. YOU KNOW, CLEARLY, THIS IS A
- 17 VERY IMPORTANT PROJECT, AND SO WE ALL WANT TO SEE THIS GO
- 18 FORWARD, BUT I THINK HER COMMENT IS TRUE. IN ONE WAY OR
- 19 ANOTHER, WHETHER IT'S STATE OR PRIVATE INSTITUTION, YOU
- 20 HAVE TO FIND THE FUNDING FOR THIS. SO IT HAS TO,
- THEREFORE, COME OUT OF SOME OTHER RESOURCE, AND THAT,
- 22 NONETHELESS, YOU KNOW, IS AN ISSUE FOR US. SO I THINK
- THIS IS AN IMPORTANT ISSUE, AND WE'LL FIGURE OUT HOW TO
- 24 GET IT DONE, BUT, YOU KNOW, THERE IS A PRICE TO IT.
- 25 CHAIRMAN KLEIN: DR. MURPHY.

1	DR. MURPHY: LET ME JUST SAY ONE OF THE THINGS
2	I'VE LEARNED AT THE CIRM, AND IT GOES AROUND A LOT, IS
3	WHEN WE MAKE A DECISION, THE BOTTOM LINE IS DOES THIS
4	HELP THE MISSION. AND I THINK MANY OF THE QUESTIONS THAT
5	HAVE BEEN RAISED HERE COULD BE ANSWERED, WELL, IF IT
6	REALLY DOES HELP THE MISSION, LET'S LET IT HAPPEN, THE
7	BUSINESS ASSOCIATION, ALL THE OTHER THINGS, ALL THE OTHER
8	GOOD SUGGESTIONS YOU'VE MADE. AND I THINK WE SHOULD LOOK
9	VERY POSITIVELY ON THOSE.
10	AS A FORMER PERSON IN THE SAME POSITION YOU
11	FOLKS ARE, I UNDERSTAND THE NEED FOR OVERHEAD. AND MR.
12	CHAIRMAN, CAN WE SUGGEST THAT THE BOARD WOULD APPROVE
13	PERHAPS A 10-PERCENT OVERHEAD ALLOWANCE FOR THIS TYPE OF
14	GRANT TO COVER THE COSTS THAT HAVE BEEN, I THINK, VERY
15	JUSTIFIABLY RAISED HERE?
16	CHAIRMAN KLEIN: COULD THE MAKER OF THE MOTION
17	AMEND THE MOTION AS A FRIENDLY AMENDMENT?
18	DR. PRIETO: YES, I'D ACCEPT THAT AS A FRIENDLY
19	AMENDMENT.
20	CHAIRMAN KLEIN: AND THE SECOND? SHERRY IS THE
21	SECOND. WOULD YOU ACCEPT AN AMENDMENT TO PERMIT A
22	10-PERCENT OVERHEAD?
23	MS. LANSING: I ACCEPT THAT.
24	CHAIRMAN KLEIN: OKAY. SO THE MAKER OF THE
25	MOTION AND THE SECOND HAVE ACCEPTED AS A FRIENDLY

1	AMENDMENT.	SO	THE	MOTTON	RFFORF	US	WOULD HAVE	FΔ
_		20		1.10 I TOI1		-	WOOLD HAV	_ ^

- 2 10-PERCENT OVERHEAD ALLOWANCE WITH IT IF IT WERE TO PASS.
- 3 AT THIS POINT I'D LIKE TO ASK ARE THERE PUBLIC
- 4 COMMENTS? MR. SIMPSON.
- 5 MR. SIMPSON: JOHN SIMPSON, FOUNDATION FOR
- 6 TAXPAYER AND CONSUMER RIGHTS. ONE IS A POINT OF
- 7 CLARIFICATION. YOU DID MAKE IT CLEAR THAT YOU WOULD BE
- 8 ABLE TO APPLY FOR THE DISEASE TEAM FULL GRANTS IF YOU
- 9 DON'T DO THE PLANNING GRANTS. BUT WHAT'S THE SITUATION IF
- 10 YOU HAVE A PLANNING GRANT? ARE YOU PRETTY MUCH
- 11 GUARANTEED? I MEAN WOULD YOU EXPECT ALL OF THEM TO LEAD
- 12 TO FRUITION? WHAT RATE IS THE SORT OF RATE THAT WOULD BE
- 13 AN ACCEPTABLE RATE?
- 14 CHAIRMAN KLEIN: I THINK THAT THIS BOARD AND
- 15 THE STAFF HAVE ALWAYS BEEN FOCUSED ON THE QUALITY AND THE
- 16 BRILLIANCE AND PROMISE OF THE GRANTS. WE DON'T HAVE THE
- 17 FACTS AT THIS POINT TO SEE WHAT THE -- WHAT COMES OF
- 18 THESE PLANNING GRANTS, AND WE WOULD NEED TO EVALUATE
- 19 THAT. BUT IF THE STAFF WOULD LIKE TO COMMENT.
- 20 MS. OLSON: THE PURPOSE OF THE PLANNING GRANT
- 21 IS TO INCREASE THE NUMBER OF POTENTIAL QUALITY
- 22 APPLICATIONS THAT WE HAVE. IT WILL BE UP TO OUR
- 23 SCIENTIFIC REVIEWERS AND TO THE BOARD WHEN WE FINALLY
- 24 ACTUALLY SEE THE DISEASE TEAM GRANTS. BUT GETTING A
- 25 PLANNING GRANT IS NO GUARANTEE OF GETTING A GRANT.

1	CHAIRMAN KLEIN: AND PLEASE REALIZE THE DISEASE
2	TEAM GRANTS THAT ARE BEING THOUGHT UP CONCEPTUALLY ARE IN
3	THE RANGE OF \$20 MILLION. SO THIS IS A VERY SERIOUS
4	UNDERTAKING WITH VERY SPECIFIC OBJECTIVES. DR. OLSON AND
5	THEN DR. HENDERSON.
6	MS. OLSON: I WAS JUST GOING TO SAY THE FULL 20
7	MILLION IS ASSUMING THEY WERE SUCCESSFUL IN GETTING
8	THE TO A KEY MILESTONE OF GETTING AN APPROVED IND AND
9	ACTUALLY WOULD INCLUDE CLINICAL STUDIES AS WELL. AS YOU
10	CAN SEE, THE DISEASE TEAM ITSELF, WE WOULD PROBABLY FUND
11	SOME PORTION OF THAT WITH THE GOAL OF GETTING TO AN
12	APPROVABLE IND, AND IT WOULD HAVE MILESTONES ALONG THE
13	WAY.
14	CHAIRMAN KLEIN: DR. OLSON, ON YOUR LAST SLIDE
15	THAT'S HERE, COULD YOU COMMENT ON THE BOXES THAT LIE
16	BELOW THE DISEASE TEAM BOX TO SPECIFICALLY RELATE HOW
17	SOME OF THESE PLANNING GRANTS MAY END UP FALLING INTO
18	TRANSLATIONAL RESEARCH GRANTS OR OTHER CATEGORIES?
19	MS. OLSON: OKAY. AS YOU CAN SEE, THE SCIENCE
20	OF THERAPY DEVELOPMENT HAS MANY STAGES TO IT. AND WHAT
21	WE CAN SEE IS THAT IF CERTAIN DISEASE TEAM PLANNING
22	GRANTS PERHAPS WERE NOT SUCCESSFUL IN COMPETING FOR A
23	DISEASE TEAM AWARD, THERE ARE OTHER OPPORTUNITIES. THERE
24	WOULD BE WE'RE GOING TO HAVE PRECLINICAL PRODUCT
25	DEVELOPMENT. SO TAKING THINGS FORWARD TO ACTUALLY WHAT'S

1	BFFN	KNOWN	AS	THF	VALLEY	ΟF	DFATH.	GETTING	THE

- 2 MANUFACTURER, DOING THE TOX STUDIES THAT YOU NEED TO DO
- 3 TO GO INTO THE CLINIC, WE WOULD ALSO HAVE TRANSLATIONAL
- 4 RESEARCH PART 2 MIGHT COVER THAT KIND OF CATEGORY AS
- 5 WELL. THE EARLIER STAGE OF TRANSLATIONAL RESEARCH MIGHT
- 6 COVER SOME IDEAS OR SOME BOTTLENECKS.
- 7 CAN WE GET -- WE HEARD THIS MORNING ABOUT
- 8 GETTING CARDIOMYOCYTES IN A QUANTITY SUFFICIENT TO TALK
- 9 ABOUT GOING TO THE CLINIC. THAT'S THE KIND OF THING THAT
- 10 I MIGHT LOOK TO SEE IN TRANSLATIONAL RESEARCH ONE,
- 11 METHODS TO ACTUALLY PRODUCE CARDIOMYOCYTES IN ENOUGH
- 12 QUANTITIES THAT WE COULD TALK ABOUT ACTUALLY LOOKING AT
- 13 THEM IN MULTIPLE DISEASE MODELS AND THAT WE COULD
- 14 ACTUALLY TALK ABOUT MOVING THEM TO THE NEXT STAGE OF
- 15 THINKING ABOUT GOING INTO PEOPLE. SO ALL THESE DIFFERENT
- 16 ASPECTS OF THE PROGRAM ARE DESIGNED TO, YOU KNOW, MOVE
- 17 RESEARCH ALONG, TO GET INTO THE CLINIC, AND THERE WILL BE
- 18 FAILURES ON THE WAY. YOU ALL KNOW THAT THINGS DON'T
- 19 ALWAYS WORK, BUT WE'RE PROVIDING LOTS OF CHANCES, I
- THINK, FOR PEOPLE TO EXPLORE THEIR IDEAS AND TO MOVE
- 21 THINGS AND TO TRANSLATE THEIR IDEAS INTO, YOU KNOW,
- 22 POSSIBLE DISCOVERIES THAT WILL MAKE A DIFFERENCE.
- 23 CHAIRMAN KLEIN: ALL RIGHT. ADDITIONAL
- 24 COMMENTS FROM THE BOARD?
- DR. BRYANT: I JUST HAD A QUESTION.

1	CHAIRMAN KLEIN: DR. HENDERSON, DID YOU STILL
2	HAVE A COMMENT?
3	DR. HENDERSON: YEAH. I JUST AGAIN REITERATE I
4	THINK THIS IS A CALL TO THE SCIENTIFIC COMMUNITY, TO ALL
5	OF OUR COLLEAGUES, AS WELL AS OURSELVES ABOUT THE MISSION
6	WE'RE ON, TO GET PRODUCTS INTO THE CLINIC. WE'VE ALL
7	BEEN TO THE SPOTLIGHT PRESENTATIONS IF WE'RE NOT AWARE OF
8	ISSUES IN OUR OWN FAMILY AND AMONG OUR FRIENDS. SO THIS
9	IS TO TRY TO GALVANIZE SOME SERIOUS EFFORT AT DISEASE
10	TRANSLATION, TREATMENT.
11	CHAIRMAN KLEIN: AND DR. BRYANT.
12	DR. BRYANT: I JUST HAD A QUESTION, AND THAT
13	WAS WILL ACCEPTANCE OF A PLANNING GRANT MEAN THAT A GRANT
14	APPLICATION NEEDS TO BE PUT IN? I'M JUST WONDERING IF
15	THOSE TWO ARE LINKED OR PEOPLE COULD CHANGE THEIR MINDS
16	OR WHAT?
17	MS. OLSON: PEOPLE CAN CHANGE THEIR MINDS.
18	DR. BRYANT: OKAY.
19	MR. SIMPSON: I WAS TRYING TO CLARIFY ON THE
20	PLANNING GRANTS, WHICH I THINK ARE TERRIBLY IMPORTANT,
21	JUST WHAT IF THERE'S A COMPARABLE SORT OF SENSE OF,
22	SAY, WHEN NIH MAKES THESE GRANTS, HOW MANY OF THEM
23	ACTUALLY GET TO THE FULL STAGE?
24	CHAIRMAN KLEIN: WE DON'T KNOW THAT. WE DON'T
25	HAVE THE FACTUAL INFORMATION THAT WILL DEVELOP AND BE THE

- 1 RESULT OF THIS PROCESS.
- MR. SIMPSON: AND I AGREE THAT THAT'S
- 3 TREMENDOUSLY IMPORTANT, BUT I ALSO HAVE TO IN GOOD
- 4 CONSCIENCE ADD A NOTE OF SKEPTICISM ABOUT THE SORT OF
- 5 ACADEMIC TENDENCY TO AUTOMATICALLY TACK ON INDIRECT
- 6 COSTS. I WISH I COULD DO THAT IN MY LIFE, BUT IT DOES
- 7 SEEM TO ME THAT THIS SEEMS A LITTLE STRANGE, TO HAVE A
- 8 GRANT THAT'S A PLANNING GRANT AND SAY, OH, AND BY THE
- 9 WAY, ADD X PERCENT. IT JUST ISN'T AS STRAIGHTFORWARD
- 10 WITH THE PUBLIC AND THE TAXPAYER. I MEAN YOU WOULD BE
- 11 BETTER TO SAY, OKAY, WE WANT THE GRANT AND WE'RE ASKING
- 12 FOR THIS MUCH TO PAY THE RENT RATHER THAN JUST
- 13 AUTOMATICALLY TACKING IN AN OVERHEAD. IT DOESN'T MAKE
- 14 SENSE.
- 15 CHAIRMAN KLEIN: I'D LIKE TO COMMENT THAT 10
- 16 PERCENT IS WAY BELOW ANY JUSTIFIABLE RANGE OF OVERHEAD.
- 17 IT IS A VERY STRINGENT STANDARD. IT IS A VERY
- 18 CONSERVATIVE STANDARD, AND THE -- IT REQUIRES SOME
- 19 SACRIFICE BY THE INSTITUTIONS.
- DR. PIZZO: MR. CHAIRMAN, IF I COULD JUST MAKE
- 21 A TANGENTIAL STATEMENT.
- 22 CHAIRMAN KLEIN: COULD I ASK IF WE COULD HAVE A
- 23 VOTE. WE'RE ABOUT TO LOSE DR. HENDERSON.
- DR. PIZZO: THAT'S ACTUALLY RELEVANT, AND THEN
- 25 IT'S ABOUT DR. HENDERSON.

1	1	I'D LIKE TO CALL THE OUESTION
J	L CHAINMAN NEEIN.	T D LINE TO CALL THE OUESTION

- 2 IF WE CAN. ALL IN FAVOR. OPPOSED? UNANIMOUS PASSAGE OF
- 3 THIS. IT'S A GREAT VOYAGE WE'RE ABOUT TO EMBARK ON.
- 4 AND, DR. PIZZO, YOU HAVE A COMMENT.
- DR. PIZZO: YES, THANK YOU. SO I JUST WANT TO
- 6 ASK YOU, MR. CHAIRMAN, TO IN YOUR CAPACITY ACKNOWLEDGE
- 7 DR. BRIAN HENDERSON, WHO MAY OR MAY NOT BE LEAVING THE
- 8 BOARD IN THE IMMEDIATE FUTURE. HE'S STEPPING DOWN IN A
- 9 MONTH IN HIS ROLE AS DEAN AT USC WHERE HE'S DONE A GREAT
- 10 JOB. HE'S BEEN A WONDERFUL COLLEAGUE AND SUPPORTER SINCE
- 11 THE INCEPTION OF THIS PROGRAM. IT'S BEEN A PRIVILEGE TO
- 12 BE WORKING WITH HIM. IF HE DOES GO OFF WILL BE WOEFULLY
- 13 MISSED, BUT I THOUGHT YOU WOULD LIKE TO SAY SOMETHING
- 14 ABOUT THAT AS WELL.
- 15 CHAIRMAN KLEIN: THANK YOU VERY MUCH.
- 16 DR. PIZZO: KNOWING THAT YOU ALWAYS CAN COME UP
- 17 WITH SOMETHING GOOD TO SAY.
- 18 CHAIRMAN KLEIN: WELL, IT HAS BEEN A TREMENDOUS
- 19 PRIVILEGE FOR ME INDIVIDUALLY AND FOR THE MEMBERS OF THIS
- 20 BOARD TO BE -- TO HAVE THE GUIDANCE, INSPIRATION, AND
- 21 CONTRIBUTIONS OF DR. HENDERSON DURING THIS HISTORIC TIME
- 22 LEADING UP TO TODAY WHEN WE ARE ISSUING OUR FIRST BONDS.
- 23 IT IS A TIME OF GREAT CHALLENGES THAT HAVE BEEN MARKED BY
- 24 TREMENDOUS ACCOMPLISHMENTS BY THIS BOARD. AND DR.
- 25 HENDERSON GAVE US AN EARLY CONTRIBUTION OF DR. HALL ALONG

	1	THE WAY.	ALONG	WITH	NUMEROUS	CALLS	AND	GUIDANCE	Α
--	---	----------	-------	------	----------	-------	-----	----------	---

- 2 DIRECTION. HE HAS BEEN A RESOURCE FOR ME AND FOR MEMBERS
- 3 OF THIS BOARD.
- 4 IT IS REMARKABLE AS WELL THE TREMENDOUS
- 5 CONTRIBUTIONS THAT HAVE OCCURRED AND THE RECRUITMENT OF
- 6 WORLD LEADERS AT USC BRINGING DR. PERA FROM AUSTRALIA,
- 7 WHICH MAY HAVE INSPIRED SUBSEQUENT RECRUITMENTS ON A
- 8 GLOBAL BASIS TO THE STEM CELL MISSION. BUT CERTAINLY
- 9 WE'VE ALL BEEN VERY PRIVILEGED TO PARTICIPATE. I WOULD
- 10 LIKE TO SEE IF WE COULD ALL STAND AND APPLAUD.
- 11 (APPLAUSE.)
- 12 CHAIRMAN KLEIN: WE STILL HAVE A QUORUM HERE,
- BUT WE JUST HAVE A QUORUM, SO WE'RE GOING TO TRY AND MOVE
- 14 EXPEDITIOUSLY. DR. MURPHY.
- DR. MURPHY: MR. CHAIRMAN, I'M WONDERING IF WE
- 16 CAN GO TO ITEM NO. 10 BECAUSE THAT REALLY IS A HIGH
- 17 PRIORITY FOR THE INSTITUTE, AND WE NEED A VOTE TO ACCEPT
- 18 THE RECOMMENDATION THAT STAFF WILL BE MAKING TO ENTER
- 19 INTO AN AGREEMENT FOR THE GRANTS MANAGEMENT SYSTEM. AND
- 20 WE WANT TO MAKE SURE THAT WE CAN GET THAT APPROVED TODAY
- 21 WHILE WE HAVE A FULL QUORUM.
- 22 CHAIRMAN KLEIN: ALL RIGHT. IF WE COULD MOVE
- 23 TO ED DORRINGTON. ED, WE HAVE GREAT APPRECIATION FOR THE
- TREMENDOUS CONTRIBUTION OF TIME, PASSION, AND COMMITMENT
- 25 YOU'VE MADE TO THIS ENTERPRISE. AND IF YOU COULD, HOW

1	MUCH TIME WILL YOU THINK YOU WILL USE IN MOVING THROUGH
2	THIS ITEM?
3	MR. DORRINGTON: ABOUT SIX OR SEVEN MINUTES.
4	CHAIRMAN KLEIN: WELL, THAT'S IMPRESSIVE.
5	MR. DORRINGTON: WELL, WE'LL SEE.
6	CHAIRMAN KLEIN: AND THEN WE WILL GO BACK, FOR
7	THE PURPOSES OF INFORMATION FOR THE BOARD AND THE
8	AUDIENCE, THEN TO ITEM 9; IS THAT CORRECT, DR. MURPHY?
9	DR. MURPHY: THAT'S RIGHT. THAT'S RIGHT. MR.
LO	CHAIRMAN, BEFORE ED BEGINS, LET ME JUST INTRODUCE ED
L1	DORRINGTON TO THE ICOC. ED IS A SOFTWARE ARCHITECT WHO
L2	HAS BEEN WITH THE INSTITUTE FOR
L3	MR. DORRINGTON: LITTLE OVER TWO YEARS.
L4	DR. MURPHY: TWO YEARS. ED IS THE PERSON
L5	WHO REALLY CREATED THE SOFTWARE THAT IS CURRENTLY BEING
L6	USED BY THE INSTITUTE FOR ITS GRANTS MANAGEMENT PROGRAM.
L7	SO HE WAS IN CHARGE OF THE SURVEY THAT WAS DONE TO CHOOSE
L8	THIS NEW SYSTEM WE'LL BE RECOMMENDING TO YOU WITH
L9	COLLEAGUES IN THE INSTITUTE. AND I JUST WANT TO ASSURE
20	YOU HE IS VERY WELL QUALIFIED TO BE RECOMMENDING THIS TO
21	US.
22	MR. DORRINGTON: THANK YOU. SO I'M GOING TO BE
23	TALKING ABOUT GRANTS MANAGEMENT SYSTEM HERE. I'M GOING
24	TO TALK ABOUT WHY WE NEED A GRANTS MANAGEMENT SYSTEM HOW

WE WENT ABOUT CHOOSING A VENDOR, AND WHO WE ENDED UP

1	RECOMMENDING.
	IVECOMMENDATIO.

- 2 SO WHY DO WE NEED A SYSTEM? THIS SLIDE, WHICH
- 3 YOU'VE ALL SEEN BEFORE, OUTLINES THE STEPS INVOLVED IN
- 4 THE LIFE CYCLE OF A GRANT. EACH STEP IN THIS LIFE CYCLE
- 5 INVOLVES A COORDINATED EFFORT AMONGST A LARGE NUMBER OF
- 6 PEOPLE, WHETHER CIRM STAFF MEMBERS, APPLICANTS, GRANTEES,
- 7 GRANTS WORKING GROUP MEMBERS, OR THE ICOC. MANY OF THESE
- 8 STEPS INVOLVE GATHERING INFORMATION FROM OTHER PROGRAMS,
- 9 QUERYING HISTORICAL INFORMATION, ETC. AND ACTUALLY,
- 10 DR. BRENNER, TO ADDRESS YOUR EARLIER POINT IN TERMS OF
- 11 TRACKING THE PROGRESS OF OUR CIRM SCHOLARS, THIS IS
- 12 EXACTLY THE TYPE OF QUALITATIVE AND QUANTITATIVE
- 13 INFORMATION THAT A GRANTS MANAGEMENT SYSTEM WOULD ALLOW
- 14 US TO TRACK.
- 15 AT ANY GIVEN TIME THERE WOULD BE SEVERAL
- 16 PROGRAMS GOING THROUGH THE YELLOW PRE-AWARD AND AWARD
- 17 STEPS AND LITERALLY DOZENS GOING THROUGH THE POSTAWARD
- 18 TRACKING PROCESSES. EACH PROGRAM COULD CONTAIN FROM
- 19 DOZENS TO HUNDREDS OF APPLICATIONS OR AWARDS, AND EACH
- 20 AWARD COULD INCLUDE MANY PROGRESS REPORTS,
- 21 CERTIFICATIONS, AND OTHER FORMS, ALL OF WHICH LEADS TO A
- 22 LOT OF PAPER. AND JUST SO YOU KNOW, THAT'S JUST THE
- 23 APPLICATIONS FOR JUST ONE PROGRAM.
- 24 WHEN YOU IMAGINE THAT VOLUME OF INFORMATION
- 25 ACROSS ALL THE PROGRAMS WE'LL BE FINISHING OVER MANY

1	YEARS, THE NEED FOR AN ELECTRONIC GRANTS MANAGEMENT
2	SYSTEM TO COORDINATE THESE EFFORTS BECOMES ABUNDANTLY
3	CLEAR.
4	SO HOW DID WE GO ABOUT FINDING THE RIGHT
5	SYSTEM? WE BEGAN EARLY THIS YEAR BY WRITING A DETAILED
6	REQUEST FOR PROPOSAL FOR SUCH A SYSTEM. BY THIS TIME,
7	AFTER HAVING GONE THROUGH SEVERAL REVIEW CYCLES, WE HAD A
8	VERY GOOD UNDERSTANDING OF OUR REQUIREMENTS AND
9	PROCESSES. SO THE RFP OUTLINED 129 SPECIFIC REQUIREMENTS
10	AND IDENTIFIED THE CRITERIA BY WHICH PROPOSALS WOULD BE
11	EVALUATED. THE RFP ALSO STATED THAT ANY CONTRACT WITH A
12	VENDOR WOULD BE ON A PAY-FOR-PERFORMANCE BASIS WHEREBY
13	THE VENDOR IS NOT PAID EXCEPT FOR ACTUAL DELIVERED
14	FUNCTIONALITY. THE RFP WAS POSTED LATE IN MAY, AND
15	RESPONSES WERE DUE AT THE END OF JUNE.
16	BY THE DEADLINE WE HAD RECEIVED FIVE PROPOSALS.

- 17 SO WE THEN CONVENED A NINE-MEMBER EVALUATION COMMITTEE
- 18 WHICH CONSISTED OF SEVEN CIRM EMPLOYEES, INCLUDING
- 19 SCIENTIFIC OFFICERS, I.T., AND SENIOR MANAGEMENT, AND TWO
- 20 OUTSIDE VOLUNTEERS WHO HAD EXTENSIVE EXPERIENCE IN GRANTS
- 21 MANAGEMENT SYSTEMS.
- THE EVALUATION COMMITTEE MET TO REVIEW AND
- 23 SCORE THE PROPOSALS ON THE BASIS OF THESE FIVE CRITERIA:
- 24 THE EXPERIENCE OF THE VENDOR, THE QUALIFICATIONS OF THE
- 25 PERSONNEL IMPLEMENTING THE SOLUTION, THE RESPONSIVENESS

1	OF THEIR PROPOSAL TO THE SCOPE OF WORK OUTLINED IN THE
2	RFP, THE COST TO IMPLEMENT AND MAINTAIN THE SYSTEM, AND
3	THE TIMING OF THE PROJECT. CAN THEY MEET OUR DEADLINES.
4	THE EVALUATION COMMITTEE CAREFULLY REVIEWED
5	EACH ELEMENT OF THE PROPOSAL AGAINST EACH OF THE CRITERIA
6	IN ORDER TO DETERMINE A FINAL SCORE. AFTER EVALUATING
7	THE PROPOSALS, WE WERE ABLE TO NARROW THE FIELD TO THREE
8	FINALISTS. HOWEVER, IN ORDER TO CHOOSE A WINNING BIDDER,
9	THE EVALUATION COMMITTEE FELT THAT WE NEEDED TO SEE THESE
10	SYSTEMS IN ACTION AND ALSO NEEDED TO MEET WITH THE PEOPLE
11	WHO WOULD BE IMPLEMENTING THE SYSTEM.
12	SO DURING JULY AND INTO EARLY AUGUST, ALL THREE
13	FINALISTS CAME AND GAVE HALF-DAY DEMONSTRATIONS OF THEIR
14	SYSTEMS. WE REQUIRED THAT THE PEOPLE GIVING THE
15	DEMONSTRATIONS BE MEMBERS OF THE TEAM WHO WOULD BE
16	IMPLEMENTING THE SYSTEM. THIS ALLOWED EVALUATION
17	COMMITTEE MEMBERS TO ASK QUESTIONS OF EACH BIDDER AND TO
18	MEET SOME OF THEIR TEAM.
19	AFTER THE DEMONSTRATIONS, THE EVALUATION
20	COMMITTEE IDENTIFIED A FEW REMAINING AMBIGUITIES IN THE
21	PROPOSALS, SO WE PUT TOGETHER A DOCUMENT ASKING FOR
22	CLARIFICATION OF THESE QUESTIONS. THE RESPONSES WERE TO
23	BE IN THE FORM OF AN ADDENDUM TO THEIR PROPOSAL. AFTER
24	RECEIVING ALL THREE RESPONSES, THE EVALUATION COMMITTEE
25	MET AGAIN TO DISCUSS THE NEW INFORMATION, AND THIS TIME

1	WE WERE ABLE TO MAKE A UNANIMOUS RECOMMENDATION.
2	THE SYSTEM WE RECOMMEND IS A SYSTEM CALLED
3	GRANTIUM. IT'S FROM A COMPANY ALSO CALLED GRANTIUM,
4	WHICH IS HEADQUARTERED IN CANADA, IS EXCLUSIVELY IN THE
5	BUSINESS OF SELLING GRANTS MANAGEMENT SOFTWARE, AND THEY
6	HAVE BEEN IN BUSINESS FOR TEN YEARS. THEY HAVE CUSTOMERS
7	IN CANADA, AUSTRALIA, AND THE U.S., AND THEIR CUSTOMERS
8	INCLUDE THE ALBERTA ADVANCED EDUCATION AND TECHNOLOGY,
9	THE INNOVATION INSTITUTE OF ONTARIO, THE U.S. AGENCY FOR
10	INTERNATIONAL DEVELOPMENT, AND THE DEPARTMENT OF STATE.
11	AND OVER THE COURSE OF OUR EVALUATION, WE
12	CONTACTED EACH OF THESE CUSTOMERS, AND THEY WERE ALL
13	EXTREMELY POSITIVE ABOUT THEIR EXPERIENCES WITH GRANTIUM,
14	BOTH AS A COMPANY AND WITH THE SOFTWARE.
15	SO THE CONTRACT THAT THEY ARE PROPOSING
16	INCLUDES A SIX-MONTH IMPLEMENTATION SCHEDULE AT AN
17	IMPLEMENTATION COST OF APPROXIMATELY \$550,000. IN
18	ADDITION, THERE'S AN ANNUAL MAINTENANCE FEE OF
19	APPROXIMATELY \$49,000, WHICH INCLUDES ALL FIXES,
20	UPGRADES, AND NEW VERSIONS OF THE SYSTEM. WE ANTICIPATE
21	SIGNING A THREE-YEAR IMPLEMENTATION AND SUPPORT CONTRACT
22	WITH THE POTENTIAL FOR ANNUAL EXTENSIONS. THE TOTAL FOR
23	THIS INITIAL CONTRACT WOULD, THEREFORE, BE \$702,000.
24	THERE WOULD ALSO BE SOME ADDITIONAL EXPENSES, BOTH
25	INITIAL AND ONGOING, INVOLVED WITH HOSTING THE SYSTEM.

1	THESE WOULD INCLUDE APPROXIMATELY \$10,000 FOR HARDWARE
2	AND APPROXIMATELY \$15,000 A YEAR IN HOSTING COSTS. SO
3	THE TOTAL OUTLAY FOR THREE YEARS WOULD, THEREFORE, BE
4	APPROXIMATELY \$757.000. AND GOING FORWARD EACH
5	ADDITIONAL YEAR WOULD BE ROUGHLY \$64,000.
6	SO THE CORE STRENGTHS OF THE PROPOSAL INCLUDE
7	THE SOFTWARE ITSELF, WHICH IS BOTH POWERFUL AND HIGHLY
8	CONFIGURABLE AND ALLOWS CIRM TO ADAPT TO CHANGING
9	REQUIREMENTS AND DIRECTIONS WITHOUT A MAJOR
10	REIMPLEMENTATION EFFORT. IT'S AN EXTENSIBLE SYSTEM,
11	WHICH ALLOWS OTHER SOFTWARE TO BE INTEGRATED WITH IT. IF
12	THERE'S FUNCTIONALITY THAT GRANTIUM DOESN'T SUPPLY, WE
13	CAN CREATE AND INTEGRATE OUR OWN SOLUTIONS OR PURCHASE
14	THEM FROM A THIRD PARTY.
15	SO, FOR EXAMPLE, REPORTING. REPORTING IS
16	CLEARLY AN IMPORTANT PIECE OF THE SYSTEM, AND GRANTIUM
17	DECIDED NOT TO REINVENT THE WHEEL, BUT, RATHER, TO
18	INTEGRATE A SYSTEM CALLED CRYSTAL REPORTS. CRYSTAL
19	REPORTS IS THE GOLD STANDARD IN REPORTING AND WILL ALLOW
20	US TO CREATE VIRTUALLY ANY REPORT THAT WE MIGHT REQUIRE.
21	THE STRENGTHS OF THE COMPANY AND TEAM
22	THEMSELVES INCLUDE PROJECT MANAGEMENT. SEVERAL GRANTIUM
23	EMPLOYEES ARE THOUGHT LEADERS IN THE FIELD OF PROJECT
24	MANAGEMENT AND HAVE BROUGHT THEIR SKILLS TO BEAR IN

CREATING A STANDARDIZED DEVELOPMENT METHODOLOGY. IN

25

1	TALKING TO THE CUSTOMERS I MENTIONED EARLIER, ONE OF THE
2	THINGS THEY KEPT REFERRING TO WAS THE CONFIDENCE THAT
3	THEY HAD IN GRANTIUM'S ABILITY TO MEET ITS DEADLINES AND
4	TO GENERALLY DO WHAT THEY SAY THEY WILL DO. AND A LOT OF
5	THAT WAS BASED ON THEIR CONFIDENCE IN THIS METHODOLOGY.
6	ANOTHER STRENGTH IS IN TRAINING. GRANTIUM'S
7	METHODOLOGY STRESSES CONTINUOUS KNOWLEDGE TRANSFER BOTH
8	FROM CIRM TO GRANTIUM, TEACHING THEM ABOUT OUR PROCESSES,
9	AND FROM GRANTIUM BACK TO CIRM, TRAINING CIRM STAFF HOW
10	TO USE THE SYSTEM IN A WAY THAT IS TAILORED DIRECTLY TO
11	OUR NEEDS AND REQUIREMENTS.
12	WE'RE CONFIDENT THAT PARTNERING WITH GRANTIUM
13	IS THE RIGHT NEXT STEP FOR CIRM TO TAKE IN GETTING A
14	COMPREHENSIVE ELECTRONIC GRANTS MANAGEMENT SYSTEM UP AND
15	RUNNING BOTH QUICKLY AND EFFICIENTLY, AND WE'RE ASKING
16	THE ICOC TO APPROVE THIS RECOMMENDATION AFTER WHICH WE'LL
17	QUICKLY BEGIN IMPLEMENTATION. THANK YOU AND I'M HAPPY TO
18	TAKE ANY QUESTIONS.
19	CHAIRMAN KLEIN: QUESTIONS FROM THE BOARD? DR.
20	LEVEY.
21	DR. LEVEY: VERY NICE PRESENTATION. MAYBE I
22	MISSED THIS, BUT DID YOU HAVE A CHANCE MAYBE TO LOOK AT
23	GRANT MANAGEMENT SYSTEMS FOR SOME COMPARABLE GRANTING
24	ORGANIZATIONS SUCH AS THE AMERICAN HEART OR THE AMERICAN
25	CANCER SOCIETY OR THE AMERICAN DIABETES?

1	MR. DORRINGTON: OVER THE COURSE OF THIS
2	EVALUATION, WE TALKED TO A NUMBER OF FOLKS, THE HOWARD
3	HUGHES MEDICAL INSTITUTE, THE
4	DR. LEVEY: NIH.
5	MR. DORRINGTON: THE PACKARD FOUNDATION, UC
6	OFFICE OF THE PRESIDENT, A NUMBER OF DIFFERENT PEOPLE TO
7	SEE WHAT DIFFERENT PEOPLE ARE USING IN THE FIELD. A
8	NUMBER OF THESE ORGANIZATIONS HAVE BEEN AROUND FOR A LONG
9	TIME. THEY'VE OFTEN MADE THEIR CHOICE MANY YEARS AGO
10	BASED ON WHAT WAS AVAILABLE THEN. AND SO TO A CERTAIN
11	EXTENT, SINCE WE HAVE THE ADVANTAGE OF BEING NEW, WE HAVE
12	THE ADVANTAGE ALSO OF SEEING WHAT IS CURRENT. AND WE DID
13	SEE A FEW PEOPLE WHO ARE CHOOSING SYSTEMS LIKE GRANTIUM,
14	OR, GIVEN THE CUSTOMERS THAT I MENTIONED, PEOPLE WHO DID
15	CHOOSE GRANTIUM.
16	BUT THE MOST THE BIGGEST SYSTEM OUT THERE IS
17	A SYSTEM CALLED GIFTS FROM MICROEDGE, WHICH A NUMBER OF
18	PEOPLE ARE USING, BUT IT'S A VERY LIMITED SYSTEM, LIMITED
19	IN ITS FUNCTIONALITY, AND REALLY WOULD NOT BE ABLE TO
20	MEET OUR REQUIREMENTS.
21	DR. LEVEY: IN FOLLOW-UP, DID YOU HAVE A CHANCE
22	TO TEST THE SYSTEM, TO PUT IT THROUGH SOME SORT OF PACE
23	TO SEE HOW IT WORKED?
24	MR. DORRINGTON: WELL, WE DID SEE THE
25	DEMONSTRATION OF THE SYSTEM; BUT BECAUSE THE WAY THESE

1	SYSTEMS	WORK.	THERE'S	NOT	SO N	MUCH	OFF-THE-SHELF	SOFTWARE

- 2 AS A SYSTEM THAT IS EXTENSIVELY CUSTOMIZED TO OUR NEEDS,
- 3 SO IT WOULD BE VERY DIFFICULT TO GET A REAL SENSE OF HOW
- 4 THE SYSTEM WOULD WORK IN OUR SITUATION UNTIL YOU GO
- 5 THROUGH IT, BUT WE DID ACTUALLY SEE THE SYSTEM WORKING.
- 6 CHAIRMAN KLEIN: OKAY. DR. PIZZO. AND WHILE
- 7 DR. PIZZO IS GETTING A MICROPHONE, ED, COULD YOU EXPLAIN
- 8 IN TERMS OF WHICH MEMBERS OF THE SCIENCE TEAM WORKED WITH
- 9 YOU TO MAKE CERTAIN THAT THE NEEDS OF THE SCIENCE TEAM
- 10 WERE BEING MET?
- MR. DORRINGTON: SURE. YEAH. THE MEMBERS OF
- 12 THE EVALUATION COMMITTEE WERE ARLENE CHIU, AMY LEWIS, GIL
- 13 SAMBRANO, KUMAR HARI, AND THEN FROM I.T. DENNIS BUTLER,
- 14 AND FROM ADMINISTRATION LORI HOFFMAN AND MYSELF, AND THEN
- 15 THE TWO EXTERNAL FOLKS THAT WE HAD WERE CHRIS MENCEL FROM
- 16 THE MOORE FOUNDATION AND MELANIE CAVANAGH LYNCH FROM THE
- 17 UC OFFICE OF THE PRESIDENT BREAST CANCER RESEARCH
- 18 PROGRAM.
- 19 CHAIRMAN KLEIN: DR. PIZZO.
- DR. PIZZO: I AGREE THIS WAS A VERY NICE
- 21 PRESENTATION. THANK YOU.
- 22 CHAIRMAN KLEIN: IS HIS MIC ON PLEASE?
- DR. PIZZO: SO VERY HELPFUL PRESENTATION, BUT I
- 24 WONDER IF YOU COULD EVEN AT SOME HIGH LEVEL -- YOU MAY
- 25 NOT HAVE THE ACTUAL DATA TO SHARE WITH US -- HOW YOU

1	ACTUALLY	MADE	THE	SELECTION	TN	COMPARISON	TO	THE	OTHER

- 2 TWO FINALISTS? YOU PRESENTED THE DATA WITH REGARD TO THE
- 3 FINALISTS, BUT I DON'T KNOW WHAT THE DIFFERENTIATING
- 4 ELEMENTS WERE THAT LED YOU TO THAT.
- 5 MR. DORRINGTON: WELL, THERE ARE BASICALLY TWO
- 6 PIECES. ONE WAS MORE QUANTITATIVE, WHICH IS THE SCORES
- 7 ON THOSE FIVE CRITERIA, IN WHICH CASE GRANTIUM DID SCORE
- 8 THE HIGHEST IN EVERY CRITERIA. AND THEN THE SECOND
- 9 FACTOR USED WAS A MORE SUBJECTIVE FACTOR WHICH WAS BASED
- 10 ON RESULTS AFTER THOSE DEMONSTRATIONS. AND IT'S BASED ON
- 11 THINGS LIKE A FEEL OF WHO WE THOUGHT MIGHT BE BEST SUITED
- 12 TO WORK WITH US, WHO LOOKS LIKE THEY WOULD BE ABLE TO
- 13 ACTUALLY GET THE JOB DONE, AND THEN IT WAS ALSO BASED ON
- 14 THE CONVERSATIONS WE HAD HAD WITH THE VARIOUS REFERENCES.
- 15 DR. PIZZO: SO I ASSUME THAT THE COST WAS
- 16 FACTORED INTO THE SCORING SYSTEM THAT YOU HAD AS WELL.
- 17 MR. DORRINGTON: YES.
- DR. PRICE: QUESTION IS WHETHER THE COST YOU
- 19 OUOTE US INCLUDES CUSTOMIZATION?
- 20 MR. DORRINGTON: YES. THIS IS A COMPLETE COST.
- 21 CHAIRMAN KLEIN: NOW, TO BE SPECIFIC, IT'S MY
- 22 UNDERSTANDING IF A YEAR FROM NOW WE HAVE A VERY --
- 23 ANOTHER CUSTOMIZED APPROACH FOR A NEW PROGRAM NOT
- 24 INITIALLY CONTEMPLATED, THERE COULD BE AN ADDITIONAL
- 25 CHARGE AT THAT TIME?

1	MR. DORRINGTON: RIGHT. AND WE DO ANTICIPATE
2	HAVING A LONG-TERM RELATIONSHIP WITH THE COMPANY, BUT ONE
3	OF THE OTHER ADVANTAGES OF THE SYSTEM IN TERMS OF ITS
4	EXTENSIBILITY, AS I SAID, IS THAT, DEPENDING ON WHAT
5	THOSE THINGS ARE, WE MAY BE ABLE TO DO THAT IN-HOUSE OR
6	WE MAY CONTRACT WITH THEM.
7	CHAIRMAN KLEIN: MICHAEL GOLDBERG.
8	MR. GOLDBERG: IN TERMS OF YOUR ANALYSIS, DID
9	YOU LOOK AT THE FINANCIAL VIABILITY OF THE FIRM?
10	MR. DORRINGTON: TO THE EXTENT POSSIBLE. ONE
11	OF THE INTERESTING ISSUES IS THAT ALL OF THE THREE
12	FINALISTS ARE PRIVATE COMPANIES AND ARE NOT VERY WILLING
13	TO SHARE FINANCIAL DATA.
14	MR. GOLDBERG: SO IN MY EXPERIENCE, THE BEST
15	WAY TO PROTECT AGAINST THAT WOULD BE MAKE SURE THAT YOU
16	OWN ACCESS TO THE CODE IN THE EVENT OF DEFAULT OR
17	BANKRUPTCY.
18	MR. DORRINGTON: RIGHT. AND ONE OF THE FACTORS
19	THAT WAS IN THE RFP WAS SPECIFICALLY THAT, TO HAVE CODE
20	IN ESCROW SO THAT SHOULD THEY GO UNDER, WE WOULD HAVE
21	ACCESS TO THAT CODE. AND ALSO WE HAD TRIED TO ADDRESS
22	THAT WITH THE PAY-FOR-PERFORMANCE ISSUE. SO THAT WE'RE
23	NOT PAYING UNLESS WE GET SOMETHING FOR IT.
24	MR. GOLDBERG: THANK YOU.
25	CHAIRMAN KLEIN: DAVID SERRANO-SEWELL.

1 MR. SERRANO-SEW	ELL: I JUST ASSUME THAT LEGAL
-------------------	-------------------------------

- 2 IS GOING TO LOOK AT THE CONTRACT BEFORE IT'S EXECUTED.
- 3 MR. DORRINGTON: OH, SURE. OF COURSE.
- 4 MR. SERRANO-SEWELL: L.A. UNIFIED SCHOOL
- 5 DISTRICT, THEY'RE JUST TRYING TO UNTANGLE A \$40 MILLION
- 6 PLUS CONTRACT THAT THEY ENTERED INTO TO UPGRADE THEIR
- 7 PAYROLL COMPUTER SYSTEM, AND THEY'VE HAD TO HIRE
- 8 ADDITIONAL CONSULTANTS TO THE TUNE OF LIKE ANOTHER 10
- 9 MILLION. SO I DON'T THINK WE'RE GOING TO FIND OURSELVES
- 10 IN THAT KIND OF SITUATION, BUT IT DOES --
- MR. DORRINGTON: YEAH. WE WILL DEFINITELY.
- MR. SERRANO-SEWELL: -- GIVE ME SOME COMFORT TO
- 13 KNOW THAT.
- MR. DORRINGTON: OH, YEAH.
- MR. SERRANO-SEWELL: MAYBE WE'LL TAKE A LOOK AT
- 16 THIS AS WELL.
- 17 CHAIRMAN KLEIN: AND IN THE PAYMENT UNDER THE
- 18 CONTRACT, IT'S CONTEMPLATED THAT THERE WILL BE MILESTONES
- 19 IN THE PAYMENT.
- 20 MR. DORRINGTON: YES. THAT IS PART OF THE PAY
- 21 FOR PERFORMANCE IS THAT THERE ARE SET MILESTONES. WHEN
- THEY REACH THOSE MILESTONES IS WHEN WE RELEASE PAYMENT,
- 23 ETC.
- 24 CHAIRMAN KLEIN: AND, DR. MURPHY, DID YOU HAVE
- 25 A COMMENT?

- DR. MURPHY: NO. ONE THING THAT I THINK MADE A
- 2 VERY GOD JOB OF THIS AND I FULLY SUPPORT THE
- 3 RECOMMENDATION.
- 4 CHAIRMAN KLEIN: IS THERE A MOTION TO SUPPORT
- 5 THIS?
- 6 DR. PIZZO: SO MOVED.
- 7 DR. WRIGHT: SECOND.
- 8 CHAIRMAN KLEIN: I THINK IT'S DR. PIZZO AND
- 9 DR. WRIGHT. AND IS THERE ADDITIONAL COMMENTS FROM THE
- 10 BOARD? IS THERE ADDITIONAL COMMENTS FROM THE PUBLIC?
- 11 JOHN SIMPSON.
- 12 MR. SIMPSON: JOHN SIMPSON FROM THE FOUNDATION
- 13 FOR TAXPAYER AND CONSUMER RIGHTS. IT LOOKS TO ME LIKE
- 14 YOU DEFINITELY GOT IT RIGHT THIS TIME. I REFLECT ON THE
- ARLINGTON GROUP THAT WENT BELLY UP, AND IT SEEMED TO ME
- 16 THAT THAT MIGHT HAVE BEEN CAUSED BECAUSE THE PROCESS OF
- 17 VETTING ALL THE POTENTIAL APPLICANTS WAS NOT THOROUGH
- 18 ENOUGH. AND I THINK I SUGGESTED THAT AT THE TIME, IN
- 19 RETROSPECT. BUT THIS LOOKS GOOD, SO I THINK IT'S A GOOD
- 20 THING AND COMMEND YOU FOR IT.
- 21 CHAIRMAN KLEIN: AND MY UNDERSTANDING IS THAT
- 22 WITH THE PRIOR GROUP, BECAUSE OF MILESTONES AND CONTROLS,
- 23 WE WERE ABLE TO KEEP THE EXPOSURE VERY LOW. IS THAT A
- 24 CORRECT STATEMENT?
- MR. DORRINGTON: YEAH. I BELIEVE THE SUM TOTAL

1	TC \$56	000	TUAT 14	E DATE	$\cap \vdash \land$	ROUGHLY	CTMTI AD	CTZE
	T2 2)() . UUU	IDAI W	VE PAID	UF A	KUUGHLI	STIMTLAK	SIZE

- 2 CONTRACT.
- 3 CHAIRMAN KLEIN: WE APPRECIATE CONTROLS AND
- 4 SCRUTINY OF THAT KIND. THANK YOU VERY MUCH.
- 5 SO I'D LIKE TO CALL FOR THE QUESTION. ALL IN
- 6 FAVOR. OPPOSED? MOTION PASSES. THANK YOU VERY MUCH FOR
- 7 THE TREMENDOUS JOB OF THE ENTIRE TEAM.
- 8 WE'D LIKE TO GO TO ITEM NO. 9 WHILE PEOPLE ARE
- 9 HUNGRY AND THEIR ATTENTION IS PEAKED.
- DR. CHIU: I WILL BE BRIEF, MR. CHAIRMAN. MR.
- 11 CHAIRMAN, I ASK THE BOARD TO CONSIDER A NEW RFA FOR
- 12 CONCEPT APPROVAL. THIS IS AGENDA ITEM NO. 9 IN YOUR
- 13 BINDERS, A PROPOSAL FOR CIRM TO FUND THE DERIVATION OF
- 14 NEW PLURIPOTENT HUMAN STEM CELL LINES. NOW, AS YOU ALL
- 15 KNOW, CURRENT FEDERAL POLICY ONLY ALLOWS THE USE OF A FEW
- 16 LINES OF HUMAN EMBRYONIC STEM CELLS FOR RESEARCH, AND NO
- 17 FUNDS ARE PROVIDED FOR THE DERIVATION OF NEW AND BETTER
- 18 LINES.
- 19 ALL THE PRESIDENTIAL LINES ARE DERIVED WITH OLD
- 20 METHODS USED BEFORE 2001; FOR EXAMPLE, METHODS THAT
- 21 EXPOSE CELLS TO ANIMAL PRODUCTS. WE NEED TO ALLOW
- 22 RESEARCHERS TO TEST AND DEVELOP NEW AND BETTER METHODS
- 23 THAT WILL PRODUCE THE CELL LINES MOST USEFUL FOR CLINICAL
- 24 USE.
- 25 RECENT REPORTS ALSO INDICATE THAT ALL HUMAN

1	EMBRYONIC	STEM	CELL	LINES	ΙN	EXISTENCE	ARE	NOT	ALL	ALIKE.

- 2 EVEN UNDER THE SAME GROWTH CONDITIONS, SOME LINES SHOW A
- 3 PREFERENCE FOR PRODUCING FOREBRAIN NEURONS WHILE OTHERS
- 4 DO NOT. IF WE WANT TO GET THE BEST CELL SOURCE FOR
- 5 DIFFERENT TREATMENTS, WE NEED TO FUND THE DERIVATION OF
- 6 MANY MORE CELL LINES.
- 7 AND THERE ARE THREE COMPELLING REASONS THAT I
- 8 CAN THINK OF FOR FUNDING THE GENERATION OF NEW CELL
- 9 LINES. THE FIRST SHOWN ON THE SLIDE IS A NEED, THE NEED
- 10 FOR NEW LINES SO THAT WE CAN HAVE GREATER GENETIC
- 11 DIVERSITY, SO THAT WE CAN GENERATE DISEASE-SPECIFIC LINES
- 12 FOR CELLULAR MODELS OF DISEASE AND FOR DRUG DISCOVERY, SO
- 13 THAT WE CAN GET CLINICAL GRADE LINES THAT CAN BE USED FOR
- 14 THERAPIES, AND SO THAT WE CAN GET OPTIMAL LINES FOR
- 15 SPECIFIC DESIRED PHENOTYPES OR CELL TYPES IN NEED.
- 16 THE SECOND REASON IS THAT NEW METHODS ARE
- 17 CONSTANTLY BEING DEVELOPED FOR DERIVING HUMAN EMBRYONIC
- 18 STEM CELLS, NEW METHODS WITHOUT EXPOSURE TO ANIMAL
- 19 PRODUCTS, NEW DEFINED GROWTH CONDITIONS, THAT IS MEDIA
- 20 FACTORS, SUBSTRATES, FETAL LAYERS, ETC., NEW METHODS
- 21 FOLLOWING GOOD MANUFACTURING PRACTICE. IN ADDITION,
- 22 DISEASE-SPECIFIC CELL LINES COULD ALSO BE GENERATED FROM
- 23 EMBRYOS IDENTIFIED DURING PREIMPLANTATION GENETIC
- 24 DIAGNOSIS OF PGD.
- 25 IN ADDITION, THERE HAVE BEEN RECENT REPORTS OF

- 1 DERIVING HUMAN EMBRYONIC STEM CELLS FROM SINGLE
- 2 BLASTOMERES. AND LAST, BUT CERTAINLY NOT LEAST, THERE IS
- 3 SCNT. A RECENT REPORT OUT OF OREGON INDICATES THAT THIS
- 4 HAS BEEN SUCCESSFULLY ACCOMPLISHED IN NONHUMAN PRIMATES,
- 5 AND THIS IS INDEED ENCOURAGING NEWS, BUT THERE ARE NO
- 6 REPORTS OF THESE BEING ACCOMPLISHED IN HUMANS WITH HUMAN
- 7 CELLS, SO THERE IS A GREAT NEED TO ATTEMPT THIS NEW
- 8 TECHNOLOGY.
- 9 NOVEL SOURCES AND PROTOCOLS FOR GENERATING
- 10 PLURIPOTENT CELL LINES, WE KNOW THAT RECENT PAPERS FROM
- 11 DRS. YAMANAKA, JAENISH, AND OTHERS DEMONSTRATE AND VERIFY
- 12 THAT IT IS POSSIBLE TO REPROGRAM MATURE ADULT SOMATIC
- 13 CELLS TO DEDIFFERENTIATE THEM, IF YOU WILL, AND GENERATE
- 14 FULLY PLURIPOTENT STEM CELLS.
- THESE STUDIES HAVE ONLY BEEN DONE IN MICE, AND
- 16 THE TIME IS RIPE TO SEE IF WE CAN DO THE SAME WITH HUMAN
- 17 CELLS.
- 18 THE SECOND POINT, THERE ARE CYBRIDS WHICH ARE
- 19 CREATED BY THE FUSION OF HUMAN EMBRYONIC STEM CELLS WITH
- 20 ADULT CELLS. THAT'S ANOTHER EXCITING POSSIBILITY, BUT
- 21 HAVE NOT BEEN SUCCESSFULLY ACHIEVED AS YET. AND FINALLY,
- 22 OTHER INNOVATIVE METHODS ARE PROBABLY BEING THOUGHT OF
- 23 AND DEVELOPED AS WE SPEAK.
- SO WITH THIS INITIATIVE, WE ASK TO SUPPORT M.D.
- 25 AND PH.D. SCIENTISTS AND THEIR EQUIVALENTS TO CONDUCT

1	RESEARCH	TOWARD	THIS	GOAL AT	Т	INSTITUTIONS	ΙN	CALIFORNIA

- 2 AND THIS IS THE ONLY CONDITION OF ELIGIBILITY. WE WANT
- 3 TO SUPPORT THE FULL SPECTRUM OF HUMAN PLURIPOTENT STEM
- 4 CELL TYPES AND EXPERIMENTAL APPROACHES, AND WE SUGGEST
- 5 TWO TIMES OF AWARDS. THE FIRST TYPE IS FOR GENERATING
- 6 HUMAN EMBRYONIC STEM CELL LINES GENERATED FROM CELLS THAT
- 7 ARE DERIVED FROM EARLY PREIMPLANTATION EMBRYOS OF LESS
- 8 THAN 12 DAYS, AS PER OUR MEDICAL AND ETHICAL STANDARDS.
- 9 THE SECOND KIND OF AWARD IS TO GENERATE NEW HUMAN
- 10 PLURIPOTENT STEM CELLS STARTING WITH OTHER SOURCES. SO
- 11 WE'RE REALLY OPENING UP THE FIELD IN THIS APPROACH.
- 12 EACH APPLICANT INSTITUTION MAY SUBMIT UP TO
- 13 FOUR APPLICATIONS, TWO OF EACH TYPE. WE'D LIKE TO ASK
- 14 YOU TO FUND EIGHT GRANTS OF EACH TYPE. EACH WILL BE A
- 15 THREE-YEAR GRANT WITH PROJECT COSTS OF UP TO \$300,000 PER
- 16 YEAR. THE TOTAL COST OF THIS PROGRAM WE ESTIMATE TO BE
- 17 APPROXIMATELY \$25 MILLION, AND OUR CURRENT DRAFT
- 18 TIMETABLE IS RFA RELEASE IN THE FALL OF THIS YEAR, REVIEW
- 19 IN THE WINTER OF '07-'08, AND FOR YOUR APPROVAL FOR
- 20 FUNDING IN THE SPRING OF '08.
- 21 AND I WANT TO POINT OUT THAT WE'VE JUST
- 22 RECRUITED A NEW SCIENCE OFFICER, DR. UTA GRIESHAMMER,
- 23 FROM DR. GAIL MARTIN'S LAB IN UCSF, AND SHE WILL BE
- 24 TAKING THE LEAD ON THIS INITIATIVE SHOULD YOU APPROVE IT.
- AND, MR. CHAIRMAN, I ASK FOR THE BOARD'S

- 1 CONSIDERATION OF THIS PROPOSAL.
- CHAIRMAN KLEIN: THANK YOU VERY MUCH, DR. CHIU.
- 3 I THINK DUANE ROTH, AND THEN I'M GOING TO GO TO THE
- 4 RIGHT.
- 5 MR. ROTH: DR. CHIU, YOU SAID IN TERMS OF
- 6 ELIGIBILITY, THAT IT WAS M.D., PH.D., OR EQUIVALENT IN AN
- 7 INSTITUTION. WILL THIS BE OPEN TO COMPANIES?
- 8 DR. CHIU: THAT'S A VERY GOOD QUESTION. IF THE
- 9 FOR-PROFIT GRANT ADMINISTRATION POLICY IS READY, WE WOULD
- 10 LIKE IT TO BE OPEN TO FOR-PROFIT ENTITIES WHEN WE LAUNCH
- 11 IT. BUT IT WAITS TO BE SEEN, AND IT'S UP TO THE BOARD TO
- 12 SEE HOW LONG WE SHOULD HOLD THIS BACK. THE OTHER
- 13 POSSIBILITY IS THAT WE RE-RELEASE THIS AGAIN WHEN THE
- 14 FOR-PROFIT GAP IS READY SO THAT COMPANIES TOO COULD
- 15 COMPETE.
- 16 MR. ROTH: YOU KNOW, I AM ANXIOUS TO GET
- 17 SOMETHING OUT THERE THAT COMPANIES CAN START TO SEE THAT
- 18 CIRM IS SERIOUS ABOUT FUNDING THEM. AND I WOULD LIKE TO
- 19 SUGGEST WE FIND A WAY TO ALLOW THEM TO SUBMIT
- 20 APPLICATIONS HERE AND MOVE IN PARALLEL VERY QUICKLY TO
- 21 FINALIZE THE FOR-PROFIT IP POLICY, WHICH IS IN VERY LATE
- 22 STAGE. I CAN'T IMAGINE THERE'S GOING TO BE MATERIAL
- 23 CHANGES TO THAT.
- DR. CHIU: IT'S FOR THAT REASON WE DID NOT PUT
- 25 UP THERE THAT IT WOULD BE RESTRICTED TO ACADEMIC AND NOT

- 1 FOR-PROFIT.
- 2 MR. ROTH: I WAS CONFUSED BY THE WORD
- 3 "INSTITUTIONS."
- 4 DR. CHIU: I SEE. I SHOULD SAY ORGANIZATIONS.
- 5 THANK YOU.
- 6 CHAIRMAN KLEIN: YES. DR. STEWARD AND THEN DR.
- 7 PIZZO.
- 8 DR. STEWARD: CAN YOU SAY A WORD, AND IT'S
- 9 ESPECIALLY IMPORTANT GIVEN THE FACT THAT THIS WOULD
- 10 POTENTIALLY BE OPEN TO PRIVATE COMPANIES AS WELL, HOW
- 11 THESE, LET'S CALL THEM, REAGENTS FALL UNDER THE CURRENT
- 12 CIRM GUIDELINES AS FAR AS MAKING ANYTHING CREATED BY CIRM
- 13 FUNDING AVAILABLE FREELY, AS I RECALL?
- DR. CHIU: YOU MAKE AN EXCELLENT POINT. YOU
- 15 KNOW WE HAVE THE IP POLICY WHICH REQUIRES SHARING OF
- 16 REAGENTS UPON PUBLICATION, AND THIS WILL HOLD. AND THE
- 17 KEY IS UPON PUBLICATION.
- 18 CHAIRMAN KLEIN: DR. PIZZO.
- DR. PIZZO: I THINK MY QUESTION IS A BIT IN THE
- 20 SAME CONTEXT AS DR. STEWARD'S. IT HAS A HYPOTHETICAL
- 21 ASSOCIATED WITH IT, AND I WOULD ASK THAT IT HAVE AN
- 22 INTERNAL REVIEW. I DON'T EXPECT THAT YOU CAN COMMENT ON
- 23 THIS RIGHT NOW. BUT THE SCENARIO IS WHAT IF THERE'S AN
- 24 INVESTIGATOR WHO COMES TO CALIFORNIA FOR PART OF HER OR
- 25 HIS WORK WHO HAS AN APPOINTMENT IN ANOTHER STATE, LET'S

1	SAY	WTSCONSTN	AS	Α	HYPOTHETICAL,	WHO	DEVELOPS	NFW	STFM

- 2 CELL LINES. AND BECAUSE OF AN ACADEMIC AFFILIATION SEEKS
- 3 TO HAVE THOSE SAID LINES BECOME PART OF, FOR EXAMPLE, THE
- 4 WISCONSIN POLICY. SO YOU DON'T NEED TO RESPOND TO IT
- 5 NOW, BUT I HOPE THAT WE CAN LOOK AT THIS BECAUSE THEIR
- 6 HYPOTHETICAL HAS SOME POTENTIAL REALITIES.
- 7 DR. CHIU: I THANK YOU FOR THAT COMMENT.
- 8 ACTUALLY WE HAVE THOUGHT ONLY HALFWAY THROUGH THAT
- 9 PARTICULAR PROBLEM. AND THAT IS, WE VERY SPECIFICALLY
- 10 WANTED TO HAVE IT OPEN TO ANYONE COMING TO DO THE
- 11 RESEARCH IN CALIFORNIA, AS WE KNOW THAT CALIFORNIA HAS
- 12 BECOME A MECCA FOR ATTRACTING A LOT OF VERY ABLE PEOPLE
- 13 WITH NOVEL IDEAS. HOWEVER, IN TERMS OF THE IP, WE WOULD
- 14 SEEK THE ADVICE AND HELP OF OUR LEGAL COUNSEL.
- 15 DR. PIZZO: BECAUSE AS WE DISCUSSED EARLIER
- 16 THIS MORNING, WE WOULD WELCOME JOINT APPOINTMENTS OR
- 17 OTHER APPOINTMENTS THAT WOULD BRING NEW TALENT TO
- 18 CALIFORNIA, RECOGNIZING THAT THE INDIVIDUAL MAY BE AT
- 19 ANOTHER PLACE, BUT I THINK WE JUST HAVE TO UNDERSTAND --
- 20 THE LEGAL FOLKS WILL NEED TO UNDERSTAND WHAT THAT MEANS
- 21 IN TERMS OF INSTITUTIONAL CONTROLS OVER IP AS WELL.
- DR. CHIU: SINCE THESE AWARDS WILL BE AWARDED
- 23 TO INSTITUTIONS IN CALIFORNIA, I HOPE THAT THAT WOULD
- 24 TAKE CARE OF IT --
- DR. PIZZO: IT MAY OBVIATE IT.

1	DR. CHIU: NO MATTER WHERE THE INVESTIGATOR
2	ACTUALLY COMES FROM TO DO THE WORK.
3	CHAIRMAN KLEIN: SO, DR. CHIU, FOR INSTITUTIONS
4	AND ORGANIZATIONS, YOU'RE SUGGESTING THAT, BECAUSE IT'S A
5	CALIFORNIA AWARD, THE PARTICIPANTS WOULD HAVE TO AGREE TO
6	OUR GAP AND OUR IP POLICY?
7	DR. CHIU: ABSOLUTELY. AND ALSO THE
8	INSTITUTION WHERE THE RESEARCH WOULD BE CONDUCTED, THE
9	ORGANIZATION WOULD BE IN CALIFORNIA.
10	CHAIRMAN KLEIN: THAT'S RIGHT. AND DR. MEYER.
11	DR. MEYER: VERY SPECIFIC QUESTION. YOU KIND
12	OF PRESENTED IT AS THIS IS A WAY OF GENERATING NEW CELL
13	LINES, WHICH I'M IMAGINING PROBABLY PRINCIPAL USE WOULD
14	BE IN REGENERATIVE MEDICINE. I DON'T KNOW WHETHER THIS
15	WILL BE SPECIFICALLY ADDRESSED IN THE RFA, BUT IT MIGHT
16	BE A GOOD IDEA WHEN IT COMES OUT BECAUSE WE HEARD OF
17	HUNTINGTON'S DISEASE THIS MORNING. THERE ARE A LOT OF
18	OPPORTUNITIES NOW WITH IVF CLINICS AND DISCARDED EMBRYOS
19	WITH GENETIC DISEASES TO ACTUALLY CREATE NEW CELL LINES,
20	FOR EXAMPLE, WITH HUNTINGTON'S DISEASE THAT WOULD BE
21	DISEASE MODELS AS OPPOSED TO CURING SOMEONE USING THOSE
22	CELLS.
23	IS THIS WITHIN THE SCOPE OF THIS RFA?
24	DR. CHIU: ABSOLUTELY. ABSOLUTELY.
25	CHAIRMAN KLEIN: OKAY. ADDITIONAL BOARD

1	DISCUSSION?	IS	THERE	Α	MOTION?	
т	DISCOSSION:	12	IHEKE	А	MO I TON !	

- DR. PIZZO: SO MOVED.
- 3 MR. ROTH: SECOND.
- 4 CHAIRMAN KLEIN: MOVED BY DR. PIZZO, SECOND BY
- 5 DUANE ROTH. ADDITIONAL PUBLIC DISCUSSION? SEEING NO
- 6 PUBLIC DISCUSSION, ALL IN FAVOR. OPPOSED? LET IT BE
- 7 SHOWN IT PASSED UNANIMOUSLY.
- 8 I THINK WE HAVE A BREAK FOR LUNCH AT THIS
- 9 POINT. LET ME ASK THIS QUESTION. IS THERE ANYONE WHO IS
- 10 LEAVING BEFORE WE RECONVENE? WE HAVE ONE MORE ITEM FOR A
- 11 QUORUM.
- MS. KING: WE COULD DO IT NOW, OR DO YOU HAVE
- 13 TO LEAVE.
- 14 CHAIRMAN KLEIN: WELL, WE DON'T EXPECT A
- 15 SIGNIFICANT EXECUTIVE SESSION, WHICH WILL BE CONCURRENT
- 16 WITH LUNCH. HOPEFULLY IT'S A QUICK ITEM.
- 17 MS. LANSING: WHY DON'T WE DO 45 MINUTES?
- 18 CHAIRMAN KLEIN: LET'S BE BACK IN 45 MINUTES.
- 19 MR. HARRISON, COULD YOU READ THE LANGUAGE THAT WOULD
- 20 ENTITLE US TO AN EXECUTIVE SESSION DURING LUNCH?
- MR. HARRISON: YES. GOING INTO EXECUTIVE
- 22 SESSION TO DISCUSS --
- 23 CHAIRMAN KLEIN: LET'S DO THIS VERY QUICKLY.
- 24 THE ITEM IS, WE THINK, FAIRLY ADMINISTRATIVE. IT'S JUST
- 25 TO CREATE A FINANCE COMMITTEE THAT DEALS WITH THE ISSUES

Т	OF TAX EXEMPTION WHERE WE'RE GOING TO GO ON TO OUR NEXT
2	STAGE AND MOVING THESE BONDS FORWARD. IT ALSO CREATES A
3	SUBCOMMITTEE, LIKE THE IP TASK FORCE, IN THIS CASE TO
4	LOOK AT THE FEASIBILITY OF HAVING A LOAN PROGRAM
5	AUTHORIZED BY THE INITIATIVE, BUT YET WE DO NOT HAVE A
6	LOAN PROGRAM AS ONE OF THE TOOLS FOR ADVANCING RESEARCH.
7	I HAVE TALKED TO TWO MEMBERS OF OUR COMMITTEE.
8	I'VE TALKED TO MICHAEL GOLDBERG, WHO IS WILLING TO BE THE
9	CHAIR OF THIS COMMITTEE, TO DEAL WITH THE ISSUES IN
10	WASHINGTON WITH THE IRS OPINIONS ON TAX EXEMPTION AND
11	BOND FINANCING ISSUES, AS WELL AS THE CHAIR OF THE AS
12	THE CHAIR OF THE TASK FORCE WITH DUANE ROTH, WHO HAS
13	SUBSTANTIAL EXPOSURE AND EXPERIENCE WITH THE PRIVATE
14	SECTOR IN LOOKING AT THE FEASIBILITY AND VETTING THE
15	POSSIBILITY OF IMPLEMENTING A LOAN PROGRAM.
16	THE COMMITTEE MEMBERSHIP WOULD BE OPEN TO ANY
17	MEMBER OF THE BOARD THAT WISHES TO PARTICIPATE. AND IF
18	THIS MATTER PASSES, IF THEY WOULD SUBMIT THEIR NAMES.
19	JUST TO MANAGE THE TOTAL NUMBER, I WOULD DISCUSS WITH
20	BOTH THE CHAIR OF THE COMMITTEE WHAT POTENTIAL VICE CHAIR
21	WE MIGHT HAVE POTENTIALLY FROM THE PATIENT ADVOCATE
22	SECTOR, BUT ALSO LOOKING AT INDUSTRY VICE CHAIRS OR
23	EXCUSE ME INSTITUTIONAL VICE CHAIRS AND WITH THE CHAIR
24	OF THE TASK FORCE LOOKING AT MEMBERSHIP THAT GIVES US A
25	DIVERSITY REPRESENTING ALL THE CONSTITUENCIES ON THE

- 1 BOARD.
- THIS HOPEFULLY IS AN ADMINISTRATIVE MATTER.
- 3 WOULD ANYONE LIKE TO MAKE A MOTION TO PASS THIS, AND WE
- 4 CAN THEN HAVE DISCUSSION ON IT?
- 5 MR. SERRANO-SEWELL: I SO MOVE.
- 6 CHAIRMAN KLEIN: MOVED BY DAVID SERRANO-SEWELL.
- 7 DR. BRYANT: SECOND.
- 8 CHAIRMAN KLEIN: SECOND BY DR. BRYANT.
- 9 COMMENTS BY THE COMMITTEE? NO COMMENTS BY THE COMMITTEE.
- 10 COMMENTS BY THE AUDIENCE?
- MR. HARRISON: JUST ONE CLARIFICATION. THERE
- 12 IS A TYPOGRAPHICAL ERROR UNDER AGENDA ITEM 11. IT REFERS
- 13 TO APPOINTMENT OF MEMBERS IN BETWEEN MEETINGS BY THE
- 14 GOVERNANCE SUBCOMMITTEE. THAT SHOULD ACTUALLY READ THE
- 15 FINANCE SUBCOMMITTEE.
- 16 CHAIRMAN KLEIN: AND THAT'S TRUE ON THE TASK
- 17 FORCE AS WELL.
- 18 MR. HARRISON: AND THAT'S TRUE ON THE TASK
- 19 FORCE AS WELL.
- 20 CHAIRMAN KLEIN: THANK YOU FOR THAT
- 21 CLARIFICATION. ANY MEMBERS OF THE PUBLIC HAVING
- 22 COMMENTS? SEEING NO MEMBERS, CALL THE QUESTION. ALL IN
- 23 FAVOR, OPPOSED.
- 24 SO AT THIS POINT WE HAVE PASSED THE ITEMS THAT
- 25 WE NEED TO. THERE ARE ADMINISTRATIVE ITEMS AND REPORTS.

Т	MIS. KING. DO B, YOU HAVE TO DO THE TASK FORCE
2	AS WELL.
3	CHAIRMAN KLEIN: HAVE TO PASS IT SEPARATELY?
4	MS. KING: IT'S A SEPARATE ITEM.
5	CHAIRMAN KLEIN: I THINK THE MOTION WAS
6	INTENDED TO INCORPORATE BOTH PARTS.
7	MS. KING: OKAY. FINE. SORRY ABOUT THAT.
8	CHAIRMAN KLEIN: SO WE HAVE ADMINISTRATIVE
9	REPORTS, SO WE WOULD LOOK FOR THE PUBLIC AND THE BOARD TO
10	RECONVENE. WOULD MR. HARRISON READ US THE LANGUAGE WHICH
11	ENTITLES US TO GO INTO AN EXECUTIVE SESSION TO DEAL WITH
12	PERSONNEL MATTERS?
13	MR. HARRISON: YES. WE'LL BE DISCUSSING TWO
14	ITEMS IN CLOSED SESSION: PENDING LITIGATION UNDER
15	GOVERNMENT CODE SECTION 11126 SUBDIVISION E AND PERSONNEL
16	PURSUANT TO GOVERNMENT CODE SECTION 1126 SUBDIVISION A,
17	AND HEALTH AND SAFETY CODE SECTION 125290.30(D)(3)(D).
18	CHAIRMAN KLEIN: THANK YOU. AND WHERE IS
19	THE WE WILL FOLLOW MELISSA KING FOR LUNCH. WE WILL
20	ATTEMPT TO BE BACK IN 45 MINUTES SO WE CAN MOVE THIS
21	AGENDA QUICKLY AND HOPEFULLY ADJOURN EARLY. THANK YOU.
22	(A RECESS WAS TAKEN.)
23	CHAIRMAN KLEIN: WE'RE RECONVENING, AND I'D
24	LIKE TO POINT OUT THAT THERE IS NO REPORT FROM THE
25	EXECUTIVE SESSION. NO ACTIONS TAKEN. IN THE

- 1 INTERMISSION INTERVENING TIME, SHERRY LANSING, IN MY
- 2 DISCUSSION WITH YOU ABOUT BAN PURCHASERS, YOU HAD A
- 3 SUGGESTION. MAYBE YOU WOULD LIKE TO MAKE IT FOR THE
- 4 WHOLE BOARD AND THE PUBLIC.
- 5 MS. LANSING: I WOULD. THIS IS, AS WE ALL
- 6 KNOW, A JOYOUS DAY BECAUSE THE BONDS ARE OUT AND IT'S A
- 7 VERY, VERY HAPPY TIME FOR ALL OF US. BUT WHENEVER
- 8 THERE'S A HAPPY TIME, WE ALSO HAVE A LOT TO BE GRATEFUL
- 9 FOR. AND IN MY MIND, IF WE CAN ALL FADE BACK TO A COUPLE
- 10 OF YEARS AGO AND A LOT OF THE DIFFICULTIES THAT WE WERE
- 11 GOING THROUGH, I REMEMBER THE PEOPLE WHO STEPPED UP AND
- 12 LOANED US THE BAN MONEY. AND THOSE PEOPLE WERE VERY,
- 13 VERY BRAVE. THEY CARED A GREAT DEAL ABOUT OUR CAUSE, AND
- 14 THEY GAVE US THE MONEY WITHOUT ANY ASSURANCES THAT THIS
- 15 MONEY WOULD BE RETURNED.
- 16 SO I WOULD LIKE TO, ALONG WITH THE LIST OF
- 17 PEOPLE, WHICH HAS BEEN PUBLIC RECORD, AS WELL AS OUR
- 18 GOVERNOR, WHO DID A REMARKABLE THING IN RELEASING MONEY
- 19 TO US AT THOSE VERY, VERY DIFFICULT TIMES, WITHOUT THE
- 20 GROUP OF PEOPLE AND OUR INCREDIBLE GOVERNOR, WE WOULD NOT
- 21 BE HERE TODAY. AND SO I SUGGEST THAT WE MAKE A
- 22 PROCLAMATION THANKING ALL OF THESE PEOPLE AND SIGN IT
- FROM ALL OF THE MEMBERS OF THE BOARD. AND I PERSONALLY,
- 24 I THINK I REPRESENT ALL THE BOARD IN THANKING ALL THE
- 25 PURCHASERS OF THE BAN AND IN THANKING OUR INCREDIBLE

1	GOVERNOR AS WELL.
2	SO I MOVE THAT WE MAKE A PROCLAMATION.
3	CHAIRMAN KLEIN: GIVEN THAT WE HAVEN'T
4	AGENDIZED THAT ITEM, THE CHAIR IS PREPARED TO ACCEPT IT
5	AS A GENERAL SENSE OF THE BODY, THAT WE WISH TO PROCEED
6	AS WE NORMALLY DO IN RECOGNIZING SUCH EXTRAORDINARY
7	LEADERSHIP FROM THE CIVIC COMMUNITY IN SUPPORTING THE
8	MISSION AND FROM THE GOVERNOR. AND IF THE BOARD GIVEN
9	THE SENSE OF THE BOARD, I WOULD SUGGEST THAT I TRY AND
10	PROCEED TO DRAW SOMETHING UP. AND I WOULD LIKE TO
11	CIRCULATE TO THE BOARD MEMBERS THAT INDIVIDUALLY FOR
12	SIGNATURE SO THAT WE CAN PRESENT IT AS A REAL UNITED
13	BODY.
14	AND IN DOING SO, I WOULD LIKE TO RECOGNIZE THAT
15	SHERRY LANSING WAS A GREAT TEAM PLAYER IN THE BAN PROCESS
16	IN GETTING SOME CRITICAL COMMITMENTS, AS WAS ALSO TRUE
17	WITH ED PENHOET AND OTHER MEMBERS OF THIS BOARD. BUT IT
18	IS REMARKABLE THAT CIVIC LEADERS IN THE STATE STEPPED UP
19	KNOWING THERE WAS LITIGATION IN PROCESS WITH A BROAD
20	DISCLOSURE ON THE BAN'S, THE BOND ANTICIPATION NOTES,
21	THEY WERE PURCHASING THAT SAID IF WE LOSE THIS CASE,
22	YOU'VE JUST MADE A \$45 MILLION CONTRIBUTION TO MEDICAL
23	RESEARCH IN CALIFORNIA. THAT IS A COURAGEOUS BOND
24	ANTICIPATION NOTE PURCHASER, ONE DRIVEN BY MISSION, NOT
25	PROFITABILITY.

1	SO WE HAVE A GREAT DEAL TO BE THANKFUL FOR, AND
2	I WILL PROCEED WITH THE SENSE OF THE BOARD.
3	MS. LANSING: THANK YOU.
4	CHAIRMAN KLEIN: OKAY. IF WE CAN GO FORWARD AT
5	THIS POINT AND ASK FOR THE ADMINISTRATIVE BUDGET ITEM.
6	DR. MURPHY, WOULD YOU LIKE TO SEE US PROCEED ON AGENDA
7	ITEM 14?
8	DR. MURPHY: WHICH IS?
9	CHAIRMAN KLEIN: THE ADMINISTRATIVE BUDGET AND
LO	CONTRACT CLOSEOUT.
L1	DR. MURPHY: YES. LORI.
L2	CHAIRMAN KLEIN: THAT ITEM IS
L3	DR. MURPHY: LORI HOFFMAN WILL BE DOING THAT.
L4	CHAIRMAN KLEIN: DR. MURPHY INDICATES LORI
L5	HOFFMAN WILL BE PRESENTING ITEM 14.
L6	MS. HOFFMAN: THANK YOU, MR. CHAIRMAN. GOOD
L7	AFTERNOON. IF YOU WILL FOCUS YOUR ATTENTION IN A MOMENT
L8	ON THE POWERPOINT PRESENTATION AS WELL AS THE ITEM UNDER
L9	TAB 14 IN YOUR BINDER. WE'RE HAVING A LITTLE TECHNICAL
20	DIFFICULTY, SO ALLOW ME TO WALK THROUGH THIS WITHOUT
21	FOCUSING YOUR ATTENTION ON THE POWERPOINT PRESENTATION
22	AND ONLY ON THE AGENDA ITEM IN YOUR PACKAGE UNDER TAB 14.
23	THANK YOU SO MUCH.
24	YOU WILL NOTICE ON THE FRONT PAGE THERE IS A

TABLE THAT PROVIDES A RECONCILIATION BETWEEN THE '06-'07

25

- 1 BUDGETED AMOUNT OF \$8.3 MILLION AND THE ACTUAL TOTAL OF
- 2 7.12, THE VARIANCE BEING \$1.2 MILLION. UNFORTUNATELY
- 3 THESE ARE NOT COST SAVINGS TO US, BUT WE WILL CERTAINLY,
- 4 IF YOU LOOK ON THE FOLLOWING PAGES UNDER OUR CONTRACTS,
- 5 MANY OF OUR CONTRACTS THAT WERE NOT BOOKED OR EXPENSED IN
- 6 '06-'07 WILL BE EXPENSED IN '07-'08. AND THOSE WERE
- 7 ACCOUNTED FOR IN THE '07-'08 BUDGET ITEM THAT WAS
- 8 PRESENTED AT THE AUGUST MEETING UNDER THE ACTING
- 9 PRESIDENT'S REPORT. IT WAS ALSO IN YOUR AGENDA PACKAGE
- 10 IN JUNE.
- MS. LANSING: I'M CONFUSED. WHY ARE THEY NOT
- 12 SAVINGS? I DON'T UNDERSTAND.
- 13 MS. HOFFMAN: I'M SORRY. SAY AGAIN. QUESTION?
- 14 MS. LANSING: WE SPENT LESS THAN OUR BUDGET --
- 15 MS. HOFFMAN: WE SPENT LESS THAN OUR BUDGET.
- 16 MS. LANSING: -- IN ALL AREAS EXCEPT ONE. WHY
- 17 IS THAT NOT A SAVINGS? I DON'T UNDERSTAND.
- 18 MS. HOFFMAN: THE ONLY AREA -- THAT'S A VERY
- 19 EXCELLENT QUESTION. THEY ONLY AREA WHERE IT IS, IN FACT,
- 20 A SAVINGS IS SALARY AND BENEFITS. SO IN THE EXTERNAL
- 21 CONTRACTS WHERE THERE'S A 20-PERCENT SAVINGS, WE WILL
- 22 SPEND THAT MONEY. WE'LL JUST SPEND IT IN '07-'08 RATHER
- 23 THAN IN THE '06-'07 FISCAL YEAR. IT'S THE WAY --
- MS. LANSING: THAT'S LIKE FOR THE STANDARDS
- 25 COMMITTEE AND EVERYTHING, YOU'RE SAYING THAT --

1	MS.	HOFFMAN:	TN MANY	CASES	YFS.	THF	POSTTNGS
_	1110.		TIM 1.1/2141		, , , ,	1111	1 02 1 1103

- 2 CLOSE FOR THE STATE CONTROLLER'S OFFICE ON JULY 20TH, SO
- 3 ANYTHING THAT WE DO NOT RECEIVE IN TERMS OF A BILL OR WE
- 4 HAVE NOT PAID THAT BILL YET, IT WOULD NOT GET POSTED TO
- 5 '06-'07.
- 6 MS. LANSING: SO FOR POINT OF INFORMATION,
- 7 BECAUSE I THINK SOME OF -- IT'S JUST INTERESTING. NO ONE
- 8 IS SUGGESTING ANYTHING. BUT SOME OF THE COMMITTEES, I
- 9 THINK. STILL WILL BE UNDER BECAUSE THEY DIDN'T HAVE
- 10 MEETINGS, YOU KNOW, WHATEVER. I WONDER IF YOU COULD
- 11 CIRCULATE SOMETHING FOR US THAT ACTUALLY SHOWS SOME
- 12 SAVINGS IF THERE ARE ANY.
- MS. HOFFMAN: WELL, AS SOON AS WE GET ALL THE
- 14 BILLS IN FOR THOSE PARTICULAR GROUPS FOR THAT PARTICULAR
- 15 YEAR, INCLUDING THE OTHER LINE ITEM, OTHER TRAVEL, AGAIN,
- 16 LOOKS LIKE THERE'S VERY SIGNIFICANT SAVINGS, BUT IN
- 17 SEVERAL CASES MANY OF THOSE TRAVEL EXPENSES WILL BE
- 18 BOOKED INTO '07-'08. SO I WILL INDEED BRING BACK TO YOU
- 19 THE RECONCILIATION.
- 20 ALSO TO YOUR POINT, FOR ALL THE MEETINGS, IN
- 21 MANY CASES WE OVERBUDGET OR WE BUDGET, FOR LET'S SAY,
- 22 FIVE OR SIX MEETINGS AND WE ONLY HAVE FOUR. WE BUDGET
- 23 FOR ALL TRAVEL EXPENSES FOR ALL MEMBERS OF THE WORKING
- 24 GROUP AND THEY DON'T ALWAYS SUBMIT. SO WE DO OUR BEST,
- 25 AND WE'RE GETTING BETTER AT IT.

	1	MS.	LANSING:	AND.	AGAIN.	I'M NOT	I'M NOT
--	---	-----	----------	------	--------	---------	---------

- 2 SAYING THIS IN A NEGATIVE WAY. I'M ACTUALLY SAYING IT IN
- 3 A POSITIVE WAY, THAT IT WOULD BE WONDERFUL TO SHOW, IF WE
- 4 DID HAVE SAVINGS, YOU KNOW, THAT IT WILL HELP YOU FOR
- 5 PLANNING, BUT I ALSO THINK IT'S JUST SOMETHING TO KNOW.
- 6 MS. HOFFMAN: OKAY. I WILL DO THAT. THANK
- 7 YOU.
- 8 CHAIRMAN KLEIN: QUESTION, LORI, THAT'S
- 9 RELEVANT TO THE QUESTION THAT SHERRY LANSING JUST ASKED.
- 10 ON ICOC MEETINGS THIS VARIANCE OF 188,000, ARE THERE
- 11 ACCRUAL EXPENSES WE HAVEN'T SEEN, OR IS THAT ACTUAL
- 12 SAVINGS AS WELL?
- MS. HOFFMAN: NO. THERE ARE ACCRUAL EXPENSES
- 14 THAT YOU WILL SEE IN '07-'08, AND IN THE '07-'08 BUDGET,
- 15 BECAUSE WE ALREADY KNEW THAT WE WEREN'T GOING TO SPEND
- 16 THE 400,000, IN '07-'08 WE BUDGETED FOR ICOC AT 323.
- 17 ASSUMING THEN, USING, AS MEMBER LANSING SUGGESTED, USING
- 18 WHAT WE HAD EXPERIENCED UP TO MAY IN TERMS OF WHAT WE
- 19 WERE SPENDING AT THOSE MEETINGS, WE KNEW WE DIDN'T NEED
- THE 400,000. THAT WAS INITIALLY AN ESTIMATED BUDGET
- 21 AMOUNT PRIOR TO A FULL YEAR OF ICOC MEETINGS THAT ARE ON
- 22 A REGULAR CYCLE LIKE WE HAVE NOW.
- 23 CHAIRMAN KLEIN: SO IT IS ESTIMATED WE WILL
- 24 HAVE SOME SAVINGS IN THAT, BUT THERE ARE ALSO SOME
- 25 ACCRUAL EXPENSES?

1	MS. HOFFMAN: THAT'S CORRECT.
2	CHAIRMAN KLEIN: OKAY.
3	MS. HOFFMAN: THE OTHER IMPORTANT FACT THAT I'D
4	LIKE TO HIGHLIGHT HERE IS THAT BELOW THE LINE EXPENSES
5	THAT ARE BEING THEN REDUCED FROM THE TOTAL. SO YOU WILL
6	SEE THREE LINE ITEMS, COST OF BOND ISSUANCE, LEGAL COST,
7	AND GIFT FUND EXPENDITURES. THIS IS BASICALLY A FUND
8	SOURCE. ANYTHING THAT WE USE THAT WAS A GIFT TO US,
9	THESE ARE SUBTRACTED FROM THE TOTAL BECAUSE THE
10	ADMINISTRATIVE TOTAL, WHICH IS FOR '06-'07 MELISSA
11	FOUND THE SLIDES. MELISSA, IF YOU COULD GO TO THE NEXT
12	SLIDE.
13	SO AGAIN, THE IMPORTANT POINT HERE IS THAT THE
14	ADMINISTRATIVE TOTAL OF 5.3 IS WHAT WE WILL TRACK. AND
15	WHEN I MEAN TRACK, YOU WILL RECALL THAT UNDER PROP 71
16	THERE IS A CAP ON ADMINISTRATIVE EXPENDITURES FOR THE
17	DURATION OF THE INSTITUTE OF 6 PERCENT OR \$180 MILLION.
18	AND THAT IS DIVIDED BETWEEN GENERAL ADMINISTRATION AND
19	GRANTS ADMINISTRATION.
20	SO AT THE NEXT SLIDE YOU WILL NOTICE THAT WE
21	HAVE NOW FOR THE FIRST TIME FOR '06-'07, AND WE WILL GO
22	BACK AND DO THIS FOR '05-'06, ALLOCATE BETWEEN GENERAL
23	ADMINISTRATION AND GRANTS ADMINISTRATION. AND THIS IS AN
24	IMPORTANT TRACKING TOOL FOR THE ICOC THAT YOU WILL NOW
25	RECEIVE THESE UPDATES ON AN ANNUAL BASIS.

1	SO TO CLOSE, I JUST WANTED YOU, AGAIN, TO KNOW
2	THAT THE STATE CONTROLLER'S OFFICE, THEIR FINAL YEAR-END
3	CLOSE WAS DONE AS OF AUGUST 23D. THE CIRM STAFF HAS
4	ALREADY HAD A KICKOFF MEETING WITH OUR FINANCIAL
5	AUDITORS, MGO, WHO DID OUR FINANCIAL AUDIT LAST YEAR, AND
6	THAT KICKOFF MEETING WAS HELD ON SEPTEMBER 21ST. WE
7	EXPECT THE AUDITORS DRAFT FINANCIAL REPORT TO US BY
8	MID-DECEMBER, AND WE ARE PLANNING FOR THE AUDITORS'
9	PRESENTATION TO YOU AT YOUR JANUARY MEETING.
10	AND I'M OPEN FOR QUESTIONS.
11	DR. POMEROY: CAN I ASK A QUESTION?
12	CHAIRMAN KLEIN: ABSOLUTELY. IF I CAN JUST
13	CREATE SOME CONTEXT TOO. I'LL REMIND US ALL THAT DR.
14	PENHOET POINTED OUT THE GORDON AND BETTY MOORE FOUNDATION
15	RUNS ON ABOUT 12 PERCENT. SO WE'RE RUNNING AT A VERY
16	STRINGENT BUDGET, ABOUT HALF AS MUCH. IT'S ONLY POSSIBLE
17	BECAUSE WE HAVE BEEN VERY STRATEGIC AND ASTUTE ABOUT
18	MAKING SURE WE WEREN'T PAYING TOO MUCH FOR FACILITIES.
19	ZERO IS A GOOD FIGURE. IN ADDITION, OPERATING COST FOR
20	FACILITIES IS NOT A COST TO US. BUT WE HAVE THE BENEFIT
21	AS WELL THAT LEGAL COST, FOR EXAMPLE, THE LITIGATION DOES
22	NOT COME OUT OF OUR BUDGET. IT HAD TO BE DESIGNED THAT
23	WAY, OTHERWISE A LITIGANT WOULD HAVE HAD AN INCENTIVE TO
24	DRAG ON LITIGATION FOREVER, JUST TRYING TO, IN FACT, PUSH
25	US OUTSIDE OF AN OPERATING BUDGET THAT WE COULD LIVE

- 1 WITHIN. SO LEGAL COST IS THE DEDUCTION, WHICH IS WHY
- 2 LORI HAS SHOWN THAT DEDUCTED FROM THE TOTAL AMOUNT WHICH
- 3 WE'RE UNDER A LIMITATION OF.
- 4 DR. POMEROY.
- DR. POMEROY: SO I DON'T QUITE UNDERSTAND THESE
- 6 NUMBERS BECAUSE UNDER ADMINISTRATION TOTAL, THE VERY
- 7 BOTTOM LINE, 7.2, BUDGET 5.3, ACTUAL, THE VARIANCE IS 1.9
- 8 MILLION, NOT 1.2 IF YOU JUST SUBTRACT. SO WHAT'S GOING
- 9 on?
- MS. HOFFMAN: WELL, WHAT HAPPENED WAS WE ONLY
- 11 BUDGETED FOR LEGAL COSTS, AS BOB JUST IDENTIFIED, AND THE
- 12 COST OF ISSUANCE IS ACTUALLY NOT -- SO WHAT HAPPENS IS
- 13 THE GIFT FUNDS IS NOT AN EXPENDITURE, BUT IT BECAME A
- 14 FUND SOURCE WHERE THE LEGAL COSTS AND THE COST OF
- 15 ISSUANCE IS ACTUALLY AN EXPENDITURE. SO YOU WILL SEE IT
- 16 ABOVE THE LINE AND BELOW THE LINE WHERE THE 586 IS JUST,
- 17 AGAIN, JUST A FUND SOURCE.
- DR. POMEROY: HOW CAN THE ACTUAL BE 5.3
- 19 AGAINST 7.2 AND THE DIFFERENCE -- THE VARIANCE BE 1.2?
- 20 IF YOU SUBTRACT THOSE, IT'S 1.9.
- MS. HOFFMAN: YOU KNOW, DR. POMEROY, YOU MAKE
- 22 AN EXCELLENT POINT, AND I CAN'T ANSWER THE QUESTION. SO
- 23 RICK CAN ANSWER THE QUESTION, BUT I CAN'T. SO ALLOW ME
- TO GO BACK; AND IF I DO NEED TO CHANGE THESE NUMBERS, I
- 25 WILL. AND I CERTAINLY WILL RE-POST IT AND SEND THIS OUT

	1	TO	YOU	AND	ANSWER	YOUR	QUESTION
--	---	----	-----	-----	--------	------	----------

- 2 ANY OTHER QUESTIONS THAT PERHAPS I MIGHT BE
- 3 ABLE TO ANSWER? OKAY. THANK YOU SO MUCH.
- 4 CHAIRMAN KLEIN: ALL RIGHT. THANK YOU, LORI
- 5 HOFFMAN. DR. MURPHY, ARE WE PREPARED TO GO TO ITEM NO.
- 6 15? AND AFTER ITEM 15, WE WILL HAVE SOME ADDITIONAL
- 7 ADMINISTRATIVE REPORTS WHICH ARE NOT TIME SENSITIVE
- 8 BECAUSE THERE'S NO VOTES ON THEM, BUT THEY'RE AN
- 9 EXTENSION OF THE PRESIDENT'S REPORT THAT WE'LL FINISH
- 10 WITH AFTER ITEM 15. SO THAT IS NOT THE END OF THE AGENDA
- 11 WHEN WE GET THROUGH ITEM 15.
- DR. MURPHY: MR. CHAIRMAN, AFTER RECEIVING ALL
- 13 OF THE KIND COMMENTS FROM THE BOARD ON THE ORGANIZATION
- 14 OF THE STAFF'S PRESENTATIONS TODAY, I WANT TO TELL YOU
- 15 THAT FOR THIS PRESENTATION I LOST MINE. I JUST CALLED MY
- 16 OFFICE, CALLED, TALKED TO PAT, I SAID, "E-MAIL THAT TO
- 17 TAMAR." SHE E-MAILED IT TO TAMAR, AND I'M READING IT
- 18 NOW. ISN'T IT A WONDERFUL TIME? REALLY IS.
- MR. CHAIRMAN, I'M REPORTING ON THE ONGOING
- 20 DISCUSSIONS WE HAVE HAD WITH THE CALIFORNIA STATE
- 21 UNIVERSITY SYSTEM AND THE CALIFORNIA COMMUNITY COLLEGE
- 22 SYSTEM ABOUT THEIR REQUEST FOR \$31 MILLION FOR RESEARCH
- 23 SUPPORT FOR A TRAINING PROGRAM IN STEM CELL RESEARCH FOR
- 24 THEIR STUDENTS. RECALL THAT THAT PROPOSAL WAS SUBMITTED
- 25 TO THE ICOC AND DISCUSSED WITH CSU AND CCC

1	REPRESENTATIVES AT THE AUGUST ICOC MEETING.
2	IN RESPONSE TO QUESTIONS RAISED AT THAT MEETING
3	BY THE ICOC, THE CSU AND CCC COMMITTEE HAS RESPONDED, AND
4	THE ANSWERS TO YOUR INQUIRIES ARE IN THE PACKAGE THAT YOU
5	HAVE IN FRONT OF YOU.
6	SINCE THAT TIME ARLENE CHIU, TAMAR PACHTER, AND
7	I HAVE MET THROUGH A CONFERENCE CALL WITH CSU AND CCC
8	OFFICIALS, JEFF THOMPSON, WHO IS THE ASSOCIATE PROVOST
9	FOR RESEARCH, CSU SAN BERNARDINO, SUSAN BAXTER, WHO IS
10	WITH CSU SAN BERNARDINO, AND MARY PAT HUXLEY, WHO IS WITH
11	THE TECHNOLOGY INITIATIVE FOR CCC. AND ON THAT CALL ALSO
12	WERE ICOC MEMBERS DAVID SERRANO-SEWELL AND MARCY FEIT.
13	WE EXPRESSED IN THAT CALL OUR SUPPORT TO THE
14	CSU AND CCC FOR THE TRAINING PROGRAMS THAT THEY WISH TO
15	PUT TOGETHER. WE TOO AGREE THAT IT IS IMPORTANT TO
16	PREPARE STUDENTS FOR WORKING IN THE STEM CELL FIELD, AND
17	WE ALSO EXPRESSED A STRONG DESIRE ON BEHALF OF CIRM TO
18	INVOLVE IN THIS FIELD THE MUCH NEEDED DIVERSITY OF THE
19	STUDENTS THAT THE CSU AND CCC SYSTEM TRAIN. HOWEVER, WE
20	ALSO EXPLAINED THAT CIRM FUNDS NEED TO BE AWARDED ON A
21	COMPETITIVE BASIS AFTER RIGOROUS PEER REVIEW TO ENSURE
22	THAT PUBLIC MONEY IS WELL SPENT.
23	WE DISCUSSED ALTERNATIVES THAT WOULD FIT INTO
24	CIRM PROGRAMS THAT WOULD ALSO PROVIDE TRAINING
25	OPPORTUNITIES FOR STUDENTS FROM CSU AND CCC AND

1	ELSEWHERE. SEVERAL ALTERNATIVES THAT WE DISCUSSED
2	INCLUDED ENCOURAGING CSU AND CCC STUDENTS TO SEEK
3	INTERNSHIPS IN CIRM-SPONSORED TRAINING PROGRAMS THAT HAVE
4	BEEN FUNDED IN SIX SITES AROUND THE STATE. THIS TRAINING
5	EXPERIENCE WOULD PROVIDE THEM ACCESS TO THE TRAINEES AND
6	FACULTY WHO ARE ON THE CUTTING EDGE OF THE FIELD
7	SUPPORTED BY CIRM AND THE PEOPLE WHO ARE REALLY CREATING
8	THE TECHNOLOGY. IT WOULD PROVIDE THESE STUDENTS
9	WONDERFUL NETWORKING OPPORTUNITIES WITH PEOPLE WHO WOULD
10	HIRE THEM, AND IT WOULD BE AN EXCELLENT TRAINING
11	EXPERIENCE THAT WOULD BE LOOKED UPON FAVORABLY BY
12	COMPANIES GETTING INTO STEM CELL SCIENCE.
13	TO SUPPORT THESE INTERNSHIPS, CIRM COULD
14	DESIGNATE SPECIAL FUNDING FOR INTERNSHIP PROGRAMS THAT
15	WOULD BE AWARDED ON A COMPETITIVE BASIS. AND ARLENE HAS
16	TOUCHED UPON THAT EARLIER TODAY. IT MAY ALSO BE POSSIBLE
17	FOR CIRM TO OFFER SPECIAL RFA'S FOR TRAINING PROGRAMS
18	THAT COULD BE COMPETED FOR BY CSU AND CCC CAMPUSES AND
19	UNDERGRADUATE PROGRAMS IN OTHER NONPROFIT SCHOOLS.
20	FINALLY, WE WOULD BE COMFORTABLE CONSIDERING
21	PROGRAMS THAT MIGHT RESULT IN STUDENTS FROM THESE
22	PROGRAMS WORKING DIRECTLY IN THE LABORATORIES OF
23	CIRM-FUNDED INVESTIGATORS. WE HAVE LEFT THESE IDEAS WITH
24	OUR CSU-CCC COLLEAGUES, AND WE ARE SCHEDULING ANOTHER
25	MEETING WITH THEM IN OCTOBER FOR FURTHER DISCUSSIONS.

1	HOPEFULLY	AAL AALTII	DE	ADI E	TΩ	CDEATE	٨	DDOCDAM	$TU\Lambda T$	\a/TII	
	HUPEFULLY	ME MILL	DE	ADLE	10	CKEALE	А	PRUGRAM	ІПАІ	WTLL	

- 2 ACHIEVE OUR SHARED GOAL OF ENGAGING THESE WORTHY STUDENTS
- 3 IN THE GROWING AND EXCITING FIELD OF STEM CELL BIOLOGY.
- 4 WITH THAT, MR. CHAIRMAN, I OPEN IT FOR
- 5 QUESTIONS.
- 6 CHAIRMAN KLEIN: QUESTIONS FOR MEMBERS OF THE
- 7 BOARD? DR. LEVEY.
- 8 DR. LEVEY: I WOULD JUST CONGRATULATE YOU FOR
- 9 GETTING TO A POINT WHERE YOU'RE WORKING WITH THEM TO TRY
- 10 TO MAKE SOMETHING HAPPEN BECAUSE I THINK THE UC SYSTEM
- 11 HAS NOW DEVELOPED A JOINT DEGREE PROGRAMS IN AUDIOLOGY.
- 12 TO GET THAT STARTED WAS VERY DIFFICULT, BUT IT CAME
- 13 THROUGH TO ALL OF US THAT RIGHT NOW MOST OF THE
- 14 LEGISLATURE CONSISTS OF MEMBERS WHO ARE PRODUCTS OF THE
- 15 CALIFORNIA STATE UNIVERSITY SYSTEM. AND, YOU KNOW, WE
- 16 ARE AN ARM OF THAT, SO I WOULD THINK THAT WE'VE DONE THE
- 17 WISE THING HERE.
- 18 I THINK WE COULD HAVE DONE THE REVERSE AND
- 19 STONEWALLED IT AND SAID -- I THINK THIS IS A VERY WISE
- 20 DECISION, AND I CONGRATULATE THE OFFICE OF THE PRESIDENT
- 21 FOR DOING THAT.
- 22 CHAIRMAN KLEIN: OKAY. LET'S GO -- WE NEED TO
- 23 FINISH ON THE LEFT AND GO TO THE RIGHT. DR. BRYANT.
- DR. BRYANT: YES. I JUST WANT TO SAY I LIKE
- THE IDEA OF THE INTERNSHIPS VERY MUCH, AND I THINK SOME

- 1 OF THESE STUDENTS THAT ARE GOING THROUGH A MASTER'S
- 2 PROGRAM, ONCE THEY GET INTO A RESEARCH LAB, COULD THEN
- 3 BECOME GREAT CANDIDATES FOR PH.D. PROGRAMS BECAUSE WE
- 4 HAVE A MASTER'S PROGRAM AT UCI THAT'S A BIOTECH PROGRAM.
- 5 AND ACTUALLY WE HAVE ONE WITH AN EMPHASIS IN STEM CELL
- 6 RESEARCH, AND THE STUDENTS GET SO TURNED ON BY IT, THEY
- 7 THINK THEY WANT TO BE MASTER'S STUDENTS, BUT THEY
- 8 ACTUALLY END UP WANTING TO DO RESEARCH. SO THEY -- YOU
- 9 KNOW, IT'S A FERTILE FEEDING OPPORTUNITY TO FEED INTO THE
- 10 SYSTEM.
- 11 CHAIRMAN KLEIN: DR. STEWARD AND THEN DR.
- 12 PRIETO.
- DR. STEWARD: ACTUALLY CAN I SAVE MINE TO THE
- 14 LAST IN THE SERIES?
- 15 CHAIRMAN KLEIN: YES. DR. PRIETO.
- 16 DR. PRIETO: JUST A QUESTION. ARLENE ALLUDED
- 17 EARLIER TO SOME OF OUR FUTURE PLANS AND LOOKING AT THE
- 18 NEED FOR TECHNICAL -- TECHNICALLY TRAINED STAFF BELOW THE
- 19 PH.D. LEVEL AND WHAT CALIFORNIA'S NEEDS MIGHT BE. I
- 20 WONDERED HOW FAR LONG ARE WE IN ASSESSING THAT PROBLEM,
- 21 ASSESSING WHAT THE NEEDS MIGHT BE, AND FORMULATING THIS
- 22 AS SOME SORT OF AN RFA THAT WE COULD THEN PUT OUT THAT
- 23 THESE INSTITUTIONS COULD THEN APPLY FOR.
- DR. MURPHY: I DON'T KNOW IF WE HAVE. ARLENE
- 25 CHIU PROBABLY SHOULD TAKE THE MIC HERE. I DON'T KNOW IF

- 1 WE HAVE REALLY ASSESSED IT. IT'S CLEAR THAT WE ARE GOING
- 2 TO NEED NEW PEOPLE DOING THIS. I THINK THE DISCUSSIONS
- 3 WITH THE CSU AND CCC COULD ACTUALLY HELP US FORMULATE THE
- 4 RFA. AND IF WE COULD NOT ONLY HAVE AN RFA FOR TRAINING,
- 5 BUT PUT IT INTO A FRAMEWORK WHERE WE'RE SERVING THE NEEDS
- 6 OF THIS VERY IMPORTANT COMMUNITY, I THINK THAT'S A
- 7 WIN-WIN SITUATION. SO WE ARE EAGER TO MOVE FORWARD ON
- 8 THIS.
- 9 AND AS I SAY, WE ARE MEETING WITH THESE FOLKS
- 10 IN OCTOBER TO CONTINUE THE DISCUSSIONS. ARLENE.
- DR. CHIU: I HAVE NOTHING MORE TO ADD. DR.
- 12 MURPHY HAS IT EXACTLY IT RIGHT. IT IS -- WITH THAT LONG
- 13 LIST OF INITIATIVES, THOSE ARE PLANS THAT WE HOPE TO
- 14 BRING IN 2008, AND NOT ALL OF THEM ARE VERY WELL FORMED,
- 15 BUT WE HOPE TO GET GOOD INPUT SUCH AS FROM OUR COLLEAGUES
- 16 AT CSU IN ORDER TO FRAME IT BETTER. BUT IT'S CERTAINLY
- 17 ON THE HORIZON, AND WE WOULD LIKE TO HAVE IT REVIEWED
- 18 TOGETHER WITH THE TRAINING GRANT PROGRAM BECAUSE IT WOULD
- 19 BE THE SAME GROUP OF PEOPLE TO REVIEW THOSE AND REDUCE
- 20 THE NUMBER OF REVIEW MEETINGS.
- 21 CHAIRMAN KLEIN: DR. STEWARD.
- DR. STEWARD: MAYBE I'LL BE THE LAST COMMENT.
- 23 WE'LL SEE. SOMETHING HAS BEEN ON MY MIND EVER SINCE THIS
- 24 STARTED, AND I ACTUALLY DIDN'T RAISE IT DURING PREVIOUS
- 25 DISCUSSIONS BECAUSE I DIDN'T WANT TO SEEM NEGATIVE ABOUT

1	THIS. I THINK IT'S A VERY IMPORTANT IDEA FOR THE
2	COMMUNITY COLLEGES.
3	WHAT HAS BOTHERED ME FROM THE BEGINNING,
4	THOUGH, IN SOME RESPECTS IS THAT THIS IS THE FIRST TIME
5	THAT CIRM, AS FAR AS I KNOW, HAS CONSIDERED IN DETAIL A
6	PROPOSAL THAT DIDN'T ORIGINATE FROM AN RFA. AND MY
7	QUESTION IS FOR THE FUTURE UNDER WHAT CIRCUMSTANCES DOES
8	CIRM CHOOSE TO EVALUATE AND CONSIDER THESE THINGS THAT
9	ARE OUT OF THE BOX OR NOT? I GUESS I'M JUST YOU COULD
10	BE LOOKING AT A WHOLE LOT OF PROPOSALS FROM A WHOLE LOT
11	OF ORGANIZATIONS, AND I'M JUST RAISING IT AS AN ISSUE.
12	DR. MURPHY: DAVID, DO YOU WANT TO SPEAK?
13	MR. SERRANO-SEWELL: THAT WAS ONE OF THE FIRST
14	ISSUES THAT MARCY AND I RAISED WITH DR. MURPHY IN OUR
15	CONVERSATIONS, AND WE ALSO SORT OF SHARED THAT WHEN WE
16	HAD OUR CONFERENCE CALL WITH THE CSU AND COMMUNITY
17	COLLEGE REPRESENTATIVES, THAT IT HAS BEEN THE PRACTICE OF
18	THIS ORGANIZATION TO AWARD GRANTS ON A COMPETITIVE BID
19	BASIS. THAT HAS BEEN OUR POSTURE, AND WE BELIEVE THAT IT
20	HAS SERVED US WELL. AND IF YOU JUDGE SORT OF THAT TRACK
21	RECORD, THEN SORT OF GOING FORTH, WE'LL CONTINUE THAT
22	MODEL. AND WE SHARED THAT WITH THE PARTICIPANTS ON THE
23	CALL. SO I THINK THAT SORT OF ANSWERS YOUR QUESTION.
24	DR. STEWARD: SORT OF, BUT NOT QUITE. SO WHAT

I'M REALLY GETTING AT IS IT TOOK OBVIOUSLY A LOT OF TIME

25

1	TΩ	THTNK	AROUT	THTS	ΔND	THFY	WFRF	AFFORDED	THE
_	10	I I I I T I A I Z	ADOUL	IIIII J.		111111	WLIL	AI I UNDED	1111

- 2 OPPORTUNITY TO COME AND PRESENT TO THE ICOC, AND I'M NOT
- 3 SAYING THAT WAS THE WRONG THING TO DO. I'M JUST ASKING
- 4 UNDER WHAT CIRCUMSTANCES DO WE DO THAT? HOW DO WE
- 5 DECIDE?
- DR. MURPHY: I CAN GIVE YOU MY ANSWER, OS. MY
- 7 FEELING IS THAT WE WANT GOOD IDEAS FROM WHEREVER THEY
- 8 COME FROM. AND SOMETIMES THE INTERESTS OF THE
- 9 ORGANIZATION ARE GOING TO LEAD -- OF ONE ORGANIZATION ARE
- 10 GOING TO LEAD THIS ORGANIZATION IN WAYS THAT WE COULD
- 11 HAVE NEVER PREDICTED. SO I THINK THAT I THINK THE
- 12 DISCUSSIONS THAT WE'RE HAVING WITH THESE FOLKS ARE VERY,
- 13 VERY HELPFUL TO CIRM. THEY FILL A NEED WE HAVE, THE NEED
- 14 FOR WELL-TRAINED PEOPLE. THE FACT IS IN THIS FIELD, AS
- 15 IN MOST FIELDS IN BIOLOGY, THERE IS NOT A DIVERSE
- 16 WORKFORCE, AND WE ALL BENEFIT FROM A DIVERSE WORKFORCE.
- 17 SO AS THEY ARE LEADING US THROUGH THIS PROCESS
- 18 AND WE IMPOSE UPON THE PROCESS OR ADD TO THE PROCESS A
- 19 COMPLEMENTARY PROCESS OF WHAT CIRM NEEDS TO MAKE THE
- 20 DECISION, I THINK IT'S A WIN-WIN SITUATION, AND I WELCOME
- 21 THE INPUT WE'RE GETTING.
- 22 CHAIRMAN KLEIN: AND I -- I'M GOING TO GO TO
- 23 SHERRY LANSING. I WOULD LIKE TO RESPOND IN PART, SINCE I
- 24 PUT IT ON THE AGENDA, AND I'D LIKE TO SAY THAT THE CSU
- 25 SYSTEM AND THE COMMUNITY COLLEGES HAD BEEN ATTEMPTING TO

1 ENGAGE WITH THIS INSTITUTION FOR OVER A YEAR. A	1	FNGAGE WTT	H THTS	TNSTTTUTTON	FOR	OVFR	A YFAR.	ΑΝΓ
---	---	------------	--------	-------------	-----	------	---------	-----

- 2 BECAUSE THEY ARE SUCH A CRITICAL PART OF THE EDUCATIONAL
- 3 SYSTEM OF THE STATE, AND A GREAT NUMBER OF THEIR STUDENTS
- 4 GO ON INTO THE UC SYSTEM IN MASTER'S AND DOCTORAL
- 5 PROGRAMS, IT APPEARED THAT IT WAS A VERY IMPORTANT
- 6 INITIATIVE ON THEIR PART THAT DESERVED THE WHOLE BOARD TO
- 7 MAKE A DECISION TO ADDRESS THIS OPPORTUNITY AND TO DECIDE
- 8 WHETHER STAFF TIME SHOULD BE COMMITTED. IT IS THE
- 9 BOARD'S DECISION.
- 10 WE HAVE TO BE CIRCUMSPECT ABOUT HOW MANY
- 11 INDIVIDUAL PETITIONS WE PUT ON OUR AGENDA OBVIOUSLY
- 12 BECAUSE OF CONSTRAINTS OF THE TIME; BUT SINCE THEY HAVE A
- 13 MONUMENTAL INFLUENCE ON EDUCATION IN THE STATE AND AS A
- 14 RESOURCE FOR PERSONNEL DEDICATED TO THIS MISSION, AT
- 15 LEAST A POTENTIAL RESOURCE, IT APPEARED APPROPRIATE TO
- 16 AGENDIZE THAT AS A MATTER OF DISCRIMINATION.
- 17 SHERRY LANSING.
- DR. STEWARD: I WASN'T QUESTIONING IT. THAT'S
- 19 WHY I DIDN'T RAISE IT AT THE TIME. I'M REALLY RAISING IT
- 20 AS A GENERAL ISSUE FOR THE FUTURE.
- MS. LANSING: I THINK WHAT OS IS RAISING, WHICH
- 22 I THINK IS A GOOD QUESTION, I DON'T THINK ANYONE IS
- 23 QUESTIONING THIS. I THINK WHAT WE'RE SAYING, AND I THINK
- 24 WE CAN KICK IT BACK TO THE PRESIDENT, IS LET US ASSUME
- 25 THIS WILL NOT BE THE ONLY OTHER GOOD IDEA THAT COMES

- 1 FORWARD. I THINK IT WOULD BE GOOD IF YOU WOULD, WITH
- 2 YOUR TEAM, COME UP WITH A PROCESS BY WHICH SOMEBODY DOES
- 3 THAT, THAT IF SOME OTHER OUTSIDE PERSON HAS AN IDEA, DO
- 4 THEY GO TO YOU FIRST? WHO DO THEY GO TO? WHAT'S THE
- 5 PROCESS BEFORE IT BECOMES TO THE BOARD? IF ONE OF US
- 6 SHOULD HAVE AN IDEA, HOW DO WE DO IT BECAUSE NO ONE IS
- 7 QUESTIONING THIS. WE'RE ONLY SAYING LET'S ASSUME THIS
- 8 ISN'T THE ONLY GOOD IDEA IN THE NEXT TEN YEARS OR SEVEN
- 9 YEARS OR WHATEVER IT IS THAT WE'LL EXIST THAT WON'T HAVE
- 10 AN RFA.
- 11 CAN YOU COME UP WITH A PROCESS BY WHICH WE HAVE
- 12 AN EQUAL OPPORTUNITY FOR OTHER PEOPLE SHOULD THEY HAVE
- 13 THAT TO AT LEAST BE HEARD? THAT'S ALL WE'RE SAYING.
- DR. MURPHY: WE THINK WE CERTAINLY CAN. THANK
- 15 YOU.
- 16 CHAIRMAN KLEIN: DR. PIZZO.
- 17 DR. PIZZO: I'M ACTUALLY HONORED TO SAY THAT I
- 18 WAS GOING TO MAKE THE SAME SUGGESTION AS SHERRY LANSING,
- 19 SO I WILL NOT REPEAT THAT, BUT THANK HER.
- 20 CHAIRMAN KLEIN: ALL RIGHT. THIS IS AN
- 21 EXCELLENT REPORT. I'D LIKE TO ASK IF THERE IS PUBLIC
- 22 COMMENT. DR. SUSAN BAXTER, WHO IS THE EXECUTIVE DIRECTOR
- 23 OF THE CALIFORNIA STATE UNIVERSITY PROGRAM FOR EDUCATION
- 24 AND RESEARCH AND BIOTECHNOLOGY, IS HERE. DR. BAXTER,
- 25 WOULD YOU LIKE TO MAKE A COMMENT FROM THE PUBLIC?

1

1	DR. BAXTER: THANK YOU. NO. WE DID NOT COME
2	WITH ANY PREPARED COMMENTS, BUT I DID WANT TO SAY THAT
3	ALSO STANLEY MALLOY IS HERE FROM CSU, DEAN OF SCIENCES,
4	IN SUPPORT OF OUR PROPOSAL, AND ALSO BETH AMBOSE FROM THE
5	CHANCELLOR'S OFFICE, THE VICE PRESIDENT FOR RESEARCH
6	INITIATIVES AND PARTNERSHIPS, IS HERE WITH ME TODAY. AND
7	WE WERE SIMPLY HERE TO ANSWER ANY QUESTIONS THAT YOU MAY
8	HAVE OF US SPECIFICALLY.
9	CHAIRMAN KLEIN: THANK YOU FOR BRINGING SOME
10	GREAT IDEAS TO US, AND HOPEFULLY WE CAN HAVE A
11	PARTNERSHIP THAT IS PRODUCTIVE FOR CIRM AND THE CSU AND
12	COMMUNITY COLLEGE SYSTEMS. IT'S WONDERFUL TO HAVE SOME
13	GREAT IDEAS TO STIMULATE US.
14	OKAY. ANY ADDITIONAL COMMENTS FROM THE BOARD?
15	IF NOT, WE HAVE AN ADMINISTRATIVE ITEM TO COVER. WE HAVE
16	SOME ADMINISTRATIVE ITEMS THAT HAVE NOT REQUIRED A VOTE
17	AND DIDN'T REQUIRE A QUORUM. AND, DR. CHIU, WOULD YOU
18	LIKE TO REPORT ON THE STATUS OF PROCESSING OF GRANTS AND
19	OVERSIGHT?
20	DR. CHIU: THANK YOU, MR. CHAIRMAN. I'D LIKE
21	TO REPORT TO THE BOARD ON THE STATUS OF TWO APPLICATIONS
22	THAT WERE APPROVED FOR FUNDING BY THE ICOC. DURING
23	CAREFUL PRE-AWARD REVIEW THAT YOU'VE HEARD SO MUCH ABOUT,
24	CIRM HAS DETERMINED THAT APPLICATION NO. RS 1305-1 FROM
25	THE BURNHAM INSTITUTE ENTITLED "GENERATION OF HESC LINES

- 1 UNDER DEFINED CONDITIONS -- MODELING NORMAL AND DISEASE
- 2 STATES FOR MATERIALS STORED AT THE BURNHAM SHARED EMBRYO
- 3 BANK" DOES NOT MEET ALL THE ELIGIBILITY REQUIREMENTS OF
- 4 THE RFA AND WILL THEREFORE NOT BE FUNDED. THIS
- 5 DETERMINATION HAS BEEN COMMUNICATED WITH THE APPLICANT.
- A SECOND APPLICATION, NO. RC 123-1 FROM THE
- 7 CHAR REGENERATIVE MEDICINE INSTITUTE ENTITLED
- 8 "ESTABLISHMENT OF STEM CELL LINES FROM SOMATIC CELL
- 9 NUCLEAR TRANSFER EMBRYOS IN HUMANS" HAS BEEN WITHDRAWN BY
- 10 THE APPLICANT INSTITUTION.
- 11 WE WILL CONTINUE TO KEEP THE ICOC UPDATED WITH
- 12 SUCH ADMINISTRATIVE ACTIONS AS THEY TAKE PLACE. THANK
- 13 YOU. ARE THERE ANY QUESTIONS?
- 14 CHAIRMAN KLEIN: DR. PRICE.
- 15 DR. PRICE: I DON'T KNOW WHETHER IT'S
- 16 APPROPRIATE, BUT CAN WE KNOW WHAT CRITERIA THEY DIDN'T
- 17 MEET?
- DR. CHIU: WELL, THE SECOND ONE WAS WITHDRAWN,
- 19 AND EVERY APPLICANT INSTITUTION HAS THE RIGHT TO WITHDRAW
- 20 AN APPLICATION.
- DR. PRICE: NO, I UNDERSTAND THAT, BUT THE
- 22 FIRST ONE WHERE WE DISALLOWED IT.
- DR. CHIU: THE FIRST ONE, WE HAD CONDITIONS,
- 24 AND I BELIEVE I HAVE A SLIDE TO SHOW. ACTUALLY THAT'S
- 25 OKAY. YOU DON'T HAVE TO SHOW IT. THE RFA STATED A

						_	
1		TIIAT TIIC		THE DT	NOT	CO DIIC	\sim D
			1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	IHE DI	NIC 1 I	(1)-01 <	112
_	REOUIREMENT	IIIAI IIIL	ALLETCAM:		IVOI	COLT	OI.

- 2 ANYBODY ELSE, THE PI HAS TO BE AN ON-SITE, FULL TIME
- 3 EMPLOYEE OF THE APPLICANT INSTITUTION. AND THAT
- 4 REQUIREMENT WAS NOT MET.
- 5 CHAIRMAN KLEIN: OKAY. ANY ADDITIONAL
- 6 QUESTIONS FROM THE BOARD? ALL RIGHT. ON THIS ITEM ANY
- 7 PUBLIC COMMENT? JOHN SIMPSON.
- 8 MR. SIMPSON: JOHN SIMPSON FROM THE FOUNDATION
- 9 FOR TAXPAYER AND CONSUMER RIGHTS. IT'S PROBABLY NOT A
- 10 HAPPY DAY FOR THOSE TWO APPLICANTS, BUT I THINK THIS
- 11 SPEAKS VERY WELL OF THE STAFF AND THE DILIGENCE THAT
- 12 THEY'VE PUT INTO THIS. AND THOSE OF US WHO FROM TIME TO
- 13 TIME HAVE WONDERED ABOUT WHETHER THINGS MIGHT JUST END UP
- 14 BEING A RUBBER STAMP WILL CONTINUE TO HAVE THOSE WORRIES
- AND TO RAISE QUESTIONS, BUT THIS IS CLEARLY A CASE WHERE
- 16 THAT DID NOT HAPPEN. AND IT SHOWS, I THINK, TO ALL
- 17 RESEARCHERS THAT CIRM HAS STANDARDS AND IS SERIOUS ABOUT
- 18 THEM. AND I THINK THIS IS A VERY, VERY, VERY IMPORTANT
- 19 TIME FOR THE AGENCY. AND IT'S A VERY SIGNIFICANT THING.
- THE ONLY OTHER THING I WOULD ADD TO IT IS THAT
- 21 IT MIGHT HAVE SERVED THE STAFF A LITTLE BIT BETTER AND
- 22 MADE THEIR WORK A LITTLE BIT EASIER IF THE INITIAL REVIEW
- 23 PROCESS HAD BEEN A LITTLE BIT MORE TRANSPARENT TO THE
- 24 PUBLIC BECAUSE THEN MAYBE SOME OF THESE ISSUES WOULD HAVE
- 25 BEEN CAUGHT WAY BACK THEN. BUT THAT'S A POSITION THAT I

1	CONTINUE	TΩ	Δ RGUF	ΔND	TΩ	RFFFR	PFOPI F	TΩ	THE	$ST\Delta TF$	ΩF
_	CONTINUE								1111	\supset \cap \cap \vdash	O.

- 2 CONNECTICUT WHERE IT IS MORE OPEN.
- 3 ALL THAT ASIDE, THOUGH, THIS IS A MOMENTOUS
- 4 TIME THAT SHOWS THAT YOU TAKE YOUR RULES AND REGULATIONS
- 5 VERY SERIOUSLY AND ACT APPROPRIATELY. THANK YOU.
- 6 CHAIRMAN KLEIN: THANK YOU VERY MUCH.
- 7 ADDITIONAL PUBLIC COMMENT?
- 8 MR. ADAMS: VERY QUICKLY, I'M BILL ADAMS. I'M
- 9 FOUNDER AND THE CFO OF INTERNATIONAL STEM CELL
- 10 CORPORATION, WHICH IS AN OCEANSIDE-BASED COMPANY THAT IS
- 11 TRYING TO BE FOR-PROFIT IF WE CAN GET THERE. I JUST --
- 12 THIS IS ACTUALLY MY SECOND MEETING. I JUST WANT TO THANK
- 13 THE EMPHASIS THAT'S GOING ON TO WORK WITH FOR-PROFIT
- 14 COMPANIES, AND WE CERTAINLY HOPE TO BRING THINGS TO THE
- 15 CLINIC RATHER QUICKLY, AND WE'VE GOT A COUPLE PROJECTS
- 16 ALREADY GOING.
- 17 AND IF ANYONE WANTS TO KNOW A LITTLE BIT ABOUT
- 18 US, WE HAD A WONDERFUL WRITE-UP IN THE SAN DIEGO UNION
- 19 THIS LAST WEEK. SO THANK YOU.
- 20 CHAIRMAN KLEIN: THANK YOU FOR YOUR COMMENTS.
- 21 ADDITIONALLY, ADDITIONAL ITEM THAT'S NOT
- 22 CALENDARED. JUST AS AN ITEM OF INFORMATION, IN NOVEMBER
- 23 THERE WILL BE AN INDEPENDENT FINANCIAL ACCOUNTABILITY
- 24 OVERSIGHT COMMITTEE MEETING AS PROVIDED FOR UNDER THE
- 25 INITIATIVE. THAT COMMITTEE IS CHAIRED BY THE TREASURER

1	AND.	TF	WF	ΑΙΙ	RFCALL.	HAS	ΑN	APPOINTEE	FROM	THE

- 2 CONTROLLER, THE PRESIDENT PRO TEM OF THE SENATE, THE
- 3 SPEAKER, AS WELL AS I MAKE ONE APPOINTMENT TO THAT BOARD.
- 4 WE HAVE A GREAT DEAL TO REPORT IN THAT ONE OF
- 5 THE AREAS WHERE WE'RE GOING TO TRY AND REALLY FOCUS SOME
- 6 NEW TIME, AS REQUIRED BY THE INITIATIVE, IS ON EVALUATING
- 7 OUR CONTRIBUTION TO THE STATE ON AN ECONOMIC BASIS. THAT
- 8 WILL REQUIRE A STUDY FROM A THIRD-PARTY FIRM AS OUTLINED
- 9 IN OUR STRATEGIC PLAN, AND THE PRESIDENT HAS THE
- 10 AUTHORITY TO CONTRACT FOR STUDIES OF THAT TYPE. THIS
- 11 YEAR I WOULD DOUBT THAT WE HAVE THE TIME TO GET FAR
- 12 ENOUGH DOWNSTREAM TO HAVE THE IN-DEPTH STUDY THAT BY NEXT
- 13 YEAR WOULD BE POTENTIALLY VERY FEASIBLE, BUT IT IS
- 14 CERTAINLY A YEAR IN WHICH WE'VE HAD REMARKABLE PROGRESS.
- 15 SO WE HAVE SOME PHENOMENAL THINGS TO REPORT TO THE
- 16 OVERSIGHT COMMITTEE.
- 17 WITH THAT, I THINK THAT'S THE FINAL ITEM OF
- 18 INFORMATION TO BE BROUGHT UP TODAY. ANY ADDITIONAL ITEMS
- 19 BY MEMBERS OF THE BOARD? ANY ADDITIONAL COMMENTS FROM
- 20 THE PUBLIC? JOHN SIMPSON.
- MR. SIMPSON: JOHN SIMPSON AGAIN, FOUNDATION
- 22 FOR TAXPAYER AND CONSUMERS RIGHTS. I UNDERSTAND THAT
- 23 CIRM WILL BE REPRESENTED AT THE INTERSTATE ALLIANCE
- 24 MEETING IN BOSTON. I BELIEVE THAT'S CORRECT. SOME OF
- 25 YOU MAY RECALL THAT I HAD SOME INTERESTING ENCOUNTERS

WITH THEM WHEN THEY MET OUT HERE. THEY THREW ME OUT.

2	AND THEY NOW HAVE AGREED THAT THESE SHOULD BE OPEN
3	MEETINGS, AND THE BOSTON MEETING WILL BE OPEN, AND I
4	THINK THAT IT IS TREMENDOUS THAT CIRM WILL BE THERE AND
5	PLAYING A KEY LEADERSHIP ROLE. SO AS LONG AS THOSE
6	MEETINGS ARE OPEN TO THE PUBLIC, AND THESE, I'M SURE,
7	WILL BE, THIS IS A VERY GOOD THING. AND I THINK DR.
8	MURPHY AND THE STAFF ARE TO BE COMMENDED FOR TAKING PART
9	IN IT.
10	CHAIRMAN KLEIN: THANK YOU VERY MUCH. WHEN OUR
11	CRITICS END THE MEETING WITH POSITIVE COMMENTS, IT IS A
12	TIME TO END.
13	(APPLAUSE.)
14	CHAIRMAN KLEIN: MELISSA, DO YOU HAVE AN
15	ADMINISTRATIVE COMMENT?
16	MS. KING: JUST VERY QUICKLY. THERE IS A
17	SHUTTLE TO THE AIRPORT. JENNA HAS ARRANGED FOR IT TO BE
18	HERE MOMENTARILY. AND ALSO WE HAD AN AFTERNOON SNACK
19	BROUGHT OUT, AND SHE HAS IT BROUGHT OUT A BIT EARLY SO
20	THAT YOU CAN GRAB IT ON YOUR WAY OUT.
21	CHAIRMAN KLEIN: THANK YOU ALL FOR
22	PARTICIPATION IN WHAT IS A VERY HISTORIC DAY. THANK YOU.
23	(THE MEETING WAS THEN ADJOURNED AT 2:35 P.M.)
24	
25	

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE PROCEEDINGS BEFORE THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD AT THE LOCATION INDICATED BELOW

HILTON SAN DIEGO AIRPORT/HARBOR ISLAND
1960 HARBOR ISLAND DRIVE
SAN DIEGO, CALIFORNIA
ON
OCTOBER 3, 2007

WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152 BARRISTER'S REPORTING SERVICE 1072 S.E. BRISTOL STREET SUITE 100 SANTA ANA HEIGHTS, CALIFORNIA (714) 444-4100

BEFORE THE

INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

REGULAR MEETING

LOCATION: HILTON SAN DIEGO AIRPORT

HARBOR ISLAND MARINA BALLROOM

1960 HARBOR ISLAND DRIVE SAN DIEGO, CALIFORNIA

DATE: WEDNESDAY, OCTOBER 3, 2007

9:30 A.M.

REPORTER: BETH C. DRAIN, CSR

CSR. NO. 7152

BRS FILE NO.: 77062

I N D E X

ITEM DI	ESCRIPTION	PAGE NO
CALL TO ORDER		3
ROLL CALL		5
PUBLIC COMMENT	RE HUNTOINGTON'S DISEASE	7
CONSENT ITEMS		11
CHAIRMAN'S REPO	ORT	12
PRESIDENT'S REP	PORT	16
ACTION ITEMS:		
	OF AMENDMENTS TO GRANTS POLICY REGARDING FACILITIES:	46
CONSIDERATION O	OF CONCEPT FOR DISEASE WARDS.	73
CONSIDERATION CLINES AWARDS.	OF CONCEPT FOR NEW CELL	111
	OF GRANTS MANAGEMENT SYSTEM ERVICES PROVIDER.	98
CONSIDERATION C SUBCOMMITTEE OF	F CREATION OF FINANCE THE ICOC	119
CLOSED SESSION		
REPORT FROM CLO	SED SESSION	NONE
DISCUSSION ITEM	1S	
SUMMARY OF THE AND CONTRACT CL	2006-07 ADMINISTRATIVE BUDGET OSE-OUT.	125
UPDATE ON CSU D	OTSCUSSTONS.	132

PUBLIC COMMENT	144
ADJOURNMENT	147

1	SAN DIEGO, CALIFORNIA; WEDNESDAY, OCTOBER 3D, 2007
2	9:30 A.M.
3	
4	CHAIRMAN KLEIN: WELCOME, EVERYONE. IN THE
5	LAND OF THE BECAUSE OF THE WATER AND THE GORGEOUS
6	SUNSHINE, WE'RE HAPPY TO BE BACK HERE IN SAN DIEGO. WE
7	HAVE THE PRIVILEGE OF BEING BACK HERE WITH A NEW BOARD
8	MEMBER, DR. MARSHA CHANDLER. SHOULD WE GIVE HER A ROUND
9	OF APPLAUSE.
10	(APPLAUSE.)
11	CHAIRMAN KLEIN: WE HAD AN OUTSTANDING
12	SPOTLIGHT THIS MORNING I LEARNED IN THE PROCEEDINGS
13	NOT TO USE THE WORD "INCREDIBLE" PREPARED BY WITH
14	THE HELP OF LYNN HARWELL OF MY STAFF IN COORDINATION WITH
15	OUR EMINENT BOARD MEMBER DR. JANET WRIGHT. AND OUR
16	FOCUS, OF COURSE, WAS ON HEART DISEASE AND STEM CELL
17	RESEARCH.
18	WE HAD THE PRIVILEGE OF HAVING DR. ANTHONY
19	DEMERIA AND DR. MARK MERCOLA SPEAK, AND I WOULD MENTION
20	TO YOU THAT DR. DEMARIA LAST WEEK MADE THE GREAT STEP
21	FORWARD AS A LEADER OF UC SAN DIEGO IN OPENING THE NEW
22	VASCULAR CENTER AT UC SAN DIEGO, ANOTHER TREMENDOUS
23	ADVANCE FOR MEDICAL RESEARCH.
24	WE HAVE A CHALLENGING SCHEDULE TODAY, BUT WE
25	HOPE TO MOVE EXPEDITIOUSLY THROUGH IT. AND WE HAVE SOME

1	EXTRAORDINARILY EXCITING NEW CONCEPT PLANS FOR PROGRAMS
2	IN THE DEVELOPMENT OF THE SCIENCE TEAM THAT THE SCIENCE
3	STAFF WILL GO THROUGH.
4	TO BEGIN TODAY'S MEETING, WE HAD A SPECIAL
5	REQUEST FROM THE HUNTINGTON DISEASE PATIENT ORGANIZATIONS
6	HERE IN SAN DIEGO TO MAKE A SPECIAL PRESENTATION TO THE
7	BOARD FOR FIVE MINUTES. WHAT I'D LIKE TO DO, THOUGH, IS
8	HAVE THE PLEDGE OF ALLEGIANCE WITH MELISSA KING LEADING
9	US IN THAT PLEDGE AND THE ROLL CALL. MELISSA.
LO	MS. KING: PLEASE STAND IF YOU ARE ABLE. THE
L1	FLAG IS AT THE FRONT OF THE ROOM.
L2	CHAIRMAN KLEIN: FOR THE HUNTINGTON DISEASE
L3	PATIENT ADVOCATES ORGANIZATION, IF KEN SERBIN WILL BE
L4	READY RIGHT AFTER THE ROLL CALL TO IMMEDIATELY PRESENT.
L5	(THE PLEDGE OF ALLEGIANCE.)
L6	MS. KING: DAVID MEYER FOR RICARDO AZZIZ.
L7	DR. MEYER: HERE.
L8	MS. KING: ROBERT PRICE FOR ROBERT BIRGENEAU.
L9	DR. PRICE: HERE.
20	MS. KING: DAVID BRENNER.
21	DR. BRENNER: HERE.
22	MS. KING: SUSAN BRYANT.
23	DR. BRYANT: HERE.
24	MS. KING: MARSHA CHANDLER.

DR. CHANDLER: HERE.

1 MS. KING: MARCY FEIT. ALEXANDRA LEVINE FOR 2 MICHAEL FRIEDMAN. 3 DR. LEVINE: HERE. 4 MS. KING: MICHAEL GOLDBERG. 5 MR. GOLDBERG: HERE. 6 MS. KING: BRIAN HENDERSON. 7 DR. HENDERSON: HERE. 8 MS. KING: DAVID KESSLER. BOB KLEIN. 9 CHAIRMAN KLEIN: HERE. 10 MS. KING: SHERRY LANSING. 11 MS. LANSING: HERE. 12 MS. KING: GERALD LEVEY. DR. LEVY: HERE. 13 14 MS. KING: MICHAEL LEVY FOR TED LOVE. 15 DR. LEVY: HERE. 16 MS. KING: TINA NOVA. ED PENHOET. PHIL PIZZO. 17 DR. PIZZO: HERE. 18 MS. KING: CLAIRE POMEROY. 19 DR. POMEROY: HERE. 20 MS. KING: FRANCISCO PRIETO. 21 DR. PRIETO: HERE. 22 MS. KING: JOHN REED. DUANE ROTH. 23 MR. ROTH: HERE. 24 MS. KING: JOAN SAMUELSON. DAVID 25 SERRANO-SEWELL.

1	MR. SERRANO-SEWELL: HERE.
2	MS. KING: JEFF SHEEHY. JONATHAN SHESTACK.
3	OSWALD STEWARD.
4	DR. STEWARD: HERE.
5	MS. KING: JANET WRIGHT.
6	DR. WRIGHT: HERE.
7	WE DO HAVE A QUORUM.
8	CHAIRMAN KLEIN: THANK YOU. KEN, AS A LEADER
9	OF THE HUNTINGTON DISEASE SOCIETY OF AMERICA,
10	REPRESENTING SAN DIEGO, WOULD YOU ADVANCE YOUR
11	PRESENTATION, PLEASE?
12	MR. SERBIN: I WANT TO INTRODUCE BILL JOHNSTON
13	AND RAMONA JOHNSTON. BILL IS THE PRESIDENT OF THE SAN
14	DIEGO CHAPTER OF THE HUNTINGTON'S DISEASE SOCIETY OF
15	AMERICA.
16	MR. JOHNSTON: THANK YOU VERY MUCH FOR GIVING
17	US A FEW MINUTES OF YOUR TIME, AND I'LL TRY TO BE
18	EXPEDITIOUS FOR YOUR MEETING HERE.
19	I WANTED TO BRING MY WIFE WITH ME TODAY,
20	RAMONA, WHO WE'VE BEEN KNOWN EACH OTHER SINCE HIGH
21	SCHOOL, AND IT'S REALLY THE REASON THAT I'M HERE AND THAT
22	THERE'S SEVERAL OTHER PEOPLE HERE REPRESENTING THE
23	HUNTINGTON'S DISEASE SOCIETY.
24	I KNOW YOU ARE GOING TO HEAR A PRESENTATION ON

7

25 HD IN DECEMBER AS WELL. I BELIEVE IT'S A SPOTLIGHT

- 1 YOU'VE AFFORDED OUR ORGANIZATION. I APPRECIATE THAT VERY
- 2 MUCH. THANK YOU. BUT I THINK IT'S JUST FIVE MINUTES OF
- 3 YOUR TIME TO GIVE YOU AN IDEA OF HD, THE PROJECTS THAT WE
- 4 HAVE GOING, AND THE OPTIMISM THAT WE FEEL IN OUR
- 5 ORGANIZATION, AND THE WAYS THAT YOUR ORGANIZATION CAN, WE
- 6 FEEL, PLAY A ROLE IN FINDING A CURE FOR HD.
- 7 LIKE KEN SAID, I'M THE PRESIDENT OF THE HDSA
- 8 HERE IN SAN DIEGO. I JOINED THE ORGANIZATION -- REALLY I
- 9 BECAME A PART OF IT, IT BECAME PART OF MY LIFE WHEN MY
- 10 WIFE WAS DIAGNOSED IN 1999, ABOUT EIGHT YEARS AGO, WITH
- 11 HUNTINGTON'S DISEASE. WE HAVE TWO CHILDREN WHO ARE AT
- 12 RISK. KIDS OF AN HD PATIENT OR A PARENT HAVE A 50-50
- 13 CHANCE OF INHERITING THE DISEASE. IT'S A GENETIC
- 14 NEUROLOGICAL DISEASE. AND I APOLOGIZE IF -- I KNOW I'M
- 15 PROBABLY SPEAKING WAY UNDER YOUR LEVEL, BUT THIS IS ALL
- 16 INFORMATION I'M SURE YOU'RE WELL AWARE OF.
- 17 BUT WHEN SHE -- WE MET IN HIGH SCHOOL. SHE
- 18 GRADUATED FROM COLLEGE SUMMA CUM LAUDE, WENT ON TO BECOME
- 19 AN EXTRAORDINARY TEACHER. AND THIS IS -- SINCE HD HAS
- TAKEN OVER HER LIFE, IT HAS NOW BECOME MY LIFE, AND SO WE
- 21 ARE IN THE -- WE ARE FACED WITH THE TASK OF FINDING A
- 22 CURE FOR HD.
- SO IN MY OTHER JOB, MY OTHER LIFE, I'M THE PR
- 24 DIRECTOR FOR THE SAN DIEGO CHARGERS. SO, AGAIN, THIS
- 25 IS -- I'M SPEAKING IN A LANGUAGE OR YOU GUYS PROBABLY

- 1 SPEAK IN A LANGUAGE MUCH OVER MY HEAD, SO I'LL TRY TO DO
- 2 THE BEST I CAN HERE. BUT I'LL TRY TO SHARE WITH YOU THE
- 3 INFORMATION THAT I HAVE ABOUT HD THAT'S CONVINCED ME THAT
- 4 RESEARCH PROJECTS -- THAT OUR RESEARCH PROJECTS DESERVE
- 5 YOUR ATTENTION OR SHOULD BE CONSIDERED HIGHLY FOR YOUR
- 6 ATTENTION.
- 7 FIRST, AS YOU KNOW, ABOUT 20 YEARS AGO, I
- 8 BELIEVE IT WAS, THE GENE THAT CAUSES HUNTINGTON DISEASE
- 9 WAS DISCOVERED, WHICH WAS A HUGE, HUGE STEP AHEAD FOR OUR
- 10 ORGANIZATION AND FOR THE SEARCH FOR A TREATMENT OR A
- 11 CURE. ONCE YOU FOUND THE GENE, THAT GIVES THE
- 12 RESEARCHERS AND SCIENTISTS A HUGE STEP AHEAD OR AT LEAST
- 13 A HUGE FOCUS ON WHAT THEY'RE DOING.
- 14 AND WITH THAT, THERE NOW IS A DEFINITIVE TEST
- 15 TO DETERMINE IF SOMEONE HAS HD, WHICH IS THE SAME TEST
- 16 THAT MY WIFE TOOK, SAME TEST THAT --
- 17 MS. JOHNSTON: OUR SON.
- 18 MR. JOHNSTON: -- OUR SON TOOK. AND THANKS TO
- 19 GOD HE WAS NEGATIVE. OUR DAUGHTER IS 19 AND HAS CHOSEN
- 20 NOT TO BE TESTED AT THIS POINT YET. BUT IT'S ALSO THE
- 21 SAME TEST THAT SHARON SHAEFFER HAS TAKEN, AND SHE WAS
- 22 POSITIVE IN THE TEST. SHE HAS A DAUGHTER HERE, ALEXA,
- 23 WHO IS AN AMAZING LITTLE GIRL AND REPRESENTATIVE OF OUR
- ORGANIZATION. SHE IS LIKE MY DAUGHTER, 50-50 CHANCE OF
- 25 INHERITING THE DISEASE.

1	SO WE HAVE WITH THAT TEST NOW, THEY HAVE THE
2	FOCUS WHICH WE FEEL THAT WITH HD, THE RESEARCH THAT CAN
3	BE DONE ON HD OR TO CURE HD CAN BENEFIT DISEASES LIKE
4	PARKINSON'S AND ALZHEIMER'S AND SEVERAL OTHERS THAT DON'T
5	HAVE HAVEN'T DISCOVERED THAT INITIAL CAUSE, THAT
6	SINGLE MUTATION THAT CAUSES THE DISEASE. SO THAT'S WHY
7	WE FEEL THAT OUR DISEASE CAN BE A ROSETTA STONE, SO TO
8	SPEAK, FOR OTHER DISEASES. AND IT CAN LEAD TO A
9	TREATMENT AND A CURE WITH THE RIGHT FUNDING AND WITH THE
10	RIGHT STEM CELL RESEARCH AVAILABILITY.
11	IT IS, LIKE I SAID, A PART OF OUR LIFE, AND WE
12	FEEL THAT WITH YOUR SUPPORT, YOUR KNOWLEDGE OF WHAT THE
13	HUNTINGTON'S DISEASE COMMUNITY IS GOING THROUGH, AND
14	THERE ARE THOUSANDS OF PEOPLE IN CALIFORNIA, 3,000 IS THE
15	ESTIMATE, 30,000 IN THE UNITED STATES JUST KNOWN, ANOTHER
16	200,000 WHO ARE AT RISK OF INHERITING THE DISEASE, THAT
17	IT CAN MAKE A HUGE DIFFERENCE IN SO MANY LIVES.
18	THEY HAVE IN A LAB IN CANADA. IT IS OUR
19	UNDERSTANDING AND THEIR UNDERSTANDING THEY HAVE CURED THE
20	DISEASE IN MICE MODELS. AND WITH YOUR SUPPORT, IT IS OUR
21	BELIEF AND RESEARCHERS' BELIEF THAT STEM CELLS, HUMAN
22	EMBRYONIC STEM CELLS, AND HUMAN MODELS, PRODUCE HUMAN
23	MODELS WHICH CAN THEN TAKE THE NEXT STEP FOR THIS
24	RESEARCH. SO WE FEEL THAT OUR RESEARCH PROJECTS, AND
25	MANY OF THOSE ARE SOME OF THE GREATEST AROUND, ARE IN

_	CALIFORNIA, CAN TAKE THAT NEXT STEP AND TO CORE THE
2	DISEASE THAT AFFECTS OUR FAMILIES.
3	IF YOU'RE IN SAN DIEGO THERE ARE RESEARCH
4	PROJECTS, HERE IN IRVINE, L.A., SAN FRANCISCO, THERE ARE
5	SOME OF THE BEST FROM OUR ORGANIZATIONS THAT ARE DOING
6	RESEARCH TO CURE THIS DISEASE. THERE ARE TWO
7	ORGANIZATIONS THAT ARE HEADQUARTERED IN CALIFORNIA, THE
8	HEREDITARY DISEASE FOUNDATION AND THE CURE HUNTINGTON'S
9	DISEASE INITIATIVE ARE ALSO HERE IN CALIFORNIA.
10	SO, AGAIN, I APPRECIATE THE TIME THAT YOU'VE
11	GIVEN US ON BEHALF OF MY WIFE, AND THAT'S WHY I'M HERE,
12	AND ON BEHALF OF OUR FAMILIES WHO ARE HERE AND OTHER
13	PEOPLE WHO ARE AFFECTED BY THIS DISEASE. THERE ARE
14	THOUSANDS OF PEOPLE OUT THERE THAT WE FEEL CAN BENEFIT
15	FROM THE OPPORTUNITY THAT YOU CAN PROVIDE THE RESEARCHERS
16	THAT ARE DOING WORK WITH HUNTINGTON'S DISEASE RESEARCH.
17	THANK YOU FOR LISTENING. IF YOU HAVE ANY QUESTIONS.
18	(APPLAUSE.)
19	CHAIRMAN KLEIN: THANK YOU VERY MUCH FOR YOUR
20	ADVOCACY AND YOUR PRESENTATION. WE'RE GOING TO LOOK
21	FORWARD TO YOUR SPOTLIGHT PRESENTATION. AND IT MAKES A
22	GREAT DIFFERENCE TO HEAR YOUR MESSAGE PERSONALLY.
23	MR. JOHNSTON: THANK YOU VERY MUCH.
24	(APPLAUSE.)
25	CHAIRMAN KLEIN: WE NEED TO MOVE TO AGENDA ITEM

- 1 NO. 4, WHICH IS THE CONSENT CALENDAR. IT'S JUST ONE ITEM
- 2 THIS TIME BEHIND TAB 4 IN YOUR BINDERS. IT'S
- 3 CONSIDERATION OF THE ICOC MEETING MINUTES FROM JUNE, TWO
- 4 FROM JULY, AND ONE FROM AUGUST. THE BOARD HAS BEEN VERY
- 5 BUSY. IS THERE A MOTION TO APPROVE THESE MINUTES?
- 6 MR. SERRANO-SEWELL: SO MOVED.
- 7 DR. WRIGHT: SECOND.
- 8 CHAIRMAN KLEIN: MOVED AND SECONDED. MOVED BY
- 9 DAVID SERRANO-SEWELL. SECONDED BY DR. WRIGHT. IS THERE
- 10 DISCUSSION? SEEING NO DISCUSSION, I WOULD CALL THE
- 11 QUESTION. ALL IN FAVOR. OPPOSED? MOTION PASSES.
- 12 I WOULD LIKE TO GO ON TO THE AGENDA ITEM NO. 5,
- 13 THE CHAIRMAN'S REPORT AT THIS TIME.
- 14 TODAY IS ANOTHER HISTORIC DAY FOR PROPOSITION
- 15 71. CALIFORNIA'S INSTITUTE FOR REGENERATIVE MEDICINE IS
- 16 TRAILBLAZING ON THE FRONTIER OF MEDICAL FUNDING. THE
- 17 PRICING STARTS TODAY FOR \$250 MILLION OF STEM CELL
- 18 RESEARCH AND CURES BONDS. FIRST TIME IN THE HISTORY OF
- 19 THIS NATION OR OF THE WORLD, TO OUR KNOWLEDGE, LONG-TERM
- 20 STATE GOVERNMENT BONDS OR GOVERNMENT BONDS ARE BEING USED
- 21 TO FINANCE INTELLECTUAL CAPITAL, THE INTELLECTUAL CAPITAL
- 22 HOPEFULLY THAT WILL DRIVE THE 21ST CENTURY JUST AS THE
- 23 FINANCING OF PHYSICAL CAPITAL, BRIDGES, ROADS, HARBORS,
- 24 DROVE THE PROSPERITY OF THE 19TH AND 20TH CENTURIES.
- 25 I WOULD CALL TO EVERYONE'S ATTENTION THAT THE

1	ROCKEFFLLER	TNSTTTUTF	DEMONSTRATES	THAT	THE	MODEL
_		TI301TI01		111/71		

- 2 FUNCTION, THE MODEL LEADERSHIP FUNCTION OF THIS INSTITUTE
- 3 HAS HAD A TREMENDOUS EFFECT IN THIS COUNTRY WITH \$3
- 4 BILLION IN INITIATIVES FROM OTHER STATES FOLLOWING THE
- 5 CALIFORNIA MODEL AND RELYING PRINCIPALLY ON BONDS TO
- 6 FINANCE THE LONG-TERM BENEFITS FOR THE SOCIETY OF THE
- 7 INTELLECTUAL CAPITAL.
- THE THEORY BEHIND THE FUNDING IS, OF COURSE,
- 9 THAT THE INTELLECTUAL BREAKTHROUGHS THAT OCCUR IN MEDICAL
- 10 SCIENCE WILL BENEFIT GENERATIONS, THAT IT IS
- 11 INAPPROPRIATE TO TAX THE CURRENT GENERATION FOR THE
- 12 BENEFITS OF MANY GENERATIONS; AND BY SPREADING THE COST,
- 13 AMORTIZING IT OVER LONG-TERM BONDS, YOU HAVE THE ABILITY
- 14 TO RAISE MORE FUNDS UP FRONT TO ADVANCE SCIENCE AT A MUCH
- 15 FASTER PACE THAN AN APPROACH TRADITIONALLY TAKEN WITH
- 16 YEAR-TO-YEAR APPROPRIATIONS.
- 17 IT IS ALSO CRITICAL TO NOTE THAT BY USING
- 18 LONG-TERM BONDS AND FOCUSING ON THIS AS INTELLECTUAL
- 19 CAPITAL AND NOT AN OPERATING COST OF GOVERNMENT, THAT
- 20 RESEARCH IS NO LONGER COMPETING AT THE STATE LEVEL WITH
- THE YEAR-TO-YEAR DEMANDS OF A HEALTH SYSTEM, WHICH ARE IN
- 22 MANY CASES DESPERATE. COUNTY HOSPITALS NEED THOSE
- 23 APPROPRIATIONS. THE CLINICS NEED THOSE APPROPRIATIONS.
- 24 BY HAVING LONG-TERM BONDS, A CAPITAL INSTRUMENT, FINANCE
- THIS RESEARCH, WE ARE NO LONGER CONTESTING OR FIGHTING

1 OVER THE SAME FUNDS BECAUSE, IN FACT, THEY'R
--

- 2 DIFFERENT KIND OF EXPENDITURES. SO THE CAPITAL STRUCTURE
- 3 HERE IS ALIGNED WITH THE NATURE OF THE EXPENDITURE, WHICH
- 4 IS ONE OF INVESTMENT, NOT AN OPERATING COST.
- 5 I WOULD POINT OUT AS WELL THAT AS THIS SPREADS
- 6 ACROSS THE COUNTRY, WE SEE ANOTHER LEVEL OF FUNDING BEING
- 7 RAISED EVEN TO THE LEVEL OF POTENTIALLY MATCHING
- 8 CALIFORNIA'S INVESTMENT EVEN THOUGH ON A NARROWER SCALE.
- 9 GOVERNOR PERRY IS NOW SEEKING \$3 BILLION FOR CANCER STEM
- 10 CELL RESEARCH IN TEXAS. OF COURSE, THEY'VE NARROWED
- 11 THEIR SCOPE BECAUSE THEY'RE AVOIDING THE POLITICAL
- 12 QUESTION ABOUT ADDRESSING THE WHOLE RANGE OF STEM CELLS,
- 13 BUT I WOULD LIKE TO DISTINGUISH WHAT THEY'RE DOING FROM
- 14 WHAT WE ARE DOING HERE IN CALIFORNIA BECAUSE ON A
- 15 HISTORICAL BASIS THE BENEFITS OF AN INVESTMENT IN MEDICAL
- 16 RESEARCH HAS BEEN MOST PRODUCTIVE BY, IN FACT -- I'D LIKE
- 17 TO POINT OUT THAT IN TEXAS BY FOCUSING ON ONE DISEASE
- 18 AREA, THEY ARE DEPARTING FROM THE CALIFORNIA APPROACH OF
- 19 ADDRESSING THE ENTIRE SPECTRUM OF MEDICINE.
- 20 HISTORICALLY THE NIH HAS BEEN VERY EFFECTIVE,
- 21 BUT IT HAS ADDRESSED A PORTFOLIO OF MEDICINE. SEVERAL
- 22 YEARS AGO THERE WAS A MAJOR INVESTMENT, THAT I'VE ALLUDED
- 23 TO BEFORE, FOR PANCREATIC CANCER. THERE WAS NO BENEFIT
- 24 FOR PANCREATIC CANCER, BUT THERE WAS A GREAT DISCOVERY
- 25 FOR JUVENILE DIABETES. IT IS IMPORTANT TO NOTE THAT WE

Т	HAVE AN ORGANIC RELATIONSHIP IN OUR SPECIRUM AND SCOPE OF
2	SUBJECT MATTER IN CALIFORNIA IN THAT WE CAN FOLLOW THE
3	BEST SCIENCE AND THE LEADS, WHETHER THEY ARE IN CANCER,
4	HEART DISEASE, DIABETES, ALS, ALZHEIMER'S. WE ARE NOT
5	TIED TO A SINGLE AREA OF RESEARCH. FORTUNATELY, CANCER
6	IS A BROAD TARGET AND THERE IS THE BENEFIT WITH THAT
7	BROAD TARGET OF HAVING A SUBSTANTIAL SCOPE TO RESEARCH
8	FUNDING, BUT THEY MIGHT FIND THAT IF THEIR CANCER
9	RESEARCH LEADS TO GREAT BREAKTHROUGHS FOR HEART DISEASE
10	OR ALZHEIMER'S, THEY MAY HAVE TO SHIP THE RESEARCH
11	REQUEST TO CALIFORNIA.
12	IT IS ALSO IMPORTANT TO NOTE AS A MATTER OF OUR
13	SCIENTIFIC LEGACY ON THIS DAY WHEN \$250 MILLION OF BONDS
14	ARE BEING PRICED THAT CALIFORNIA LED THE EFFORT WITH
15	RECOMBINANT DNA. THIS IS THE CALIFORNIA LEGACY. IT WAS
16	THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO AND CITY OF
17	HOPE THAT CREATED THE FIRST COMMERCIAL PRODUCT FROM THAT
18	RESEARCH, ARTIFICIAL HUMAN INSULIN. AND, IN FACT, LED,
19	THEN, IN THE NEXT DECADE TO A HUNDRED CRITICAL HEART AND
20	CANCER DRUGS THAT HAVE SAVED MILLIONS OF LIVES.
21	WE HOPE THAT WE ARE AT LEAST PARTIALLY AS
22	SUCCESSFUL, ALTHOUGH DR. PAUL BERG, WHO RECEIVED THE
23	NOBEL PRIZE FOR RECOMBINANT DNA, AS DID DR. BALTIMORE,
24	BOTH MEMBERS OF THIS BOARD AT DIFFERENT TIMES, HAVE SAID

ON OCCASION THAT THE POTENTIAL OF STEM CELL RESEARCH MAY,

2	FINALLY,	THERE'S A	SPECIAL	MESSAGE	FROM	OUR	NEW

IN FACT, BE MUCH BROADER THAN FROM RECOMBINANT DNA.

- 3 PRESIDENT, DR. ALAN TROUNSON, FROM AUSTRALIA. IN TALKING
- 4 WITH HIM LAST NIGHT, HE WANTED THE BOARD TO KNOW THAT HE
- 5 HAS TREMENDOUS APPRECIATION FOR THE COMMUNICATIONS
- 6 BETWEEN THIS BOARD AND HIS OFFICE AND IN PARTICULAR FOR
- 7 THE TREMENDOUS JOB THAT OUR INTERIM PRESIDENT, DR.
- 8 RICHARD MURPHY, IS DOING IN REALLY LIFTING THIS
- 9 ORGANIZATION TO THE NEXT LEVEL OF DEVELOPMENT FOR THE
- 10 IMPLEMENTATION OF OUR MISSION. HE TELLS ME THAT HE IS
- 11 EXCITED, HE IS THRILLED WITH THE CONSTANT COMMUNICATION
- 12 AND UPDATES FROM DR. MURPHY, AND THE PARTNERSHIP IN WHICH
- OUR MISSION IS BEING ADVANCED BY THIS TREMENDOUS DUAL
- 14 TEAM THAT WE HAVE.

- 15 I WOULD LIKE AT THIS TIME, THEREFORE, TO GO TO
- 16 DR. MURPHY, AND I THINK IT WOULD BE APPROPRIATE FOR SOME
- 17 APPLAUSE FOR HIS PERFORMANCE.
- 18 (APPLAUSE.)
- DR. MURPHY: THANK YOU VERY MUCH AND THANK YOU,
- 20 CHAIRMAN KLEIN. FIRST, LET ME THANK ALL THE MEMBERS OF
- 21 THE ICOC FOR GIVING ME THE PRIVILEGE TO SERVE AS INTERIM
- 22 PRESIDENT. I ACCEPTED YOUR VERY KIND OFFER BECAUSE I
- 23 THINK THIS IS A VERY IMPORTANT TIME IN THE HISTORY OF
- 24 CIRM. WE HAVE BYPASSED ALL OF THE LEGAL HURDLES THAT
- 25 FACED US, AND NOW WE ARE REALLY READY TO RELEASE THE

1	MONEY THAT WILL BE NECESSARY TO DO THE RESEARCH THAT
2	CALIFORNIANS REQUESTED OF US. AND I'M VERY HAPPY TO SIT
3	ON THIS SIDE OF THE ICOC TABLE TO HELP IN THAT PROCESS,
4	HAVING SERVED FOR THREE YEARS ON THAT SIDE OF THE TABLE.
5	I'M REMINDED OF BILL GATES' COMMENTS TO A
6	GRADUATING CLASS OF STUDENTS. HE ONCE SAID, "ALWAYS BE
7	NICE TO NERDS BECAUSE YOU COULD BE WORKING FOR THEM."
8	YOU ARE NOT NERDS, BUT I HOPE I WAS NICE TO YOU.
9	I WOULD LIKE VERY BRIEFLY TO PRESENT TO YOU
10	FOUR GOALS THAT I HAVE OVER THE BRIEF TIME I'M GOING TO
11	BE SERVING AS INTERIM PRESIDENT. THOSE GOALS ARE TO
12	TRANSITION THE PRESIDENCY FOR DR. TROUNSON, TO IMPROVE
13	OPERATIONS, TO PROMOTE OUR SCIENTIFIC PROGRAMS, AND TO
14	EXPAND OUR PUBLIC OUTREACH.
15	WITH RESPECT TO THE FIRST GOAL, TRANSITIONING
16	THE PRESIDENCY, I HAD HOPED THAT MY EFFORTS WOULD ALLOW
17	US TO ATTRACT A GOOD PRESIDENT AND THAT I COULD HELP IN
18	THE TRANSITION TO THAT PERSON. JUST FOR HISTORICAL
19	PURPOSES, I SHOULD TELL THE ICOC THAT I BEGAN WORKING ON
20	SEPTEMBER 6TH, WHICH WAS A THURSDAY, I CONTINUED ON THE
21	7TH, AND THEN I WAS AWAY THE NEXT WEEK ON A COMMITMENT
22	THAT I HAD IN CANADA, COMMITMENT THAT I HAD MADE PREVIOUS
23	TO TAKING THIS POSITION. ABOUT MIDWEEK ON MY TRIP I GOT
24	A CALL FROM CHAIRMAN KLEIN SAYING THAT DR. TROUNSON HAD

BEEN IDENTIFIED AS AN EXCELLENT CANDIDATE, THAT HE

	1	ACCEPTED	THE	TERMS	OF	THE	APPOINTMENT,	AND	THAT	HIS
--	---	----------	-----	-------	----	-----	--------------	-----	------	-----

- 2 APPOINTMENT WOULD BE RATIFIED OR DISCUSSED BY THE ICOC ON
- 3 FRIDAY. BY THE TIME I RETURNED AND GOT OFF THE PLANE,
- 4 THE VOTE HAD BEEN TAKEN AND THE ANNOUNCEMENT HAD BEEN
- 5 MADE.
- 6 I CONGRATULATE THE ICOC FOR THIS EXCELLENT
- 7 CHOICE, BUT I ALSO WANT TO MAKE CERTAIN THAT IN THE
- 8 EUPHORIA SURROUNDING DR. TROUNSON'S APPOINTMENT, THE
- 9 VALUE OF MY LEADERSHIP IN THAT PROCESS NOT BE FORGOTTEN.
- 10 AS BOB SAID, ALAN AND I HAVE VISITED, AND HE AND I HAVE
- 11 BEEN IN CONSTANT COMMUNICATION ABOUT HOW WE SHOULD WORK
- 12 TOGETHER; AND I THINK I AGREE WITH YOU, YOU MADE A SUPERB
- 13 CHOICE.
- 14 IT'S CLEAR THAT ALAN AND I SHARE THE SAME GOALS
- 15 FOR THE INSTITUTE AND THAT WE HAVE THE SAME SENSE AS TO
- 16 HOW WE SHOULD PROCEED TO ACHIEVE THE INSTITUTE'S MISSION.
- 17 AND SINCE THOSE MEETINGS, AS BOB SAID, WE HAVE SHARED IN
- 18 NUMEROUS E-MAILS, AND THE DECISIONS WE ARE MAKING WITH
- 19 BOB'S INPUT GO TOWARDS COMMON ENDS. SHARED
- 20 DECISION-MAKING WILL BE A VERY IMPORTANT ASPECT OF MY
- 21 PRESIDENCY TO ALLOW ALAN TO SEAMLESSLY INTEGRATE INTO THE
- 22 INSTITUTE AND ALSO TO GET HIM OFF TO A RUNNING START WHEN
- 23 HE ARRIVES.
- 24 IT'S ALSO IMPORTANT FOR THE ICOC AND THE CIRM
- 25 STAFF TO KNOW THAT THE SHARED DECISIONS WE ARE MAKING NOW

1 WILL BE CONSISTENT WITH ALAN'S FUTURE PLANS AND PROGR

- 2 I.E., WHEN ALAN COMES, IT WILL NOT BE A BIG SHIFT.
- 3 HOPEFULLY WE WILL ALL HAVE BEEN WORKING TOGETHER SO THAT
- 4 WHEN HE ARRIVES, IT WILL BE BUSINESS AS USUAL.
- THE OTHER GOAL, MY SECOND GOAL, WAS TO IMPROVE
- 6 OPERATIONS. TO UNDERSTAND HOW THE INSTITUTE WORKS
- 7 INTERNALLY, I'VE MET ONE ON ONE WITH EVERYONE IN THE
- 8 INSTITUTE OVER THE LAST SEVERAL WEEKS, WHICH WAS AN
- 9 ABSOLUTE PLEASURE. WHAT I LEARNED IS THAT CIRM STAFF ARE
- 10 SMART, DEDICATED, SUPPORTIVE VERY MUCH OF CIRM'S MISSION.
- 11 AND I VERY MUCH ENJOYED LEARNING ABOUT THEIR HOPES AND
- 12 DREAMS FOR THE INSTITUTE AND ABOUT THEIR OWN GOALS. I
- 13 LEARNED HOW OUR SCIENTIFIC PEOPLE HAVE ACCOMPLISHED SO
- 14 MUCH IN SUPPORTING THE PROGRAMS WE HAVE FUNDED, GOING
- 15 THROUGH VERY DIFFICULT STEPS OF PROGRAM DESIGN, SEEKING
- 16 PUBLIC INPUT, PUTTING OUT RFA'S, ACCEPTING AND PROCESSING
- 17 APPLICATIONS, ORGANIZING PEER REVIEW, PREPARING GRANT
- 18 SUMMARIES, AND BEING METICULOUS ABOUT ENSURING THAT ALL
- 19 THE ADMINISTRATIVE REQUIREMENTS THAT ARE NECESSARY ARE
- 20 MET BEFORE MONEY FLOWS.
- THE ADMINISTRATIVE GROUP HAS CREATED MECHANISMS
- 22 TO ENSURE THAT INSTITUTE OPERATIONS ARE CONSISTENT WITH
- 23 STATE POLICIES, BUT AT THE SAME TIME CAN SUPPORT THE
- 24 EVERCHANGING NEEDS OF A FUNDING AGENCY THAT REQUIRES
- 25 FLEXIBILITY TO MEET THE INSTITUTE'S SCIENTIFIC MISSION.

1	AND THE CHAIR'S OFFICE HAS TAKEN ON THE
2	ADMINISTRATIVE TASKS THAT ARE NECESSARY FOR SERVING THE
3	NEEDS OF THE ICOC, FOR ISSUING BONDS, AS YOU HEARD ABOUT,
4	AND FOR MUCH OF THE INTERNATIONAL OUTREACH THAT'S
5	ESSENTIAL TO PROVIDE LEADERSHIP IN STEM CELL RESEARCH
6	AROUND THE WORLD.
7	IN SUMMARY, THE INSTITUTE IS OPERATIONALLY
8	HEALTHY AND DOING ITS JOBS WELL. THANKS GO TO BOB, ZACH,
9	ARLENE, LORI, AND OTHERS IN LEADERSHIP POSITIONS FOR OUR
10	ORGANIZATIONAL SUCCESS.
11	NOW, I HAVE ASKED MANY OF THE PEOPLE AT CIRM
12	OVER THE NEXT ICOC MEETINGS TO MEET WITH THE ICOC
13	DIRECTLY BECAUSE THEY ARE THE EXPERTS IN THE POLICIES AND
14	ADVANCES THAT CIRM IS MAKING, THEY ARE THE PEOPLE WHO YOU
15	WILL MEET AND I KNOW WILL ENJOY, AND I KNOW THAT THEY
16	WILL ENJOY MEETING YOU. IT'S IMPORTANT TO ME THAT THE
17	ICOC GET TO KNOW CIRM STAFF DIRECTLY; AND I'M SURE WHEN
18	YOU DO THAT, YOU WILL BE AS PLEASED AS I AM WITH THE
19	QUALITY OF WHO YOU ARE DEALING WITH.
20	THAT SAID, THERE ARE STILL IMPROVEMENTS THAT
21	NEED TO BE PUT IN PLACE OVER THE NEXT SEVERAL MONTHS.
22	AND THESE INCLUDE CHANGING ORGANIZATIONAL STRUCTURE. WE
23	NEED TO ASSESS THE ORGANIZATIONAL STRUCTURE OF THE
24	INSTITUTE TO BE CERTAIN WE HAVE THE APPROPRIATE WORKING
25	AND EMPLOYEE REPORTING RELATIONSHIPS. I WILL BE

	1	RECOMMENDING	CHANGES	ΙN	THE	ORGANIZATIONAL	CHART	TH⊅
--	---	--------------	---------	----	-----	----------------	-------	-----

- 2 HOPEFULLY WILL MAKE THE INSTITUTE MOVE MORE SMOOTHLY,
- 3 INCLUDING HAVING HUMAN RESOURCES REPORT TO THE PRESIDENT,
- 4 GRANTS MANAGEMENT REPORT TO FINANCE. AND THE CHAIRMAN'S
- 5 OFFICE REPORT TO THE CHAIR AND THROUGH THE CHAIR TO THE
- 6 PRESIDENT. THERE MAY BE OTHER CHANGES AS WELL THAT WILL
- 7 REQUIRE A FRESH LOOK AT MANY OF THE POLICIES THAT EXIST
- 8 AT THE INSTITUTE AND THAT MAY NEED REEXAMINATION AS WELL.
- 9 AND I'M THINKING ABOUT WORK FLOW MECHANISMS, ETC.
- 10 WE ALSO NEED TO BEGIN THE HIRING OF ADDITIONAL
- 11 PEOPLE TO FULFILL CIRM'S SCIENTIFIC MISSION. RECALL THAT
- 12 WE HAVE A MAXIMUM OF 50 EMPLOYEES WITH 26 NOW ON STAFF.
- 13 MANY OF THESE PEOPLE HAVE CARRIED OUT THEIR
- 14 RESPONSIBILITIES BECAUSE OF HEROIC EFFORTS AND LONG
- 15 HOURS, WELL BEYOND WHAT ANY OF US WOULD EXPECT OF OUR
- 16 EMPLOYEES IN A WORKING DAY. I FEAR EMPLOYEE BURNOUT
- 17 UNLESS WE BRING INTO THE INSTITUTE THOSE ADDITIONAL
- 18 PEOPLE THAT WE NEED. CURRENTLY WE HAVE NEEDS FOR AT
- 19 LEAST FIVE PEOPLE ON THE SCIENTIFIC STAFF. INCLUDING A
- 20 HIGH LEVEL REPLACEMENT FOR ARLENE CHIU. ARLENE CAN NEVER
- 21 BE REPLACED, BUT WE NEED TO TRY IT. WE NEED AT LEAST
- 22 FOUR PEOPLE ON OUR ADMINISTRATIVE STAFF. THE CHAIR'S
- 23 OFFICE MAY NEED ADDITIONAL PEOPLE FOR ADMINISTRATIVE
- 24 MATTERS ASSOCIATED WITH THE ICOC, BOND SALES, AND
- 25 GOVERNMENT RELATIONS. AND FINALLY, DR. TROUNSON AND I

1	HAVF	DTSCUSSED	THE	POTENTIAL	NFFD	FOR A	000	ONCF	HF

- 2 ARRIVES ON SCENE. AND I THINK THAT IS VERY MUCH IN THE
- 3 INTEREST OF CIRM.
- 4 SOME OF THESE RECRUITMENTS ARE COMPLETE. IN
- 5 FACT, THREE OF THE SCIENTIFIC PEOPLE HAVE BEEN IDENTIFIED
- 6 AND OTHERS ARE IN VARIOUS STAGES OF BEING PROCESSED. WE
- 7 ALSO NEED TO RETAIN THE STAFF WE HAVE, AND WE NEED TO
- 8 TAKE A FRESH LOOK AT THE SALARIES WE PAY CIRM'S EMPLOYEES
- 9 AND THE GRADE LEVELS THEY OCCUPY. WE ARE CURRENTLY DOING
- 10 A SALARY COMPARISON WITH MERCER ASSOCIATES AND SHOULD BE
- 11 ABLE TO ADVISE THE GOVERNANCE COMMITTEE AND THEN THE ICOC
- 12 ON SALARY AND ORGANIZATIONAL CHALLENGES -- CHANGES AT OUR
- 13 NEXT MEETING.
- 14 FINALLY, WE NEED TO PLAN FOR THE FUTURE.
- 15 PROPOSITION 71 IS NOW THREE YEARS OLD, AND WE SHOULD USE
- 16 ITS ORIGINAL VISION, WHICH WAS ADMIRABLE, AS THE
- 17 FOUNDATION ABOUT THINKING ABOUT THE FUTURE OF THE
- 18 ORGANIZATION. ONE OF THE NEEDS I HEARD IN MY INTERVIEWS
- 19 WITH THE STAFF WAS THE NEED TO CONSIDER CIRM'S FUTURE AND
- 20 HOW WE WILL ADAPT TO ADVANCES IN THE STEM CELL FIELD. TO
- 21 DO THAT, WE NEED TO GIVE OUR TIME -- OUR STAFF TIME TO
- 22 THINK AND TO EXPOSE THEM TO OUTSIDE PEOPLE AND INFLUENCES
- 23 SO THAT THEY WILL CONTINUE TO ADVISE US HOW TO IMPROVE
- 24 THE INSTITUTE. WE NEED TO BENEFIT NOT ONLY FROM THEIR
- DAILY WORK, BUT WE ALSO NEED TO BENEFIT FROM THEIR

1	EXPERIENCE.	THE	KNOWI FDGF	THFY	GENERATE	ΤN	THE	COURSE	ΩF
_			KINOWELDGE			T 1.4		COUNSE	\sim 1

- THEIR WORK, AND FROM THEIR CONSTANT OBSERVATIONS OF
- 3 PROGRESS IN THE STEM CELL FIELD, WHICH WILL LEAD US IN
- 4 NEW DIRECTIONS.
- 5 THIRDLY, WE WANTED TO PROMOTE SCIENTIFIC
- 6 PROGRAMS. AND HERE IT TURNS OUT THAT MY EFFORTS WILL NOT
- 7 BE NECESSARY BECAUSE THE STAFF HAVE ALREADY DONE THAT
- 8 RESPONSIBILITY WELL AND HAVE THE RESPONSIBILITY WELL IN
- 9 HAND. WE ARE CURRENTLY IN THE MIDST OF PROGRAMS FOR
- 10 MAJOR FACILITIES AND NEW INVESTIGATORS, AND RFA'S ARE
- 11 BEING PREPARED FOR DISEASE-RELATED RESEARCH GROUPS AND
- 12 NEW CELL LINES. IN MY VIEW, IMPLEMENTING FOR ALL OF
- 13 THESE PROGRAMS THE RFA'S, THE GRANT PROCESSES, AND THE
- 14 HEAVY ADMINISTRATIVE LOADS THAT WILL SURROUND THOSE
- 15 INITIATIVES WILL PUT OUR STAFF AT FULL CAPACITY. AND TO
- 16 INCREASE THEIR RESPONSIBILITIES AT LEAST IN THE NEAR TERM
- 17 IS UNWISE. AND YOU WILL BE HEARING ABOUT THE CURRENT
- 18 PROGRAMS AND FUTURE PROGRAMS FROM ARLENE.
- 19 NOW. ONE OF THE NECESSITIES FOR ENSURING THAT
- 20 WE PROCESS THE ENORMOUS AMOUNT OF PEER REVIEW ASSOCIATED
- 21 PAPER THAT COMES WITH ALL OF THESE PROGRAMS IS AN
- 22 EFFICIENT AND EFFECTIVE WAY TO IMPLEMENT OUR GRANTS
- 23 MANAGEMENT SYSTEM. AND TODAY WE WILL BE MAKING A
- 24 RECOMMENDATION TO YOU FOR THE PURCHASE OF A GRANTS
- 25 MANAGEMENT PROGRAM AND COMPUTER WARE THAT WILL ALLOW THAT

1	TO HAPPEN, AND THAT PURCHASE IS ESSENTIAL FOR OUR FUTURE.
2	AND FINALLY, WHAT WE WANT TO DO IS EXPAND
3	PUBLIC OUTREACH. CIRM HAS GONE THROUGH SOME VERY
4	INTERESTING TIMES, MUCH OF WHICH HAS BEEN DOMINATED BY
5	OUR LEGAL CHALLENGES. HOWEVER, THE TIDE HAS TURNED. WE
6	ARE FUNDING OUR TRAINEES AND PRINCIPAL INVESTIGATORS, AND
7	NEW KNOWLEDGE ABOUT STEM CELLS IS BEGINNING TO EMERGE
8	FROM CIRM-SPONSORED PROGRAMS. IT'S TIME FOR CIRM TO
9	EXPAND ITS PUBLIC OUTREACH TO TELL CALIFORNIANS ABOUT OUR
10	SUCCESSES, TO EDUCATE THEM BETTER ON STEM CELL BIOLOGY,
11	AND TO SHARE THE PROGRESS WE ARE MAKING IN STEM CELL
12	RESEARCH.
13	AND YOU WILL HEAR ABOUT TWO STUDENT MEETINGS
14	THAT WERE HELD RECENTLY WITH STUDENT TRAINEES FROM THE
15	NORTH AND SOUTH OF THE STATE IN WHICH THESE YOUNG PEOPLE
16	ARE NOW BEGINNING TO PRODUCE THE RESULTS THAT WE'RE
17	FUNDING THEM TO DO. AND YOU HAVE ASSOCIATED WITH YOUR
18	MATERIALS TODAY SUMMARY BOOKS OF THE ABSTRACTS OF THEIR
19	PROGRESS.
20	WE ALSO NEED TO UPDATE THE MANY ORGANIZATIONS
21	THAT SUPPORTED PROPOSITION 71 ON OUR PROGRESS AND TO
22	CONVINCE THEM THAT THEY MADE A GOOD DECISION IN
23	SUPPORTING US. NOW, DALE CARLSON, HEAD OF PUBLIC
24	INFORMATION AT CIRM, HAS ANNOUNCED THAT HE HAS DECIDED TO
25	LEAVE CIRM TO CONTINUE HIS CAREER IN THE PRIVATE SECTOR.

1	DALE HAS PROVIDED SERVICE TO CIRM UNDER VERY DIFFICULT
2	CIRCUMSTANCES WHEN OUR LEGAL ACTIVITIES SLOWED DOWN OUR
3	PROGRESS. IN MY SHORT TIME WORKING WITH DALE, I CAME TO
4	ENJOY HIM, AND I KNOW YOU WILL BE WISHING HIM WELL ALSO.
5	TO REPLACE DALE AND TO MOVE FORWARD, WE NEED TO
6	CONSIDER EXPANDING OUR PUBLIC OUTREACH PROGRAM THROUGH
7	PROBABLY THE ENGAGEMENT OF AN OUTSIDE FIRM WORKING WITH
8	AN INTERNAL PUBLIC RELATIONS COORDINATOR. ALAN AND BOB
9	AGREE WITH THIS APPROACH, AND WE WILL BEGIN TO SEARCH FOR
LO	A FIRM THAT IS STRONG IN MEDICAL AFFAIRS AND JOURNALISM
L1	AND HAS GOOD RELATIONS WITH GOVERNMENT. BOB AND I WILL
L2	BE DISCUSSING THIS ISSUE WITH ALAN AND COMING BACK TO YOU
L3	FOR INPUT AND WITH A RECOMMENDATION.
L4	IN MY VIEW WHAT WE NEED TO DO IS TO PROVIDE
L5	PUBLIC EDUCATION INFORMATION AND UPDATING TO THE PUBLIC.
L6	WE NEED TO INFORM THE PUBLIC, GOVERNMENT, PATIENTS, AND
L7	THEIR FAMILIES, AND THE PATIENT ADVOCATES TO WHOM OUR
L8	WORK IS SO IMPORTANT. WE ALSO NEED TO RECOGNIZE THAT WE
L9	ARE PLAYING ON MANY STAGES WHICH INCLUDE THE STATE AND
20	LOCAL LEVELS, NATIONAL INTERESTS AND INTERNATIONAL
21	AUDIENCE AS WELL.
22	SO, MR. CHAIRMAN, WITH THAT STATEMENT, I WOULD
23	LIKE TO TERMINATE MY COMMENTS. AND I'M VERY HAPPY,

25

BEFORE WE MOVE ON IN THE PRESIDENT'S REPORT, TO ANSWER

ANY QUESTIONS THAT THE MEMBERS MAY HAVE.

24

1	CHAIRMAN KLEIN: THANK YOU VERY MUCH, DR.
2	MURPHY. IT HAS BEEN AN INSPIRATION AND A TREMENDOUS LIFT
3	OF THE MORALE AS THE STAFF HAS SEEN THAT WE'RE GOING TO
4	HAVE STRONG LEADERSHIP ALL THE WAY TO WHEN DR. TROUNSON
5	GETS HERE AND THE OVERLAPPING LEADERSHIP FOR A COUPLE OF
6	MONTHS AS DR. MURPHY SETTLES INTO THIS NEW POSITION TO
7	HAVE TWO STRONG LEADERS AT OUR INSTITUTION WITH THEIR
8	TREMENDOUS BACKGROUND OF INFORMATION. YOUR INCREDIBLE
9	HISTORY WITH THIS BOARD AND GUIDANCE IN THE EARLY STAGES
10	OF PUTTING TOGETHER THE INITIATIVE, WE HAVE A TEAM THAT'S
11	IRREPLACEABLE. SO WE ARE DEEPLY APPRECIATIVE.
12	ARE THERE QUESTIONS FROM THE BOARD? SHERRY
13	LANSING.
14	MS. LANSING: THIS ISN'T A QUESTION. I JUST
15	REALLY WANT TO REITERATE ON BEHALF OF ALL THE BOARD
16	MEMBERS, IT WAS AN HONOR WHEN YOU WERE ON THE BOARD, AND
17	I THINK I SPEAK FOR ALL OF US IN SAYING THE FACT THAT YOU
18	WOULD STEP IN IN THIS TRANSITORY POSITION WAS SO
19	WONDERFUL, AND WE WERE ALL SO EXCITED ABOUT IT. AND NOW
20	I THINK I SPEAK FOR ALL OF US IN SAYING WHAT YOU JUST
21	PRESENTED TO US SHOWS YOUR PASSION, YOUR COMMITMENT, YOUR
22	EXTRAORDINARY INTELLIGENCE, AND ORGANIZATIONAL ABILITY.
23	AND I THINK I SPEAK FOR ALL OF US IN SAYING THAT THANK
24	YOU, THANK YOU, THANK YOU, AND YOUR LEADERSHIP IS JUST
25	EXTRAORDINARY. SO THANK YOU FROM ALL OF US.

1	(APPLAUSE.)
2	CHAIRMAN KLEIN: DAVID.
3	MR. SERRANO-SEWELL: THANK YOU. DR. MURPHY, I
4	JUST WANTED TO ADD AND SHARE WITH YOU AS PART OF YOUR
5	REPORT AND SHARE WITH MY COLLEAGUES AS WELL, AND I THINK
6	IT DOES SPEAK TO ONE OF THE GOALS THAT YOU'VE SET, AND
7	THAT IS EXPANDING PUBLIC OUTREACH. A COUPLE OF WEEKS AGO
8	I HAD THE OPPORTUNITY TO BE IN LOS ANGELES WITH OUR
9	GENERAL COUNSEL, TAMAR PACHTER, AT THE CALIFORNIA
10	MINORITY COUNSEL'S ASSOCIATION ANNUAL EVENT. THAT IS AN
11	ASSOCIATION THAT IS A LEGAL ASSOCIATION THAT HAS BEEN
12	AROUND A LONG TIME. IT'S PRIMARILY COMPRISED OF LAWYERS
13	OF COLOR AND SMALLER LAW FIRMS. AND WHAT IT IS IS AN
14	OPPORTUNITY FOR THE LARGER LAW FIRMS TO MEET WITH SMALLER
15	BOUTIQUE FIRMS AND SORT OF INTERACT AND SEE WHERE THERE
16	MIGHT BE OPPORTUNITIES TO WORK TOGETHER.
17	THERE WERE A COUPLE OF STATE AGENCIES THERE.
18	WE WERE ONE OF THEM IN ADDITION TO SOME LOCAL
19	MUNICIPALITIES. IT WAS DULY NOTED BY EVERYBODY THERE,
20	AND I THOUGHT IT WAS A VERY PRODUCTIVE MEETING. AND I
21	ALSO WANTED TO THANK TAMAR FOR ATTENDING IT.
22	CHAIRMAN KLEIN: DR. LEVEY.
23	DR. LEVEY: RICHARD, AGAIN, LET ME ADD MY
24	THANKS FOR WHAT YOU'VE DONE, WHICH IS TERRIFIC. AND I
25	JUST WANTED TO ASK ONE QUESTION. WHEN YOU WERE TALKING

1	A D ∩IIT	EVEDVONE	WHO	NEEDED	TO DE	LITDED	\4/LI A T ! C	VALID	EADIV
L	ABUUI	EVERYONE	WHU	NEEDED	IU BE	HIKEU.	WHAI S	YUUK	EAKLY

- 2 ASSESSMENT OF HOW WELL STOCKED OUR GRANT REVIEW PANELS
- 3 ARE? HOW MANY NEW REVIEWERS DO YOU THINK WE NEED?
- 4 DR. MURPHY: WELL, THAT IS AN ONGOING PROBLEM,
- 5 JERRY. THE PROBLEM IS WE HAVE A SOLID GROUP OF PRIMARY
- 6 REVIEWERS, BUT THEY CANNOT ALWAYS BE AT THE MEETINGS. SO
- 7 WHAT THE STAFF HAS DONE VERY -- IN A VERY EXCELLENT WAY
- 8 IS IDENTIFIED AD HOC REVIEWERS WHO CAN CONTRIBUTE TO THE
- 9 PROCESS WHO -- AND THEY HAVE BEEN ABLE TO MAKE THE QUORUM
- 10 FOR EVERY ONE OF OUR GRANT COMPETITIONS.
- 11 BUT I THINK ONE OF THE THINGS WE NEED TO DO IS
- 12 INCREASE THE STABLE OF VERY QUALIFIED REVIEWERS WHO ARE
- 13 AVAILABLE TO CIRM, ESPECIALLY AS THE NEW PROGRAMS COME
- 14 IN. AND FRANKLY, WE'RE JUST NOT GOING TO BE ABLE TO GET
- 15 THE SAME PEOPLE COMING TO CALIFORNIA FOR EVERY ONE OF THE
- 16 REVIEWS.
- 17 ONE OF THE THINGS THAT ALAN AND I HAVE TALKED
- 18 ABOUT IS MY OWN EXPERIENCE. HAVING BEEN IN CANADA FOR 14
- 19 YEARS OPENS UP A WHOLE NEW BEVY OF POSSIBILITIES TO BRING
- 20 IN CANADIANS INTO THE SYSTEM. ALAN CERTAINLY WITH HIS
- 21 EXPERTISE IN STEM CELLS IS CAPABLE OF DOING THAT ALL
- 22 AROUND THE WORLD. AND I THINK, WORKING WITH THE
- 23 SCIENTIFIC STAFF, WE NEED TO INCREASE THE NUMBER OF
- 24 REVIEWERS WHO ARE AVAILABLE TO US SO WE CAN ENSURE THAT
- 25 FOR EVERY ONE OF THE COMPETITIONS WE HAVE, AT LEAST THE

1	MINIMUM NUMBER THAT WE NEED.
2	CHAIRMAN KLEIN: THANK YOU.
3	DR. HENDERSON: WE DISCUSSED BRIEFLY AT A
4	MEETING A POSSIBILITY OF TRYING MORE VIDEOCONFERENCING TO
5	KEEP THE BEST REVIEWERS ENGAGED, EVEN THOUGH THEY DON'T
6	NECESSARILY WANT TO TRAVEL ALL THE WAY TO CALIFORNIA.
7	AND I THINK IT'S SOMETHING TO PUT NEAR THE TOP OF THE
8	LIST BECAUSE I THINK WE REALLY DO NEED THE BEST PEOPLE.
9	AND THE TENDENCY WILL BE FOR THAT TO CHANGE AS PEOPLE GET
10	FATIGUED, JUST LIKE STAFF. HOW DO WE KEEP THEM ENGAGED?
11	MAKE IT AS EASY AS POSSIBLE FOR THEM BY BEING AS FLEXIBLE
12	AS WE CAN BE.
13	DR. MURPHY: BRIAN, WE AGREE WITH THAT. AND IT
14	TURNS OUT I'VE LEARNED FROM BOB THAT AT&T PARK RIGHT
15	ACROSS FROM CIRM HEADQUARTERS HAS A VERY ELABORATE
16	TELECONFERENCE FACILITY WHICH IS AVAILABLE TO US. AND
17	WE'VE ALSO ASKED DENNIS BUTLER AT CIRM TO DO TWO THINGS.
18	ONE IS TO MAKE CERTAIN THAT THE CIRM HEADQUARTERS IS
19	GOING TO BE FULLY CAPABLE FOR WI-FI SO THAT WE CAN HAVE
20	PEOPLE COMING IN AND BEING VERY COMFORTABLE AT CIRM
21	HEADQUARTERS USING THEIR OWN COMPUTER EQUIPMENT, BUT ALSO
22	UPDATING THE CIRM HEADQUARTERS SO IT WILL HAVE
23	TELECONFERENCING FACILITIES AS WELL, SPEAKING VERY MUCH
24	TO WHAT YOU'VE JUST SUGGESTED.
25	CHAIRMAN KLEIN: ALL RIGHT. ADDITIONAL BOARD

- 2 COMMENT.
- 3 MR. SIMPSON: ACTUALLY IT MIGHT BE MORE
- 4 APPROPRIATE AFTER THE UPDATES.
- 5 CHAIRMAN KLEIN: ALL RIGHT. GREAT. WE
- 6 WILL --
- 7 DR. MURPHY: MR. CHAIRMAN, TO COMPLETE THE
- 8 PRESIDENT'S REPORT, I'VE ASKED GIL SAMBRANO TO SUMMARIZE
- 9 WHAT HAS HAPPENED WITH THE TRAINING PROGRAMS, AMY LEWIS
- 10 WILL GIVE ICOC AN UPDATE ON THE NUMBER OF GRANTS WE HAVE
- 11 AWARDED AND PAID OUT, AND ARLENE WILL TALK ABOUT THE
- 12 CURRENT AND FUTURE RFA'S, AND THEN WE WILL OPEN UP FOR
- 13 QUESTIONS.
- DR. SAMBRANO: THANK YOU, DR. MURPHY. I AM
- 15 VERY PLEASED TO BRING TO YOU TODAY A REPORT ON THE ANNUAL
- 16 CIRM SCHOLAR'S MEETING. AS YOU WILL RECALL, IN APRIL OF
- 17 2006, THE CIRM AWARDED TRAINING GRANTS TO 16 CALIFORNIA
- 18 NONPROFIT AND ACADEMIC INSTITUTIONS TO FOSTER TRAINING OF
- 19 PREDOCTORAL, POSTDOCTORAL, AND CLINICAL TRAINEES ALL IN
- 20 STEM CELL RESEARCH. THIS WAS THE FIRST INITIATIVE OF THE
- 21 CIRM, IT WAS THE FIRST REVIEW BY OUR GRANTS WORKING
- 22 GROUP, AND IT WAS THE FIRST APPROVAL OF APPLICATIONS BY
- 23 THIS BOARD.
- 24 EACH OF THE GRANTEE INSTITUTIONS BRINGS UNIQUE
- 25 STRENGTHS AND AREAS OF SPECIALIZATION IN STEM CELL

1	RESEARCH TRAINING, AND OVERALL THE PROGRAM CAN SUPPORT UP
2	TO 170 TRAINEES PER YEAR.
3	SO THIS SEPTEMBER WE HELD THE FIRST ANNUAL CIRM
4	SCHOLAR'S MEETING. AND THE PURPOSE OF THIS MEETING WAS
5	TO OFFER TRAINEES THE OPPORTUNITY TO PRESENT THEIR
6	PRELIMINARY DATA, TO ENGAGE IN SCIENTIFIC DISCUSSION, AND
7	EXCHANGE IDEAS. IT WAS AN OCCASION FOR THEM TO MEET WITH
8	PEERS AND MENTORS ACROSS DIFFERENT INSTITUTIONS AND TO
9	SHARE AND DISCOVER WHAT OTHERS ARE WORKING ON. FOR THE
10	CIRM IT WAS AN OPPORTUNITY TO SEE FIRSTHAND THE PRODUCT
11	OF OUR TRAINING PROGRAM.
12	NOW, BECAUSE WE HAVE A LARGE NUMBER OF
13	TRAINEES, ASSOCIATED MENTORS AND PROGRAM DIRECTORS, WE
14	HAD ACTUALLY JUST A LITTLE OVER 200 PEOPLE REGISTER FOR
15	THIS MEETING. AND IN ADDITION, TO REDUCE TRAVEL, WE SET
16	UP TWO MEETINGS, ONE IN NORTHERN CALIFORNIA AND ONE IN
17	SOUTHERN CALIFORNIA, AS SHOWN ON THE SLIDE. THE NORTHERN
18	CALIFORNIA MEETING TOOK PLACE SEPTEMBER 11TH AT UC SAN
19	FRANCISCO MISSION BAY CAMPUS, AND THE SOUTHERN CALIFORNIA
20	COHORT MET JUST LAST WEEK AT THE UCI CAMPUS.
21	NOW, BOTH MEETINGS FEATURED THE SAME OVERALL
22	AGENDA THAT INCLUDED SHORT TALKS THAT WERE GIVEN BY ONE
23	SELECTED TRAINEE FROM EACH OF THE INSTITUTIONS. AND
24	THOSE PHOTOS THAT YOU ARE SEEING HERE ARE ACTUALLY FROM
25	THE NORTHERN CALIFORNIA MEETING, SO THESE ARE ACTUALLY
	21

- 1 TAKEN FROM THE MEETINGS. THERE WAS ALSO A POSTER SESSION
- 2 AT EACH IN WHICH TRAINEES HAD THE OPPORTUNITY TO DISPLAY
- 3 AND DISCUSS RESEARCH ON A ONE-TO-ONE BASIS. THERE WERE
- 4 ABOUT 115 ABSTRACTS OVERALL, AND THOSE ARE SHOWN AND
- 5 AVAILABLE IN THIS BOOK THAT WAS JUST PASSED AROUND A
- 6 LITTLE EARLIER.
- 7 THE SCHOLARS ALSO HAD THE OPPORTUNITY TO LEAD
- 8 AND PARTICIPATE IN DISCUSSION GROUPS ON VARIED SELECTED
- 9 TOPICS THAT INCLUDED THINGS LIKE TRANSLATIONAL
- 10 CHALLENGES, DIRECTED DIFFERENTIATION, AND CAREER
- 11 TRANSITIONS. AND THIS LAST PHOTO WAS IN ONE OF THE
- 12 POSTERS PRESENTED BY THE TRAINEES; AND AS YOU CAN SEE,
- 13 THEY ARE ALREADY LOOKING TO THE FUTURE OF THE CIRM
- 14 SCHOLARS.
- 15 SO LET ME JUST SAY THAT, IN CLOSING, WE REALLY
- 16 LEARNED A GREAT DEAL FROM THESE MEETINGS. IN PARTICULAR
- 17 IT REINFORCED THE FACT THAT THERE IS GREAT VALUE IN
- 18 HOLDING SUCH MEETINGS. NOT ONLY WAS IT IMPRESSIVE TO SEE
- 19 THE QUALITY PRESENTATIONS AND THE ENTHUSIASTIC
- 20 PARTICIPATION OF THE TRAINEES, BUT I THINK WE TOOK A GOOD
- 21 FIRST STEP TOWARDS DEVELOPING A NETWORK AND A COMMUNITY
- 22 OF SCIENTISTS IN STEM CELL RESEARCH. FOR THE TRAINEES
- 23 THIS WAS A FIRST TIME IN MEETING MANY OTHERS AT OTHER
- 24 INSTITUTIONS, SO I THINK THEY BENEFITED A LOT. I THINK
- 25 THIS HAS ALSO GOTTEN US TO THINK ABOUT HOLDING AN ANNUAL

1	MEETING FOR ALL CIRM INVESTIGATORS IN THE NEAR FUTURE,
2	SOMETHING THAT, AGAIN, WOULD HELP CREATE AND MAINTAIN A
3	COMMUNITY OF SCIENTISTS TO SYNERGIZE THEIR EFFORTS.
4	THANK YOU. I THINK AMY WILL BE SPEAKING NEXT.
5	MS. LEWIS: GOOD MORNING. I'M PLEASED TO
6	PROVIDE TO YOU AND TO THE PUBLIC A COMPILATION OF THE
7	CIRM'S AWARDS AND APPLICATIONS APPROVED FOR FUNDING. YOU
8	SHOULD HAVE A COPY AT YOUR PLACE OF THIS DOCUMENT. THERE
9	ARE SEVERAL COPIES AT THE BACK TABLE FOR THE PUBLIC TO
10	VIEW HERE AT THE MEETING. PLEASE NOTE THAT THIS IS AN
11	ADVANCE DRAFT COPY, AND WE WILL MAKE THE FINAL COPY
12	AVAILABLE TO YOU AND TO THE PUBLIC IN A FEW WEEKS AFTER
13	IT IS PRODUCED.
14	THE PUBLICATION INCLUDES FUNDING DATA AND
15	PUBLIC ABSTRACTS FOR ALL OF THE AWARDS AND APPROVED
16	APPLICATIONS AS OF AUGUST 2007. SO THIS BOOKLET IS
17	ORGANIZED INTO THREE CHAPTERS. THE FIRST CHAPTER COVERS
18	THE CIRM TRAINING GRANT AWARDS, THE TRAINEES THAT GIL
19	JUST REFERENCED. THOSE ARE ORGANIZED ALPHABETICALLY BY
20	INSTITUTION. THE SECOND CHAPTER, THE LEON J. THAL SEED
21	GRANTS AND COMPREHENSIVE RESEARCH GRANTS, ARE ORGANIZED
22	BY SPECIFIC INJURIES AND DISEASES AND THEN BY TYPES OF
23	RESEARCH. AND FINALLY, CHAPTER 3 COVERS THE SHARED
24	RESEARCH LABORATORIES AND TECHNIQUES COURSES, ALSO
25	ORGANIZED ALPHABETICALLY BY INSTITUTION.

1	I'D LIKE NOW TO TAKE JUST A MOMENT TO UPDATE
2	YOU ON THE PROGRESS OF THE GRANT AWARDS FOR THE SEED,
3	COMPREHENSIVE, AND SHARED LABS PROGRAMS.
4	MANY OF YOU MAY REMEMBER THE SLIDE THAT DR.
5	CHIU USED AT THE JUNE ICOC MEETING TO SUMMARIZE THE
6	GRANTS ADMINISTRATION PROCESS. FOR THE THREE PROGRAMS I
7	JUST MENTIONED, WE ARE CURRENTLY IN STAGES 4 AND 5,
8	PRE-AWARD REVIEW AND AWARD ACCEPTANCE.
9	AS A QUICK REMINDER, IN STAGE 4, PRE-AWARD
10	REVIEW, EACH APPLICATION IS CAREFULLY REVIEWED BY CIRM
11	GRANTS MANAGEMENT AND SCIENTIFIC STAFF FOR COMPLIANCE
12	WITH THE GRANTS ADMINISTRATION POLICY AND CONDITIONS OF
13	THE RFA ON ISSUES SUCH AS ELIGIBILITY, BUDGET, AND PUBLIC
14	POLICY ASSURANCES. THOSE ASSURANCES ARE THE SCRO, OR
15	STEM CELL RESEARCH OVERSIGHT COMMITTEE, APPROVAL FOR WORK
16	WITH HUMAN EMBRYONIC STEM CELLS, ALSO APPROVAL FOR WORK
17	WITH HUMAN SUBJECTS, AND APPROVAL FOR WORK WITH
18	VERTEBRATE ANIMALS.
19	AT THIS STAGE THE APPLICANT IS ASKED TO PROVIDE
20	TO CIRM PROVIDE CIRM WITH THE REQUIRED ASSURANCES AND
21	CERTIFICATIONS AS THEY APPLY TO THE RESEARCH PROPOSED.
22	WE DEPEND ON THE APPLICANTS TO PROVIDE US WITH THE
23	REQUIRED AND APPROPRIATE MATERIAL IN ORDER TO MOVE
24	FORWARD WITH ISSUING THE NOTICE OF GRANT AWARD. WHEN ALL
25	THE MATERIALS HAVE BEEN RECEIVED AND ALL REQUIREMENTS

1	MET, WE MOVE ON TO STAGE 5. THAT'S AWARD ACCEPTANCE.
2	CIRM SENDS OUT A NOTICE OF GRANT AWARD STATING
3	THE TERMS AND CONDITIONS OF THE AWARD. WHEN THE NOTICE
4	OF GRANT AWARD IS SIGNED AND RETURNED TO US BY THE
5	APPLICANT, WE NOTIFY THE STATE CONTROLLER, WHO ISSUES
6	CHECKS OR WARRANTS, AS THE STATE CALLS THEM, TO GRANTEES.
7	AT THE END OF STAGE 5, AN APPLICATION BECOMES A GRANT.
8	JUST A LITTLE BIT MORE DETAIL ON OUR NEXT
9	SLIDE, I HOPE. SO EARLIER THIS YEAR THE ICOC APPROVED
10	THE FUNDING OF 74 SEED APPLICATIONS, 29 COMPREHENSIVE
11	RESEARCH APPLICATIONS, AND 17 SHARED LABS APPLICATIONS
12	FOR A TOTAL OF 120 APPLICATIONS APPROVED FOR FUNDING.
13	SINCE THEN WE'VE BEEN WORKING HARD ON STAGE 4 AND STAGE 5
14	OF THE GRANTS ADMINISTRATION PROCESS WITH EACH APPLICANT,
15	MANY OF WHOM ARE NEW AT THIS AND UNFAMILIAR WITH OUR
16	CONDITIONS AND PROCESSES. WE'VE ALSO AUGMENTED OUR
17	GRANTS MANAGEMENT OFFICE, UP FROM ONE TO THREE STAFF.
18	YOU WILL NOTE THAT THERE ARE 33 APPLICATIONS
19	TOTAL IN THE FIRST COLUMN WITH DOCUMENTS PENDING. FOR
20	THESE APPLICATIONS WE AWAIT FINAL REQUIRED DOCUMENTATION
21	NECESSARY TO ISSUE A NOTICE OF GRANT AWARD, AND A HANDFUL
22	OF THOSE ARE FOR CASES WHERE A PRINCIPAL INVESTIGATOR HAS
23	REQUESTED TO DEFER THE START DATE OF THE AWARD.
24	WE HAVE SUCCESSFULLY ENTERED STAGE 5 WITH ABOUT
25	75 PERCENT OF THE APPROVED APPLICATIONS, ISSUING 87 AWARD

1	NOTICES BETWEEN AUGUST 1ST AND OCTOBER 1ST.
2	FINALLY, HERE'S A QUICK VISUAL SUMMARY OF THE
3	CURRENTLY FUNDED CIRM PROGRAMS WHICH FALL INTO THREE
4	MAJOR AREAS. FIRST, CIRM IS TRAINING NEW PEOPLE THROUGH
5	THE TRAINING GRANTS PROGRAM, PREPARING EXCEPTIONAL
6	PREDOCTORAL, POSTDOCTORAL, AND CLINICAL FELLOWS FOR
7	CAREERS IN STEM CELL RESEARCH, AND ALSO AS PART OF THE
8	SHARED LABS PROGRAMS, THROUGH THE TECHNIQUES COURSES,
9	PROVIDING HANDS-ON TRAINING FOR WORK WITH HUMAN EMBRYONIC
10	STEM CELLS FOR SCIENTISTS AND TECHNICAL STAFF.
11	CIRM IS SUPPORTING TALENTED INVESTIGATORS
12	WORKING ON BOTH GROUNDBREAKING CONCEPTS AND APPROACHES
13	AND MATURE ONGOING STUDIES IN THE SEED AND COMPREHENSIVE
14	RESEARCH GRANT PROGRAMS, AND CIRM IS FUNDING DEDICATED
15	LABORATORY SPACE AND EQUIPMENT THAT IS FREE OF FEDERAL
16	FUNDING THROUGH THE SHARED RESEARCH LABORATORY GRANT
17	PROGRAM.
18	AS YOU CAN SEE, THE ICOC HAS APPROVED MORE THAN
19	208 MILLION FOR RESEARCH AND FACILITIES FUNDING AT 23
20	CALIFORNIA INSTITUTIONS. THANK YOU VERY MUCH FOR YOUR
21	TIME AND ATTENTION. I BELIEVE DR. CHIU IS NEXT.
22	DR. CHIU: WITH THE LITIGATION BEHIND US AND IN
23	ANTICIPATION OF THE SALE OF BONDS, I'D TODAY LIKE TO
24	SUMMARIZE FOR THE BOARD OUR CURRENT INITIATIVES AND
25	PRESENT TO YOU PRELIMINARY PLANS FOR FUTURE INITIATIVES

1	WITH 2007 AND 2008.
2	SO FOR CURRENT INITIATIVES, WHICH YOU'VE
3	ALREADY SEEN, WE HAVE TWO THAT ARE POSTED, THE NEW
4	FACULTY AWARD WHERE THE BOARD APPROVED THE CONCEPT IN
5	JUNE, AND WE EXPECT TO BRING THE RESULTS FOR BOARD REVIEW
6	AND APPROVAL IN DECEMBER OF THIS YEAR. THE MAJOR
7	FACILITIES AWARDS, YOU APPROVED THE CONCEPT IN AUGUST OF
8	THIS YEAR, AND WE ANTICIPATE FINAL ICOC REVIEW AND
9	APPROVAL IN APRIL OF '08.
10	WE HAVE NEW INITIATIVES, TWO MORE NEW
11	INITIATIVES PLANNED FOR 2007. AND STAFF WILL BE
12	PRESENTING THESE IN MORE DETAIL IN AGENDA ITEMS 8 AND 9
13	THAT WILL FOLLOW. I JUST WANT TO POINT OUT THAT THE
14	DISEASE TEAM PLANNING GRANTS AND THE NEW PLURIPOTENT
15	HUMAN CELL LINES PROGRAM, WE EXPECT, WITH YOUR APPROVAL
16	TODAY, WE EXPECT THE RFA'S TO BE POSTED IN THE FALL OF

17 THIS YEAR FOR REVIEW TO TAKE PLACE IN THE WINTER AND TO

18 COME FOR YOUR APPROVAL ON THE INDIVIDUAL APPLICATIONS IN

19 THE SPRING OF '08.

20 SO AS YOU HAVE SEEN, FOR 2007 OUR PLATE IS NOW

21 VERY FULL. HOWEVER, WE DO ENVISION MORE INITIATIVES

22 COMING DOWN THE PIKE FOR 2008. NOW, I WANT TO WARN YOU

23 THE BIG WORD "DRAFT." THESE ARE JUST PRELIMINARY PLANS

24 AND ARE MEANT TO BE VERY FLEXIBLE. THE TIMING AND EXACT

25 NATURE OF EACH INITIATIVE MAY CHANGE DEPENDING ON NEW

1	PI ANS	MADE	RY	THE	TNTFRTM	PRESIDENT	AND	THE	NFW	PRESTDENT
			-		TIM LIVE 1	1 1/22776111	\neg		14 - 77	1 1/2277711

- 2 AS WELL AS ON CIRCUMSTANCES SUCH AS REVIEWER AVAILABILITY
- 3 AND STAFF RESOURCES. AND, OF COURSE, BEFORE EACH
- 4 INITIATIVE IS FINALIZED AND LAUNCHED, IT WILL BE BROUGHT
- 5 BEFORE THE BOARD FOR CONCEPT APPROVAL.
- 6 SO FUTURE INITIATIVES CAN BE CLASSIFIED UNDER
- 7 FOUR CATEGORIES. UNDER BASIC DISCOVERY RESEARCH, WE
- 8 PROPOSE SEVERAL POSSIBILITIES, NOT ALL OF WHICH MIGHT BE
- 9 PUT UP FOR 2008. AND THESE ARE BIOLOGY OF STEM CELLS,
- 10 TOOLS AND REAGENTS, EGG AND EMBRYO RESEARCH, AND TISSUE
- 11 ENGINEERING, EACH OF WHICH IS MORE FULLY DESCRIBED IN THE
- 12 SCIENTIFIC STRATEGIC PLAN.
- 13 UNDER TRANSLATIONAL RESEARCH, WE ENVISION TWO
- 14 IMPORTANT INITIATIVES, AN RFA FOR STAGE 1 TRANSLATIONAL
- 15 OR PRECLINICAL RESEARCH AND A MAJOR DISEASE TEAM GRANT
- 16 PROGRAM TO BE LAUNCHED LATE IN 2008. AND PAT OLSON WILL
- 17 BE TALKING MORE ABOUT THIS PROGRAM IN A FEW MINUTES.
- 18 TWO OTHER AREAS. TRAINING PROGRAMS, OUR
- 19 CURRENT TRAINING PROGRAM THAT YOU HEARD A LITTLE BIT
- 20 ABOUT RUNS FOR THREE YEARS, BUT WILL EXPIRE AT THE END OF
- 21 MARCH IN 2009. WE WOULD LIKE TO RENEW IT UNDER TRAINING
- 22 PROGRAM II. IN ADDITION, WE HOPE TO INITIATE A TECHNICAL
- 23 TRAINING PROGRAM SPECIFICALLY TO EXTEND THE SKILLS OF
- 24 TECHNICAL STAFF IN STEM CELL RESEARCH.
- AND FINALLY, CORES AND FACILITIES. WE

1	ANTICIPATE	ΔN	TNTTTATTVF	TΩ	SUPPORT	CRTTTCAL	CORFS	AND
_		\neg			2011011		COILES	\neg

- 2 SERVICES SUCH AS STEM CELL BANKING AND TRAINING AND OTHER
- 3 IMPORTANT RESOURCES SOMETIME NEXT YEAR. TO CARRY OUT ALL
- 4 THESE AMBITIOUS PLANS WILL REQUIRE STAFFING UP THE
- 5 SCIENCE OFFICE, WHICH IS ALREADY WORKING FLAT OUT TO MEET
- 6 THIS YEAR'S GOALS. AND I THANK YOU FOR YOUR ATTENTION.
- 7 (APPLAUSE.)
- 8 DR. MURPHY: MR. CHAIRMAN, THAT IS THE
- 9 PRESIDENT'S REPORT, AND I'M HAPPY TO OPEN THE FLOOR TO
- 10 QUESTIONS FROM THE ICOC FOR ANY OF OUR STAFF.
- 11 CHAIRMAN KLEIN: THANK YOU VERY MUCH. IT'S A
- 12 VERY IMPRESSIVE REPORT AND VERY INSPIRING. MEMBERS OF
- 13 THE BOARD? DR. PRIETO.
- DR. PRIETO: I WONDER IF YOU COULD GIVE US SOME
- 15 IDEA HOW MUCH HAS ACTUALLY HAS GONE OUT OF THE APPROVED
- 16 GRANTS. WHAT HAVE WE ACTUALLY FUNDED AND WRITTEN CHECKS
- 17 FOR?
- 18 DR. MURPHY: I THINK AMY CAN.
- 19 MS. LEWIS: 75 PERCENT.
- 20 DR. MURPHY: 75 PERCENT OF YEAR ONE GRANTS HAVE
- 21 NOW GONE OUT. MONEY HAS FLOWED.
- DR. PRICE: THAT INCLUDES THE SEED GRANTS YEAR
- 23 ONE WHEN YOU SAY YEAR ONE?
- DR. MURPHY: FOR ALL THREE PROGRAMS.
- 25 CHAIRMAN KLEIN: OKAY. DR. PIZZO.

1	DR. PIZZO: I WAS VERY PLEASED TO HEAR ALL THE
2	REPORTS, OF COURSE. THE ONE ON THE TRAINING GRANTS AND
3	THE SCHOLARS IS, OF COURSE, OF INCREDIBLE IMPORTANCE TO
4	ALL OF US. TWO THINGS, ONE JUST VERY PRACTICAL. I KNOW
5	THAT YOU NEEDED TO DIVIDE THEM INTO A NORTH-SOUTH
6	CORRIDOR FOR THE FIRST PASS. I THINK OBVIOUSLY IT WILL
7	BE GREAT GOING FORWARD TO MIX UP OUR COMMUNITIES SO THAT
8	WE DON'T HAVE A UNNATURAL DIVIDE.
9	THE OTHER IS THAT IT MAY BE VERY WORTHWHILE
10	THINKING ABOUT A GATHERING OF THE PROGRAM DIRECTORS FROM
11	THOSE TRAINING GRANTS AS WELL TO SHARE THEIR EXPERIENCES,
12	WHAT'S WORKING, WHAT'S NOT WORKING IN MENTORING AND
13	GUIDING THESE EXTRAORDINARY YOUNG FUTURE TALENTS SO THAT
14	WE CAN OPTIMIZE THIS, NOT ONLY FOR THE CURRENT TRAINEES,
15	BUT ALSO AS TO HOW IT MIGHT APPLY TO FUTURE ONES AS WELL.
16	DR. MURPHY: I THINK THAT'S AN EXCELLENT
17	SUGGESTION.
18	CHAIRMAN KLEIN: THANK YOU. ADDITIONAL BOARD
19	COMMENTS?
20	DR. MURPHY: EXCUSE ME, BOB. I THINK GIL HAS A
21	COMMENT.
22	DR. SAMBRANO: I JUST WANTED TO REPLY. I THINK
23	THOSE ARE TWO VERY GOOD POINTS, AND I JUST WANT TO NOTE
24	THAT WE ACTUALLY DID HAVE A MEETING OF THE PROGRAM

DIRECTORS LAST YEAR. AND THAT WAS ACTUALLY VERY

25

_										
7	PRODUCTIVE.	TT	COT	EVERYBODY	\sim	THE	$C \wedge M =$	$D \wedge C \Gamma$	TNI	TEDMO
1	PRUDUCITVE.	_ I I	GUL	EVERYBUDY	UN	1 11 12	SAME	PAGE	TIN	LEKIVIS

- 2 OF WHAT THEY NEEDED TO DO WITH TRAINING PROGRAMS AND ALSO
- 3 A SHARE OF IDEAS OF HOW THEY CAN DO IT IN THE FUTURE.
- 4 I THINK THE TRAINING MEETINGS THAT WE HAD AS
- 5 WELL WAS ANOTHER OPPORTUNITY FOR THE PROGRAM DIRECTORS TO
- 6 COME TOGETHER, AND THEY NOTED THAT THAT WAS AN IMPORTANT
- 7 ASPECT OF HAVING SUCH MEETINGS.
- 8 AND THEN TO YOUR OTHER POINT, AGAIN BRINGING
- 9 TOGETHER ALL THE TRAINEES IN A SINGLE MEETING WAS BROUGHT
- 10 UP BY SEVERAL, AND SO THAT'S SOMETHING THAT WE ARE GOING
- 11 TO THINK ABOUT POSSIBLY FOR NEXT YEAR.
- 12 DR. PIZZO: IT WOULD BE GOOD. IF YOU CAN JUST
- 13 GET THEM ALTOGETHER, IT BECOMES A BIG MEETING, MIXING
- 14 THEM UP SO THAT THEY HAVE AN OPPORTUNITY TO SHARE MORE
- 15 BROADLY WOULD BE WORTHWHILE.
- DR. SAMBRANO: THANK YOU.
- DR. MURPHY: MR. CHAIRMAN, MAY I JUST ADD ONE
- 18 THING?
- 19 CHAIRMAN KLEIN: ABSOLUTELY.
- DR. MURPHY: JUST TO PUT A LITTLE FACE ON THE
- 21 TRAINING PROGRAM. I WAS AT THE IRVINE MEETING. AND
- 22 GOING AROUND THE POSTERS, AND I ENDED UP TALKING WITH TWO
- 23 YOUNG WOMEN, BOTH OF WHOM WERE SURGICAL RESIDENTS AT L.A.
- 24 CHILDREN'S HOSPITAL. ONE WAS A -- PRESENTED A POSTER
- THAT SHE WAS DOING ON THE STEM CELLS OF CANCER, AND THE

T OIH	EK UNE	PRESENTED	А	POSTER	SHE	WAS	DOTING	UN	IHE	SIEM
-------	--------	-----------	---	--------	-----	-----	--------	----	-----	------

- 2 CELLS IN THE GUT. AND AFTER HEARING THEIR SCIENCE, I
- 3 THEN SAID WHAT ARE YOUR CAREER PLANS? IN BOTH CASES
- 4 THESE TWO YOUNG LADIES, BOTH NOW AT THE END OF THEIR
- 5 TRAINING AS SURGEONS, WERE SPENDING THREE YEARS DOING THE
- 6 CELL BIOLOGY OF STEM CELLS. AND BOTH HAD MADE THE
- 7 DECISION THAT THEY NOW WANTED TO BE ACADEMIC PHYSICIANS.
- 8 SO I THINK THAT THAT'S THE IMPACT THAT CIRM
- 9 PROGRAMS ARE HAVING, WHICH I THINK, IF NOTHING ELSE EVER
- 10 HAPPENED TO ME, THAT'S WORTH THE PROGRAM RIGHT THERE.
- 11 CHAIRMAN KLEIN: DR. BRENNER.
- DR. BRENNER: ACTUALLY THAT'S SORT OF MY
- 13 QUESTION. I THINK IT'S VERY IMPORTANT IF WE DOCUMENT THE
- 14 FOLLOW-UP SO IT'S NOT BASED ON TESTIMONIALS, WE KNOW
- 15 ACTUALLY WHERE THEY ARE ONE YEAR, TWO YEARS, THREE YEARS
- 16 OF OUR TRAINEES. I THINK THAT'S VERY IMPORTANT TO
- 17 VALIDATE THE PROGRAM.
- DR. MURPHY: THAT'S A GREAT IDEA, DAVID.
- 19 CHAIRMAN KLEIN: THAT'S A SUPERB IDEA. IT
- 20 WOULD BE VERY HELPFUL IN OUR OVERSIGHT HEARINGS TO REALLY
- 21 PROVIDE THAT DATA.
- 22 ADDITIONAL BOARD COMMENTS? DR. HENDERSON.
- DR. HENDERSON: YEAH. I DON'T KNOW HOW
- 24 FEASIBLE IT IS IN THE SCHOLARS MEETING, BUT IF THERE'S A
- 25 WAY TO WORK IN PARTICIPATION FROM SOME SENIOR SCIENTISTS

	1	IN THE	DIFFERENT	ACADEMIC	INSTITUTIONS	JUST	WITHIN	TH!
--	---	--------	-----------	----------	--------------	------	--------	-----

- 2 STATE AS SORT OF VISITING FELLOWS OR SOMETHING WHO CAN,
- 3 LIKE YOU, GO AROUND AND INTERACT WITH DIFFERENT TRAINEES
- 4 FROM DIFFERENT INSTITUTIONS TO SORT OF BROADEN THE
- 5 TRAINEE'S EXPOSURE TO THE WEALTH OF SCIENTIFIC EXPERTISE
- 6 WE HAVE IN THIS STATE. SORT OF ALONG THE MARQUIS
- 7 SCHOLARS MEETING MODEL, BUT MAYBE NOT THAT ELABORATE, BUT
- 8 I'M SURE MANY OF US WOULD BE WILLING TO DO THIS, AND IT
- 9 MIGHT JUST ADD SOME MORE DEPTH TO THE EXPERIENCE FOR THE
- 10 SCHOLARS.
- DR. MURPHY: EXCELLENT.
- 12 CHAIRMAN KLEIN: DUANE ROTH.
- MR. ROTH: SO I REALLY APPRECIATE THE COMMENTS
- 14 YOU ALL MADE ABOUT THE NEED TO GET THE STAFF THAT'S
- 15 NECESSARY TO KEEP THE MOMENTUM GOING. AND I REALLY WANT
- 16 TO ENCOURAGE THAT. I THINK, YOU KNOW, WE'VE BEEN THROUGH
- 17 SO MUCH WITH THE LITIGATION AND THE DELAYS, AND NOW THAT
- 18 WE'RE THERE, I HOPE WE DON'T LET INTERNAL LACK OF
- 19 RESOURCES, WHETHER IT BE REVIEWERS OR STAFFERS, SLOW US
- 20 DOWN. AND EVEN THE TEMPTATION TO WAIT TILL THE NEW
- 21 PRESIDENT ARRIVES, I THINK, WOULD BE A MISTAKE. WE
- 22 SHOULD KEEP MOVING AND MAKE SURE THAT WE AREN'T THE
- 23 LIMITING STEP TO GET THE MONEY AND GRANTS ISSUED.
- DR. MURPHY: AGREED.
- CHAIRMAN KLEIN: OKAY. I'D ALSO LIKE TO

1	RECOUNT	Α	SHORT	STORY	FOR	ALL	OF	THOSE	ON	THE	BOARD	AND

- 2 THOSE WHO HAVE SAT THROUGH PEER REVIEW SESSIONS AND
- 3 WATCHED DR. CHIU LEAD THOSE REVIEW SESSIONS SEAMLESSLY.
- 4 THERE'S SOME BACKGROUND THAT YOU SHOULD KNOW BECAUSE
- 5 WE'VE ACCOMPLISHED A TREMENDOUS AMOUNT EVEN UNDER THE
- 6 THREAT OF LITIGATION HERE. IT TOOK A REAL DRIVING
- 7 INSPIRATION TO GET THOSE PEER REVIEW SESSIONS COMPLETED
- 8 AND THE SCIENCE MOVING FORWARD.
- 9 SO WE WERE -- DR. MURPHY AND I WERE AT A DINNER
- 10 WITH DR. TROUNSON, AND DR. CHIU WAS THERE, AND WE
- 11 RECOUNTED THAT DURING THE CAMPAIGN FOR PROPOSITION 71,
- 12 WHEN OTHERS THOUGHT THAT IT MIGHT NOT PASS, THERE WAS A
- 13 GREAT INSPIRED SCIENTIST AT THE NIH, DR. ARLENE CHIU.
- 14 AND SHE CALLED THE CAMPAIGN OFFICE DURING THE CAMPAIGN
- 15 AND SHE SAID, "YOU KNOW, WHEN THIS PASSES," NOT IF, "WHEN
- 16 THIS PASSES, YOU SHOULD HIRE ME. I CAN GET IT DONE."
- 17 (APPLAUSE.)
- 18 CHAIRMAN KLEIN: SO HER SPIRIT AND HER
- 19 COMMITMENT, I THINK, ARE ALWAYS THERE. SHE WAS PART OF
- 20 THE BIRTH OF THIS ORGANIZATION AND IS COMMITTED TO
- 21 CONTINUE TO ADVISE US AS WE MATURE. BUT IT'S THAT
- 22 DRIVING SPIRIT EVEN WHEN OTHERS WERE DOUBTING THE
- 23 POSSIBILITY THAT HAS MADE THIS SUCH AN ENERGETIC DYNAMIC
- 24 AND DELIVERING INSTITUTION.
- I BELIEVE THAT WE HAVE A PUBLIC COMMENT AT THIS

1	TIME. JOHN SIMPSON.
2	MR. SIMPSON: JOHN SIMPSON FROM THE FOUNDATION
3	FOR TAXPAYER AND CONSUMER RIGHTS. THREE VERY QUICK
4	ITEMS, TWO OF THEM ARE MAYBE HOUSEKEEPING. YOU MAY HAVE
5	NOTED THAT DON REED IS NOT HERE, AND HE ASKED ME TO NOTE
6	THAT, IN CASE YOU HADN'T NOTED IT, BECAUSE EVEN THOUGH
7	HE'S AN AMAZING FELLOW AND TREMENDOUSLY COMMITTED, HE
8	CANNOT BE IN TWO PLACES AT ONCE. HE IS AT THE STEM CELL
9	SUMMIT IN BOSTON AND SENDS HIS REGRETS, AND HE ASKED ME
10	TO PLEASE DO THAT.
11	THE SECOND THING, I ONCE SPENT A YEAR IN
12	IRELAND TEACHING AND LEARNED THAT ENGLISH IS SPOKEN IN
13	MANY DIFFERENT WAYS AROUND THE WORLD. AND I HAVE
14	ACQUIRED FOR THE STAFF A WORD BOOK OF AUSTRALIAN IDIOM,
15	AUSSIE SLANG, NO WORRIES. SHE'S APPLES. AND I THINK
16	THIS MIGHT HELP AS YOU DEAL WITH ALAN TROUNSON. SO I
17	GIVE THIS TO THE PRESIDENT, AND THE ICOC CAN PERHAPS DRAW
18	ON THAT RESOURCE.
19	(APPLAUSE.)
20	MR. SIMPSON: THE SERIOUS POINT I WANTED TO
21	MAKE ON THE AWARDS THAT WERE ANNOUNCED IN THE REVIEW. IT
22	SEEMS TO ME THAT THE FACT THAT 33 ARE STILL PENDING IS A

VERY GOOD THING IN A SENSE BECAUSE IT SHOWS THAT THE

24 PROCEDURES ARE BEING FOLLOWED AND YOU ARE VETTING THINGS

25 VERY CAREFULLY, AND THAT'S VERY IMPORTANT. BUT I WOULD

- 1 ASK A FURTHER QUESTION ABOUT THOSE, AND MAYBE IT'S HERE
- 2 AND I DIDN'T HEAR IT. ARE THERE ANY THAT YOU HAVE
- 3 CONCLUDED WILL NOT PASS MUSTER AND WILL ULTIMATELY BE
- 4 TURNED DOWN?
- 5 CHAIRMAN KLEIN: WE ACTUALLY HAVE AN
- 6 ADMINISTRATIVE ITEM THAT'S GOING TO COME UP ON, AND THERE
- 7 WILL BE A REPORT ON THAT VERY SPECIFICALLY. SO WHEN WE
- 8 GET TO THAT REPORT, WE'RE GOING TO COVER IT.
- 9 MR. SIMPSON: THAT WILL BE VERY APPROPRIATE.
- 10 THANK YOU.
- 11 CHAIRMAN KLEIN: THANK YOU. SO AT THIS TIME
- 12 I'D LIKE TO ASK DR. MURPHY IF IT'S APPROPRIATE THAT WE
- 13 CAN MOVE TO AGENDA ITEM 7, CONSIDERATION OF AMENDMENTS TO
- 14 GRANTS ADMINISTRATION POLICY REGARDING FACILITIES. THIS
- 15 ITEM IS IN TWO PARTS, BOTH FOUND BEHIND TAB 7 IN YOUR
- 16 BINDERS. PART A IS THE FACILITIES PORTION OF THE GAP
- 17 RECOMMENDED BY THE FACILITIES WORKING GROUP THAT WILL BE
- 18 PRESENTED LATER BY RICK KELLER, AND PART B WILL BE
- 19 PRESENTED BY DR. MURPHY. DR. MURPHY, IT'S YOUR PLEASURE.
- DR. MURPHY: MR. CHAIRMAN, THAT IS THE
- 21 INTRODUCTION I WAS GOING TO GIVE. SO LET ME INTRODUCE TO
- 22 YOU RICK KELLER, WHO HAS BEEN RESPONSIBLE FOR THE ONGOING
- 23 ACTIVITIES OF THE FACILITIES WORKING GROUP.
- DR. POMEROY: BOB, IN TERMS OF CLARIFICATION,
- 25 IS THIS THE DISCUSSION ITEM FROM WHICH MANY OF US HAVE TO

1	RECUSE	OURSELVES?
	NECOSE	CONSELVES.

- 2 CHAIRMAN KLEIN: LET ME HAVE COUNSEL ADDRESS
- 3 THIS. FIRST TAMAR PACHTER AND THEN IF I COULD ALSO HAVE
- 4 JAMES HARRISON MAKE A COMMENT.
- 5 MS. PACHTER: DR. POMEROY, THIS ITEM IS BEING
- 6 PRESENTED IN TWO PARTS, 7 A AND 7 B. THE MEMBERS OF THE
- 7 ICOC HAVE NO KNOWN CONFLICTS OF INTEREST WITH RESPECT TO
- 8 ITEM 7 A; HOWEVER, WE HAVE IDENTIFIED POTENTIAL CONFLICTS
- 9 OF INTEREST WITH RESPECT TO ITEM 7 B, WHICH WILL AFFECT,
- 10 MAY AFFECT, EXISTING CONTRACTS AT INSTITUTIONS WITH WHICH
- 11 SOME OF YOU ARE AFFILIATED.
- 12 SO WITH RESPECT TO ITEM A, THERE IS NO
- 13 RESTRICTION THAT WE ARE AWARE OF ON DISCUSSION OR VOTING.
- 14 THERE ARE RESTRICTIONS WITH RESPECT TO ITEM 7 B.
- 15 CHAIRMAN KLEIN: AND MR. HARRISON, COULD YOU
- 16 PUT THIS 7 B DISCUSSION IN CONTEXT?
- 17 MR. HARRISON: SURE. FIRST OF ALL, AS YOU
- 18 KNOW, THERE IS AN EXCEPTION IN PROPOSITION 71 THAT
- 19 PERMITS THE BOARD TO PARTICIPATE IN DECISIONS WITH
- 20 RESPECT TO STANDARDS OF GENERAL APPLICATION WITHOUT
- 21 RESPECT TO POTENTIAL CONFLICTS OF INTEREST. AND AS YOU
- 22 ALSO KNOW, AND AS THE COURT OF APPEAL RECOGNIZED, ONE OF
- THE REASONS THAT PROPOSITION 71 WAS STRUCTURED AS IT WAS
- 24 WAS IN ORDER TO DRAW UPON THE EXPERTISE OF PEOPLE WHO
- 25 COME FROM INSTITUTIONS THAT HAVE MANAGED SCIENTIFIC AND

1	MEDICAL GRANTS AND THAT ARE EXPERIENCED IN THIS AREA.
2	SO IN THE PAST YOU HAVE PARTICIPATED IN ALL
3	DECISIONS WITH RESPECT TO STANDARDS ON A PROSPECTIVE
4	BASIS. HERE, WITH RESPECT TO ITEM 7 B, THERE ARE A
5	COUPLE OF DISTINCTIONS. ONE IS THAT LETTERS OF INTENT
6	HAVE ALREADY BEEN SUBMITTED FOR THE MAJOR FACILITIES
7	GRANTS. THE SECOND IS THAT THIS PARTICULAR DECISION
8	WOULD AFFECT EXISTING GRANTS.
9	SO FOR THOSE OF YOU WHO COME FROM INSTITUTIONS
10	THAT HAVE ALREADY RECEIVED RESEARCH GRANT AWARDS, THIS
11	DECISION MAY HAVE AN IMPACT ON THOSE AWARDS. SO
12	NOTWITHSTANDING THE EXCEPTION, WE BELIEVE THAT IN THIS
13	PARTICULAR CIRCUMSTANCE THAT IT WOULD BE ADVISABLE FOR
14	THOSE MEMBERS WHO COME FROM INSTITUTIONS WHO HAVE
15	SUBMITTED LOI'S OR THAT INTEND TO APPLY FOR A MAJOR
16	FACILITIES GRANT AND THAT HAVE EXISTING RESEARCH GRANTS
17	RECUSE THEMSELVES FROM PARTICIPATING IN THE DECISION.
18	AND THAT'S OUT OF AN ABUNDANCE OF CAUTION, AGAIN, TO
19	MAINTAIN PUBLIC TRUST AND TRANSPARENCY.
20	CHAIRMAN KLEIN: AND THIS ADVICE IS BASED ON
21	THIS VERY SPECIFIC FACT. IT'S NOT MEANT TO ESTABLISH ANY
22	BROAD PRECEDENT. IT IS NARROWLY LIMITED TO THESE VERY
23	SPECIFIC FACTS, BUT THANK YOU. DR. POMEROY. DR. PIZZO.
24	DR. PIZZO:NOT BEING INVOLVED IN THE
25	DISCUSSION, I UNDERSTAND THE WHOLE, BUT NOT THE

1	DISCUSSION EITHER?
2	MR. HARRISON: THAT'S CORRECT. IT APPLIES TO
3	BOTH.
4	CHAIRMAN KLEIN: ON PART B.
5	DR. BRYANT: WILL THAT LEAVE A QUORUM?
6	CHAIRMAN KLEIN: YES. IN WRITING THE
7	INITIATIVE, THE RULES WERE SET UP SO THAT THE QUORUM
8	AUTOMATICALLY ADJUSTS SO THAT WHENEVER INDIVIDUALS ARE
9	RECUSED, THE QUORUM ADJUSTS FOR EXCLUDING THOSE THAT ARE
10	RECUSED. THERE WERE GREAT LEGAL MINDS THAT WERE PROVIDED
11	AS SUPPORT FOR THAT. BUT I WILL TELL YOU THAT IT'S ALSO
12	IN AN AREA WE HAD SOME CONCERN BECAUSE THERE WERE
13	CANDIDATES RUNNING IN THAT ELECTION WHO WERE NOT
14	SUPPORTIVE OF STEM CELL RESEARCH. IT WOULD ADJUST IF
15	THERE IS AT ANY TIME A CONSTITUTIONAL OFFICER WHO DOES
16	NOT MAKE THE APPOINTMENTS. IT ALSO THEN ADJUSTS FOR
17	VACANT SEATS. RICK KELLER.
18	MR. KELLER: GOOD MORNING. TODAY YOU'RE GOING
19	TO CONSIDER THE GRANTS ADMINISTRATION POLICY OR GAP WHICH
20	PROVIDES GUIDANCE TO APPLICANTS AND GRANTEES ABOUT THE
21	POLICIES AND RULES THAT WILL APPLY TO CIRM GRANTS. YOU
22	HAVE PREVIOUSLY APPROVED SEVEN CHAPTERS WITHIN THE GAP,
23	AND TODAY YOU WILL BE CONSIDERING, AS MENTIONED, CHAPTER

PRESENTING THE REVISIONS TO CHAPTER 5.

25

8 OF THE MAJOR FACILITIES, AND LATER DR. MURPHY WILL BE

1	SO WHERE DO THESE RULES ORIGINATE FROM? WELL,
2	FIRST OF ALL, THERE'S BASICALLY THREE AREAS. THERE ARE
3	PROVISIONS WITHIN PROPOSITION 71 THAT ARE SPECIFIC
4	REQUIREMENTS THAT WE MUST INCORPORATE INTO THE
5	ADMINISTRATIVE LAW FOR APPLICANTS AND GRANTEES TO BE
6	AWARE OF.
7	SECONDLY, YOU HAVE COMMISSIONED OR PROPOSITION
8	71, RATHER, COMMISSIONS THE FACILITIES WORKING GROUP TO
9	"MAKE RECOMMENDATIONS TO THE ICOC ON INTERIM AND FINAL
10	CRITERIA REQUIREMENTS AND STANDARDS FOR APPLICATIONS FOR
11	AND THE AWARDING OF GRANTS AND LOANS FOR BUILDINGS,
12	BUILDING LEASES, AND CAPITAL EQUIPMENT." SO THIS PUTS
13	THE FACILITIES WORKING GROUP IN A POSITION OF
14	RECOMMENDING TO YOU SPECIFIC POLICIES THAT ARE
15	DISCRETIONARY TO YOU.
16	AND THEN THIRDLY, THERE IS ALSO THE STAFF OR
17	CIRM PRESIDENT'S RECOMMENDATIONS AS WILL BE PRESENTED
18	LATER BY DR. MURPHY.
19	LET ME GO THROUGH THE SPECIFIC AREAS HERE THAT
20	I JUST REVIEWED. WITH RESPECT TO THE PROVISIONS APPLYING
21	TO PROPOSITION 71, YOU WILL SEE THAT IT CALLS FOR
22	SPECIFIC REQUIREMENTS RELATED TO BEING NONPROFIT, THAT A
23	GOAL BE ESTABLISHED FOR CALIFORNIA SUPPLIERS THAT WORKERS
24	BE PAID PREVAILING WAGE, THAT FACILITIES HAVE A

20-PERCENT MATCHING REQUIREMENT FROM THE INSTITUTION, AND

25

	1	THAT	THERE	BE	A P	RIORITY	CONSIDERATION	FOR	PROJECTS	THA
--	---	------	-------	----	-----	---------	---------------	-----	----------	-----

- 2 ARE COMPLETED WITHIN TWO YEARS.
- THE RECOMMENDATIONS FROM YOUR FACILITIES
- 4 WORKING GROUP, WHICH MET YESTERDAY, IS WHAT I REVIEW NOW.
- 5 I WANT TO MAKE SURE THAT YOU'RE AWARE OF THE FACT THAT,
- 6 IN ADDITION TO THE MATERIAL THAT YOU RECEIVED IN YOUR
- 7 PACKET IN SECTION 7, THERE IS ALSO AN ADDENDUM REFLECTING
- 8 CHANGES THAT WERE ADOPTED YESTERDAY BY THE FACILITIES
- 9 WORKING GROUP IN THE FRONT LEAF OF THE BINDER AND SHOULD
- 10 BE TITLED AS SUCH. SO AGENDA ITEM 7 A AMENDMENT.
- 11 THE REQUIREMENTS THAT HAVE BEEN ESTABLISHED BY
- 12 THE -- RECOMMENDED, RATHER, BY THE FACILITIES WORKING
- 13 GROUP CONSIST OF MATCHING FUNDS BEING LIMITED TO CASH
- 14 CONTRIBUTIONS TO THE PROJECT. AND THIS LEADS TO REALLY A
- 15 CONCEPT OF PROJECT LEVERAGE, AND I'LL GET INTO MORE
- 16 DETAIL ABOUT PROJECT LEVERAGE LATER. BUT IT BASICALLY IS
- 17 UNDER -- IT ESTABLISHES THE NOTION THAT ALL THE
- 18 CONTRIBUTIONS TO THE PROJECT THAT ARE BEYOND THE
- 19 20-PERCENT CASH MATCH WILL BE CONSIDERED PROJECT LEVERAGE
- 20 AND BE CONSIDERED IN THE EVALUATION OF PROPOSALS.
- THERE'S ALSO A PROVISION THAT ESTABLISHES SPACE
- 22 WILL BE USED FOR STEM CELL RESEARCH FOR AT LEAST TEN
- 23 YEARS, AND THIS IS SECTION F. IT WAS MODIFIED FOR
- 24 CLARITY AND TO GIVE SOME FLEXIBILITY IN THE VERSION THAT
- 25 WAS ADOPTED LAST NIGHT.

1

1	IN ADDITION, BY VIRTUE OF THE SUBSTANTIAL
2	INVESTMENT BY THE STATE OF CALIFORNIA IN THESE
3	FACILITIES, THE FACILITIES WORKING GROUP RECOMMENDS A
4	PROVISION TO ENSURE THAT CIRM RECEIVES RECOGNITION IN THE
5	NAMING OF THESE FACILITIES AND IS ABLE TO PARTICIPATE IN
6	CEREMONIES CONCERNING THESE FACILITIES. AND THAT ALSO IS
7	A SUBJECT OF SECTION F REVISIONS.
8	SOME OF THE OTHER ISSUES RECOMMENDED BY THE
9	FACILITIES WORKING GROUP, IF THE TWO-YEAR PREFERENCE THAT
10	WAS NOTED IN PROP 71 IS REQUESTED, A PRIORITY
11	CONSIDERATION, THERE WILL HAVE TO BE SOME PENALTY
12	ASSESSED IN THE EVENT THAT COMPLETION IS NOT ACCOMPLISHED
13	AS STATED IN THE APPLICATION. SO WE HAVE INCLUDED A
14	PROVISION TO DEAL WITH THAT.
15	AND THEN THERE ARE ISSUES ABOUT HOW PAYMENTS
16	WILL BE MADE TO THE INDIVIDUAL GRANTEES, AND THERE'S
17	TECHNICAL AND FINANCIAL ISSUES ASSOCIATED WITH OUR
18	ABILITY TO REQUEST PROGRESS REPORTS AND TO CONDUCT
19	POSTAUDITS.
20	ONCE THE GAP REVISIONS ARE APPROVED BY THE
21	ICOC, THEY ARE ADOPTED INTO CALIFORNIA CODE OF
22	REGULATIONS. BEFORE I GO TO THE FINAL, I WANT TO MAKE
23	SURE THAT I SAID I WAS GOING TO REVIEW SOMEWHAT THE
24	CALCULATION OF LEVERAGE. WE WANTED TO MAKE SURE YOU HAD
25	A FIRM UNDERSTANDING OF THIS.

1	SO JUST IN TWO SLIDES I WANT TO EXPLAIN A
2	THEORETICAL EXAMPLE. IN THIS CASE, IF THE CONSTRUCTION
3	COSTS WERE TO BE \$65 MILLION AND FUNDS THAT WERE BUDGETED
4	FOR FEES AND ADMINISTRATION 11, EQUIPMENT 14 MILLION WITH
5	A CONTINGENCY OF 5, THERE WOULD BE A TOTAL PROJECT COST
6	OF \$95 MILLION. WE WOULD THEN PROCEED TO CALCULATE THE
7	LEVERAGE ASSOCIATED WITH THIS BUDGET FOR THE FACILITY.
8	AND THAT CALCULATION WOULD TAKE THE 95 MILLION AND SAY
9	PRESUMING THAT CIRM WAS FUNDING 40 MILLION OF THE 95,
LO	THERE WOULD HAVE TO BE MATCHING FUNDS OF 8 MILLION,
L1	LEAVING LEVERAGE FUNDS OF 47 MILLION.
L2	THERE'S A PROVISION RECOMMENDED BY THE
L3	FACILITIES WORKING GROUP THAT SAYS THAT THE AMOUNT OF
L4	LEVERAGE, HOWEVER, SHOULD NOT INCLUDE AN EXCESSIVE AMOUNT
L5	FOR DESIGN FEES WHERE INSTITUTIONS SPEND WHERE IN THEIR
L6	JUDGMENT THEY MAY BE SPENDING TOO MUCH MONEY ON THE
L7	ADMINISTRATION OR DESIGN FEES OF A FACILITY. SO THEY
L8	HAVE LIMITED OR RECOMMENDED IN THE PROVISIONS FOR YOU TO
L9	APPROVE THAT THE ADMINISTRATIVE FEES BE LIMITED TO 10
20	PERCENT OF THE CONSTRUCTION AMOUNT, EXCLUDING AMOUNTS
21	BUDGETED FOR STRUCTURAL ENGINEERING OR SEISMIC SAFETY
22	CONSIDERATIONS IN THE FEES.
23	SO IN THIS LITTLE CALCULATION, THE FEES ARE 11,
24	I'M ASSUMING THAT THE EXCLUDED AMOUNT IS 2 MILLION,
25	LEAVING THE BUDGET PROPOSAL AT 9 MILLION. WHEN WE LOOK

- 1 BACK AT THE CONSTRUCTION COSTS OF 65 MILLION, 10 PERCENT
- 2 OF THAT WOULD ALLOW 6.5 MILLION, SO THERE'S AN ADJUSTMENT
- 3 HERE IN THE LEVERAGE CALCULATION TO SAY THAT 2.5 MILLION
- 4 OF BUDGETED FEES AND ADMINISTRATION WILL NOT BE
- 5 CONSIDERED, SO THE NET LEVERAGE IS 44.5 MILLION, WHICH IS
- 6 ESSENTIALLY THAT WHICH CIRM IS RECOGNIZING OVER AND ABOVE
- 7 THE MATCHING FUNDS.
- 8 IF WE EXPRESS THAT AS A RATIO BETWEEN THE
- 9 AMOUNT OF FUNDS PROVIDED IN THE LEVERAGE BY THE APPLICANT
- 10 AND THE AMOUNT OF FUNDS PROVIDED BY CIRM, THEN THAT WOULD
- 11 BE A 1.11-TO-1 RATIO HERE. SO IT JUST CAME OUT THAT WAY
- 12 IN THE EXAMPLE.
- 13 CHAIRMAN KLEIN: AND, RICK, JUST SO EVERYONE
- 14 UNDERSTANDS, FOR THE BENEFIT OF CALIFORNIA TAXPAYERS AND
- 15 PATIENTS, OUR GROSS LEVERAGE IS REALLY APPROXIMATELY 130
- 16 PERCENT BECAUSE YOU WOULD ADD BACK THE MATCHING FUNDS AS
- 17 WELL TO GET TO GROSS LEVERAGE. SO NET LEVERAGE IS
- 18 CONSIDERED AFTER THE MANDATORY 20 PERCENT, AND THE GROSS
- 19 LEVERAGE, YOU WOULD ADD IT BACK.
- DR. LEVEY: CAN WE GET THIS ON A PIECE OF PAPER
- 21 SO WE CAN MAYBE TRY TO RATIONALIZE THROUGH ALL OF THIS?
- 22 NOT THAT IT --
- MR. KELLER: THIS PARTICULAR EXAMPLE? ALL OF
- 24 OUR SLIDE DECKS ARE POSTED ON THE INTERNET AFTER THE
- 25 MEETING, AND SO WE WILL MAKE SURE THAT THAT'S AVAILABLE

	1	TO ANYONE	WHO WANTS	TO TAKE A	LOOK AT IT.	AND WE HAVE
--	---	-----------	-----------	-----------	-------------	-------------

- 2 SHORT EXAMPLE OF IT IN THE APPENDIX.
- 3 DR. PIZZO: MR. CHAIRMAN.
- 4 CHAIRMAN KLEIN: YES, DR. PIZZO.
- DR. PIZZO: THANK YOU FOR THAT PRESENTATION. I
- 6 HAVE THREE OR SO QUESTIONS THAT ARE JUST CLARIFICATIONS,
- 7 I HOPE. THE FIRST IS WITH REGARD TO MATCHING FUNDS,
- 8 WHICH I THINK SOME DEFINITION ABOUT WOULD BE HELPFUL.
- 9 I'M INTERPRETING THIS AS EITHER FUNDS THAT COME FROM
- 10 PHILANTHROPY OR FROM INSTITUTIONAL MATCH IN SOME WAYS.
- 11 SO YOU'RE TALKING ABOUT INSTITUTIONAL RESOURCES. IS THAT
- 12 CORRECT?
- MR. KELLER: YES. THE MATCHING FUNDS ARE
- 14 INTENDED TO BE A CASH CONTRIBUTION TO THE PROJECT.
- DR. PIZZO: SO THEN I WANT TO FURTHER, THEN,
- 16 CLARIFY THE ISSUE OF THE CASH CONTRIBUTION. AND, AGAIN,
- 17 THIS MAY BE JUST A NUANCE QUESTION. THINKING ABOUT HOW
- 18 VARIOUS INSTITUTIONS DO THIS, I'LL SPEAK SPECIFICALLY,
- 19 WHEN ONE GETS A LARGE CAPITAL GIFT, FOR EXAMPLE, IT'S
- 20 OFTEN PAID AS A PLEDGE OVER A NUMBER OF YEARS. SO WHEN
- 21 WE'LL THINK ABOUT EITHER DOES THE PLEDGE COUNT OR IS IT A
- 22 MATTER OF BACKSTOPPING THE PLEDGE THAT YOU'RE LOOKING AT?
- 23 IS THAT --
- MR. KELLER: OUR APPROACH TO THIS IS TO REQUEST
- 25 AS PART OF THE APPLICATION A FUNDS FLOW STATEMENT OR

1

DRAW-DOWN SCHEDULE.

2	DR. PIZZO: OKAY.
3	MR. KELLER: SO THAT WE CAN UNDERSTAND THE FLOW
4	OF FUNDS, BUT OUR PRESUMPTION IS THAT
5	DR. PIZZO: BECAUSE THAT'S HOW WE WOULD TAKE
6	CARE OF IT INSTITUTIONALLY.
7	THE SECOND IS WITH REGARD TO THE ISSUE OF
8	CEREMONIES IN NAMING OPPORTUNITIES. OBVIOUSLY THIS IS
9	VERY IMPORTANT, AND I THINK VERY APPROPRIATE FOR THERE TO
10	BE RECOGNITION THESE FACILITIES. BUT I WANT TO ALSO
11	UNDERSTAND A LITTLE BIT FURTHER WHAT THAT MEANS IN TERMS
12	OF HOW WE HANDLE NAMING OPPORTUNITIES. SO THAT'S GOING
13	TO VARY DEPENDING UPON THE INSTITUTION.
14	IN OUR OWN INSTITUTION, NAMING OPPORTUNITIES
15	ARE USUALLY SET AT ABOUT HALF THE COST OF THE BUILDING.
16	SO, YOU KNOW, IN THIS EXAMPLE IT WOULD BE, YOU KNOW,
17	POTENTIALLY A \$50 MILLION OPPORTUNITY, SO TO SPEAK.
18	WE'RE OUT RAISING MONEY FOR BUILDINGS, ALL OF
19	US IN DIFFERENT WAYS, AND WE'RE SEEKING OFTEN NAMING
20	DONORS FOR THEM. SO I THINK UNDERSTANDING HOW THAT'S
21	GOING TO APPLY SO THAT WE CAN MERGE THESE IN A WAY THAT
22	WILL ALLOW US TO GET THESE NAMING GIFTS, BUT ALSO PROVIDE
23	VALUE TO THE STATE FOR ITS CONTRIBUTIONS WILL BE
24	IMPORTANT AS WELL. HAS THE COMMITTEE THOUGHT THROUGH
25	THAT ISSUE AS WELL?

- 1 MR. SERRANO-SEWELL: PHIL, DID YOU HAVE A
- 2 CHANCE TO LOOK AT THE -- THERE WAS A DISCUSSION LAST
- 3 NIGHT ON THAT VERY ISSUE.
- 4 DR. PIZZO: OKAY.
- 5 MR. SERRANO-SEWELL: AND THIS LANGUAGE FOR
- 6 SECTION G 2 HAD TO BE MASSAGED A LITTLE BIT.
- 7 DR. PIZZO: OKAY. LET ME JUST --
- 8 MR. SERRANO-SEWELL: IT WAS AN ISSUE THAT DUANE
- 9 ROTH AND OTHER MEMBERS OF THE PUBLIC HAD RAISED, AND LAST
- 10 NIGHT MR. KELLER AND DR. MURPHY WORKED ON THIS REVISED
- 11 LANGUAGE. AND I HOPE IT ADDRESSES THE BALANCE THAT NEEDS
- 12 TO HAPPEN BETWEEN THE CIRM CONTRIBUTION AND ANY
- 13 THIRD-PARTY DONORS YOU MIGHT GET. I HOPE THIS CAPTURES,
- 14 YOU KNOW, THE BALANCING THAT NEEDS TO HAPPEN.
- DR. PIZZO: IT'S A DIFFICULT BALANCING ACT, AS
- 16 YOU KNOW.
- 17 MR. SERRANO-SEWELL: I DON'T THINK ANYONE
- 18 INTENDS TO INTERFERE WITH AN INSTITUTION'S OBJECTIVES IN
- 19 RAISING MONEY AND THE SORT OF THINGS THAT ANY GIVEN
- 20 INSTITUTION NEEDS TO DO, BUT I THINK COMMON SENSE SHOULD
- 21 PREVAIL IN THIS ONE, YOU KNOW.
- DR. PIZZO: RIGHT. RIGHT.
- MR. SERRANO-SEWELL: AND IF THERE ARE ANY
- 24 QUESTIONS, AN INSTITUTION CAN SUBMIT IT TO THE
- 25 PRESIDENT'S OFFICE --

1	DR. PIZZO: THAT'S FINE. AND I AGREE WITH
2	THAT.
3	MR. SERRANO-SEWELL: TO GET IT RESOLVED.
4	DR. PIZZO: SO I HAVE ONE LAST QUESTION, THEN
5	I'LL PASS THE MICROPHONE, WHICH IS WITH REGARD TO THE
6	TIME TO COMPLETION. AND MAYBE THIS IS COVERED BY THE
7	STATEMENT THAT IT WOULD HAVE A PRESIDENTIAL REVIEW.
8	CLEARLY WE ALL WANT TO GET THESE FACILITIES COMPLETED
9	RAPIDLY AND ON TIME, BUT THERE IS A SCALING EFFECT AS
10	WELL, COMPLETING A SMALL FACILITY AS COMPARED TO A VERY
11	LARGE ONE, YOU KNOW, BY DEFINITION MAY TAKE MORE TIME.
12	AND THE SECOND IS I'M A LITTLE CONCERNED ABOUT
13	THE RECOMMENDATION THAT WE USE EXPEDITED SUPPLY LINKS AND
14	THE LIKE BECAUSE THOSE ARE GOING TO BE MORE EXPENSIVE.
15	AND WE ALL RECOGNIZE HOW HARD IT IS TO BRING RESOURCES TO
16	COMPLETING A FACILITY, AND I THINK WE WANT TO BALANCE THE
17	COST, YOU KNOW, OVER THE TOTAL COST VERSUS THE WAY WE
18	GENERATE THE FUNDS TO PAY FOR THOSE TOTAL COSTS.
19	SO CLEARLY OUR GOAL IS THE SAME AS YOURS. WE
20	WANT THESE TO BE UP AS RAPIDLY AS POSSIBLE. I'D HATE TO
21	SEE AN ADDITIONAL ESCALATOR GO INTO THE TOTAL COST OF THE
22	BUILDINGS BECAUSE WE WERE USING A LOT OF OVERTIME AND
23	RELATED ACTIVITIES BECAUSE THAT JUST MAKES THE FUNDING OF
24	THE PROJECT ALL THE MORE DIFFICULT IN THE LONG RUN.
25	MR. KELLER: MY RESPONSE IS I THINK THE TWO ARE

- 1 VERY INTERRELATED, BUT I THINK THE GOVERNING ISSUE HERE
- 2 IS THAT PROPOSITION 71 ESTABLISHES A RESPONSIBILITY THAT
- 3 THERE IS AN URGENCY, AND THAT PROJECTS THAT WILL BE
- 4 COMPLETED WITHIN TWO YEARS WILL RECEIVE PRIORITY. NOW,
- 5 THAT DOESN'T MEAN THAT OTHERS CAN'T COMPETE BECAUSE, AS
- 6 YOU SAY, I THINK IT'S IMPORTANT TO STRIKE A BALANCE
- 7 BETWEEN THAT WHICH CAN BE ACHIEVED AND THE COST
- 8 ASSOCIATED WITH THAT ON A REASONABLE BASIS OR
- 9 INSTITUTIONAL BASIS.
- 10 AND SO I VERY MUCH THINK IT DEPENDS UPON THE
- 11 APPLICANT TO TAKE RESPONSIBILITY FOR WHAT THAT BALANCE IS
- 12 RATHER THAN CIRM BASICALLY MANDATING IT. SO I AGREE WITH
- 13 YOUR PHILOSOPHY. I THINK IT'S PERMITTED WITHIN THE
- 14 LANGUAGE.
- DR. PIZZO: THE LANGUAGE THAT I SEE, AT LEAST
- 16 ON -- IN THE RELEVANT SECTION IS AT THE COMPLETION OF THE
- 17 PROJECT, THE PRESIDENT OF THE CIRM WILL REVIEW ANY DELAYS
- 18 AND MAY ASSESS PENALTY IF THE PRESIDENT IN HIS OR HER
- 19 SOLE DISCRETION DETERMINES THAT THE GRANTEE DID NOT USE
- 20 BEST EFFORTS TO COMPLETE THE PROJECT, ETC., ETC. SO, YOU
- 21 KNOW, IT SEEMS TO ME THAT THAT OFFERS AT LEAST SOME
- 22 SUBJECTIVE EVALUATION BECAUSE WE WANT THESE THINGS TO GO
- 23 AS RAPIDLY AS POSSIBLE, BUT ANYONE, ALL OF US HAVE BEEN
- 24 INVOLVED IN BUILDING PROJECTS AND KNOW THE LIABILITIES
- 25 ASSOCIATED WITH THAT.

1	CHAIRMAN KLEIN: THIS SPECIFIC QUESTION WAS
2	RAISED IN THE FACILITIES COMMITTEE, AND DAVID, AS THE
3	VICE CHAIR, IF YOU WILL PLEASE CORRECT IF YOU THINK THIS
4	IS NOT A FULL SUMMARY, FULL, BUT TERSE SUMMARY OF THOSE
5	THOUGHTS. ONE IS THAT THERE IS A PRIORITY FOR BUILDINGS
6	TO BE COMPLETED WITHIN TWO YEARS. IT'S NOT TWO YEARS
7	FROM THE DATE THE BOARD ACTS. IT'S TWO YEARS FROM NOTICE
8	OF GRANT AWARD. SO IF THE BOARD WERE TO ACT IN APRIL,
9	FOR EXAMPLE, AND THE GRANT AWARD WERE JULY, IT'S TWO
10	YEARS FROM THAT CLOCK.
11	NOW, IN THE APPLICATION THERE'S A REQUEST TO
12	SUBMIT A CRITICAL PATH CHART. IF, IN FACT, THE
13	INSTITUTION SUBMITS AND SAYS TWO YEARS FROM THE NOTICE OF
14	GRANT AWARD, ABOUT TWO YEARS AND FOUR MONTHS FROM THE
15	DATE OF THE BOARD APPROVAL, WE'RE GOING TO BE COMPLETE,
16	SO WE WANT A PRIORITY AND WE WANT POINTS FOR THAT, THEN
17	THEY'RE GOING TO BE GENERALLY HELD FORCE MAJEURE
18	EXCEPTION, ETC., FOR CLAIMING THOSE POINTS. AND THAT'S
19	THE CONTEXT.
20	IF THEY SAY IT'S GOING TO TAKE US THREE YEARS,
21	THEY'LL BE HELD ACCOUNTABLE FOR THREE YEARS. SO THEY'RE
22	HELD ACCOUNTABLE FOR THEIR REPRESENTATIONS, KNOWING THAT
23	THERE'S A PRIORITY FOR THOSE THAT ARE TWO YEARS FROM
24	GRANT AWARD.
25	DR. PIZZO: BUT I'M THINKING I THINK THAT

60

1	THAT'S	HELPFUL,	RUT	YOU	KNOW	TF	YOU'	'RF	WORKTNG	ΟN	Δ
_	IIIAI 3	IILLFFUL,	BUI,	100	INIOW .	T L	100	Γ	MOUNTING	OIN	$\overline{}$

- 2 BUILDING THAT IS SMALLER VERSUS VERY LARGE, YOU KNOW,
- 3 THAT HAS AN IMPACT UPON HOW FAST YOU CAN GET IT DONE. SO
- 4 GOING FROM ARCHITECTURAL DESIGN, I MEAN THERE'S ALL THESE
- 5 ELEMENTS THAT WE ALL UNDERSTAND, YOU KNOW, THROUGH THE
- 6 SITE APPROVALS AND THE LIKE TO ACTUAL CONSTRUCTION DATE
- 7 WILL BE INFLUENCED BY THE MAGNITUDE OR SIZE OF THE
- 8 BUILDING.
- 9 IS THERE SOME WAY OF THINKING ABOUT THAT SO
- 10 THAT THERE IS SOME ACCOMMODATION TO THAT?
- 11 CHAIRMAN KLEIN: I THINK THE BOTTOM LINE IS GET
- 12 A HIGHER SCIENCE SCORE BECAUSE THIS IS ALL -- THIS ALL
- 13 GETS BALANCED IN THE RECOMMENDATIONS, BUT BASICALLY THE
- 14 INITIATIVE IS QUITE SPECIFIC TO GIVE A PRIORITY FOR THOSE
- 15 COMPLETED WITHIN TWO YEARS BECAUSE OF THE NECESSITY OF
- 16 GETTING THIS CAPACITY ONLINE. SO AN ENTITY MAY HAVE
- 17 HIGHER LEVERAGE, IT MAY HAVE A HIGHER SCIENCE SCORE, IT
- 18 MAY HAVE A NUMBER OF CONTRIBUTORS TO BEING COMPETITIVE
- 19 EVEN THOUGH IT'S NOT MEETING THE TWO YEARS.
- 20 BUT I WOULD ALSO SUGGEST THAT THE -- IF YOU
- 21 LOOK AT THE CHINESE STEEL MARKETS AND PROJECT THE DEMAND
- 22 LEVELS --
- DR. PIZZO: I KNOW. I UNDERSTAND. THE PRICES
- 24 ARE ONLY GOING UP. I KNOW. WE'RE RESERVING STILL FOR
- 25 OTHER PROJECTS RIGHT NOW. I UNDERSTAND THE PROBLEM, BUT

- 1 I'M JUST REALLY TRYING TO BE VERY SORT OF THOUGHTFULLY
- 2 PRACTICAL ABOUT THIS SO THAT WE DON'T GET BOXED IN.
- 3 MAYBE IT'S SORT OF THE A PERSONALITY AND YOU LIKE TO GET
- 4 THE BEST IN EVERY SCORE, NOT JUST ONE, TO ACCOMMODATE,
- 5 BUT I DO THINK THIS IS AN IMPORTANT ISSUE AND I HOPE
- 6 THERE WILL BE CONSIDERATION.
- 7 CHAIRMAN KLEIN: I'D LIKE TO CALL ON THE VICE
- 8 CHAIR, AND THEN WE HAVE TWO COMMENTS.
- 9 MR. SERRANO-SEWELL: I'D DEFER MY COMMENTS.
- 10 CHAIRMAN KLEIN: THEN DR. CHANDLER HAS A
- 11 COMMENT. SO DAVID SERRANO-SEWELL IS HOLDING HIS
- 12 COMMENTS. DR. CHANDLER HAS BEEN VERY PATIENT. DR.
- 13 CHANDLER.
- 14 DR. CHANDLER: ACTUALLY WHAT I'D LIKE TO DO IS
- 15 GO BACK TO THE QUESTION ON THE MATCHING. I'M NOT SURE
- 16 THAT I UNDERSTOOD, BUT I THOUGHT THAT YOU'VE SAID THAT
- 17 MONEY COULD BE PLEDGED. IRREVOCABLE PLEDGES WERE
- 18 ACCEPTABLE, WHICH I THINK IS IMPORTANT WHEN IT'S A FAIRLY
- 19 LARGE CHUNK OF MONEY. THAT BEING SAID THOUGH, I DIDN'T
- 20 UNDERSTAND HOW THAT FITS WITH THE IDEA THAT THE MATCHING
- 21 MONEY HAS TO BE SPENT FIRST BEFORE THE CIRM MONEY COMES
- 22 IN.
- MR. SERRANO-SEWELL: WHAT'S UNCLEAR ABOUT THAT?
- DR. CHANDLER: WHAT'S UNCLEAR ABOUT IT IS
- 25 YOU'RE ASKING ME IS THAT IF IT'S A -- UNLESS THE

- 1 ORGANIZATION IS GOING TO DO IT, BUT IF SOMEONE SAYS WE'RE
- 2 GOING TO GIVE IT TO YOU OVER THREE YEARS, AND WE'RE GOING
- 3 TO GIVE YOU 20 MILLION OVER THREE YEARS OR WHATEVER --
- 4 MR. SERRANO-SEWELL: CASH FLOW STATEMENT IN THE
- 5 APPLICATION.
- 6 MR. KELLER: AND THAT WOULD BE A BACKSTOP
- 7 CIRCUMSTANCE THAT YOU JUST DESCRIBED.
- 8 DR. CHANDLER: AND SO IT WOULD HAVE TO BE THAT
- 9 ESSENTIALLY, THEN, THE INSTITUTION WOULD HAVE TO DO THE
- 10 BACKSTOP?
- MR. KELLER: RIGHT. BUT I GUESS I WAS MAKING A
- 12 DISTINCTION BETWEEN HAVING CASH THE FIRST DAY OF THE
- 13 PROJECT APPROVAL VERSUS THE CASH AS IT'S NEEDED BASED ON
- 14 A FUNDS FLOW STATEMENT OF PROGRESS PAYMENTS. IF YOU HAD
- 15 A THREE-YEAR GIFT, THEN CLEARLY IF THAT ISN'T GOING TO
- 16 PROVIDE THE CASH, THEN THERE'S GOING TO BE A BACKSTOP
- 17 SOURCE.
- DR. CHANDLER: SO YOU HAVE TO BE ABLE TO DO
- 19 THAT THEN?
- DR. PIZZO: I THINK, IN FACT, I'M SURE THIS IS
- 21 TRUE AT EVERY INSTITUTION, BUT WE WOULD NOT BE ALLOWED TO
- 22 START A PROJECT UNLESS WE HAD A CASH FLOW MODEL THAT
- 23 SHOWED EVERYTHING WAS THERE WHEN THE PROJECT STARTED. SO
- 24 I'M SURE THAT'S GOING TO BE A PRACTICAL ISSUE FOR ALL OF
- 25 US.

1	MR. KELLER: AND ONE OTHER POINT I WANTED TO
2	CLARIFY ABOUT DR. PIZZO'S COMMENT ABOUT THE PREFERENCE OR
3	THE PRIORITY. IT MIGHT BE IMPORTANT TO KEEP IN MIND THAT
4	THE WAY WE'VE STRUCTURED THE RFA, THAT THERE ARE THREE
5	TIERS OF FUNDING, THREE TIERS, THE XYZ, THE XY AND THE
6	YZ'S, AND THE X, Y, OR Z'S. AND SO EACH OF THOSE WILL
7	COMPETE AS AN INDIVIDUAL STRATA, IF YOU WILL. SO SOMEONE
8	WHO'S GOT A SMALL \$5 MILLION PROJECT THAT COULD POSSIBLY
9	COULD GET DONE IN TWO YEARS IS NOT COMPETING WITH THE
10	LARGER PROJECTS.
11	CHAIRMAN KLEIN: I HAVE
12	DR. BRYANT: I CHANGED MY MIND.
13	CHAIRMAN KLEIN: DUANE ROTH.
14	MR. ROTH: I JUST WANTED TO FOLLOW UP BECAUSE I
15	SUSPECT WHAT YOU ARE GOING TO GET IS EVERYBODY IS GOING
16	TO SUBMIT A TWO-YEAR PLAN. AND I THINK WHAT DR. PIZZO IS
17	SAYING IS THAT IT'S LIKELY THAT THOSE BIG FACILITIES ARE
18	GOING TO GO BEYOND THAT TWO-YEAR PLAN. AND SO I'M
19	COMFORTABLE THAT THE PRESIDENT CAN USE DISCRETION HERE,
20	AND I WANT TO MAKE SURE THAT'S THE INTENT OF THE WAY IT'S
21	WRITTEN IS THAT UNDERSTANDING THAT THERE WILL BE
22	CONSIDERATION FOR OVERRUNS. I DOUBT THAT YOU ARE GOING
23	TO GET ANYBODY THAT SAYS IT'S GOING TO BE FOUR YEARS TO
24	GET THE BUILDING UP BECAUSE THEY'RE GOING TO WANT THOSE
25	POINTS.

MR. KELLER: I THINK THE SENTIMENT OF THE

1

2	FACILITIES WORKING GROUP, AFTER MORE THAN TEN HOURS OF
3	PUBLIC MEETINGS AND DISCOURSE ABOUT THE MAJOR FACILITIES
4	GRANT, WAS THAT IF PRIORITY WAS GOING TO BE PROVIDED,
5	THERE HAD TO BE A MECHANISM TO HOLD THOSE FOLKS WHO
6	REQUESTED IT ACCOUNTABLE FOR THE SCHEDULE THAT THEY
7	SUBMIT, OR ELSE IT WOULD JUST BE MEANINGLESS IN TERMS OF
8	PROVIDING THE PRIORITY. SO I THINK THE LANGUAGE WAS
9	INTENDED TO AT LEAST SAY THERE IS A PENALTY, BUT CLEARLY
10	IF IT'S DELAYS THAT ARE UNAVOIDABLE, THE PRESIDENT CAN
11	MAKE A JUDGMENT.
12	CHAIRMAN KLEIN: THERE'S THE OTHER POINT AS
13	WELL THAT IF YOU'RE COMPETING IN A CATEGORY WITH VERY
14	LARGE FACILITIES, NONE OF WHICH CAN GET DONE WITHIN TWO
15	YEARS, THEY'RE COMPETING IN A CATEGORY WHERE YOU'RE ALL
16	PROPOSING THREE YEARS OR SOMETHING, BUT IF YOU'RE
17	COMPETING IN A CATEGORY THAT CAN GET DONE IN TWO YEARS,
18	IF YOU DON'T HAVE THAT PRIORITY, YOU'VE GOT A
19	DISADVANTAGE.
20	MR. ROTH: BUT MY POINT IS I DOUBT THAT YOU'RE
21	GOING TO SEE ANYBODY WITH A THREE-YEAR PROGRAM IF IT
22	COUNTS. DON'T YOU EXPECT THAT ALL OF THEM WILL COME IN
23	WITHIN THE DEADLINE?
24	CHAIRMAN KLEIN: I WOULD HOPE THAT AS MANY AS
25	CAN LEGITIMATELY CREATE AN AGGRESSIVE PROGRAM FOR

1	CONSTRUCTION W	TII. AND	THOSE	THAT	FACE	THE	RFAI TTTFS	THAT

- 2 THEY CAN'T DELIVER IN THAT TIME PERIOD WILL FACE UP TO
- 3 THAT REALITY IN THEIR SCHEDULE THEY PROPOSE. BUT
- 4 CERTAINLY FOLLOWING THE INITIATIVE, WE WOULD ENCOURAGE
- 5 AND THE SYSTEM ENCOURAGES INDIVIDUAL INSTITUTIONS TO
- 6 CREATE A PROGRAM FOR FAST-TRACK CONSTRUCTION.
- 7 ADDITIONAL COMMENTS? YES, DR. STEWARD.
- 8 DR. STEWARD: THIS IS ACTUALLY WITH REGARD TO
- 9 SECTION F.
- 10 CHAIRMAN KLEIN: IS YOUR MICROPHONE ON THERE?
- DR. STEWARD: NO. 6. THIS IS WITH REGARD TO
- 12 SECTION F, AND I HAVE A QUESTION AND A COMMENT, I GUESS,
- 13 ABOUT THE LANGUAGE. THE PART OF THE THING THAT PROP 71
- 14 IS MEANT TO OVERCOME IS THE ARTIFICIAL
- 15 COMPARTMENTALIZATION OF STEM CELL ACTIVITIES BASED ON
- 16 FEDERAL REGULATIONS. AND SAYING THAT THESE FACILITIES
- 17 ARE INTENDED TO HAVE AS ACTIVITIES FUNDED BY CIRM COULD
- 18 BE INTERPRETED AS --
- 19 MR. KELLER: ARE YOU WORKING FROM THE ADDENDUM?
- DR. STEWARD: NO.
- MR. KELLER: SO THAT VERY POINT, DR. STEWARD,
- 22 WAS EXACTLY THE POINT THAT WE ADDRESSED IN THE ADDENDUM,
- 23 WHICH IS TO MAKE IT BROAD AND TO UNDERSTAND THAT IT'S NOT
- JUST CIRM-FUNDED, BUT OTHER SOURCES.
- DR. STEWARD: I THINK THAT SOLVES IT. LET ME

- 1 THINK ABOUT IT. 2 CHAIRMAN KLEIN: ALL RIGHT. WE HAD A VERY GOOD 3 DISCUSSION OF THESE POINTS. DR. HENDERSON. 4 DR. HENDERSON: DO WE NEED APPROVAL OF THIS? 5 CHAIRMAN KLEIN: WE NEED APPROVAL OF THIS. 6 DR. HENDERSON: I SO MOVE. 7 CHAIRMAN KLEIN: MOVED AND IS THERE A SECOND? 8 MR. ROTH: SECOND. 9 CHAIRMAN KLEIN: SECOND BY DUANE ROTH. I'D 10 LIKE TO ASK IF THERE'S PUBLIC COMMENT. SEEING NO PUBLIC 11 COMMENT, CALL THE QUESTION. ALL IN FAVOR. OPPOSED? 12 MOTION PASSES. 13 IF WE COULD PROCEED, DR. MURPHY, TO PART B. 14 MS. PACHTER: MR. CHAIR. 15 CHAIRMAN KLEIN: YES. 16 MS. PACHTER: FOR THE BENEFIT OF THOSE MEMBERS 17 WHO ARE RECUSED, I'D JUST LIKE TO LIST THE MEMBERS WHO 18 MAY PARTICIPATE IN THE DISCUSSION AND VOTING ON ITEM 7 B, 19 WHICH DR. MURPHY IS ABOUT TO PRODUCE, SO EVERYBODY IS 20 CLEAR.
- 21 CHAIRMAN KLEIN: IF YOU WOULD PROCEED.
- MS. PACHTER: MICHAEL GOLDBERG, DR. LEVY, NOT
- DR. LEVEY, TINA NOVA IS NOT HERE, DR. PRIETO, DUANE ROTH,
- 24 DAVID SERRANO-SEWELL, JON SHESTACK IS NOT HERE, AND
- 25 DR. WRIGHT, AND BOB KLEIN.

Т	CHAIRMAN KLEIN: ALL RIGHT. DR. MURPHY.
2	DR. MURPHY: MR. CHAIRMAN, I LOOK FORWARD TO
3	SPEAKING TO A VERY SMALL GROUP OF ICOC MEMBERS. THIS
4	ITEM 7 B IS NOW PART OF CHAPTER 5 OF THE GRANT WORKING
5	GROUP'S RECOMMENDATIONS. AND THIS IS A VERY THE WHOLE
6	THING IS VERY DIFFICULT, AND I JUST WANT TO THANK DAVID
7	AND THE OTHER MEMBERS OF THE GRANTS WORKING GROUP FOR
8	REALLY A HEROIC EFFORT IN PUTTING THESE REGULATIONS
9	TOGETHER.
10	THE REGULATION WE'RE GOING TO BE TALKING ABOUT
11	IS IN YOUR BINDER. IT'S THE LAST PAGE IN 7 B. AND WHAT
12	THIS PAGE DEALS WITH IS THE RECOMMENDATIONS WE ARE MAKING
13	THAT ENSURE THAT RESEARCH INSTITUTES THAT ARE FUNDED WITH
14	CIRM MONEY WILL BE PAID ONCE FOR THE COST OF DOING THAT
15	RESEARCH, BUT WILL NOT BE PAID TWICE.
16	IF WE LOOK AT SLIDE ONE, UNDER PROPOSITION 71
17	AND THE GAP, THE CIRM WILL PAY FACILITIES DIRECT COSTS
18	AND IT PAYS THESE COSTS IN TWO WAYS, WHAT WE CALL
19	FACILITIES DIRECT A, WHICH PAYS FOR OPERATIONS,
20	MAINTENANCE, AND LIBRARY COSTS, AND FACILITIES DIRECT B,
21	WHICH PAYS FOR THE COSTS OF SPACE UTILIZATION.
22	NOW, THE PROPOSAL IN FRONT OF YOU DOES NOT
23	AFFECT FACILITIES A, OPERATIONS, MAINTENANCE, LIBRARIES.
24	IN FACT, THOSE PAYMENTS ARE DICTATED BY THE OVERHEAD
25	PAYMENTS THAT ARE ALREADY NEGOTIATED WITH NIH. WHAT THIS

1 POLICY DOES IS AFFECT FACILITIES DIRECT B, WHICH
--

- 2 COST OF SPACE UTILIZATION.
- NOW, WHAT THIS MEASURE DOES IS IT SETS THE
- 4 STANDARDS FOR THOSE INSTITUTIONS THAT ARE AWARDED A
- 5 FACILITIES B -- SORRY -- ARE AWARDED A MAJOR FACILITIES
- 6 GRANT. NOW, THE NEXT SLIDE WILL SHOW YOU THAT IN
- 7 PARAGRAPH 1 OF THE PAGE BEFORE YOU, THAT PARAGRAPH
- 8 INDICATES THAT COSTS FUNDED BY A CIRM FACILITIES OR
- 9 INFRASTRUCTURE GRANT OR BY ANOTHER RESEARCH GRANT FROM
- 10 ANY SOURCE ARE NOT FACILITIES COSTS TO BE PART OF THE
- 11 CIRM RESEARCH GRANT. SO THAT IF FACILITIES MONIES ARE
- 12 ALREADY BEING PROVIDED FROM CIRM OR ANYONE ELSE, CIRM
- 13 WILL NOT COVER THOSE COSTS AGAIN.
- 14 IN THE NEXT PARAGRAPH, PARAGRAPH 2, IT TELLS
- 15 YOU THAT THE CIRM FACILITY CAN ONLY BE USED FOR STEM CELL
- 16 RESEARCH, AND WE TALK ABOUT THAT IN A BROAD SENSE BECAUSE
- 17 WE RECOGNIZE THAT THERE WILL BE OTHER DISCIPLINES THAT
- 18 WILL GO INTO DOING THE KIND OF STEM CELL RESEARCH WE NEED
- 19 TO DO. AND IT ALSO INDICATES THAT INSTITUTIONS THAT
- 20 RECEIVE A MAJOR FACILITIES GRANT MUST LOCATE THEIR CIRM
- 21 RESEARCH-FUNDED ACTIVITIES IN THE CIRM-FUNDED FACILITIES
- 22 AS DESCRIBED IN THEIR APPLICATIONS.
- NOW, THAT DOES NOT MEAN THAT AN INVESTIGATOR
- 24 CAN'T WORK IN AN ALREADY ESTABLISHED LAB ON A CIRM-FUNDED
- 25 GRANT. WE ENCOURAGE THAT. BUT IF YOU DESCRIBE IN YOUR

1 — APPLICATION THAT THERE IS GOING TO BE A C		APPLICATION	THAT	THFRF	TS	GOTNG T	O BF	Α	CTRM-FUNDER
---	--	-------------	------	-------	----	---------	------	---	-------------

- 2 RESEARCHER IN THAT BUILDING WITH CIRM FUNDING, YOU NEED
- 3 TO DO THAT. SO WE DON'T WANT PEOPLE TO SAY THIS
- 4 SCIENTIST IS GOING TO BE IN THE BUILDING IN THE
- 5 APPLICATION; AND THEN WHEN THE BUILDING IS FUNDED, WE
- 6 FIND OUT THAT THAT PERSON IS NOT IN THE BUILDING.
- 7 CHAIRMAN KLEIN: DR. MURPHY, BEFORE GOING ON,
- 8 SINCE THAT'S SO IMPORTANT, MAYBE WE CAN JUST REEMPHASIZE
- 9 THAT. AGAIN, IF SOMEONE HAS PROPOSED A GRANT AND THAT
- 10 GRANT IS PROPOSED TO BE TAKING PLACE IN SOME OTHER
- 11 BUILDING, THAT IS ACCEPTABLE. BUT IN THE COMPETITION FOR
- 12 THE FACILITIES AWARD, IF THAT INSTITUTION PROPOSES THAT
- 13 THAT SPECIFIC RESEARCH WILL TAKE PLACE IN THIS BUILDING,
- 14 THEN THEY HAVE MADE A REPRESENTATION THAT THEY NEED TO
- 15 FOLLOW THROUGH ON. RIGHT? OKAY.
- 16 DR. MURPHY: IN PARAGRAPH 3, WHAT THAT
- 17 PARAGRAPH INDICATES IS THAT THOSE CIRM-FUNDED RESEARCH
- 18 GRANTS THAT ARE LOCATED IN A CIRM-FUNDED FACILITY WILL
- 19 NOT BE REIMBURSED FOR FACILITIES B COSTS. THEY WILL NOT
- 20 RECEIVE THAT FUNDING, ALTHOUGH THEY WILL CONTINUE TO
- 21 RECEIVE FACILITIES A COSTS. SO THIS ONLY AFFECTS THE B
- 22 COSTS.
- AND FINALLY, IN SLIDE 5 OR THE NEXT SLIDE,
- 24 PARAGRAPH 4 INDICATES THAT REIMBURSEMENT OF FACILITIES
- 25 PART B COSTS WILL RESUME WHEN THE SUM OF THE PART B COSTS

- 1 THAT ARE NOT REIMBURSED TO AN INSTITUTION AS JUST
- 2 DESCRIBED EQUALS THE AMOUNT FUNDED BY THE MAJOR
- 3 FACILITIES GRANT PLUS THE COST OF FUNDS. AND ONCE THIS
- 4 THRESHOLD IS PASSED; I.E., THE MONEY IS PAID BACK, IN
- 5 ESSENCE, THEN FACILITIES PART B COSTS WILL BE FULLY
- 6 REIMBURSED TO INSTITUTIONS THAT RECEIVE A MAJOR
- 7 FACILITIES GRANT.
- 8 SO THIS IS JUST DURING THAT PERIOD WHEN THOSE
- 9 MONIES WOULD NOT HAVE -- ARE NOT PAID TO THEM. ONCE THAT
- 10 CIRM CONTRIBUTION IS ACCOUNTED FOR, THEN FACILITIES B
- 11 COSTS WOULD BE REIMBURSED.
- MR. CHAIRMAN, I RECOMMEND THIS PROPOSAL FOR THE
- 13 ICOC'S CONSIDERATION, AND WE ARE HAPPY TO ANSWER ANY
- 14 QUESTIONS THAT MAY ARISE. DAVID.
- MR. SERRANO-SEWELL: DR. MURPHY, IT'S MY --
- 16 THIS IS A VERY COMPLICATED ISSUE, BUT IT'S MY
- 17 UNDERSTANDING THAT YOU WORKED ON THIS AND YOU LED A
- 18 DISCUSSION WITH OUR VICE CHAIRMAN, DR. PENHOET, OUR
- 19 CHAIRMAN, MR. KLEIN, AND THERE WAS A FOURTH PERSON. WHO
- 20 AM I FORGETTING?
- DR. MURPHY: DR. TROUNSON WAS INVOLVED.
- MR. SERRANO-SEWELL: YES, OF COURSE. DR.
- 23 TROUNSON, OUR INCOMING PRESIDENT. THANK YOU. IN
- 24 CRAFTING THIS LANGUAGE. SO IT NOT ONLY COMES WITH YOUR
- 25 STRONG RECOMMENDATION, BUT HAD THE INPUT FROM YOUR

- 1 TRUSTED COLLEAGUES AND INCOMING PRESIDENT. IF THERE'S NO
- OTHER QUESTIONS, I'LL MAKE THE MOTION TO APPROVE IT.
- 3 CHAIRMAN KLEIN: SO DAVID SERRANO-SEWELL, IF
- 4 YOU COULD MAKE A MOTION.
- 5 MR. SERRANO-SEWELL: SURE. I MOVE TO APPROVE
- 6 THE AMENDMENTS TO CHAPTER 7, SECTION H, PARAGRAPH 4 OF
- 7 THE GRANTS ADMINISTRATION POLICY FOR ACADEMIC AND
- 8 NONPROFIT INSTITUTIONS.
- 9 DR. WRIGHT: SECOND.
- 10 CHAIRMAN KLEIN: SECOND BY DR. WRIGHT. IS
- 11 THERE DISCUSSION BY THE BOARD? IS THERE DISCUSSION BY
- 12 THE PUBLIC? I THINK THAT WE NEED A ROLL CALL VOTE HERE
- 13 BECAUSE WE HAVE -- WE WANT TO VERIFY A COPY OF THE VOTE
- 14 SO THAT WE CAN CONFIRM THE MEMBERS WHO VOTED.
- 15 MS. KING: MICHAEL GOLDBERG.
- MR. GOLDBERG: YES.
- 17 MS. KING: BOB KLEIN.
- 18 CHAIRMAN KLEIN: YES.
- 19 MS. KING: MICHAEL LEVY.
- 20 DR. LEVY: YES.
- 21 MS. KING: FRANCISCO PRIETO.
- DR. PRIETO: YES.
- MS. KING: DUANE ROTH.
- MR. ROTH: YES.
- MS. KING: JANET WRIGHT.

1	DR. WRIGHT: YES.
2	MS. KING: DAVID SERRANO-SEWELL.
3	MR. SERRANO-SEWELL: YES.
4	THAT MOTION CARRIES.
5	CHAIRMAN KLEIN: THAT MOTION CARRIES, AND I
6	BELIEVE THAT DR. PENHOET WAS NOT CONSULTED ON THIS
7	LANGUAGE WE HAVE BEFORE US BECAUSE HE DID NOT PARTICIPATE
8	IN THAT DISCUSSION JUST FOR THE RECORD. SO THE OTHER
9	MEMBERS ALL DID PARTICIPATE.
10	I WOULD LIKE TO GO ON TO ITEM 8, BUT I'M GOING
11	TO GIVE THE DEDICATED BOARD AND PUBLIC A FIVE-MINUTE
12	BREAK HERE.
13	(A RECESS WAS TAKEN.)
14	CHAIRMAN KLEIN: ALL RIGHT. WE WILL CONVENE
15	HERE FOR ITEM NO. 8. MY UNDERSTANDING IS DR. PATRICIA
16	OLSON IS GOING TO GUIDE US IN WHAT IS AN EXTRAORDINARY
17	FIRST STEP ON A MAJOR INITIATIVE OF THIS BODY, ONE THAT
18	IS EXTREMELY EXCITING WITH INCREDIBLE POTENTIAL FOR THIS
19	INSTITUTION AND THE RESEARCH BEING CONDUCTED. DR.
20	PATRICIA OLSON.
21	MS. OLSON: THANK YOU, MR. CHAIRMAN. BOARD
22	MEMBERS, MEMBERS OF THE PUBLIC, TODAY I'D LIKE TO UPDATE
23	YOU ON THE DISEASE TEAM INITIATIVE. THIS IS AGENDA ITEM
24	NO. 8. AND I AM SPEAKING ON BEHALF OF DR. BETTINA
25	STEFFEN, WHO IS LEADING THIS INITIATIVE, BUT WAS UNABLE

TO BRING US HERE TODAY OR BE WITH US TODAY.

1

2	EARLIER TODAY DR. CHIU PRESENTED TO YOU AN
3	OUTLINE OF THE SCIENTIFIC PROGRAMS FOR THE UPCOMING YEAR.
4	AMONG THESE ARE THOSE WHICH MARK OUR ENTRY INTO A NEW
5	EXCITING PHASE. WE ARE BEGINNING TO FUND PROGRAMS THAT
6	WILL HELP BRING STEM CELL THERAPIES TO THE CLINIC. ONE
7	OF THESE PROGRAMS IS THE DISEASE TEAM INITIATIVE.
8	THE DIAGRAM YOU HAVE IN FRONT OF YOU ON THE
9	SCREEN REPRESENTS THE PATH THAT A TYPICAL THERAPY WOULD
10	TAKE FROM DISCOVERY FORWARD INTO CLINICAL TRIALS.
11	UNDERNEATH YOU SEE WHERE WE CONTEMPLATE THE
12	SCOPE OF THE DISEASE TEAM INITIATIVE. TODAY WE WOULD
13	LIKE TO ASK FOR YOUR APPROVAL FOR THE CONCEPT OF A
14	DISEASE TEAM PLANNING GRANT. THE DISEASE TEAM INITIATIVE
15	HAS THREE PARTS. IT HAS A WORKSHOP THAT WAS HELD IN JULY
16	OF THIS YEAR. IT INCLUDES A PLANNING GRANT, THE CONCEPT
17	OF WHICH WE'RE BRINGING FOR YOUR CONSIDERATION TODAY, AND
18	IT HAS THE ACTUAL DISEASE TEAM GRANT, WHICH WE ANTICIPATE
19	IN THE FALL OF NEXT YEAR.
20	THE PURPOSE OF THE WORKSHOP WAS TO ASSEMBLE
21	RESEARCHERS AND REPRESENTATIVES OF OTHER FUNDING AGENCIES
22	WHO HAVE HAD EXPERIENCE WITH TEAM-BASED PROJECTS AND HAVE
23	THEM TALK TO US ABOUT WHAT WORKS AND PERHAPS, MORE
24	IMPORTANTLY, WHAT HASN'T WORKED. WE ASKED ABOUT SCOPE,
25	RESOURCES, FUNDING OF EFFECTIVE TEAMS, PROGRAM

1	MANAGEMENT,	AND	THE	STRENGTHS	AND	WEAKNESSES	OF	THESE

- 2 APPROACHES. WE PRESENTED THE FINDINGS FROM THE WORKSHOP
- 3 TO OUR GRANTS WORKING GROUP IN A PUBLIC MEETING THAT WAS
- 4 HELD ON SEPTEMBER 19TH AND RECEIVED ADDITIONAL INPUT FROM
- 5 THEM AS WELL.
- 6 A COPY OF THE DRAFT WORKSHOP REPORT SUMMARIZING
- 7 THE FINDINGS OF THE WORKSHOP AS WELL AS INCLUDING AN
- 8 APPENDIX WITH COMMENTS FROM THE WORKING GROUP HAS BEEN
- 9 PROVIDED TO YOU. SO YOU SHOULD HAVE THAT. THERE ARE
- 10 COPIES AVAILABLE FOR MEMBERS OF THE PUBLIC ON BOTH THE
- 11 TABLE IN HERE AND THE TABLE OUTSIDE. AND WE WILL BE
- 12 PUBLISHING A FINAL REPORT ON THE WEB WITHIN THE NEXT FEW
- WEEKS.
- 14 MOVING ON TO THE PLANNING GRANT, THE PURPOSE OF
- 15 THIS IS TO ALLOW POTENTIAL TEAMS TO ASSEMBLE AND TO
- 16 PREPARE A COMPREHENSIVE RESEARCH PROPOSAL. FINALLY, WE
- 17 DO ANTICIPATE A MULTIYEAR DISEASE TEAM GRANT IN THE FALL
- 18 OF NEXT YEAR. THESE WOULD BE THE LARGE GRANTS.
- 19 THERE ARE THREE REASONS THAT WE ARE LAUNCHING
- 20 THE DISEASE TEAM INITIATIVE. THIS PROGRAM WILL HELP THE
- 21 INSTITUTE ACHIEVE ITS GOAL OF DEVELOPING STEM CELL-BASED
- 22 THERAPIES BY MOVING CANDIDATES TOWARDS THE CLINIC.
- 23 TRANSLATING DISCOVERIES INTO CLINICALLY VIABLE THERAPIES
- 24 IS REALLY VERY DIFFICULT, AND THIS INITIATIVE WILL
- 25 EXPLORE NEW METHODS FOR INTEGRATING AN ORGANIZING

1	MULTIDISCIPLINARY	TFAMS	FINALLY.	TT	ALLOWS	THE	USF	ΩF
_	MOLITOTOCTLETINALI	ILAMO.	I TINALLI,		ALLUWS	1111	UJL	O1

- 2 INNOVATIVE RESEARCH MODELS THAT INCLUDE ACTIVE MANAGEMENT
- 3 AND DEFINE MILESTONES AS PART OF A COMPREHENSIVE RESEARCH
- 4 PLAN.
- 5 WHAT ARE THE BENEFITS THAT WE SEE ACCRUING FROM
- 6 A DISEASE TEAM PLANNING GRANT? I WOULD NOTE THAT THIS
- 7 PROGRAM DIFFERS FROM THE TRADITIONAL SINGLE INVESTIGATOR,
- 8 PRINCIPAL INVESTIGATOR, FUNDED PI GRANTS THAT WE HAVE
- 9 DONE SO FAR. SO BECAUSE OF THIS, WE ARE RECOMMENDING
- 10 APPROVAL OF A PLANNING GRANT TO ALLOW FOR TEAM FORMATION
- 11 AND PROPOSAL DEVELOPMENT IN ANTICIPATION OF THE ACTUAL
- 12 DISEASE TEAM GRANTS. WE BELIEVE THAT THE PLANNING GRANT
- 13 WILL ENRICH THE POOL OF APPLICATIONS FOR DISEASE TEAM
- 14 GRANTS.
- 15 THE PLANNING GRANT AWARD WILL PROVIDE SUPPORT
- 16 FOR UP TO SIX MONTHS FOR PLANNING AND PROPOSAL
- 17 DEVELOPMENT. WHAT WE WOULD HOPE IS THAT THE TEAM LEADER
- 18 WOULD USE THAT TIME TO IDENTIFY AND RECRUIT A TEAM AND
- 19 THAT THAT TEAM WOULD BE INVOLVED IN THE DEVELOPMENT OF
- THE CONTENT OF THE PROPOSAL, ADMINISTRATION, AND
- 21 MANAGEMENT OF THE TEAM.
- THE DISEASE TEAM INITIATIVE AND THE PLANNING
- 23 GRANT WILL SUPPORT THE FULL SPECTRUM OF STEM CELL TYPES
- 24 AND DISEASES, SO WE ARE NOT IMPOSING ANY LIMITATIONS IN
- 25 THIS REGARD.

1	THE ACTUAL CONCEPT THAT WE BRING FOR YOUR
2	CONSIDERATION IS THAT WE WOULD FUND SIX-MONTH PLANNING
3	AWARDS FOR UP TO 20 TEAMS AT A TOTAL COST OF 50,000 PER
4	AWARD. I WOULD NOTE THAT THIS IS A DIRECT PROJECT COST
5	ONLY AWARD. THERE WILL BE NO INDIRECT COSTS INCLUDED,
6	AND NO FACILITIES COSTS WILL BE PART OF THIS.
7	WE ESTIMATE THAT THE TOTAL COST OF THE PROGRAM
8	WILL BE UP TO \$1 MILLION. THE DRAFT TIMETABLE THAT WE
9	HAVE PROPOSED AND THAT I THINK WAS ALLUDED TO BY ARLENE
10	AS WELL IS WE ANTICIPATE THE RELEASE OF THE RFA FOR THE
11	PLANNING GRANTS IN THE NEXT MONTH, IN NOVEMBER. WE
12	ANTICIPATE REVIEW OF APPLICATIONS IN WINTER OF 2008, AND
13	WE ANTICIPATE COMING TO YOU FOR APPROVAL FOR FUNDING IN
14	THE SPRING OF 2008.
15	FINALLY, AS NOTED, WE DO ANTICIPATE A CALL FOR
16	APPLICATIONS FOR THE DISEASE TEAM GRANT ITSELF IN 2008.
17	FINALLY, I WOULD LIKE TO SAY THAT THE DISEASE TEAM
18	INITIATIVE IS ONE OF SEVERAL INITIATIVES THAT HAVE BEEN
19	OUTLINED IN THE SCIENTIFIC STRATEGIC PLAN FOR ACTUALLY
20	MOVING RESEARCH FROM DISCOVERY TO CLINICAL TESTING. AS
21	YOU SEE HERE, THIS IS THE ANTICIPATED SCOPE OF THE
22	DISEASE TEAM. OTHER INITIATIVES ARE OUTLINED HERE AND
23	HOW THEY MAP ON THE SPECTRUM OF CLINICAL DEVELOPMENT.
24	YOU'VE ALREADY HEARD FROM DR. CHIU THAT WE ANTICIPATE
25	MOVING FORWARD WITH THE TRANSLATIONAL RESEARCH INITIATIVE

- 1 THIS YEAR, AND I THINK I SPEAK FOR MYSELF AS WELL AS ALL
- 2 MEMBERS OF SCIENCE TEAM THAT WE WOULD LOOK FORWARD TO
- 3 BRINGING OTHER INITIATIVES FORWARD TO YOU IN THE FUTURE.
- 4 THANK YOU FOR YOUR CONSIDERATION.
- 5 CHAIRMAN KLEIN: THANK YOU, DR. OLSON. I THINK
- 6 FOR PURPOSES OF THE TRANSCRIPT, THE PEER REVIEW IS WINTER
- 7 OF 2007 VERSUS 2008.
- 8 MS. OLSON: WELL, IT'S LIKELY TO BE ACTUALLY
- 9 PROBABLY IN JANUARY OR FEBRUARY.
- 10 CHAIRMAN KLEIN: RIGHT. OKAY. VERY GOOD
- 11 CLARIFICATION. APPRECIATE THAT. VERY GOOD
- 12 CLARIFICATION.
- SO WITH THAT, ARE THERE QUESTIONS OF DR. OLSON?
- 14 DAVID SERRANO-SEWELL.
- MR. SERRANO-SEWELL: YOU'RE REQUESTING APPROVAL
- 16 FOR THE DISEASE TEAM PLANNING AWARDS, WHICH I SUPPORT,
- 17 BUT THEN YOU MENTIONED THE NEXT PHASE WOULD BE THE
- 18 DISEASE TEAMS GRANTS?
- 19 MS. OLSON: THE ACTUAL GRANTS TO FUND THE WORK
- 20 OF THE DISEASE TEAMS.
- 21 CHAIRMAN KLEIN: THAT WILL BE A SEPARATE.
- MS. OLSON: YES.
- MR. SERRANO-SEWELL: AN ENTITY ISN'T PRECLUDED
- 24 IF THEY DON'T GET THE DISEASE TEAM PLANNING AWARD.
- MS. OLSON: THAT IS CORRECT. THANK YOU FOR

- 1 THAT CLARIFICATION. IF YOU DO NOT APPLY FOR AND RECEIVE
- 2 A PLANNING GRANT, THAT DOES NOT PRECLUDE YOUR
- 3 PARTICIPATING IN THE COMPETITION FOR THE DISEASE TEAM
- 4 GRANTS.
- DR. LEVEY: I WAS PLEASED TO SEE BEFORE THAT
- 6 THERE'S A PLAN FOR A MAJOR INITIATIVE WITH REGARD TO
- 7 CORES. AND I THINK IF WE GO AHEAD WITH THIS DISEASE
- 8 TEAM, IN FACT, YOU MIGHT EVEN WANT TO DO THAT BEFORE YOU
- 9 ACTUALLY HAD THE FULL DECISIONS FOR THE DISEASE TEAMS
- 10 BECAUSE DISEASE TEAMS, IF YOU HAD MULTIPLE TEAMS ON THE
- 11 UNIVERSITY OR LIKE WE'D LIKE TO DO PROBABLY ACROSS
- 12 UNIVERSITY LINES AND BRING POOLS OF GROUPS TOGETHER, IT
- 13 EVEN PUTS GREATER STRESS ON HAVING CORE FACILITIES. SO
- 14 YOU MIGHT WANT TO THINK ABOUT THE TIMING OF THESE AND HOW
- 15 MUCH YOU WANT TO PUT INTO THE CORE -- HOW MUCH WE WANT TO
- 16 PUT INTO THE CORE FACILITIES GRANTS.
- 17 MS. OLSON: I BELIEVE IT IS OUR INTENT, AS
- 18 OUTLINED IN DR. CHIU'S PLAN, TO, IN FACT, MOVE FORWARD
- 19 WITH CORES AS WELL. HOWEVER, I GUESS THEY'RE GOING TO BE
- 20 MOVING FORWARD SIMULTANEOUSLY, AND WE'LL PROBABLY HAVE TO
- 21 RELY TO SOME EXTENT ON RESOURCES ALREADY EXISTING;
- 22 ALTHOUGH AS TIME GOES ON, CERTAINLY THOSE CORES THAT WE
- 23 HOPE TO BRING FORTH WILL CONTRIBUTE TO THEM AS WELL.
- 24 CHAIRMAN KLEIN: DR. PIZZO.
- 25 DR. PIZZO: I'D LIKE TO FOLLOW UP ON JERRY

1	LEVEY'S COMMENT.	IN MANY	LARGE PRO	GRAM PROJECTS,	CORES
---	------------------	---------	-----------	----------------	-------

- 2 ARE OFTEN EMBEDDED INTO THE PROJECTS THEMSELVES. AND IT
- 3 MAY BE A DIFFERENT WAY OF THINKING ABOUT THIS, AND I
- 4 DON'T KNOW WHETHER THERE'S TIME TO DO THAT, BUT THAT
- 5 COULD MAKE A TREMENDOUS DIFFERENCE BECAUSE IN THE ABSENCE
- 6 OF ADDRESSING CORE FACILITIES, WHEN WE'RE LOOKING AT
- 7 DISEASE-BASED PROJECT RESEARCH, WE MISS, I THINK, AN
- 8 IMPORTANT NEED. SO I WOULD MAKE THE REQUEST THAT WE
- 9 THINK ABOUT THIS AND THINK ABOUT WHETHER OR NOT CORES
- 10 COULD BECOME PART OF THE DISEASE-BASED PROCESS ITSELF.
- 11 CHAIRMAN KLEIN: CERTAINLY WE HAVE THE
- 12 OPPORTUNITY WHEN THE PLANNING GRANTS, WHICH IS WHAT WE'RE
- 13 FOCUSED ON TODAY, PROGRESS TO GET FEEDBACK IN REAL-TIME
- 14 FROM THOSE INSTITUTIONS WITH PLANNING GRANTS THAT MIGHT
- 15 CONTRIBUTE TO OUR CONSIDERATION OF CORES BEFORE THE
- 16 DISEASE TEAM GRANTS ARE MADE.
- 17 DR. PIZZO: WELL, NO, I REALLY MEAN SOMETHING
- 18 DIFFERENT. I THINK THAT, YOU KNOW, IF YOU ARE APPLYING
- 19 FOR A COMPREHENSIVE CANCER CENTER PROGRAM OR SOMETHING OF
- THE LIKE AS A MAJOR PROJECT GRANT, WHICH DOES BUILD TEAMS
- 21 IN AN INTERDISCIPLINARY WAY, THERE IS OFTEN CORES AS PART
- 22 OF THAT JUST SORT OF BUILT INTO THE GRANT ITSELF, AND IT
- 23 JUST MAY OBVIATE THIS CHALLENGE.
- DR. CHIU: MAY I RESPOND TO THAT?
- DR. PIZZO: PLEASE. BY ALL MEANS.

1	DR	CHIU:	WΕ	DO	NOT	KNOW	WHAT	KTND	ΩF	DISEASE
_	DIV.	CHILD:	₩.	טט	1101	ININOW	VV I I/~ I	KTIND	OI.	DIJLAJL

- 2 TEAMS WILL ARISE AND THE NEEDS OF EACH OR ANY OF THE
- 3 DISEASE TEAMS, SO IT WOULD BE UP TO WRITING OF THE
- 4 PROPOSAL OF THE BIG MULTIYEAR DISEASE TEAM GRANT TO STATE
- 5 WHAT THEIR NEEDS ARE AT WHAT STAGE AND HOW THESE
- 6 INTEGRATE. HOWEVER, I DO NOT ALSO WANT TO DEPEND ON
- 7 THOSE FOR THE CORES. AND WHAT WE ENVISION AND WILL BRING
- 8 BEFORE YOU IS THAT CORES AND SERVICES ARE A SEPARATE RFA
- 9 FROM THE DISEASE TEAMS.
- 10 DR. PIZZO: RIGHT. AND I RESPECT THAT AND I
- 11 THINK THAT THAT SHOULD BE THE CASE. I WAS JUST LOOKING
- 12 AT A WAY OF FACILITATING SOME OF THE CORE DEVELOPMENT AS
- 13 PART OF THIS EFFORT SINCE I DON'T KNOW THE SEQUENCING OF
- 14 THE LATTER.
- 15 CHAIRMAN KLEIN: OKAY. DR. MEYER.
- 16 DR. MEYER: I HAVE ACTUALLY TWO SEPARATE
- 17 ISSUES, ONE MORE SPECIFIC AND ONE MORE GENERAL. WHEN
- 18 YOU'RE TALKING ABOUT TEAMS, IT BEGS THE QUESTION ABOUT
- 19 PI'S. AND NOW NIH HAS MULTIPLE PI'S. IS THIS GOING TO
- 20 BE SOMETHING THAT IS GOING TO BE PART OF THIS RFA, THAT
- 21 THERE WILL BE MULTIPLE PI'S ELIGIBLE?
- MS. OLSON: THAT IS NOT HOW WE'RE CONTEMPLATING
- 23 IT AT THE MOMENT. BUT LET ME JUST SAY MY EXPERIENCE WITH
- 24 TEAM-BASED RESEARCH IS THERE IS USUALLY A PROJECT LEADER,
- 25 NOT A PI IN THE SENSE THAT ACADEMIC INSTITUTIONS ARE USED

- 1 TO THINKING ABOUT A PI. BUT THE ROLE OF THE PROJECT
- 2 LEADER IS ALMOST, CALL IT, A HIGH LEVEL MANAGER, MAKE
- 3 SURE THAT BRINGS TOGETHER THE RIGHT PEOPLE, IS A DRIVING
- 4 FORCE. CALL THEM A LEADER AMONG EQUALS, HIM OR HER A
- 5 LEADER AMONG EQUALS BECAUSE THAT -- AND I THINK WHEN
- 6 YOU -- BECAUSE THE EXPECTATION HERE IS THAT FOR A DISEASE
- 7 TEAM, YOU WILL NEED MULTIPLE KINDS OF EXPERTISE, YOU WILL
- 8 NEED PI EQUIVALENTS IN DIFFERENT AREAS.
- 9 SO I TAKE IT UNDER CONSIDERATION, BUT, YOU
- 10 KNOW, WE CRINGE IN TERMS OF ADMINISTRATION AS TO HOW WE
- 11 WOULD MOVE FORWARD WITH THAT PARTICULAR MODEL.
- DR. MEYER: AND MY SECOND QUESTION IS MORE
- 13 GENERAL. AND BOB, IF YOU WANT TO TAKE THIS UP MAYBE
- 14 LATER, THAT'S FINE. BUT I GET BACK TO AN ISSUE THAT I
- 15 RAISED WITH ZACH AND WITH ARLENE, POSSIBLY ALSO WITH BOB,
- 16 AND THAT'S THE ISSUE OF ELIGIBILITY OF HIGHLY QUALIFIED
- 17 PEOPLE WHO HAVE FULL-TIME LABORATORIES IN A CALIFORNIA
- 18 INSTITUTION, BUT THEMSELVES ARE JOINTLY APPOINTED AT
- 19 ANOTHER INSTITUTION OUTSIDE OF CALIFORNIA.
- 20 WHAT I WAS TOLD, AND I THINK IT MADE A LOT OF
- 21 SENSE AT THE TIME, WAS THAT, WELL, WE DON'T REALLY WANT
- 22 TO HAVE THIS BE AN ISSUE WITH THE COURT CASES GOING ON;
- 23 AND THAT ONCE WE HAVE THE MONEY AND THE BONDS ARE SOLD
- 24 AND SO ON, THAT WE WOULD MOVE TOWARD A DIRECTION OF
- 25 MAKING ELIGIBILITY BASED ON WHERE THE LABORATORY IS

1 LOCATED AND THE INSTITUTION AS OPPOSED TO WHER	Τ.	SED TO WHERE	THE P.	Т
--	----	--------------	--------	---

- 2 SPENDS THEIR TIME.
- 3 SO MY QUESTION, THEN, IS BECAUSE THIS IS A
- 4 PI-BASED RFA, NOT LIKE THE FACILITIES ONE, WHICH, YOU
- 5 KNOW, YOU CAN ARGUE, BUT THIS IS MUCH MORE RESEARCH
- 6 ORIENTED, ARE WE NOW, BECAUSE THERE'S NOTHING SPECIFIC
- 7 HERE, ACCEPTING APPLICATIONS FROM INSTITUTIONS WHERE THE
- 8 PI IS, LET'S SAY FOR THE SAKE OF ARGUMENT, 50-PERCENT
- 9 TIME AT THAT INSTITUTION, BUT HAS A HUNDRED PERCENT TIME
- 10 RESEARCH ENTERPRISE GOING ON AT THAT INSTITUTION?
- 11 CHAIRMAN KLEIN: SO IF I CAN UNDERSTAND, VERY
- 12 SPECIFICALLY, IF THERE IS AN APPROPRIATE ALLOCATION OF
- 13 TIME TO THE RESEARCH BEING DONE IN CALIFORNIA, AND WE
- 14 WOULD BE PAYING FOR THE TIME BEING SPENT IN CALIFORNIA
- 15 AND THE STAFF IN CALIFORNIA IN THE FUTURE GRANTS,
- 16 INCLUDING THOSE THAT WE'RE CONTEMPLATING HERE, CAN WE, IN
- 17 FACT, CAPTURE THE OPPORTUNITY TO HAVE THOSE GREAT MINDS
- 18 THAT ARE PARTITIONING THEIR TIME TO CALIFORNIA? AND DR.
- 19 OLSON, IF I COULD CALL ON DR. CHIU BECAUSE IT HAS
- 20 PREVIOUSLY BEEN DIRECTED AT DR. CHIU, AND THEN ON YOU
- 21 AGAIN.
- DR. CHIU: I THINK YOU BRING UP AN EXCELLENT
- 23 POINT BECAUSE THE GOAL OF THESE DISEASE TEAMS IS TO GET
- 24 IT TO WORK AND TO GET IT TO A FINAL PRODUCT READY FOR
- 25 CLINIC. ONE OF THE THINGS WE LEARNED AND YOU WILL SEE IN

1	YOUR	DRAFT	OF	THE	WORKSHOP	TS	THAT	LEADERSHIP	TS	KFY.
_	1001		\sim 1		WONISHIOL		111/71			11

- 2 AND WE WANT TO CAPTURE THE BEST LEADERS THAT WOULD BRING
- 3 THE PROJECT TO FRUITION.
- 4 THE SECOND THING ABOUT THESE DISEASE TEAMS THAT
- 5 DR. OLSON POINTED TO IS THAT THEY'RE GOING TO BE
- 6 MILESTONE DRIVEN. AND SHOULD THEY AT ANY POINT NOT NEED
- 7 THE MILESTONES, THEY WILL END. SO, THEREFORE, WE ARE NOT
- 8 SO WORRIED ABOUT WHO IS GOING TO BE LEADING AS LONG AS
- 9 THE LEADER IS EFFECTIVE AND WILL GET THE PROJECTS DONE
- 10 AND THAT THE WORK WILL BE DONE IN CALIFORNIA BECAUSE WE
- 11 CAN ONLY FUND WORK THAT'S DONE IN CALIFORNIA.
- DR. MEYER: SO IN OTHER WORDS, AND I WILL STOP
- 13 BEAT ON THIS HORSE AFTER I SAY THIS, IT'S BEEN, FROM WHAT
- 14 I HAVE HEARD, AND THIS IS HEARSAY, IS THAT UP UNTIL THIS
- 15 POINT, THE REVIEW COMMITTEES, THE STUDY SECTIONS THAT
- 16 HAVE BEEN REVIEWING GRANTS, HAVE MADE AN ISSUE OUT OF
- 17 THIS AND HAVE NEGATIVELY COMMENTED ON THE POTENTIAL OF
- 18 THESE CERTAIN GRANTS BECAUSE OF WHAT I BRING UP; I.E.,
- 19 THE PART-TIME NATURE. I'M HAPPY TO HEAR THAT THAT'S NOT
- 20 TRUE.
- MS. OLSON: I THINK IT WAS BASED ON THE
- 22 ELIGIBILITY CRITERIA FOR THE RFA'S AND THE APPLICATIONS
- 23 THAT WE HAVE PUT OUT -- THAT WE PUT OUT. SO IT'S THE
- 24 ELIGIBILITY CRITERIA THAT THE REVIEWERS WERE REACTING TO.
- DR. MEYER: PERFECT.

1	CHAIRMAN KLEIN: AND AS I UNDERSTAND THE
2	COMMENTS AND PRIOR DISCUSSIONS AT EXECUTIVE COMMITTEE,
3	DR. CHIU OR DR. OLSON PARTICIPATED IN, THAT THERE IS THE
4	INTENT TO CAPTURE THESE BRILLIANT SCIENTISTS WHO ARE
5	PREPARED TO MAKE A PART-TIME COMMITMENT TO CALIFORNIA,
6	PAYING FOR THE TIME THEY SPEND IN CALIFORNIA AS A PART OF
7	A TEAM THAT WOULD APPROACH THESE VERY COMPLICATED ISSUES.
8	AND, DR. MURPHY, IS THAT CONSISTENT WITH THE POLICY THAT
9	YOU ARE LOOKING AT?
10	DR. MURPHY: YES.
11	CHAIRMAN KLEIN: SO DR. POMEROY.
12	DR. POMEROY: CAN YOU JUST CLARIFY FOR ME ON
13	THESE GRANTS, ARE THESE AIMED AT ACADEMIC INSTITUTIONS,
14	INDUSTRY, AND HOW ABOUT ACADEMIC-INDUSTRY PARTNERSHIPS
15	BECAUSE WE'RE REALLY TALKING ABOUT TRYING TO BRING THESE
16	THERAPIES TO CLINICAL TESTING AND MARKET. SO WHAT DID
17	YOU ENVISION FOR THESE TEAMS?
18	MS. OLSON: CERTAINLY BY THE TIME OF THE
19	DISEASE TEAM GRANTS, WE WOULD EXPECT TO HAVE THEM OPEN TO
20	BOTH ACADEMIC AND FOR-PROFIT IN WHATEVER COLLABORATION,
21	YOU KNOW, YOU CHOOSE TO COME UP WITH. FOR THE PLANNING
22	GRANTS, I THINK WE'RE STILL FINALIZING OUR GRANTS
23	ADMINISTRATION POLICY FOR FOR-PROFITS, SO WE HAVEN'T
24	TOTALLY COME TO TERMS YET WITH WHO'S GOING TO BE ELIGIBLE
25	FOR THOSE, BUT WE'RE LEANING TOWARDS THE NONPROFIT ONLY.

1	CHAIRMAN KLEIN: AND LET ME ASK THE FOLLOW-ON
2	QUESTION TO THAT. IF THE NONPROFITS ARE ELIGIBLE FOR
3	THESE PLANNING GRANTS, THAT DOESN'T NECESSARILY PRECLUDE
4	THEM FROM HAVING FOR-PROFIT SCIENTISTS AS A PART OF THE
5	TEAM. IS THAT A CORRECT STATEMENT?
6	MS. OLSON: THAT IS A CORRECT STATEMENT.
7	CHAIRMAN KLEIN: DR. PRIETO AND THEN DUANE
8	ROTH.
9	DR. PRIETO: JUST A COMMENT REALLY. I THINK
10	THE STRENGTH OF THIS APPROACH IS THAT IT ALLOWS
11	INVESTIGATORS TO PUT TIME DEVOTE TIME AND RESOURCES TO
12	ADDRESSING EXACTLY THESE QUESTIONS AS THEY THINK ABOUT
13	WHAT A DISEASE TEAM WILL LOOK LIKE AND HOW THEY WILL PUT
14	IT TOGETHER AND ALLOWS THEM TO DO THAT WITH SPECIFICALLY
15	SET ASIDE TIME AND RESOURCES THAT WE'RE GIVING THEM. I'M
16	VERY EXCITED ABOUT THIS PROPOSAL BECAUSE THIS REALLY IS,
17	I THINK, WHAT I SIGNED ON FOR, TO, YOU KNOW, DRIVE US TO
18	THE CLINIC AND TO CURES FOR DISEASES. AND I THINK THIS
19	IS A VERY DIRECT STEP IN THAT DIRECTION. AND IF IT'S NOT
20	TOO EARLY, I'D LIKE TO MAKE A MOTION FOR APPROVAL.
21	CHAIRMAN KLEIN: THERE IS WE CAN CONTINUE
22	DEBATE WITH A MOTION, SO YOUR MOTION WOULD BE IN ORDER IF
23	YOU WOULD LIKE TO MAKE A MOTION FOR APPROVAL.
24	DR. PRIETO: I WOULD.
25	CHAIRMAN KLEIN: IS THERE A SECOND?

1	MS. LANSING: SECOND.
2	CHAIRMAN KLEIN: SECOND BY SHERRY LANSING. AND
3	WE HAVE A COMMENT BY DUANE ROTH.
4	MR. ROTH: I WANTED TO MAKE THE MOTION AS WELL,
5	BUT WHAT I REALLY WANTED TO ADD TO IT IS THAT I WOULD
6	LIKE CONSIDERATION TO THE COMMENTS THAT HAVE BEEN MADE BY
7	DR. PIZZO ABOUT CORES, THE CONCEPT OF INCLUDING INDUSTRY
8	SO THAT YOU GET SOME REALLY GOOD FEEDBACK HERE ABOUT WHAT
9	THE ULTIMATE GRANT SHOULD LOOK LIKE.
10	CHAIRMAN KLEIN: AND DR. PRICE.
11	DR. PRICE: YOU VERY RAPIDLY SAID SOMETHING
12	ABOUT INDIRECT COST RECOVERY, SO COULD YOU REPEAT IT, AND
13	COULD YOU GIVE US THE RATIONALE?
14	MS. OLSON: THESE ARE PLANNING GRANTS. WE WERE
15	NOT PLANNING ON INCLUDING ANYTHING IN AN INDIRECT COST.
16	WE DID NOT SEE THAT IT WOULD BE USING LAB FACILITIES OR
17	ANYTHING LIKE THAT.
18	DR. PRICE: OFFICE FACILITIES. I'M SERIOUS.
19	WELL, I HAVE A QUESTION FOR SUE BRYANT, A VCR IN THE UC
20	SYSTEM. I'M JUST WONDERING WHETHER THESE GRANTS COULD BE
21	PROCESSED THROUGH THE UC SYSTEM IF THEY'RE ZERO COST
22	RECOVERY.
23	DR. BRYANT: I'M SURE
24	DR POMEROV: I'D LIKE TO CLARIEV THAT HE

87

POLICY IS THAT WE HAVE TO APPLY THE INDIRECT RATES UNLESS

25

$1 - WE \ GET \ A \ SPECIFIC \ REVIEW \ AND \ WAIVER. \ AND \ SO \ THE$: UC	SO THE	AND	WAIVER.	AND	REVIEW	SPECIFIC	Α	GET	WE	1
---	------	--------	-----	---------	-----	--------	----------	---	-----	----	---

- 2 INSTITUTIONS APPLYING, AND THERE'S PROBABLY SOMETHING
- 3 COMPARABLE AT THE OTHER INSTITUTIONS THAT MIGHT BE
- 4 APPLYING, WOULD HAVE TO GO THROUGH THEIR INTERNAL
- 5 PROCESSES, I WOULD PRESUME, IN ORDER TO DOCUMENT THAT.
- 6 DR. PRICE: I DON'T THINK THAT THIS WILL MEET
- 7 THOSE CRITERIA, SO WE'LL HAVE TO GET AN EXCEPTION TO THE
- 8 CRITERIA. AND BOARD OF REGENTS IS NOT ALLOWING US TO
- 9 HAVE EXCEPTIONS. NOW I'M BEING FACETIOUS.
- 10 MS. LANSING: BOARD OF REGENTS IS FLEXIBLE.
- 11 CHAIRMAN KLEIN: SO SHERRY LANSING.
- 12 MS. LANSING: I JUST AS A MEMBER OF THE CIRM
- 13 BOARD AND AS A REGENT, I AM EXTREMELY SUPPORTIVE OF THIS
- 14 BECAUSE WHAT I THINK THIS IS IS WE'VE BEEN TALKING ABOUT
- 15 INTERDISCIPLINARY APPROACH AND TAKING IT FROM THE
- 16 ABSTRACT INTO THE CLINICAL AND INTO EVENTUALLY CURES.
- 17 AND THIS IS EXACTLY, THOUGH DR. PIZZO INFORMS ME THAT
- 18 THERE HAVE BEEN THINGS LIKE THIS BEFORE, AS A LAYPERSON I
- 19 DON'T HEAR A LOT ABOUT IT, SO I HAVE TO SAY THAT I'M GLAD
- 20 WE'RE AT LEAST AT THE FOREFRONT OF THIS. AND I THINK
- 21 IT'S EVERYTHING THAT OUR GROUP HAS BEEN TALKING ABOUT IN
- 22 TERMS OF SHARED INFORMATION, IN TERMS OF BEING
- 23 INNOVATIVE, IN TERMS OF CROSSING DISCIPLINES. SO I JUST
- 24 THINK IT'S EXTRAORDINARY, SO AS A PATIENT ADVOCATE I
- 25 THANK YOU.

1		CHAIRMAN	KLEIN:	AND I	WOULD	LIKE	TO	SAY	THAT	
_	•	_								

- WE'RE VERY APPRECIATIVE TO HAVE THE RICHNESS OF THE
- 3 REPRESENTATION ON THIS BOARD THAT WE CAN INTERFACE SO
- 4 MANY DIFFERENT LEVELS OF INPUT INTO THIS GRANT SYSTEM.
- 5 DR. PIZZO.
- DR. PIZZO: I'LL FOREGO. THANK YOU.
- 7 CHAIRMAN KLEIN: OKAY.
- 8 DR. BRYANT: COULD I JUST FOLLOW UP? I DO
- 9 BELIEVE IT WOULD BE POSSIBLE. I WANT TO JUST RETURN TO
- 10 THAT, BUT THERE ARE COSTS ASSOCIATED WITH BRINGING MONEY
- 11 IN AND ACCOUNTING FOR IT AND ALL OF THAT, SO IT'S NOT
- 12 THAT THERE AREN'T -- THE LAB ISN'T THE ONLY THING THAT
- 13 GETS PAID. SO I WOULD PREFER IF WE COULD HAVE A REDUCED,
- 14 BUT STILL APPROPRIATE INDIRECT RATE.
- 15 DR. PIZZO: SO NOW THAT SUE HAS MADE THAT
- 16 COMMENT, MAYBE I WILL ALSO. YOU KNOW, CLEARLY, THIS IS A
- 17 VERY IMPORTANT PROJECT, AND SO WE ALL WANT TO SEE THIS GO
- 18 FORWARD, BUT I THINK HER COMMENT IS TRUE. IN ONE WAY OR
- 19 ANOTHER, WHETHER IT'S STATE OR PRIVATE INSTITUTION, YOU
- 20 HAVE TO FIND THE FUNDING FOR THIS. SO IT HAS TO,
- THEREFORE, COME OUT OF SOME OTHER RESOURCE, AND THAT,
- 22 NONETHELESS, YOU KNOW, IS AN ISSUE FOR US. SO I THINK
- THIS IS AN IMPORTANT ISSUE, AND WE'LL FIGURE OUT HOW TO
- 24 GET IT DONE, BUT, YOU KNOW, THERE IS A PRICE TO IT.
- 25 CHAIRMAN KLEIN: DR. MURPHY.

1	DR. MURPHY: LET ME JUST SAY ONE OF THE THINGS
2	I'VE LEARNED AT THE CIRM, AND IT GOES AROUND A LOT, IS
3	WHEN WE MAKE A DECISION, THE BOTTOM LINE IS DOES THIS
4	HELP THE MISSION. AND I THINK MANY OF THE QUESTIONS THAT
5	HAVE BEEN RAISED HERE COULD BE ANSWERED, WELL, IF IT
6	REALLY DOES HELP THE MISSION, LET'S LET IT HAPPEN, THE
7	BUSINESS ASSOCIATION, ALL THE OTHER THINGS, ALL THE OTHER
8	GOOD SUGGESTIONS YOU'VE MADE. AND I THINK WE SHOULD LOOK
9	VERY POSITIVELY ON THOSE.
10	AS A FORMER PERSON IN THE SAME POSITION YOU
11	FOLKS ARE, I UNDERSTAND THE NEED FOR OVERHEAD. AND MR.
12	CHAIRMAN, CAN WE SUGGEST THAT THE BOARD WOULD APPROVE
13	PERHAPS A 10-PERCENT OVERHEAD ALLOWANCE FOR THIS TYPE OF
14	GRANT TO COVER THE COSTS THAT HAVE BEEN, I THINK, VERY
15	JUSTIFIABLY RAISED HERE?
16	CHAIRMAN KLEIN: COULD THE MAKER OF THE MOTION
17	AMEND THE MOTION AS A FRIENDLY AMENDMENT?
18	DR. PRIETO: YES, I'D ACCEPT THAT AS A FRIENDLY
19	AMENDMENT.
20	CHAIRMAN KLEIN: AND THE SECOND? SHERRY IS THE
21	SECOND. WOULD YOU ACCEPT AN AMENDMENT TO PERMIT A
22	10-PERCENT OVERHEAD?
23	MS. LANSING: I ACCEPT THAT.
24	CHAIRMAN KLEIN: OKAY. SO THE MAKER OF THE
25	MOTTON AND THE SECOND HAVE ACCEPTED AS A EPTENDLY

1	AMENDMENT.	SO	THE	MOTTON	RFFORF	US	WOULD HAVE	FΔ
_		20		1.10 I TOI1		-	WOOLD HAV	_ ^

- 2 10-PERCENT OVERHEAD ALLOWANCE WITH IT IF IT WERE TO PASS.
- 3 AT THIS POINT I'D LIKE TO ASK ARE THERE PUBLIC
- 4 COMMENTS? MR. SIMPSON.
- 5 MR. SIMPSON: JOHN SIMPSON, FOUNDATION FOR
- 6 TAXPAYER AND CONSUMER RIGHTS. ONE IS A POINT OF
- 7 CLARIFICATION. YOU DID MAKE IT CLEAR THAT YOU WOULD BE
- 8 ABLE TO APPLY FOR THE DISEASE TEAM FULL GRANTS IF YOU
- 9 DON'T DO THE PLANNING GRANTS. BUT WHAT'S THE SITUATION IF
- 10 YOU HAVE A PLANNING GRANT? ARE YOU PRETTY MUCH
- 11 GUARANTEED? I MEAN WOULD YOU EXPECT ALL OF THEM TO LEAD
- 12 TO FRUITION? WHAT RATE IS THE SORT OF RATE THAT WOULD BE
- 13 AN ACCEPTABLE RATE?
- 14 CHAIRMAN KLEIN: I THINK THAT THIS BOARD AND
- 15 THE STAFF HAVE ALWAYS BEEN FOCUSED ON THE QUALITY AND THE
- 16 BRILLIANCE AND PROMISE OF THE GRANTS. WE DON'T HAVE THE
- 17 FACTS AT THIS POINT TO SEE WHAT THE -- WHAT COMES OF
- 18 THESE PLANNING GRANTS, AND WE WOULD NEED TO EVALUATE
- 19 THAT. BUT IF THE STAFF WOULD LIKE TO COMMENT.
- 20 MS. OLSON: THE PURPOSE OF THE PLANNING GRANT
- 21 IS TO INCREASE THE NUMBER OF POTENTIAL QUALITY
- 22 APPLICATIONS THAT WE HAVE. IT WILL BE UP TO OUR
- 23 SCIENTIFIC REVIEWERS AND TO THE BOARD WHEN WE FINALLY
- 24 ACTUALLY SEE THE DISEASE TEAM GRANTS. BUT GETTING A
- 25 PLANNING GRANT IS NO GUARANTEE OF GETTING A GRANT.

1	CHAIRMAN KLEIN: AND PLEASE REALIZE THE DISEASE
2	TEAM GRANTS THAT ARE BEING THOUGHT UP CONCEPTUALLY ARE IN
3	THE RANGE OF \$20 MILLION. SO THIS IS A VERY SERIOUS
4	UNDERTAKING WITH VERY SPECIFIC OBJECTIVES. DR. OLSON AND
5	THEN DR. HENDERSON.
6	MS. OLSON: I WAS JUST GOING TO SAY THE FULL 20
7	MILLION IS ASSUMING THEY WERE SUCCESSFUL IN GETTING
8	THE TO A KEY MILESTONE OF GETTING AN APPROVED IND AND
9	ACTUALLY WOULD INCLUDE CLINICAL STUDIES AS WELL. AS YOU
10	CAN SEE, THE DISEASE TEAM ITSELF, WE WOULD PROBABLY FUND
11	SOME PORTION OF THAT WITH THE GOAL OF GETTING TO AN
12	APPROVABLE IND, AND IT WOULD HAVE MILESTONES ALONG THE
13	WAY.
14	CHAIRMAN KLEIN: DR. OLSON, ON YOUR LAST SLIDE
15	THAT'S HERE, COULD YOU COMMENT ON THE BOXES THAT LIE
16	BELOW THE DISEASE TEAM BOX TO SPECIFICALLY RELATE HOW
17	SOME OF THESE PLANNING GRANTS MAY END UP FALLING INTO
18	TRANSLATIONAL RESEARCH GRANTS OR OTHER CATEGORIES?
19	MS. OLSON: OKAY. AS YOU CAN SEE, THE SCIENCE
20	OF THERAPY DEVELOPMENT HAS MANY STAGES TO IT. AND WHAT
21	WE CAN SEE IS THAT IF CERTAIN DISEASE TEAM PLANNING
22	GRANTS PERHAPS WERE NOT SUCCESSFUL IN COMPETING FOR A
23	DISEASE TEAM AWARD, THERE ARE OTHER OPPORTUNITIES. THERE
24	WOULD BE WE'RE GOING TO HAVE PRECLINICAL PRODUCT
25	DEVELOPMENT. SO TAKING THINGS FORWARD TO ACTUALLY WHAT'S

1	BFFN	KNOWN	AS	THF	VALLEY	ΟF	DFATH.	GETTING	THE

- 2 MANUFACTURER, DOING THE TOX STUDIES THAT YOU NEED TO DO
- 3 TO GO INTO THE CLINIC, WE WOULD ALSO HAVE TRANSLATIONAL
- 4 RESEARCH PART 2 MIGHT COVER THAT KIND OF CATEGORY AS
- 5 WELL. THE EARLIER STAGE OF TRANSLATIONAL RESEARCH MIGHT
- 6 COVER SOME IDEAS OR SOME BOTTLENECKS.
- 7 CAN WE GET -- WE HEARD THIS MORNING ABOUT
- 8 GETTING CARDIOMYOCYTES IN A QUANTITY SUFFICIENT TO TALK
- 9 ABOUT GOING TO THE CLINIC. THAT'S THE KIND OF THING THAT
- 10 I MIGHT LOOK TO SEE IN TRANSLATIONAL RESEARCH ONE,
- 11 METHODS TO ACTUALLY PRODUCE CARDIOMYOCYTES IN ENOUGH
- 12 QUANTITIES THAT WE COULD TALK ABOUT ACTUALLY LOOKING AT
- 13 THEM IN MULTIPLE DISEASE MODELS AND THAT WE COULD
- 14 ACTUALLY TALK ABOUT MOVING THEM TO THE NEXT STAGE OF
- 15 THINKING ABOUT GOING INTO PEOPLE. SO ALL THESE DIFFERENT
- 16 ASPECTS OF THE PROGRAM ARE DESIGNED TO, YOU KNOW, MOVE
- 17 RESEARCH ALONG, TO GET INTO THE CLINIC, AND THERE WILL BE
- 18 FAILURES ON THE WAY. YOU ALL KNOW THAT THINGS DON'T
- 19 ALWAYS WORK, BUT WE'RE PROVIDING LOTS OF CHANCES, I
- THINK, FOR PEOPLE TO EXPLORE THEIR IDEAS AND TO MOVE
- 21 THINGS AND TO TRANSLATE THEIR IDEAS INTO, YOU KNOW,
- 22 POSSIBLE DISCOVERIES THAT WILL MAKE A DIFFERENCE.
- 23 CHAIRMAN KLEIN: ALL RIGHT. ADDITIONAL
- 24 COMMENTS FROM THE BOARD?
- DR. BRYANT: I JUST HAD A QUESTION.

1	CHAIRMAN KLEIN: DR. HENDERSON, DID YOU STILL
2	HAVE A COMMENT?
3	DR. HENDERSON: YEAH. I JUST AGAIN REITERATE I
4	THINK THIS IS A CALL TO THE SCIENTIFIC COMMUNITY, TO ALL
5	OF OUR COLLEAGUES, AS WELL AS OURSELVES ABOUT THE MISSION
6	WE'RE ON, TO GET PRODUCTS INTO THE CLINIC. WE'VE ALL
7	BEEN TO THE SPOTLIGHT PRESENTATIONS IF WE'RE NOT AWARE OF
8	ISSUES IN OUR OWN FAMILY AND AMONG OUR FRIENDS. SO THIS
9	IS TO TRY TO GALVANIZE SOME SERIOUS EFFORT AT DISEASE
10	TRANSLATION, TREATMENT.
11	CHAIRMAN KLEIN: AND DR. BRYANT.
12	DR. BRYANT: I JUST HAD A QUESTION, AND THAT
13	WAS WILL ACCEPTANCE OF A PLANNING GRANT MEAN THAT A GRANT
14	APPLICATION NEEDS TO BE PUT IN? I'M JUST WONDERING IF
15	THOSE TWO ARE LINKED OR PEOPLE COULD CHANGE THEIR MINDS
16	OR WHAT?
17	MS. OLSON: PEOPLE CAN CHANGE THEIR MINDS.
18	DR. BRYANT: OKAY.
19	MR. SIMPSON: I WAS TRYING TO CLARIFY ON THE
20	PLANNING GRANTS, WHICH I THINK ARE TERRIBLY IMPORTANT,
21	JUST WHAT IF THERE'S A COMPARABLE SORT OF SENSE OF,
22	SAY, WHEN NIH MAKES THESE GRANTS, HOW MANY OF THEM
23	ACTUALLY GET TO THE FULL STAGE?
24	CHAIRMAN KLEIN: WE DON'T KNOW THAT. WE DON'T
25	HAVE THE FACTUAL INFORMATION THAT WILL DEVELOP AND BE THE

- 1 RESULT OF THIS PROCESS.
- MR. SIMPSON: AND I AGREE THAT THAT'S
- 3 TREMENDOUSLY IMPORTANT, BUT I ALSO HAVE TO IN GOOD
- 4 CONSCIENCE ADD A NOTE OF SKEPTICISM ABOUT THE SORT OF
- 5 ACADEMIC TENDENCY TO AUTOMATICALLY TACK ON INDIRECT
- 6 COSTS. I WISH I COULD DO THAT IN MY LIFE, BUT IT DOES
- 7 SEEM TO ME THAT THIS SEEMS A LITTLE STRANGE, TO HAVE A
- 8 GRANT THAT'S A PLANNING GRANT AND SAY, OH, AND BY THE
- 9 WAY, ADD X PERCENT. IT JUST ISN'T AS STRAIGHTFORWARD
- 10 WITH THE PUBLIC AND THE TAXPAYER. I MEAN YOU WOULD BE
- 11 BETTER TO SAY, OKAY, WE WANT THE GRANT AND WE'RE ASKING
- 12 FOR THIS MUCH TO PAY THE RENT RATHER THAN JUST
- 13 AUTOMATICALLY TACKING IN AN OVERHEAD. IT DOESN'T MAKE
- 14 SENSE.
- 15 CHAIRMAN KLEIN: I'D LIKE TO COMMENT THAT 10
- 16 PERCENT IS WAY BELOW ANY JUSTIFIABLE RANGE OF OVERHEAD.
- 17 IT IS A VERY STRINGENT STANDARD. IT IS A VERY
- 18 CONSERVATIVE STANDARD, AND THE -- IT REQUIRES SOME
- 19 SACRIFICE BY THE INSTITUTIONS.
- DR. PIZZO: MR. CHAIRMAN, IF I COULD JUST MAKE
- 21 A TANGENTIAL STATEMENT.
- 22 CHAIRMAN KLEIN: COULD I ASK IF WE COULD HAVE A
- 23 VOTE. WE'RE ABOUT TO LOSE DR. HENDERSON.
- DR. PIZZO: THAT'S ACTUALLY RELEVANT, AND THEN
- 25 IT'S ABOUT DR. HENDERSON.

1	1	I'D LIKE TO CALL THE OUESTION
J	L CHAIRMAN KLEIN.	T D LINE TO CALL THE OUESTION

- 2 IF WE CAN. ALL IN FAVOR. OPPOSED? UNANIMOUS PASSAGE OF
- 3 THIS. IT'S A GREAT VOYAGE WE'RE ABOUT TO EMBARK ON.
- 4 AND, DR. PIZZO, YOU HAVE A COMMENT.
- DR. PIZZO: YES, THANK YOU. SO I JUST WANT TO
- 6 ASK YOU, MR. CHAIRMAN, TO IN YOUR CAPACITY ACKNOWLEDGE
- 7 DR. BRIAN HENDERSON, WHO MAY OR MAY NOT BE LEAVING THE
- 8 BOARD IN THE IMMEDIATE FUTURE. HE'S STEPPING DOWN IN A
- 9 MONTH IN HIS ROLE AS DEAN AT USC WHERE HE'S DONE A GREAT
- 10 JOB. HE'S BEEN A WONDERFUL COLLEAGUE AND SUPPORTER SINCE
- 11 THE INCEPTION OF THIS PROGRAM. IT'S BEEN A PRIVILEGE TO
- 12 BE WORKING WITH HIM. IF HE DOES GO OFF WILL BE WOEFULLY
- 13 MISSED, BUT I THOUGHT YOU WOULD LIKE TO SAY SOMETHING
- 14 ABOUT THAT AS WELL.
- 15 CHAIRMAN KLEIN: THANK YOU VERY MUCH.
- 16 DR. PIZZO: KNOWING THAT YOU ALWAYS CAN COME UP
- 17 WITH SOMETHING GOOD TO SAY.
- 18 CHAIRMAN KLEIN: WELL, IT HAS BEEN A TREMENDOUS
- 19 PRIVILEGE FOR ME INDIVIDUALLY AND FOR THE MEMBERS OF THIS
- 20 BOARD TO BE -- TO HAVE THE GUIDANCE, INSPIRATION, AND
- 21 CONTRIBUTIONS OF DR. HENDERSON DURING THIS HISTORIC TIME
- 22 LEADING UP TO TODAY WHEN WE ARE ISSUING OUR FIRST BONDS.
- 23 IT IS A TIME OF GREAT CHALLENGES THAT HAVE BEEN MARKED BY
- 24 TREMENDOUS ACCOMPLISHMENTS BY THIS BOARD. AND DR.
- 25 HENDERSON GAVE US AN EARLY CONTRIBUTION OF DR. HALL ALONG

	1	THE WAY.	ALONG	WITH	NUMEROUS	CALLS	AND	GUIDANCE	Α
--	---	----------	-------	------	----------	-------	-----	----------	---

- 2 DIRECTION. HE HAS BEEN A RESOURCE FOR ME AND FOR MEMBERS
- 3 OF THIS BOARD.
- 4 IT IS REMARKABLE AS WELL THE TREMENDOUS
- 5 CONTRIBUTIONS THAT HAVE OCCURRED AND THE RECRUITMENT OF
- 6 WORLD LEADERS AT USC BRINGING DR. PERA FROM AUSTRALIA,
- 7 WHICH MAY HAVE INSPIRED SUBSEQUENT RECRUITMENTS ON A
- 8 GLOBAL BASIS TO THE STEM CELL MISSION. BUT CERTAINLY
- 9 WE'VE ALL BEEN VERY PRIVILEGED TO PARTICIPATE. I WOULD
- 10 LIKE TO SEE IF WE COULD ALL STAND AND APPLAUD.
- 11 (APPLAUSE.)
- 12 CHAIRMAN KLEIN: WE STILL HAVE A QUORUM HERE,
- BUT WE JUST HAVE A QUORUM, SO WE'RE GOING TO TRY AND MOVE
- 14 EXPEDITIOUSLY. DR. MURPHY.
- DR. MURPHY: MR. CHAIRMAN, I'M WONDERING IF WE
- 16 CAN GO TO ITEM NO. 10 BECAUSE THAT REALLY IS A HIGH
- 17 PRIORITY FOR THE INSTITUTE, AND WE NEED A VOTE TO ACCEPT
- 18 THE RECOMMENDATION THAT STAFF WILL BE MAKING TO ENTER
- 19 INTO AN AGREEMENT FOR THE GRANTS MANAGEMENT SYSTEM. AND
- 20 WE WANT TO MAKE SURE THAT WE CAN GET THAT APPROVED TODAY
- 21 WHILE WE HAVE A FULL QUORUM.
- 22 CHAIRMAN KLEIN: ALL RIGHT. IF WE COULD MOVE
- 23 TO ED DORRINGTON. ED, WE HAVE GREAT APPRECIATION FOR THE
- TREMENDOUS CONTRIBUTION OF TIME, PASSION, AND COMMITMENT
- 25 YOU'VE MADE TO THIS ENTERPRISE. AND IF YOU COULD, HOW

1	MUCH TIME WILL YOU THINK YOU WILL USE IN MOVING THROUGH
2	THIS ITEM?
3	MR. DORRINGTON: ABOUT SIX OR SEVEN MINUTES.
4	CHAIRMAN KLEIN: WELL, THAT'S IMPRESSIVE.
5	MR. DORRINGTON: WELL, WE'LL SEE.
6	CHAIRMAN KLEIN: AND THEN WE WILL GO BACK, FOR
7	THE PURPOSES OF INFORMATION FOR THE BOARD AND THE
8	AUDIENCE, THEN TO ITEM 9; IS THAT CORRECT, DR. MURPHY?
9	DR. MURPHY: THAT'S RIGHT. THAT'S RIGHT. MR.
LO	CHAIRMAN, BEFORE ED BEGINS, LET ME JUST INTRODUCE ED
L1	DORRINGTON TO THE ICOC. ED IS A SOFTWARE ARCHITECT WHO
L2	HAS BEEN WITH THE INSTITUTE FOR
L3	MR. DORRINGTON: LITTLE OVER TWO YEARS.
L4	DR. MURPHY: TWO YEARS. ED IS THE PERSON
L5	WHO REALLY CREATED THE SOFTWARE THAT IS CURRENTLY BEING
L6	USED BY THE INSTITUTE FOR ITS GRANTS MANAGEMENT PROGRAM.
L7	SO HE WAS IN CHARGE OF THE SURVEY THAT WAS DONE TO CHOOSE
L8	THIS NEW SYSTEM WE'LL BE RECOMMENDING TO YOU WITH
L9	COLLEAGUES IN THE INSTITUTE. AND I JUST WANT TO ASSURE
20	YOU HE IS VERY WELL QUALIFIED TO BE RECOMMENDING THIS TO
21	US.
22	MR. DORRINGTON: THANK YOU. SO I'M GOING TO BE
23	TALKING ABOUT GRANTS MANAGEMENT SYSTEM HERE. I'M GOING
24	TO TALK ABOUT WHY WE NEED A GRANTS MANAGEMENT SYSTEM HOW

WE WENT ABOUT CHOOSING A VENDOR, AND WHO WE ENDED UP

1	RECOMMENDING.
	IVECOMMENDATIO.

- 2 SO WHY DO WE NEED A SYSTEM? THIS SLIDE, WHICH
- 3 YOU'VE ALL SEEN BEFORE, OUTLINES THE STEPS INVOLVED IN
- 4 THE LIFE CYCLE OF A GRANT. EACH STEP IN THIS LIFE CYCLE
- 5 INVOLVES A COORDINATED EFFORT AMONGST A LARGE NUMBER OF
- 6 PEOPLE, WHETHER CIRM STAFF MEMBERS, APPLICANTS, GRANTEES,
- 7 GRANTS WORKING GROUP MEMBERS, OR THE ICOC. MANY OF THESE
- 8 STEPS INVOLVE GATHERING INFORMATION FROM OTHER PROGRAMS,
- 9 QUERYING HISTORICAL INFORMATION, ETC. AND ACTUALLY,
- 10 DR. BRENNER, TO ADDRESS YOUR EARLIER POINT IN TERMS OF
- 11 TRACKING THE PROGRESS OF OUR CIRM SCHOLARS, THIS IS
- 12 EXACTLY THE TYPE OF QUALITATIVE AND QUANTITATIVE
- 13 INFORMATION THAT A GRANTS MANAGEMENT SYSTEM WOULD ALLOW
- 14 US TO TRACK.
- 15 AT ANY GIVEN TIME THERE WOULD BE SEVERAL
- 16 PROGRAMS GOING THROUGH THE YELLOW PRE-AWARD AND AWARD
- 17 STEPS AND LITERALLY DOZENS GOING THROUGH THE POSTAWARD
- 18 TRACKING PROCESSES. EACH PROGRAM COULD CONTAIN FROM
- 19 DOZENS TO HUNDREDS OF APPLICATIONS OR AWARDS, AND EACH
- 20 AWARD COULD INCLUDE MANY PROGRESS REPORTS,
- 21 CERTIFICATIONS, AND OTHER FORMS, ALL OF WHICH LEADS TO A
- 22 LOT OF PAPER. AND JUST SO YOU KNOW, THAT'S JUST THE
- 23 APPLICATIONS FOR JUST ONE PROGRAM.
- 24 WHEN YOU IMAGINE THAT VOLUME OF INFORMATION
- 25 ACROSS ALL THE PROGRAMS WE'LL BE FINISHING OVER MANY

1	YEARS, THE NEED FOR AN ELECTRONIC GRANTS MANAGEMENT
2	SYSTEM TO COORDINATE THESE EFFORTS BECOMES ABUNDANTLY
3	CLEAR.
4	SO HOW DID WE GO ABOUT FINDING THE RIGHT
5	SYSTEM? WE BEGAN EARLY THIS YEAR BY WRITING A DETAILED
6	REQUEST FOR PROPOSAL FOR SUCH A SYSTEM. BY THIS TIME,
7	AFTER HAVING GONE THROUGH SEVERAL REVIEW CYCLES, WE HAD A
8	VERY GOOD UNDERSTANDING OF OUR REQUIREMENTS AND
9	PROCESSES. SO THE RFP OUTLINED 129 SPECIFIC REQUIREMENTS
10	AND IDENTIFIED THE CRITERIA BY WHICH PROPOSALS WOULD BE
11	EVALUATED. THE RFP ALSO STATED THAT ANY CONTRACT WITH A
12	VENDOR WOULD BE ON A PAY-FOR-PERFORMANCE BASIS WHEREBY
13	THE VENDOR IS NOT PAID EXCEPT FOR ACTUAL DELIVERED
14	FUNCTIONALITY. THE RFP WAS POSTED LATE IN MAY, AND
15	RESPONSES WERE DUE AT THE END OF JUNE.
16	BY THE DEADLINE WE HAD RECEIVED FIVE PROPOSALS.

- 17 SO WE THEN CONVENED A NINE-MEMBER EVALUATION COMMITTEE
- 18 WHICH CONSISTED OF SEVEN CIRM EMPLOYEES, INCLUDING
- 19 SCIENTIFIC OFFICERS, I.T., AND SENIOR MANAGEMENT, AND TWO
- 20 OUTSIDE VOLUNTEERS WHO HAD EXTENSIVE EXPERIENCE IN GRANTS
- 21 MANAGEMENT SYSTEMS.
- THE EVALUATION COMMITTEE MET TO REVIEW AND
- 23 SCORE THE PROPOSALS ON THE BASIS OF THESE FIVE CRITERIA:
- 24 THE EXPERIENCE OF THE VENDOR, THE QUALIFICATIONS OF THE
- 25 PERSONNEL IMPLEMENTING THE SOLUTION, THE RESPONSIVENESS

1	OF THEIR PROPOSAL TO THE SCOPE OF WORK OUTLINED IN THE
2	RFP, THE COST TO IMPLEMENT AND MAINTAIN THE SYSTEM, AND
3	THE TIMING OF THE PROJECT. CAN THEY MEET OUR DEADLINES.
4	THE EVALUATION COMMITTEE CAREFULLY REVIEWED
5	EACH ELEMENT OF THE PROPOSAL AGAINST EACH OF THE CRITERIA
6	IN ORDER TO DETERMINE A FINAL SCORE. AFTER EVALUATING
7	THE PROPOSALS, WE WERE ABLE TO NARROW THE FIELD TO THREE
8	FINALISTS. HOWEVER, IN ORDER TO CHOOSE A WINNING BIDDER,
9	THE EVALUATION COMMITTEE FELT THAT WE NEEDED TO SEE THESE
10	SYSTEMS IN ACTION AND ALSO NEEDED TO MEET WITH THE PEOPLE
11	WHO WOULD BE IMPLEMENTING THE SYSTEM.
12	SO DURING JULY AND INTO EARLY AUGUST, ALL THREE
13	FINALISTS CAME AND GAVE HALF-DAY DEMONSTRATIONS OF THEIR
14	SYSTEMS. WE REQUIRED THAT THE PEOPLE GIVING THE
15	DEMONSTRATIONS BE MEMBERS OF THE TEAM WHO WOULD BE
16	IMPLEMENTING THE SYSTEM. THIS ALLOWED EVALUATION
17	COMMITTEE MEMBERS TO ASK QUESTIONS OF EACH BIDDER AND TO
18	MEET SOME OF THEIR TEAM.
19	AFTER THE DEMONSTRATIONS, THE EVALUATION
20	COMMITTEE IDENTIFIED A FEW REMAINING AMBIGUITIES IN THE
21	PROPOSALS, SO WE PUT TOGETHER A DOCUMENT ASKING FOR
22	CLARIFICATION OF THESE QUESTIONS. THE RESPONSES WERE TO
23	BE IN THE FORM OF AN ADDENDUM TO THEIR PROPOSAL. AFTER
24	RECEIVING ALL THREE RESPONSES, THE EVALUATION COMMITTEE
25	MET AGAIN TO DISCUSS THE NEW INFORMATION, AND THIS TIME

1	WE WERE ABLE TO MAKE A UNANIMOUS RECOMMENDATION.
2	THE SYSTEM WE RECOMMEND IS A SYSTEM CALLED
3	GRANTIUM. IT'S FROM A COMPANY ALSO CALLED GRANTIUM,
4	WHICH IS HEADQUARTERED IN CANADA, IS EXCLUSIVELY IN THE
5	BUSINESS OF SELLING GRANTS MANAGEMENT SOFTWARE, AND THEY
6	HAVE BEEN IN BUSINESS FOR TEN YEARS. THEY HAVE CUSTOMERS
7	IN CANADA, AUSTRALIA, AND THE U.S., AND THEIR CUSTOMERS
8	INCLUDE THE ALBERTA ADVANCED EDUCATION AND TECHNOLOGY,
9	THE INNOVATION INSTITUTE OF ONTARIO, THE U.S. AGENCY FOR
10	INTERNATIONAL DEVELOPMENT, AND THE DEPARTMENT OF STATE.
11	AND OVER THE COURSE OF OUR EVALUATION, WE
12	CONTACTED EACH OF THESE CUSTOMERS, AND THEY WERE ALL
13	EXTREMELY POSITIVE ABOUT THEIR EXPERIENCES WITH GRANTIUM,
14	BOTH AS A COMPANY AND WITH THE SOFTWARE.
15	SO THE CONTRACT THAT THEY ARE PROPOSING
16	INCLUDES A SIX-MONTH IMPLEMENTATION SCHEDULE AT AN
17	IMPLEMENTATION COST OF APPROXIMATELY \$550,000. IN
18	ADDITION, THERE'S AN ANNUAL MAINTENANCE FEE OF
19	APPROXIMATELY \$49,000, WHICH INCLUDES ALL FIXES,
20	UPGRADES, AND NEW VERSIONS OF THE SYSTEM. WE ANTICIPATE
21	SIGNING A THREE-YEAR IMPLEMENTATION AND SUPPORT CONTRACT
22	WITH THE POTENTIAL FOR ANNUAL EXTENSIONS. THE TOTAL FOR
23	THIS INITIAL CONTRACT WOULD, THEREFORE, BE \$702,000.
24	THERE WOULD ALSO BE SOME ADDITIONAL EXPENSES, BOTH
25	INITIAL AND ONGOING, INVOLVED WITH HOSTING THE SYSTEM.

1	THESE WOULD INCLUDE APPROXIMATELY \$10,000 FOR HARDWARE
2	AND APPROXIMATELY \$15,000 A YEAR IN HOSTING COSTS. SO
3	THE TOTAL OUTLAY FOR THREE YEARS WOULD, THEREFORE, BE
4	APPROXIMATELY \$757.000. AND GOING FORWARD EACH
5	ADDITIONAL YEAR WOULD BE ROUGHLY \$64,000.
6	SO THE CORE STRENGTHS OF THE PROPOSAL INCLUDE
7	THE SOFTWARE ITSELF, WHICH IS BOTH POWERFUL AND HIGHLY
8	CONFIGURABLE AND ALLOWS CIRM TO ADAPT TO CHANGING
9	REQUIREMENTS AND DIRECTIONS WITHOUT A MAJOR
10	REIMPLEMENTATION EFFORT. IT'S AN EXTENSIBLE SYSTEM,
11	WHICH ALLOWS OTHER SOFTWARE TO BE INTEGRATED WITH IT. IF
12	THERE'S FUNCTIONALITY THAT GRANTIUM DOESN'T SUPPLY, WE
13	CAN CREATE AND INTEGRATE OUR OWN SOLUTIONS OR PURCHASE
14	THEM FROM A THIRD PARTY.
15	SO, FOR EXAMPLE, REPORTING. REPORTING IS
16	CLEARLY AN IMPORTANT PIECE OF THE SYSTEM, AND GRANTIUM
17	DECIDED NOT TO REINVENT THE WHEEL, BUT, RATHER, TO
18	INTEGRATE A SYSTEM CALLED CRYSTAL REPORTS. CRYSTAL
19	REPORTS IS THE GOLD STANDARD IN REPORTING AND WILL ALLOW
20	US TO CREATE VIRTUALLY ANY REPORT THAT WE MIGHT REQUIRE.
21	THE STRENGTHS OF THE COMPANY AND TEAM
22	THEMSELVES INCLUDE PROJECT MANAGEMENT. SEVERAL GRANTIUM
23	EMPLOYEES ARE THOUGHT LEADERS IN THE FIELD OF PROJECT
24	MANAGEMENT AND HAVE BROUGHT THEIR SKILLS TO BEAR IN

CREATING A STANDARDIZED DEVELOPMENT METHODOLOGY. IN

25

1	TALKING TO THE CUSTOMERS I MENTIONED EARLIER, ONE OF THE
2	THINGS THEY KEPT REFERRING TO WAS THE CONFIDENCE THAT
3	THEY HAD IN GRANTIUM'S ABILITY TO MEET ITS DEADLINES AND
4	TO GENERALLY DO WHAT THEY SAY THEY WILL DO. AND A LOT OF
5	THAT WAS BASED ON THEIR CONFIDENCE IN THIS METHODOLOGY.
6	ANOTHER STRENGTH IS IN TRAINING. GRANTIUM'S
7	METHODOLOGY STRESSES CONTINUOUS KNOWLEDGE TRANSFER BOTH
8	FROM CIRM TO GRANTIUM, TEACHING THEM ABOUT OUR PROCESSES,
9	AND FROM GRANTIUM BACK TO CIRM, TRAINING CIRM STAFF HOW
10	TO USE THE SYSTEM IN A WAY THAT IS TAILORED DIRECTLY TO
11	OUR NEEDS AND REQUIREMENTS.
12	WE'RE CONFIDENT THAT PARTNERING WITH GRANTIUM
13	IS THE RIGHT NEXT STEP FOR CIRM TO TAKE IN GETTING A
14	COMPREHENSIVE ELECTRONIC GRANTS MANAGEMENT SYSTEM UP AND
15	RUNNING BOTH QUICKLY AND EFFICIENTLY, AND WE'RE ASKING
16	THE ICOC TO APPROVE THIS RECOMMENDATION AFTER WHICH WE'LL
17	QUICKLY BEGIN IMPLEMENTATION. THANK YOU AND I'M HAPPY TO
18	TAKE ANY QUESTIONS.
19	CHAIRMAN KLEIN: QUESTIONS FROM THE BOARD? DR.
20	LEVEY.
21	DR. LEVEY: VERY NICE PRESENTATION. MAYBE I
22	MISSED THIS, BUT DID YOU HAVE A CHANCE MAYBE TO LOOK AT
23	GRANT MANAGEMENT SYSTEMS FOR SOME COMPARABLE GRANTING
24	ORGANIZATIONS SUCH AS THE AMERICAN HEART OR THE AMERICAN
25	CANCER SOCIETY OR THE AMERICAN DIABETES?

1	MR. DORRINGTON: OVER THE COURSE OF THIS
2	EVALUATION, WE TALKED TO A NUMBER OF FOLKS, THE HOWARD
3	HUGHES MEDICAL INSTITUTE, THE
4	DR. LEVEY: NIH.
5	MR. DORRINGTON: THE PACKARD FOUNDATION, UC
6	OFFICE OF THE PRESIDENT, A NUMBER OF DIFFERENT PEOPLE TO
7	SEE WHAT DIFFERENT PEOPLE ARE USING IN THE FIELD. A
8	NUMBER OF THESE ORGANIZATIONS HAVE BEEN AROUND FOR A LONG
9	TIME. THEY'VE OFTEN MADE THEIR CHOICE MANY YEARS AGO
10	BASED ON WHAT WAS AVAILABLE THEN. AND SO TO A CERTAIN
11	EXTENT, SINCE WE HAVE THE ADVANTAGE OF BEING NEW, WE HAVE
12	THE ADVANTAGE ALSO OF SEEING WHAT IS CURRENT. AND WE DID
13	SEE A FEW PEOPLE WHO ARE CHOOSING SYSTEMS LIKE GRANTIUM,
14	OR, GIVEN THE CUSTOMERS THAT I MENTIONED, PEOPLE WHO DID
15	CHOOSE GRANTIUM.
16	BUT THE MOST THE BIGGEST SYSTEM OUT THERE IS
17	A SYSTEM CALLED GIFTS FROM MICROEDGE, WHICH A NUMBER OF
18	PEOPLE ARE USING, BUT IT'S A VERY LIMITED SYSTEM, LIMITED
19	IN ITS FUNCTIONALITY, AND REALLY WOULD NOT BE ABLE TO
20	MEET OUR REQUIREMENTS.
21	DR. LEVEY: IN FOLLOW-UP, DID YOU HAVE A CHANCE
22	TO TEST THE SYSTEM, TO PUT IT THROUGH SOME SORT OF PACE
23	TO SEE HOW IT WORKED?
24	MR. DORRINGTON: WELL, WE DID SEE THE
25	DEMONSTRATION OF THE SYSTEM; BUT BECAUSE THE WAY THESE

1	SYSTEMS	WORK.	THERE'S	NOT	S0 I	MUCH	OFF-THE-SHELF	SOFTWARE

- 2 AS A SYSTEM THAT IS EXTENSIVELY CUSTOMIZED TO OUR NEEDS,
- 3 SO IT WOULD BE VERY DIFFICULT TO GET A REAL SENSE OF HOW
- 4 THE SYSTEM WOULD WORK IN OUR SITUATION UNTIL YOU GO
- 5 THROUGH IT, BUT WE DID ACTUALLY SEE THE SYSTEM WORKING.
- 6 CHAIRMAN KLEIN: OKAY. DR. PIZZO. AND WHILE
- 7 DR. PIZZO IS GETTING A MICROPHONE, ED, COULD YOU EXPLAIN
- 8 IN TERMS OF WHICH MEMBERS OF THE SCIENCE TEAM WORKED WITH
- 9 YOU TO MAKE CERTAIN THAT THE NEEDS OF THE SCIENCE TEAM
- 10 WERE BEING MET?
- MR. DORRINGTON: SURE. YEAH. THE MEMBERS OF
- 12 THE EVALUATION COMMITTEE WERE ARLENE CHIU, AMY LEWIS, GIL
- 13 SAMBRANO, KUMAR HARI, AND THEN FROM I.T. DENNIS BUTLER,
- 14 AND FROM ADMINISTRATION LORI HOFFMAN AND MYSELF, AND THEN
- 15 THE TWO EXTERNAL FOLKS THAT WE HAD WERE CHRIS MENCEL FROM
- 16 THE MOORE FOUNDATION AND MELANIE CAVANAGH LYNCH FROM THE
- 17 UC OFFICE OF THE PRESIDENT BREAST CANCER RESEARCH
- 18 PROGRAM.
- 19 CHAIRMAN KLEIN: DR. PIZZO.
- DR. PIZZO: I AGREE THIS WAS A VERY NICE
- 21 PRESENTATION. THANK YOU.
- 22 CHAIRMAN KLEIN: IS HIS MIC ON PLEASE?
- DR. PIZZO: SO VERY HELPFUL PRESENTATION, BUT I
- 24 WONDER IF YOU COULD EVEN AT SOME HIGH LEVEL -- YOU MAY
- 25 NOT HAVE THE ACTUAL DATA TO SHARE WITH US -- HOW YOU

1	ACTUALLY	MADE	THE	SELECTION	TN	COMPARISON	TO	THE	OTHER

- 2 TWO FINALISTS? YOU PRESENTED THE DATA WITH REGARD TO THE
- 3 FINALISTS, BUT I DON'T KNOW WHAT THE DIFFERENTIATING
- 4 ELEMENTS WERE THAT LED YOU TO THAT.
- 5 MR. DORRINGTON: WELL, THERE ARE BASICALLY TWO
- 6 PIECES. ONE WAS MORE QUANTITATIVE, WHICH IS THE SCORES
- 7 ON THOSE FIVE CRITERIA, IN WHICH CASE GRANTIUM DID SCORE
- 8 THE HIGHEST IN EVERY CRITERIA. AND THEN THE SECOND
- 9 FACTOR USED WAS A MORE SUBJECTIVE FACTOR WHICH WAS BASED
- 10 ON RESULTS AFTER THOSE DEMONSTRATIONS. AND IT'S BASED ON
- 11 THINGS LIKE A FEEL OF WHO WE THOUGHT MIGHT BE BEST SUITED
- 12 TO WORK WITH US, WHO LOOKS LIKE THEY WOULD BE ABLE TO
- ACTUALLY GET THE JOB DONE, AND THEN IT WAS ALSO BASED ON
- 14 THE CONVERSATIONS WE HAD HAD WITH THE VARIOUS REFERENCES.
- 15 DR. PIZZO: SO I ASSUME THAT THE COST WAS
- 16 FACTORED INTO THE SCORING SYSTEM THAT YOU HAD AS WELL.
- 17 MR. DORRINGTON: YES.
- DR. PRICE: QUESTION IS WHETHER THE COST YOU
- 19 OUOTE US INCLUDES CUSTOMIZATION?
- 20 MR. DORRINGTON: YES. THIS IS A COMPLETE COST.
- 21 CHAIRMAN KLEIN: NOW, TO BE SPECIFIC, IT'S MY
- 22 UNDERSTANDING IF A YEAR FROM NOW WE HAVE A VERY --
- 23 ANOTHER CUSTOMIZED APPROACH FOR A NEW PROGRAM NOT
- 24 INITIALLY CONTEMPLATED, THERE COULD BE AN ADDITIONAL
- 25 CHARGE AT THAT TIME?

1	MR. DORRINGTON: RIGHT. AND WE DO ANTICIPATE
2	HAVING A LONG-TERM RELATIONSHIP WITH THE COMPANY, BUT ONE
3	OF THE OTHER ADVANTAGES OF THE SYSTEM IN TERMS OF ITS
4	EXTENSIBILITY, AS I SAID, IS THAT, DEPENDING ON WHAT
5	THOSE THINGS ARE, WE MAY BE ABLE TO DO THAT IN-HOUSE OR
6	WE MAY CONTRACT WITH THEM.
7	CHAIRMAN KLEIN: MICHAEL GOLDBERG.
8	MR. GOLDBERG: IN TERMS OF YOUR ANALYSIS, DID
9	YOU LOOK AT THE FINANCIAL VIABILITY OF THE FIRM?
10	MR. DORRINGTON: TO THE EXTENT POSSIBLE. ONE
11	OF THE INTERESTING ISSUES IS THAT ALL OF THE THREE
12	FINALISTS ARE PRIVATE COMPANIES AND ARE NOT VERY WILLING
13	TO SHARE FINANCIAL DATA.
14	MR. GOLDBERG: SO IN MY EXPERIENCE, THE BEST
15	WAY TO PROTECT AGAINST THAT WOULD BE MAKE SURE THAT YOU
16	OWN ACCESS TO THE CODE IN THE EVENT OF DEFAULT OR
17	BANKRUPTCY.
18	MR. DORRINGTON: RIGHT. AND ONE OF THE FACTORS
19	THAT WAS IN THE RFP WAS SPECIFICALLY THAT, TO HAVE CODE
20	IN ESCROW SO THAT SHOULD THEY GO UNDER, WE WOULD HAVE
21	ACCESS TO THAT CODE. AND ALSO WE HAD TRIED TO ADDRESS
22	THAT WITH THE PAY-FOR-PERFORMANCE ISSUE. SO THAT WE'RE
23	NOT PAYING UNLESS WE GET SOMETHING FOR IT.
24	MR. GOLDBERG: THANK YOU.
25	CHAIRMAN KLEIN: DAVID SERRANO-SEWELL.

1 MR. SERRANO-SEW	ELL: I JUST ASSUME THAT LEGAL
-------------------	-------------------------------

- 2 IS GOING TO LOOK AT THE CONTRACT BEFORE IT'S EXECUTED.
- 3 MR. DORRINGTON: OH, SURE. OF COURSE.
- 4 MR. SERRANO-SEWELL: L.A. UNIFIED SCHOOL
- 5 DISTRICT, THEY'RE JUST TRYING TO UNTANGLE A \$40 MILLION
- 6 PLUS CONTRACT THAT THEY ENTERED INTO TO UPGRADE THEIR
- 7 PAYROLL COMPUTER SYSTEM, AND THEY'VE HAD TO HIRE
- 8 ADDITIONAL CONSULTANTS TO THE TUNE OF LIKE ANOTHER 10
- 9 MILLION. SO I DON'T THINK WE'RE GOING TO FIND OURSELVES
- 10 IN THAT KIND OF SITUATION, BUT IT DOES --
- MR. DORRINGTON: YEAH. WE WILL DEFINITELY.
- MR. SERRANO-SEWELL: -- GIVE ME SOME COMFORT TO
- 13 KNOW THAT.
- MR. DORRINGTON: OH, YEAH.
- MR. SERRANO-SEWELL: MAYBE WE'LL TAKE A LOOK AT
- 16 THIS AS WELL.
- 17 CHAIRMAN KLEIN: AND IN THE PAYMENT UNDER THE
- 18 CONTRACT, IT'S CONTEMPLATED THAT THERE WILL BE MILESTONES
- 19 IN THE PAYMENT.
- 20 MR. DORRINGTON: YES. THAT IS PART OF THE PAY
- 21 FOR PERFORMANCE IS THAT THERE ARE SET MILESTONES. WHEN
- THEY REACH THOSE MILESTONES IS WHEN WE RELEASE PAYMENT,
- 23 ETC.
- 24 CHAIRMAN KLEIN: AND, DR. MURPHY, DID YOU HAVE
- 25 A COMMENT?

- DR. MURPHY: NO. ONE THING THAT I THINK MADE A
- 2 VERY GOD JOB OF THIS AND I FULLY SUPPORT THE
- 3 RECOMMENDATION.
- 4 CHAIRMAN KLEIN: IS THERE A MOTION TO SUPPORT
- 5 THIS?
- 6 DR. PIZZO: SO MOVED.
- 7 DR. WRIGHT: SECOND.
- 8 CHAIRMAN KLEIN: I THINK IT'S DR. PIZZO AND
- 9 DR. WRIGHT. AND IS THERE ADDITIONAL COMMENTS FROM THE
- 10 BOARD? IS THERE ADDITIONAL COMMENTS FROM THE PUBLIC?
- 11 JOHN SIMPSON.
- 12 MR. SIMPSON: JOHN SIMPSON FROM THE FOUNDATION
- 13 FOR TAXPAYER AND CONSUMER RIGHTS. IT LOOKS TO ME LIKE
- 14 YOU DEFINITELY GOT IT RIGHT THIS TIME. I REFLECT ON THE
- ARLINGTON GROUP THAT WENT BELLY UP, AND IT SEEMED TO ME
- 16 THAT THAT MIGHT HAVE BEEN CAUSED BECAUSE THE PROCESS OF
- 17 VETTING ALL THE POTENTIAL APPLICANTS WAS NOT THOROUGH
- 18 ENOUGH. AND I THINK I SUGGESTED THAT AT THE TIME, IN
- 19 RETROSPECT. BUT THIS LOOKS GOOD, SO I THINK IT'S A GOOD
- 20 THING AND COMMEND YOU FOR IT.
- 21 CHAIRMAN KLEIN: AND MY UNDERSTANDING IS THAT
- 22 WITH THE PRIOR GROUP, BECAUSE OF MILESTONES AND CONTROLS,
- 23 WE WERE ABLE TO KEEP THE EXPOSURE VERY LOW. IS THAT A
- 24 CORRECT STATEMENT?
- MR. DORRINGTON: YEAH. I BELIEVE THE SUM TOTAL

1	TC \$56	000	TUAT 14	E DATE	$\cap \vdash \land$	ROUGHLY	CTMTI AD	CTZE
	T2 2)() . UUU	IDAI W	VE PAID	UF A	KUUGHLI	STIMTLAK	SIZE

- 2 CONTRACT.
- 3 CHAIRMAN KLEIN: WE APPRECIATE CONTROLS AND
- 4 SCRUTINY OF THAT KIND. THANK YOU VERY MUCH.
- 5 SO I'D LIKE TO CALL FOR THE QUESTION. ALL IN
- 6 FAVOR. OPPOSED? MOTION PASSES. THANK YOU VERY MUCH FOR
- 7 THE TREMENDOUS JOB OF THE ENTIRE TEAM.
- 8 WE'D LIKE TO GO TO ITEM NO. 9 WHILE PEOPLE ARE
- 9 HUNGRY AND THEIR ATTENTION IS PEAKED.
- 10 DR. CHIU: I WILL BE BRIEF, MR. CHAIRMAN. MR.
- 11 CHAIRMAN, I ASK THE BOARD TO CONSIDER A NEW RFA FOR
- 12 CONCEPT APPROVAL. THIS IS AGENDA ITEM NO. 9 IN YOUR
- 13 BINDERS, A PROPOSAL FOR CIRM TO FUND THE DERIVATION OF
- 14 NEW PLURIPOTENT HUMAN STEM CELL LINES. NOW, AS YOU ALL
- 15 KNOW, CURRENT FEDERAL POLICY ONLY ALLOWS THE USE OF A FEW
- 16 LINES OF HUMAN EMBRYONIC STEM CELLS FOR RESEARCH, AND NO
- 17 FUNDS ARE PROVIDED FOR THE DERIVATION OF NEW AND BETTER
- 18 LINES.
- 19 ALL THE PRESIDENTIAL LINES ARE DERIVED WITH OLD
- 20 METHODS USED BEFORE 2001; FOR EXAMPLE, METHODS THAT
- 21 EXPOSE CELLS TO ANIMAL PRODUCTS. WE NEED TO ALLOW
- 22 RESEARCHERS TO TEST AND DEVELOP NEW AND BETTER METHODS
- 23 THAT WILL PRODUCE THE CELL LINES MOST USEFUL FOR CLINICAL
- 24 USE.
- 25 RECENT REPORTS ALSO INDICATE THAT ALL HUMAN

1	EMBRYONIC	STEM	CELL	LINES	ΙN	EXISTENCE	ARE	NOT	ALL	ALIKE.

- 2 EVEN UNDER THE SAME GROWTH CONDITIONS, SOME LINES SHOW A
- 3 PREFERENCE FOR PRODUCING FOREBRAIN NEURONS WHILE OTHERS
- 4 DO NOT. IF WE WANT TO GET THE BEST CELL SOURCE FOR
- 5 DIFFERENT TREATMENTS, WE NEED TO FUND THE DERIVATION OF
- 6 MANY MORE CELL LINES.
- 7 AND THERE ARE THREE COMPELLING REASONS THAT I
- 8 CAN THINK OF FOR FUNDING THE GENERATION OF NEW CELL
- 9 LINES. THE FIRST SHOWN ON THE SLIDE IS A NEED, THE NEED
- 10 FOR NEW LINES SO THAT WE CAN HAVE GREATER GENETIC
- 11 DIVERSITY, SO THAT WE CAN GENERATE DISEASE-SPECIFIC LINES
- 12 FOR CELLULAR MODELS OF DISEASE AND FOR DRUG DISCOVERY, SO
- 13 THAT WE CAN GET CLINICAL GRADE LINES THAT CAN BE USED FOR
- 14 THERAPIES, AND SO THAT WE CAN GET OPTIMAL LINES FOR
- 15 SPECIFIC DESIRED PHENOTYPES OR CELL TYPES IN NEED.
- 16 THE SECOND REASON IS THAT NEW METHODS ARE
- 17 CONSTANTLY BEING DEVELOPED FOR DERIVING HUMAN EMBRYONIC
- 18 STEM CELLS, NEW METHODS WITHOUT EXPOSURE TO ANIMAL
- 19 PRODUCTS, NEW DEFINED GROWTH CONDITIONS, THAT IS MEDIA
- 20 FACTORS, SUBSTRATES, FETAL LAYERS, ETC., NEW METHODS
- 21 FOLLOWING GOOD MANUFACTURING PRACTICE. IN ADDITION,
- 22 DISEASE-SPECIFIC CELL LINES COULD ALSO BE GENERATED FROM
- 23 EMBRYOS IDENTIFIED DURING PREIMPLANTATION GENETIC
- 24 DIAGNOSIS OF PGD.
- 25 IN ADDITION, THERE HAVE BEEN RECENT REPORTS OF

- 1 DERIVING HUMAN EMBRYONIC STEM CELLS FROM SINGLE
- 2 BLASTOMERES. AND LAST, BUT CERTAINLY NOT LEAST, THERE IS
- 3 SCNT. A RECENT REPORT OUT OF OREGON INDICATES THAT THIS
- 4 HAS BEEN SUCCESSFULLY ACCOMPLISHED IN NONHUMAN PRIMATES,
- 5 AND THIS IS INDEED ENCOURAGING NEWS, BUT THERE ARE NO
- 6 REPORTS OF THESE BEING ACCOMPLISHED IN HUMANS WITH HUMAN
- 7 CELLS, SO THERE IS A GREAT NEED TO ATTEMPT THIS NEW
- 8 TECHNOLOGY.
- 9 NOVEL SOURCES AND PROTOCOLS FOR GENERATING
- 10 PLURIPOTENT CELL LINES, WE KNOW THAT RECENT PAPERS FROM
- 11 DRS. YAMANAKA, JAENISH, AND OTHERS DEMONSTRATE AND VERIFY
- 12 THAT IT IS POSSIBLE TO REPROGRAM MATURE ADULT SOMATIC
- 13 CELLS TO DEDIFFERENTIATE THEM, IF YOU WILL, AND GENERATE
- 14 FULLY PLURIPOTENT STEM CELLS.
- THESE STUDIES HAVE ONLY BEEN DONE IN MICE, AND
- 16 THE TIME IS RIPE TO SEE IF WE CAN DO THE SAME WITH HUMAN
- 17 CELLS.
- 18 THE SECOND POINT, THERE ARE CYBRIDS WHICH ARE
- 19 CREATED BY THE FUSION OF HUMAN EMBRYONIC STEM CELLS WITH
- 20 ADULT CELLS. THAT'S ANOTHER EXCITING POSSIBILITY, BUT
- 21 HAVE NOT BEEN SUCCESSFULLY ACHIEVED AS YET. AND FINALLY,
- 22 OTHER INNOVATIVE METHODS ARE PROBABLY BEING THOUGHT OF
- 23 AND DEVELOPED AS WE SPEAK.
- SO WITH THIS INITIATIVE, WE ASK TO SUPPORT M.D.
- 25 AND PH.D. SCIENTISTS AND THEIR EQUIVALENTS TO CONDUCT

1	RESEARCH	TOWARD	THIS	GOAL AT	Т	INSTITUTIONS	ΙN	CALIFORNIA

- 2 AND THIS IS THE ONLY CONDITION OF ELIGIBILITY. WE WANT
- 3 TO SUPPORT THE FULL SPECTRUM OF HUMAN PLURIPOTENT STEM
- 4 CELL TYPES AND EXPERIMENTAL APPROACHES, AND WE SUGGEST
- 5 TWO TIMES OF AWARDS. THE FIRST TYPE IS FOR GENERATING
- 6 HUMAN EMBRYONIC STEM CELL LINES GENERATED FROM CELLS THAT
- 7 ARE DERIVED FROM EARLY PREIMPLANTATION EMBRYOS OF LESS
- 8 THAN 12 DAYS, AS PER OUR MEDICAL AND ETHICAL STANDARDS.
- 9 THE SECOND KIND OF AWARD IS TO GENERATE NEW HUMAN
- 10 PLURIPOTENT STEM CELLS STARTING WITH OTHER SOURCES. SO
- 11 WE'RE REALLY OPENING UP THE FIELD IN THIS APPROACH.
- 12 EACH APPLICANT INSTITUTION MAY SUBMIT UP TO
- 13 FOUR APPLICATIONS, TWO OF EACH TYPE. WE'D LIKE TO ASK
- 14 YOU TO FUND EIGHT GRANTS OF EACH TYPE. EACH WILL BE A
- 15 THREE-YEAR GRANT WITH PROJECT COSTS OF UP TO \$300,000 PER
- 16 YEAR. THE TOTAL COST OF THIS PROGRAM WE ESTIMATE TO BE
- 17 APPROXIMATELY \$25 MILLION, AND OUR CURRENT DRAFT
- 18 TIMETABLE IS RFA RELEASE IN THE FALL OF THIS YEAR, REVIEW
- 19 IN THE WINTER OF '07-'08, AND FOR YOUR APPROVAL FOR
- 20 FUNDING IN THE SPRING OF '08.
- 21 AND I WANT TO POINT OUT THAT WE'VE JUST
- 22 RECRUITED A NEW SCIENCE OFFICER, DR. UTA GRIESHAMMER,
- 23 FROM DR. GAIL MARTIN'S LAB IN UCSF, AND SHE WILL BE
- 24 TAKING THE LEAD ON THIS INITIATIVE SHOULD YOU APPROVE IT.
- AND, MR. CHAIRMAN, I ASK FOR THE BOARD'S

- 1 CONSIDERATION OF THIS PROPOSAL.
- CHAIRMAN KLEIN: THANK YOU VERY MUCH, DR. CHIU.
- 3 I THINK DUANE ROTH, AND THEN I'M GOING TO GO TO THE
- 4 RIGHT.
- 5 MR. ROTH: DR. CHIU, YOU SAID IN TERMS OF
- 6 ELIGIBILITY, THAT IT WAS M.D., PH.D., OR EQUIVALENT IN AN
- 7 INSTITUTION. WILL THIS BE OPEN TO COMPANIES?
- 8 DR. CHIU: THAT'S A VERY GOOD QUESTION. IF THE
- 9 FOR-PROFIT GRANT ADMINISTRATION POLICY IS READY, WE WOULD
- 10 LIKE IT TO BE OPEN TO FOR-PROFIT ENTITIES WHEN WE LAUNCH
- 11 IT. BUT IT WAITS TO BE SEEN, AND IT'S UP TO THE BOARD TO
- 12 SEE HOW LONG WE SHOULD HOLD THIS BACK. THE OTHER
- 13 POSSIBILITY IS THAT WE RE-RELEASE THIS AGAIN WHEN THE
- 14 FOR-PROFIT GAP IS READY SO THAT COMPANIES TOO COULD
- 15 COMPETE.
- 16 MR. ROTH: YOU KNOW, I AM ANXIOUS TO GET
- 17 SOMETHING OUT THERE THAT COMPANIES CAN START TO SEE THAT
- 18 CIRM IS SERIOUS ABOUT FUNDING THEM. AND I WOULD LIKE TO
- 19 SUGGEST WE FIND A WAY TO ALLOW THEM TO SUBMIT
- 20 APPLICATIONS HERE AND MOVE IN PARALLEL VERY QUICKLY TO
- 21 FINALIZE THE FOR-PROFIT IP POLICY, WHICH IS IN VERY LATE
- 22 STAGE. I CAN'T IMAGINE THERE'S GOING TO BE MATERIAL
- 23 CHANGES TO THAT.
- DR. CHIU: IT'S FOR THAT REASON WE DID NOT PUT
- 25 UP THERE THAT IT WOULD BE RESTRICTED TO ACADEMIC AND NOT

- 1 FOR-PROFIT.
- 2 MR. ROTH: I WAS CONFUSED BY THE WORD
- 3 "INSTITUTIONS."
- 4 DR. CHIU: I SEE. I SHOULD SAY ORGANIZATIONS.
- 5 THANK YOU.
- 6 CHAIRMAN KLEIN: YES. DR. STEWARD AND THEN DR.
- 7 PIZZO.
- 8 DR. STEWARD: CAN YOU SAY A WORD, AND IT'S
- 9 ESPECIALLY IMPORTANT GIVEN THE FACT THAT THIS WOULD
- 10 POTENTIALLY BE OPEN TO PRIVATE COMPANIES AS WELL, HOW
- 11 THESE, LET'S CALL THEM, REAGENTS FALL UNDER THE CURRENT
- 12 CIRM GUIDELINES AS FAR AS MAKING ANYTHING CREATED BY CIRM
- 13 FUNDING AVAILABLE FREELY, AS I RECALL?
- DR. CHIU: YOU MAKE AN EXCELLENT POINT. YOU
- 15 KNOW WE HAVE THE IP POLICY WHICH REQUIRES SHARING OF
- 16 REAGENTS UPON PUBLICATION, AND THIS WILL HOLD. AND THE
- 17 KEY IS UPON PUBLICATION.
- 18 CHAIRMAN KLEIN: DR. PIZZO.
- DR. PIZZO: I THINK MY QUESTION IS A BIT IN THE
- 20 SAME CONTEXT AS DR. STEWARD'S. IT HAS A HYPOTHETICAL
- 21 ASSOCIATED WITH IT, AND I WOULD ASK THAT IT HAVE AN
- 22 INTERNAL REVIEW. I DON'T EXPECT THAT YOU CAN COMMENT ON
- 23 THIS RIGHT NOW. BUT THE SCENARIO IS WHAT IF THERE'S AN
- 24 INVESTIGATOR WHO COMES TO CALIFORNIA FOR PART OF HER OR
- 25 HIS WORK WHO HAS AN APPOINTMENT IN ANOTHER STATE, LET'S

1	SAY	WTSCONSTN	AS	Α	HYPOTHETICAL,	WHO	DEVELOPS	NFW	STFM

- 2 CELL LINES. AND BECAUSE OF AN ACADEMIC AFFILIATION SEEKS
- 3 TO HAVE THOSE SAID LINES BECOME PART OF, FOR EXAMPLE, THE
- 4 WISCONSIN POLICY. SO YOU DON'T NEED TO RESPOND TO IT
- 5 NOW, BUT I HOPE THAT WE CAN LOOK AT THIS BECAUSE THEIR
- 6 HYPOTHETICAL HAS SOME POTENTIAL REALITIES.
- 7 DR. CHIU: I THANK YOU FOR THAT COMMENT.
- 8 ACTUALLY WE HAVE THOUGHT ONLY HALFWAY THROUGH THAT
- 9 PARTICULAR PROBLEM. AND THAT IS, WE VERY SPECIFICALLY
- 10 WANTED TO HAVE IT OPEN TO ANYONE COMING TO DO THE
- 11 RESEARCH IN CALIFORNIA, AS WE KNOW THAT CALIFORNIA HAS
- 12 BECOME A MECCA FOR ATTRACTING A LOT OF VERY ABLE PEOPLE
- 13 WITH NOVEL IDEAS. HOWEVER, IN TERMS OF THE IP, WE WOULD
- 14 SEEK THE ADVICE AND HELP OF OUR LEGAL COUNSEL.
- 15 DR. PIZZO: BECAUSE AS WE DISCUSSED EARLIER
- 16 THIS MORNING, WE WOULD WELCOME JOINT APPOINTMENTS OR
- 17 OTHER APPOINTMENTS THAT WOULD BRING NEW TALENT TO
- 18 CALIFORNIA, RECOGNIZING THAT THE INDIVIDUAL MAY BE AT
- 19 ANOTHER PLACE, BUT I THINK WE JUST HAVE TO UNDERSTAND --
- 20 THE LEGAL FOLKS WILL NEED TO UNDERSTAND WHAT THAT MEANS
- 21 IN TERMS OF INSTITUTIONAL CONTROLS OVER IP AS WELL.
- DR. CHIU: SINCE THESE AWARDS WILL BE AWARDED
- 23 TO INSTITUTIONS IN CALIFORNIA, I HOPE THAT THAT WOULD
- 24 TAKE CARE OF IT --
- DR. PIZZO: IT MAY OBVIATE IT.

1	DR. CHIU: NO MATTER WHERE THE INVESTIGATOR
2	ACTUALLY COMES FROM TO DO THE WORK.
3	CHAIRMAN KLEIN: SO, DR. CHIU, FOR INSTITUTIONS
4	AND ORGANIZATIONS, YOU'RE SUGGESTING THAT, BECAUSE IT'S A
5	CALIFORNIA AWARD, THE PARTICIPANTS WOULD HAVE TO AGREE TO
6	OUR GAP AND OUR IP POLICY?
7	DR. CHIU: ABSOLUTELY. AND ALSO THE
8	INSTITUTION WHERE THE RESEARCH WOULD BE CONDUCTED, THE
9	ORGANIZATION WOULD BE IN CALIFORNIA.
10	CHAIRMAN KLEIN: THAT'S RIGHT. AND DR. MEYER.
11	DR. MEYER: VERY SPECIFIC QUESTION. YOU KIND
12	OF PRESENTED IT AS THIS IS A WAY OF GENERATING NEW CELL
13	LINES, WHICH I'M IMAGINING PROBABLY PRINCIPAL USE WOULD
14	BE IN REGENERATIVE MEDICINE. I DON'T KNOW WHETHER THIS
15	WILL BE SPECIFICALLY ADDRESSED IN THE RFA, BUT IT MIGHT
16	BE A GOOD IDEA WHEN IT COMES OUT BECAUSE WE HEARD OF
17	HUNTINGTON'S DISEASE THIS MORNING. THERE ARE A LOT OF
18	OPPORTUNITIES NOW WITH IVF CLINICS AND DISCARDED EMBRYOS
19	WITH GENETIC DISEASES TO ACTUALLY CREATE NEW CELL LINES,
20	FOR EXAMPLE, WITH HUNTINGTON'S DISEASE THAT WOULD BE
21	DISEASE MODELS AS OPPOSED TO CURING SOMEONE USING THOSE
22	CELLS.
23	IS THIS WITHIN THE SCOPE OF THIS RFA?
24	DR. CHIU: ABSOLUTELY. ABSOLUTELY.
25	CHAIRMAN KLEIN: OKAY. ADDITIONAL BOARD

1	DISCUSSION?	IS	THERE	Α	MOTION?	
т	DISCOSSION:	12	IHEKE	А	MO I TON !	

- DR. PIZZO: SO MOVED.
- 3 MR. ROTH: SECOND.
- 4 CHAIRMAN KLEIN: MOVED BY DR. PIZZO, SECOND BY
- 5 DUANE ROTH. ADDITIONAL PUBLIC DISCUSSION? SEEING NO
- 6 PUBLIC DISCUSSION, ALL IN FAVOR. OPPOSED? LET IT BE
- 7 SHOWN IT PASSED UNANIMOUSLY.
- 8 I THINK WE HAVE A BREAK FOR LUNCH AT THIS
- 9 POINT. LET ME ASK THIS QUESTION. IS THERE ANYONE WHO IS
- 10 LEAVING BEFORE WE RECONVENE? WE HAVE ONE MORE ITEM FOR A
- 11 QUORUM.
- MS. KING: WE COULD DO IT NOW, OR DO YOU HAVE
- 13 TO LEAVE.
- 14 CHAIRMAN KLEIN: WELL, WE DON'T EXPECT A
- 15 SIGNIFICANT EXECUTIVE SESSION, WHICH WILL BE CONCURRENT
- 16 WITH LUNCH. HOPEFULLY IT'S A QUICK ITEM.
- 17 MS. LANSING: WHY DON'T WE DO 45 MINUTES?
- 18 CHAIRMAN KLEIN: LET'S BE BACK IN 45 MINUTES.
- 19 MR. HARRISON, COULD YOU READ THE LANGUAGE THAT WOULD
- 20 ENTITLE US TO AN EXECUTIVE SESSION DURING LUNCH?
- MR. HARRISON: YES. GOING INTO EXECUTIVE
- 22 SESSION TO DISCUSS --
- 23 CHAIRMAN KLEIN: LET'S DO THIS VERY QUICKLY.
- 24 THE ITEM IS, WE THINK, FAIRLY ADMINISTRATIVE. IT'S JUST
- 25 TO CREATE A FINANCE COMMITTEE THAT DEALS WITH THE ISSUES

Т	OF TAX EXEMPTION WHERE WE'RE GOING TO GO ON TO OUR NEXT
2	STAGE AND MOVING THESE BONDS FORWARD. IT ALSO CREATES A
3	SUBCOMMITTEE, LIKE THE IP TASK FORCE, IN THIS CASE TO
4	LOOK AT THE FEASIBILITY OF HAVING A LOAN PROGRAM
5	AUTHORIZED BY THE INITIATIVE, BUT YET WE DO NOT HAVE A
6	LOAN PROGRAM AS ONE OF THE TOOLS FOR ADVANCING RESEARCH.
7	I HAVE TALKED TO TWO MEMBERS OF OUR COMMITTEE.
8	I'VE TALKED TO MICHAEL GOLDBERG, WHO IS WILLING TO BE THE
9	CHAIR OF THIS COMMITTEE, TO DEAL WITH THE ISSUES IN
10	WASHINGTON WITH THE IRS OPINIONS ON TAX EXEMPTION AND
11	BOND FINANCING ISSUES, AS WELL AS THE CHAIR OF THE AS
12	THE CHAIR OF THE TASK FORCE WITH DUANE ROTH, WHO HAS
13	SUBSTANTIAL EXPOSURE AND EXPERIENCE WITH THE PRIVATE
14	SECTOR IN LOOKING AT THE FEASIBILITY AND VETTING THE
15	POSSIBILITY OF IMPLEMENTING A LOAN PROGRAM.
16	THE COMMITTEE MEMBERSHIP WOULD BE OPEN TO ANY
17	MEMBER OF THE BOARD THAT WISHES TO PARTICIPATE. AND IF
18	THIS MATTER PASSES, IF THEY WOULD SUBMIT THEIR NAMES.
19	JUST TO MANAGE THE TOTAL NUMBER, I WOULD DISCUSS WITH
20	BOTH THE CHAIR OF THE COMMITTEE WHAT POTENTIAL VICE CHAIR
21	WE MIGHT HAVE POTENTIALLY FROM THE PATIENT ADVOCATE
22	SECTOR, BUT ALSO LOOKING AT INDUSTRY VICE CHAIRS OR
23	EXCUSE ME INSTITUTIONAL VICE CHAIRS AND WITH THE CHAIR
24	OF THE TASK FORCE LOOKING AT MEMBERSHIP THAT GIVES US A
25	DIVERSITY REPRESENTING ALL THE CONSTITUENCIES ON THE

- 1 BOARD.
- THIS HOPEFULLY IS AN ADMINISTRATIVE MATTER.
- 3 WOULD ANYONE LIKE TO MAKE A MOTION TO PASS THIS, AND WE
- 4 CAN THEN HAVE DISCUSSION ON IT?
- 5 MR. SERRANO-SEWELL: I SO MOVE.
- 6 CHAIRMAN KLEIN: MOVED BY DAVID SERRANO-SEWELL.
- 7 DR. BRYANT: SECOND.
- 8 CHAIRMAN KLEIN: SECOND BY DR. BRYANT.
- 9 COMMENTS BY THE COMMITTEE? NO COMMENTS BY THE COMMITTEE.
- 10 COMMENTS BY THE AUDIENCE?
- MR. HARRISON: JUST ONE CLARIFICATION. THERE
- 12 IS A TYPOGRAPHICAL ERROR UNDER AGENDA ITEM 11. IT REFERS
- 13 TO APPOINTMENT OF MEMBERS IN BETWEEN MEETINGS BY THE
- 14 GOVERNANCE SUBCOMMITTEE. THAT SHOULD ACTUALLY READ THE
- 15 FINANCE SUBCOMMITTEE.
- 16 CHAIRMAN KLEIN: AND THAT'S TRUE ON THE TASK
- 17 FORCE AS WELL.
- 18 MR. HARRISON: AND THAT'S TRUE ON THE TASK
- 19 FORCE AS WELL.
- 20 CHAIRMAN KLEIN: THANK YOU FOR THAT
- 21 CLARIFICATION. ANY MEMBERS OF THE PUBLIC HAVING
- 22 COMMENTS? SEEING NO MEMBERS, CALL THE QUESTION. ALL IN
- 23 FAVOR, OPPOSED.
- 24 SO AT THIS POINT WE HAVE PASSED THE ITEMS THAT
- 25 WE NEED TO. THERE ARE ADMINISTRATIVE ITEMS AND REPORTS.

Т	MIS. KING. DO B, YOU HAVE TO DO THE TASK FORCE
2	AS WELL.
3	CHAIRMAN KLEIN: HAVE TO PASS IT SEPARATELY?
4	MS. KING: IT'S A SEPARATE ITEM.
5	CHAIRMAN KLEIN: I THINK THE MOTION WAS
6	INTENDED TO INCORPORATE BOTH PARTS.
7	MS. KING: OKAY. FINE. SORRY ABOUT THAT.
8	CHAIRMAN KLEIN: SO WE HAVE ADMINISTRATIVE
9	REPORTS, SO WE WOULD LOOK FOR THE PUBLIC AND THE BOARD TO
10	RECONVENE. WOULD MR. HARRISON READ US THE LANGUAGE WHICH
11	ENTITLES US TO GO INTO AN EXECUTIVE SESSION TO DEAL WITH
12	PERSONNEL MATTERS?
13	MR. HARRISON: YES. WE'LL BE DISCUSSING TWO
14	ITEMS IN CLOSED SESSION: PENDING LITIGATION UNDER
15	GOVERNMENT CODE SECTION 11126 SUBDIVISION E AND PERSONNEL
16	PURSUANT TO GOVERNMENT CODE SECTION 1126 SUBDIVISION A,
17	AND HEALTH AND SAFETY CODE SECTION 125290.30(D)(3)(D).
18	CHAIRMAN KLEIN: THANK YOU. AND WHERE IS
19	THE WE WILL FOLLOW MELISSA KING FOR LUNCH. WE WILL
20	ATTEMPT TO BE BACK IN 45 MINUTES SO WE CAN MOVE THIS
21	AGENDA QUICKLY AND HOPEFULLY ADJOURN EARLY. THANK YOU.
22	(A RECESS WAS TAKEN.)
23	CHAIRMAN KLEIN: WE'RE RECONVENING, AND I'D
24	LIKE TO POINT OUT THAT THERE IS NO REPORT FROM THE
25	EXECUTIVE SESSION. NO ACTIONS TAKEN. IN THE

- 1 INTERMISSION INTERVENING TIME, SHERRY LANSING, IN MY
- 2 DISCUSSION WITH YOU ABOUT BAN PURCHASERS, YOU HAD A
- 3 SUGGESTION. MAYBE YOU WOULD LIKE TO MAKE IT FOR THE
- 4 WHOLE BOARD AND THE PUBLIC.
- 5 MS. LANSING: I WOULD. THIS IS, AS WE ALL
- 6 KNOW, A JOYOUS DAY BECAUSE THE BONDS ARE OUT AND IT'S A
- 7 VERY, VERY HAPPY TIME FOR ALL OF US. BUT WHENEVER
- 8 THERE'S A HAPPY TIME, WE ALSO HAVE A LOT TO BE GRATEFUL
- 9 FOR. AND IN MY MIND, IF WE CAN ALL FADE BACK TO A COUPLE
- 10 OF YEARS AGO AND A LOT OF THE DIFFICULTIES THAT WE WERE
- 11 GOING THROUGH, I REMEMBER THE PEOPLE WHO STEPPED UP AND
- 12 LOANED US THE BAN MONEY. AND THOSE PEOPLE WERE VERY,
- 13 VERY BRAVE. THEY CARED A GREAT DEAL ABOUT OUR CAUSE, AND
- 14 THEY GAVE US THE MONEY WITHOUT ANY ASSURANCES THAT THIS
- 15 MONEY WOULD BE RETURNED.
- 16 SO I WOULD LIKE TO, ALONG WITH THE LIST OF
- 17 PEOPLE, WHICH HAS BEEN PUBLIC RECORD, AS WELL AS OUR
- 18 GOVERNOR, WHO DID A REMARKABLE THING IN RELEASING MONEY
- 19 TO US AT THOSE VERY, VERY DIFFICULT TIMES, WITHOUT THE
- 20 GROUP OF PEOPLE AND OUR INCREDIBLE GOVERNOR, WE WOULD NOT
- 21 BE HERE TODAY. AND SO I SUGGEST THAT WE MAKE A
- 22 PROCLAMATION THANKING ALL OF THESE PEOPLE AND SIGN IT
- FROM ALL OF THE MEMBERS OF THE BOARD. AND I PERSONALLY,
- 24 I THINK I REPRESENT ALL THE BOARD IN THANKING ALL THE
- 25 PURCHASERS OF THE BAN AND IN THANKING OUR INCREDIBLE

1	GOVERNOR AS WELL.
2	SO I MOVE THAT WE MAKE A PROCLAMATION.
3	CHAIRMAN KLEIN: GIVEN THAT WE HAVEN'T
4	AGENDIZED THAT ITEM, THE CHAIR IS PREPARED TO ACCEPT IT
5	AS A GENERAL SENSE OF THE BODY, THAT WE WISH TO PROCEED
6	AS WE NORMALLY DO IN RECOGNIZING SUCH EXTRAORDINARY
7	LEADERSHIP FROM THE CIVIC COMMUNITY IN SUPPORTING THE
8	MISSION AND FROM THE GOVERNOR. AND IF THE BOARD GIVEN
9	THE SENSE OF THE BOARD, I WOULD SUGGEST THAT I TRY AND
10	PROCEED TO DRAW SOMETHING UP. AND I WOULD LIKE TO
11	CIRCULATE TO THE BOARD MEMBERS THAT INDIVIDUALLY FOR
12	SIGNATURE SO THAT WE CAN PRESENT IT AS A REAL UNITED
13	BODY.
14	AND IN DOING SO, I WOULD LIKE TO RECOGNIZE THAT
15	SHERRY LANSING WAS A GREAT TEAM PLAYER IN THE BAN PROCESS
16	IN GETTING SOME CRITICAL COMMITMENTS, AS WAS ALSO TRUE
17	WITH ED PENHOET AND OTHER MEMBERS OF THIS BOARD. BUT IT
18	IS REMARKABLE THAT CIVIC LEADERS IN THE STATE STEPPED UP
19	KNOWING THERE WAS LITIGATION IN PROCESS WITH A BROAD
20	DISCLOSURE ON THE BAN'S, THE BOND ANTICIPATION NOTES,
21	THEY WERE PURCHASING THAT SAID IF WE LOSE THIS CASE,
22	YOU'VE JUST MADE A \$45 MILLION CONTRIBUTION TO MEDICAL
23	RESEARCH IN CALIFORNIA. THAT IS A COURAGEOUS BOND
24	ANTICIPATION NOTE PURCHASER, ONE DRIVEN BY MISSION, NOT
25	PROFITABILITY.

1	SO WE HAVE A GREAT DEAL TO BE THANKFUL FOR, AND
2	I WILL PROCEED WITH THE SENSE OF THE BOARD.
3	MS. LANSING: THANK YOU.
4	CHAIRMAN KLEIN: OKAY. IF WE CAN GO FORWARD AT
5	THIS POINT AND ASK FOR THE ADMINISTRATIVE BUDGET ITEM.
6	DR. MURPHY, WOULD YOU LIKE TO SEE US PROCEED ON AGENDA
7	ITEM 14?
8	DR. MURPHY: WHICH IS?
9	CHAIRMAN KLEIN: THE ADMINISTRATIVE BUDGET AND
LO	CONTRACT CLOSEOUT.
L1	DR. MURPHY: YES. LORI.
L2	CHAIRMAN KLEIN: THAT ITEM IS
L3	DR. MURPHY: LORI HOFFMAN WILL BE DOING THAT.
L4	CHAIRMAN KLEIN: DR. MURPHY INDICATES LORI
L5	HOFFMAN WILL BE PRESENTING ITEM 14.
L6	MS. HOFFMAN: THANK YOU, MR. CHAIRMAN. GOOD
L7	AFTERNOON. IF YOU WILL FOCUS YOUR ATTENTION IN A MOMENT
L8	ON THE POWERPOINT PRESENTATION AS WELL AS THE ITEM UNDER
L9	TAB 14 IN YOUR BINDER. WE'RE HAVING A LITTLE TECHNICAL
20	DIFFICULTY, SO ALLOW ME TO WALK THROUGH THIS WITHOUT
21	FOCUSING YOUR ATTENTION ON THE POWERPOINT PRESENTATION
22	AND ONLY ON THE AGENDA ITEM IN YOUR PACKAGE UNDER TAB 14.
23	THANK YOU SO MUCH.
24	YOU WILL NOTICE ON THE FRONT PAGE THERE IS A

TABLE THAT PROVIDES A RECONCILIATION BETWEEN THE '06-'07

25

- 1 BUDGETED AMOUNT OF \$8.3 MILLION AND THE ACTUAL TOTAL OF
- 2 7.12, THE VARIANCE BEING \$1.2 MILLION. UNFORTUNATELY
- 3 THESE ARE NOT COST SAVINGS TO US, BUT WE WILL CERTAINLY,
- 4 IF YOU LOOK ON THE FOLLOWING PAGES UNDER OUR CONTRACTS,
- 5 MANY OF OUR CONTRACTS THAT WERE NOT BOOKED OR EXPENSED IN
- 6 '06-'07 WILL BE EXPENSED IN '07-'08. AND THOSE WERE
- 7 ACCOUNTED FOR IN THE '07-'08 BUDGET ITEM THAT WAS
- 8 PRESENTED AT THE AUGUST MEETING UNDER THE ACTING
- 9 PRESIDENT'S REPORT. IT WAS ALSO IN YOUR AGENDA PACKAGE
- 10 IN JUNE.
- MS. LANSING: I'M CONFUSED. WHY ARE THEY NOT
- 12 SAVINGS? I DON'T UNDERSTAND.
- 13 MS. HOFFMAN: I'M SORRY. SAY AGAIN. QUESTION?
- 14 MS. LANSING: WE SPENT LESS THAN OUR BUDGET --
- 15 MS. HOFFMAN: WE SPENT LESS THAN OUR BUDGET.
- 16 MS. LANSING: -- IN ALL AREAS EXCEPT ONE. WHY
- 17 IS THAT NOT A SAVINGS? I DON'T UNDERSTAND.
- 18 MS. HOFFMAN: THE ONLY AREA -- THAT'S A VERY
- 19 EXCELLENT QUESTION. THEY ONLY AREA WHERE IT IS, IN FACT,
- 20 A SAVINGS IS SALARY AND BENEFITS. SO IN THE EXTERNAL
- 21 CONTRACTS WHERE THERE'S A 20-PERCENT SAVINGS, WE WILL
- 22 SPEND THAT MONEY. WE'LL JUST SPEND IT IN '07-'08 RATHER
- 23 THAN IN THE '06-'07 FISCAL YEAR. IT'S THE WAY --
- MS. LANSING: THAT'S LIKE FOR THE STANDARDS
- 25 COMMITTEE AND EVERYTHING, YOU'RE SAYING THAT --

1	MS.	HOFFMAN:	TN MANY	CASES	YFS.	THF	POSTTNGS
_	1110.		TIM 1.1/2141		, , , ,	1111	1 02 1 1103

- 2 CLOSE FOR THE STATE CONTROLLER'S OFFICE ON JULY 20TH, SO
- 3 ANYTHING THAT WE DO NOT RECEIVE IN TERMS OF A BILL OR WE
- 4 HAVE NOT PAID THAT BILL YET, IT WOULD NOT GET POSTED TO
- 5 '06-'07.
- 6 MS. LANSING: SO FOR POINT OF INFORMATION,
- 7 BECAUSE I THINK SOME OF -- IT'S JUST INTERESTING. NO ONE
- 8 IS SUGGESTING ANYTHING. BUT SOME OF THE COMMITTEES, I
- 9 THINK. STILL WILL BE UNDER BECAUSE THEY DIDN'T HAVE
- 10 MEETINGS, YOU KNOW, WHATEVER. I WONDER IF YOU COULD
- 11 CIRCULATE SOMETHING FOR US THAT ACTUALLY SHOWS SOME
- 12 SAVINGS IF THERE ARE ANY.
- MS. HOFFMAN: WELL, AS SOON AS WE GET ALL THE
- 14 BILLS IN FOR THOSE PARTICULAR GROUPS FOR THAT PARTICULAR
- 15 YEAR, INCLUDING THE OTHER LINE ITEM, OTHER TRAVEL, AGAIN,
- 16 LOOKS LIKE THERE'S VERY SIGNIFICANT SAVINGS, BUT IN
- 17 SEVERAL CASES MANY OF THOSE TRAVEL EXPENSES WILL BE
- 18 BOOKED INTO '07-'08. SO I WILL INDEED BRING BACK TO YOU
- 19 THE RECONCILIATION.
- 20 ALSO TO YOUR POINT, FOR ALL THE MEETINGS, IN
- 21 MANY CASES WE OVERBUDGET OR WE BUDGET, FOR LET'S SAY,
- 22 FIVE OR SIX MEETINGS AND WE ONLY HAVE FOUR. WE BUDGET
- 23 FOR ALL TRAVEL EXPENSES FOR ALL MEMBERS OF THE WORKING
- 24 GROUP AND THEY DON'T ALWAYS SUBMIT. SO WE DO OUR BEST,
- 25 AND WE'RE GETTING BETTER AT IT.

	1	MS.	LANSING:	AND.	AGAIN.	I'M NOT	I'M NOT
--	---	-----	----------	------	--------	---------	---------

- 2 SAYING THIS IN A NEGATIVE WAY. I'M ACTUALLY SAYING IT IN
- 3 A POSITIVE WAY, THAT IT WOULD BE WONDERFUL TO SHOW, IF WE
- 4 DID HAVE SAVINGS, YOU KNOW, THAT IT WILL HELP YOU FOR
- 5 PLANNING, BUT I ALSO THINK IT'S JUST SOMETHING TO KNOW.
- 6 MS. HOFFMAN: OKAY. I WILL DO THAT. THANK
- 7 YOU.
- 8 CHAIRMAN KLEIN: QUESTION, LORI, THAT'S
- 9 RELEVANT TO THE QUESTION THAT SHERRY LANSING JUST ASKED.
- 10 ON ICOC MEETINGS THIS VARIANCE OF 188,000, ARE THERE
- 11 ACCRUAL EXPENSES WE HAVEN'T SEEN, OR IS THAT ACTUAL
- 12 SAVINGS AS WELL?
- MS. HOFFMAN: NO. THERE ARE ACCRUAL EXPENSES
- 14 THAT YOU WILL SEE IN '07-'08, AND IN THE '07-'08 BUDGET,
- 15 BECAUSE WE ALREADY KNEW THAT WE WEREN'T GOING TO SPEND
- 16 THE 400,000, IN '07-'08 WE BUDGETED FOR ICOC AT 323.
- 17 ASSUMING THEN, USING, AS MEMBER LANSING SUGGESTED, USING
- 18 WHAT WE HAD EXPERIENCED UP TO MAY IN TERMS OF WHAT WE
- 19 WERE SPENDING AT THOSE MEETINGS, WE KNEW WE DIDN'T NEED
- THE 400,000. THAT WAS INITIALLY AN ESTIMATED BUDGET
- 21 AMOUNT PRIOR TO A FULL YEAR OF ICOC MEETINGS THAT ARE ON
- 22 A REGULAR CYCLE LIKE WE HAVE NOW.
- 23 CHAIRMAN KLEIN: SO IT IS ESTIMATED WE WILL
- 24 HAVE SOME SAVINGS IN THAT, BUT THERE ARE ALSO SOME
- 25 ACCRUAL EXPENSES?

1	MS. HOFFMAN: THAT'S CORRECT.
2	CHAIRMAN KLEIN: OKAY.
3	MS. HOFFMAN: THE OTHER IMPORTANT FACT THAT I'D
4	LIKE TO HIGHLIGHT HERE IS THAT BELOW THE LINE EXPENSES
5	THAT ARE BEING THEN REDUCED FROM THE TOTAL. SO YOU WILL
6	SEE THREE LINE ITEMS, COST OF BOND ISSUANCE, LEGAL COST,
7	AND GIFT FUND EXPENDITURES. THIS IS BASICALLY A FUND
8	SOURCE. ANYTHING THAT WE USE THAT WAS A GIFT TO US,
9	THESE ARE SUBTRACTED FROM THE TOTAL BECAUSE THE
10	ADMINISTRATIVE TOTAL, WHICH IS FOR '06-'07 MELISSA
11	FOUND THE SLIDES. MELISSA, IF YOU COULD GO TO THE NEXT
12	SLIDE.
13	SO AGAIN, THE IMPORTANT POINT HERE IS THAT THE
14	ADMINISTRATIVE TOTAL OF 5.3 IS WHAT WE WILL TRACK. AND
15	WHEN I MEAN TRACK, YOU WILL RECALL THAT UNDER PROP 71
16	THERE IS A CAP ON ADMINISTRATIVE EXPENDITURES FOR THE
17	DURATION OF THE INSTITUTE OF 6 PERCENT OR \$180 MILLION.
18	AND THAT IS DIVIDED BETWEEN GENERAL ADMINISTRATION AND
19	GRANTS ADMINISTRATION.
20	SO AT THE NEXT SLIDE YOU WILL NOTICE THAT WE
21	HAVE NOW FOR THE FIRST TIME FOR '06-'07, AND WE WILL GO
22	BACK AND DO THIS FOR '05-'06, ALLOCATE BETWEEN GENERAL
23	ADMINISTRATION AND GRANTS ADMINISTRATION. AND THIS IS AN
24	IMPORTANT TRACKING TOOL FOR THE ICOC THAT YOU WILL NOW
25	RECEIVE THESE UPDATES ON AN ANNUAL BASIS.

1	SO TO CLOSE, I JUST WANTED YOU, AGAIN, TO KNOW
2	THAT THE STATE CONTROLLER'S OFFICE, THEIR FINAL YEAR-END
3	CLOSE WAS DONE AS OF AUGUST 23D. THE CIRM STAFF HAS
4	ALREADY HAD A KICKOFF MEETING WITH OUR FINANCIAL
5	AUDITORS, MGO, WHO DID OUR FINANCIAL AUDIT LAST YEAR, AND
6	THAT KICKOFF MEETING WAS HELD ON SEPTEMBER 21ST. WE
7	EXPECT THE AUDITORS DRAFT FINANCIAL REPORT TO US BY
8	MID-DECEMBER, AND WE ARE PLANNING FOR THE AUDITORS'
9	PRESENTATION TO YOU AT YOUR JANUARY MEETING.
10	AND I'M OPEN FOR QUESTIONS.
11	DR. POMEROY: CAN I ASK A QUESTION?
12	CHAIRMAN KLEIN: ABSOLUTELY. IF I CAN JUST
13	CREATE SOME CONTEXT TOO. I'LL REMIND US ALL THAT DR.
14	PENHOET POINTED OUT THE GORDON AND BETTY MOORE FOUNDATION
15	RUNS ON ABOUT 12 PERCENT. SO WE'RE RUNNING AT A VERY
16	STRINGENT BUDGET, ABOUT HALF AS MUCH. IT'S ONLY POSSIBLE
17	BECAUSE WE HAVE BEEN VERY STRATEGIC AND ASTUTE ABOUT
18	MAKING SURE WE WEREN'T PAYING TOO MUCH FOR FACILITIES.
19	ZERO IS A GOOD FIGURE. IN ADDITION, OPERATING COST FOR
20	FACILITIES IS NOT A COST TO US. BUT WE HAVE THE BENEFIT
21	AS WELL THAT LEGAL COST, FOR EXAMPLE, THE LITIGATION DOES
22	NOT COME OUT OF OUR BUDGET. IT HAD TO BE DESIGNED THAT
23	WAY, OTHERWISE A LITIGANT WOULD HAVE HAD AN INCENTIVE TO
24	DRAG ON LITIGATION FOREVER, JUST TRYING TO, IN FACT, PUSH
25	US OUTSIDE OF AN OPERATING BUDGET THAT WE COULD LIVE

- 1 WITHIN. SO LEGAL COST IS THE DEDUCTION, WHICH IS WHY
- 2 LORI HAS SHOWN THAT DEDUCTED FROM THE TOTAL AMOUNT WHICH
- 3 WE'RE UNDER A LIMITATION OF.
- 4 DR. POMEROY.
- DR. POMEROY: SO I DON'T QUITE UNDERSTAND THESE
- 6 NUMBERS BECAUSE UNDER ADMINISTRATION TOTAL, THE VERY
- 7 BOTTOM LINE, 7.2, BUDGET 5.3, ACTUAL, THE VARIANCE IS 1.9
- 8 MILLION, NOT 1.2 IF YOU JUST SUBTRACT. SO WHAT'S GOING
- 9 on?
- MS. HOFFMAN: WELL, WHAT HAPPENED WAS WE ONLY
- 11 BUDGETED FOR LEGAL COSTS, AS BOB JUST IDENTIFIED, AND THE
- 12 COST OF ISSUANCE IS ACTUALLY NOT -- SO WHAT HAPPENS IS
- 13 THE GIFT FUNDS IS NOT AN EXPENDITURE, BUT IT BECAME A
- 14 FUND SOURCE WHERE THE LEGAL COSTS AND THE COST OF
- 15 ISSUANCE IS ACTUALLY AN EXPENDITURE. SO YOU WILL SEE IT
- 16 ABOVE THE LINE AND BELOW THE LINE WHERE THE 586 IS JUST,
- 17 AGAIN, JUST A FUND SOURCE.
- DR. POMEROY: HOW CAN THE ACTUAL BE 5.3
- 19 AGAINST 7.2 AND THE DIFFERENCE -- THE VARIANCE BE 1.2?
- 20 IF YOU SUBTRACT THOSE, IT'S 1.9.
- MS. HOFFMAN: YOU KNOW, DR. POMEROY, YOU MAKE
- 22 AN EXCELLENT POINT, AND I CAN'T ANSWER THE QUESTION. SO
- 23 RICK CAN ANSWER THE QUESTION, BUT I CAN'T. SO ALLOW ME
- TO GO BACK; AND IF I DO NEED TO CHANGE THESE NUMBERS, I
- 25 WILL. AND I CERTAINLY WILL RE-POST IT AND SEND THIS OUT

	1	TO	YOU	AND	ANSWER	YOUR	QUESTION
--	---	----	-----	-----	--------	------	----------

- 2 ANY OTHER QUESTIONS THAT PERHAPS I MIGHT BE
- 3 ABLE TO ANSWER? OKAY. THANK YOU SO MUCH.
- 4 CHAIRMAN KLEIN: ALL RIGHT. THANK YOU, LORI
- 5 HOFFMAN. DR. MURPHY, ARE WE PREPARED TO GO TO ITEM NO.
- 6 15? AND AFTER ITEM 15, WE WILL HAVE SOME ADDITIONAL
- 7 ADMINISTRATIVE REPORTS WHICH ARE NOT TIME SENSITIVE
- 8 BECAUSE THERE'S NO VOTES ON THEM, BUT THEY'RE AN
- 9 EXTENSION OF THE PRESIDENT'S REPORT THAT WE'LL FINISH
- 10 WITH AFTER ITEM 15. SO THAT IS NOT THE END OF THE AGENDA
- 11 WHEN WE GET THROUGH ITEM 15.
- DR. MURPHY: MR. CHAIRMAN, AFTER RECEIVING ALL
- 13 OF THE KIND COMMENTS FROM THE BOARD ON THE ORGANIZATION
- 14 OF THE STAFF'S PRESENTATIONS TODAY, I WANT TO TELL YOU
- 15 THAT FOR THIS PRESENTATION I LOST MINE. I JUST CALLED MY
- 16 OFFICE, CALLED, TALKED TO PAT, I SAID, "E-MAIL THAT TO
- 17 TAMAR." SHE E-MAILED IT TO TAMAR, AND I'M READING IT
- 18 NOW. ISN'T IT A WONDERFUL TIME? REALLY IS.
- MR. CHAIRMAN, I'M REPORTING ON THE ONGOING
- 20 DISCUSSIONS WE HAVE HAD WITH THE CALIFORNIA STATE
- 21 UNIVERSITY SYSTEM AND THE CALIFORNIA COMMUNITY COLLEGE
- 22 SYSTEM ABOUT THEIR REQUEST FOR \$31 MILLION FOR RESEARCH
- 23 SUPPORT FOR A TRAINING PROGRAM IN STEM CELL RESEARCH FOR
- 24 THEIR STUDENTS. RECALL THAT THAT PROPOSAL WAS SUBMITTED
- 25 TO THE ICOC AND DISCUSSED WITH CSU AND CCC

1	REPRESENTATIVES AT THE AUGUST ICOC MEETING.
2	IN RESPONSE TO QUESTIONS RAISED AT THAT MEETING
3	BY THE ICOC, THE CSU AND CCC COMMITTEE HAS RESPONDED, AND
4	THE ANSWERS TO YOUR INQUIRIES ARE IN THE PACKAGE THAT YOU
5	HAVE IN FRONT OF YOU.
6	SINCE THAT TIME ARLENE CHIU, TAMAR PACHTER, AND
7	I HAVE MET THROUGH A CONFERENCE CALL WITH CSU AND CCC
8	OFFICIALS, JEFF THOMPSON, WHO IS THE ASSOCIATE PROVOST
9	FOR RESEARCH, CSU SAN BERNARDINO, SUSAN BAXTER, WHO IS
10	WITH CSU SAN BERNARDINO, AND MARY PAT HUXLEY, WHO IS WITH
11	THE TECHNOLOGY INITIATIVE FOR CCC. AND ON THAT CALL ALSO
12	WERE ICOC MEMBERS DAVID SERRANO-SEWELL AND MARCY FEIT.
13	WE EXPRESSED IN THAT CALL OUR SUPPORT TO THE
14	CSU AND CCC FOR THE TRAINING PROGRAMS THAT THEY WISH TO
15	PUT TOGETHER. WE TOO AGREE THAT IT IS IMPORTANT TO
16	PREPARE STUDENTS FOR WORKING IN THE STEM CELL FIELD, AND
17	WE ALSO EXPRESSED A STRONG DESIRE ON BEHALF OF CIRM TO
18	INVOLVE IN THIS FIELD THE MUCH NEEDED DIVERSITY OF THE
19	STUDENTS THAT THE CSU AND CCC SYSTEM TRAIN. HOWEVER, WE
20	ALSO EXPLAINED THAT CIRM FUNDS NEED TO BE AWARDED ON A
21	COMPETITIVE BASIS AFTER RIGOROUS PEER REVIEW TO ENSURE
22	THAT PUBLIC MONEY IS WELL SPENT.
23	WE DISCUSSED ALTERNATIVES THAT WOULD FIT INTO
24	CIRM PROGRAMS THAT WOULD ALSO PROVIDE TRAINING
25	OPPORTUNITIES FOR STUDENTS FROM CSU AND CCC AND

1	ELSEWHERE. SEVERAL ALTERNATIVES THAT WE DISCUSSED
2	INCLUDED ENCOURAGING CSU AND CCC STUDENTS TO SEEK
3	INTERNSHIPS IN CIRM-SPONSORED TRAINING PROGRAMS THAT HAVE
4	BEEN FUNDED IN SIX SITES AROUND THE STATE. THIS TRAINING
5	EXPERIENCE WOULD PROVIDE THEM ACCESS TO THE TRAINEES AND
6	FACULTY WHO ARE ON THE CUTTING EDGE OF THE FIELD
7	SUPPORTED BY CIRM AND THE PEOPLE WHO ARE REALLY CREATING
8	THE TECHNOLOGY. IT WOULD PROVIDE THESE STUDENTS
9	WONDERFUL NETWORKING OPPORTUNITIES WITH PEOPLE WHO WOULD
10	HIRE THEM, AND IT WOULD BE AN EXCELLENT TRAINING
11	EXPERIENCE THAT WOULD BE LOOKED UPON FAVORABLY BY
12	COMPANIES GETTING INTO STEM CELL SCIENCE.
13	TO SUPPORT THESE INTERNSHIPS, CIRM COULD
14	DESIGNATE SPECIAL FUNDING FOR INTERNSHIP PROGRAMS THAT
15	WOULD BE AWARDED ON A COMPETITIVE BASIS. AND ARLENE HAS
16	TOUCHED UPON THAT EARLIER TODAY. IT MAY ALSO BE POSSIBLE
17	FOR CIRM TO OFFER SPECIAL RFA'S FOR TRAINING PROGRAMS
18	THAT COULD BE COMPETED FOR BY CSU AND CCC CAMPUSES AND
19	UNDERGRADUATE PROGRAMS IN OTHER NONPROFIT SCHOOLS.
20	FINALLY, WE WOULD BE COMFORTABLE CONSIDERING
21	PROGRAMS THAT MIGHT RESULT IN STUDENTS FROM THESE
22	PROGRAMS WORKING DIRECTLY IN THE LABORATORIES OF
23	CIRM-FUNDED INVESTIGATORS. WE HAVE LEFT THESE IDEAS WITH
24	OUR CSU-CCC COLLEAGUES, AND WE ARE SCHEDULING ANOTHER
25	MEETING WITH THEM IN OCTOBER FOR FURTHER DISCUSSIONS.

1	HOPEFULLY	AAL AALTII	DE	ADI E	TΩ	CDEATE	٨	DDOCDAM	$TU\Lambda T$	\a/TII	
	HUPEFULLY	ME MILL	DE	ADLE	10	CKEALE	А	PRUGRAM	ІПАІ	WTLL	

- 2 ACHIEVE OUR SHARED GOAL OF ENGAGING THESE WORTHY STUDENTS
- 3 IN THE GROWING AND EXCITING FIELD OF STEM CELL BIOLOGY.
- 4 WITH THAT, MR. CHAIRMAN, I OPEN IT FOR
- 5 QUESTIONS.
- 6 CHAIRMAN KLEIN: QUESTIONS FOR MEMBERS OF THE
- 7 BOARD? DR. LEVEY.
- 8 DR. LEVEY: I WOULD JUST CONGRATULATE YOU FOR
- 9 GETTING TO A POINT WHERE YOU'RE WORKING WITH THEM TO TRY
- 10 TO MAKE SOMETHING HAPPEN BECAUSE I THINK THE UC SYSTEM
- 11 HAS NOW DEVELOPED A JOINT DEGREE PROGRAMS IN AUDIOLOGY.
- 12 TO GET THAT STARTED WAS VERY DIFFICULT, BUT IT CAME
- 13 THROUGH TO ALL OF US THAT RIGHT NOW MOST OF THE
- 14 LEGISLATURE CONSISTS OF MEMBERS WHO ARE PRODUCTS OF THE
- 15 CALIFORNIA STATE UNIVERSITY SYSTEM. AND, YOU KNOW, WE
- 16 ARE AN ARM OF THAT, SO I WOULD THINK THAT WE'VE DONE THE
- 17 WISE THING HERE.
- 18 I THINK WE COULD HAVE DONE THE REVERSE AND
- 19 STONEWALLED IT AND SAID -- I THINK THIS IS A VERY WISE
- 20 DECISION, AND I CONGRATULATE THE OFFICE OF THE PRESIDENT
- 21 FOR DOING THAT.
- 22 CHAIRMAN KLEIN: OKAY. LET'S GO -- WE NEED TO
- 23 FINISH ON THE LEFT AND GO TO THE RIGHT. DR. BRYANT.
- DR. BRYANT: YES. I JUST WANT TO SAY I LIKE
- THE IDEA OF THE INTERNSHIPS VERY MUCH, AND I THINK SOME

- 1 OF THESE STUDENTS THAT ARE GOING THROUGH A MASTER'S
- 2 PROGRAM, ONCE THEY GET INTO A RESEARCH LAB, COULD THEN
- 3 BECOME GREAT CANDIDATES FOR PH.D. PROGRAMS BECAUSE WE
- 4 HAVE A MASTER'S PROGRAM AT UCI THAT'S A BIOTECH PROGRAM.
- 5 AND ACTUALLY WE HAVE ONE WITH AN EMPHASIS IN STEM CELL
- 6 RESEARCH, AND THE STUDENTS GET SO TURNED ON BY IT, THEY
- 7 THINK THEY WANT TO BE MASTER'S STUDENTS, BUT THEY
- 8 ACTUALLY END UP WANTING TO DO RESEARCH. SO THEY -- YOU
- 9 KNOW, IT'S A FERTILE FEEDING OPPORTUNITY TO FEED INTO THE
- 10 SYSTEM.
- 11 CHAIRMAN KLEIN: DR. STEWARD AND THEN DR.
- 12 PRIETO.
- DR. STEWARD: ACTUALLY CAN I SAVE MINE TO THE
- 14 LAST IN THE SERIES?
- 15 CHAIRMAN KLEIN: YES. DR. PRIETO.
- 16 DR. PRIETO: JUST A QUESTION. ARLENE ALLUDED
- 17 EARLIER TO SOME OF OUR FUTURE PLANS AND LOOKING AT THE
- 18 NEED FOR TECHNICAL -- TECHNICALLY TRAINED STAFF BELOW THE
- 19 PH.D. LEVEL AND WHAT CALIFORNIA'S NEEDS MIGHT BE. I
- 20 WONDERED HOW FAR LONG ARE WE IN ASSESSING THAT PROBLEM,
- 21 ASSESSING WHAT THE NEEDS MIGHT BE, AND FORMULATING THIS
- 22 AS SOME SORT OF AN RFA THAT WE COULD THEN PUT OUT THAT
- 23 THESE INSTITUTIONS COULD THEN APPLY FOR.
- DR. MURPHY: I DON'T KNOW IF WE HAVE. ARLENE
- 25 CHIU PROBABLY SHOULD TAKE THE MIC HERE. I DON'T KNOW IF

- 1 WE HAVE REALLY ASSESSED IT. IT'S CLEAR THAT WE ARE GOING
- 2 TO NEED NEW PEOPLE DOING THIS. I THINK THE DISCUSSIONS
- 3 WITH THE CSU AND CCC COULD ACTUALLY HELP US FORMULATE THE
- 4 RFA. AND IF WE COULD NOT ONLY HAVE AN RFA FOR TRAINING,
- 5 BUT PUT IT INTO A FRAMEWORK WHERE WE'RE SERVING THE NEEDS
- 6 OF THIS VERY IMPORTANT COMMUNITY, I THINK THAT'S A
- 7 WIN-WIN SITUATION. SO WE ARE EAGER TO MOVE FORWARD ON
- 8 THIS.
- 9 AND AS I SAY, WE ARE MEETING WITH THESE FOLKS
- 10 IN OCTOBER TO CONTINUE THE DISCUSSIONS. ARLENE.
- DR. CHIU: I HAVE NOTHING MORE TO ADD. DR.
- 12 MURPHY HAS IT EXACTLY IT RIGHT. IT IS -- WITH THAT LONG
- 13 LIST OF INITIATIVES, THOSE ARE PLANS THAT WE HOPE TO
- 14 BRING IN 2008, AND NOT ALL OF THEM ARE VERY WELL FORMED,
- 15 BUT WE HOPE TO GET GOOD INPUT SUCH AS FROM OUR COLLEAGUES
- 16 AT CSU IN ORDER TO FRAME IT BETTER. BUT IT'S CERTAINLY
- 17 ON THE HORIZON, AND WE WOULD LIKE TO HAVE IT REVIEWED
- 18 TOGETHER WITH THE TRAINING GRANT PROGRAM BECAUSE IT WOULD
- 19 BE THE SAME GROUP OF PEOPLE TO REVIEW THOSE AND REDUCE
- 20 THE NUMBER OF REVIEW MEETINGS.
- 21 CHAIRMAN KLEIN: DR. STEWARD.
- DR. STEWARD: MAYBE I'LL BE THE LAST COMMENT.
- 23 WE'LL SEE. SOMETHING HAS BEEN ON MY MIND EVER SINCE THIS
- 24 STARTED, AND I ACTUALLY DIDN'T RAISE IT DURING PREVIOUS
- 25 DISCUSSIONS BECAUSE I DIDN'T WANT TO SEEM NEGATIVE ABOUT

1	THIS. I THINK IT'S A VERY IMPORTANT IDEA FOR THE
2	COMMUNITY COLLEGES.
3	WHAT HAS BOTHERED ME FROM THE BEGINNING,
4	THOUGH, IN SOME RESPECTS IS THAT THIS IS THE FIRST TIME
5	THAT CIRM, AS FAR AS I KNOW, HAS CONSIDERED IN DETAIL A
6	PROPOSAL THAT DIDN'T ORIGINATE FROM AN RFA. AND MY
7	QUESTION IS FOR THE FUTURE UNDER WHAT CIRCUMSTANCES DOES
8	CIRM CHOOSE TO EVALUATE AND CONSIDER THESE THINGS THAT
9	ARE OUT OF THE BOX OR NOT? I GUESS I'M JUST YOU COULD
10	BE LOOKING AT A WHOLE LOT OF PROPOSALS FROM A WHOLE LOT
11	OF ORGANIZATIONS, AND I'M JUST RAISING IT AS AN ISSUE.
12	DR. MURPHY: DAVID, DO YOU WANT TO SPEAK?
13	MR. SERRANO-SEWELL: THAT WAS ONE OF THE FIRST
14	ISSUES THAT MARCY AND I RAISED WITH DR. MURPHY IN OUR
15	CONVERSATIONS, AND WE ALSO SORT OF SHARED THAT WHEN WE
16	HAD OUR CONFERENCE CALL WITH THE CSU AND COMMUNITY
17	COLLEGE REPRESENTATIVES, THAT IT HAS BEEN THE PRACTICE OF
18	THIS ORGANIZATION TO AWARD GRANTS ON A COMPETITIVE BID
19	BASIS. THAT HAS BEEN OUR POSTURE, AND WE BELIEVE THAT IT
20	HAS SERVED US WELL. AND IF YOU JUDGE SORT OF THAT TRACK
21	RECORD, THEN SORT OF GOING FORTH, WE'LL CONTINUE THAT
22	MODEL. AND WE SHARED THAT WITH THE PARTICIPANTS ON THE
23	CALL. SO I THINK THAT SORT OF ANSWERS YOUR QUESTION.
24	DR. STEWARD: SORT OF, BUT NOT QUITE. SO WHAT

I'M REALLY GETTING AT IS IT TOOK OBVIOUSLY A LOT OF TIME

25

1	TΩ	THTNK	AROUT	THTS	ΔND	THFY	WFRF	AFFORDED	THE
_	10	I I I I T I A I Z	ADOUL	IIIII J.		111111	WLIL	AI I UNDED	1111

- 2 OPPORTUNITY TO COME AND PRESENT TO THE ICOC, AND I'M NOT
- 3 SAYING THAT WAS THE WRONG THING TO DO. I'M JUST ASKING
- 4 UNDER WHAT CIRCUMSTANCES DO WE DO THAT? HOW DO WE
- 5 DECIDE?
- DR. MURPHY: I CAN GIVE YOU MY ANSWER, OS. MY
- 7 FEELING IS THAT WE WANT GOOD IDEAS FROM WHEREVER THEY
- 8 COME FROM. AND SOMETIMES THE INTERESTS OF THE
- 9 ORGANIZATION ARE GOING TO LEAD -- OF ONE ORGANIZATION ARE
- 10 GOING TO LEAD THIS ORGANIZATION IN WAYS THAT WE COULD
- 11 HAVE NEVER PREDICTED. SO I THINK THAT I THINK THE
- 12 DISCUSSIONS THAT WE'RE HAVING WITH THESE FOLKS ARE VERY,
- 13 VERY HELPFUL TO CIRM. THEY FILL A NEED WE HAVE, THE NEED
- 14 FOR WELL-TRAINED PEOPLE. THE FACT IS IN THIS FIELD, AS
- 15 IN MOST FIELDS IN BIOLOGY, THERE IS NOT A DIVERSE
- 16 WORKFORCE, AND WE ALL BENEFIT FROM A DIVERSE WORKFORCE.
- 17 SO AS THEY ARE LEADING US THROUGH THIS PROCESS
- 18 AND WE IMPOSE UPON THE PROCESS OR ADD TO THE PROCESS A
- 19 COMPLEMENTARY PROCESS OF WHAT CIRM NEEDS TO MAKE THE
- 20 DECISION, I THINK IT'S A WIN-WIN SITUATION, AND I WELCOME
- 21 THE INPUT WE'RE GETTING.
- 22 CHAIRMAN KLEIN: AND I -- I'M GOING TO GO TO
- 23 SHERRY LANSING. I WOULD LIKE TO RESPOND IN PART, SINCE I
- 24 PUT IT ON THE AGENDA, AND I'D LIKE TO SAY THAT THE CSU
- 25 SYSTEM AND THE COMMUNITY COLLEGES HAD BEEN ATTEMPTING TO

1 ENGAGE WITH THIS INSTITUTION FOR OVER A YEAR. A	1	ANI
---	---	-----

- 2 BECAUSE THEY ARE SUCH A CRITICAL PART OF THE EDUCATIONAL
- 3 SYSTEM OF THE STATE, AND A GREAT NUMBER OF THEIR STUDENTS
- 4 GO ON INTO THE UC SYSTEM IN MASTER'S AND DOCTORAL
- 5 PROGRAMS, IT APPEARED THAT IT WAS A VERY IMPORTANT
- 6 INITIATIVE ON THEIR PART THAT DESERVED THE WHOLE BOARD TO
- 7 MAKE A DECISION TO ADDRESS THIS OPPORTUNITY AND TO DECIDE
- 8 WHETHER STAFF TIME SHOULD BE COMMITTED. IT IS THE
- 9 BOARD'S DECISION.
- 10 WE HAVE TO BE CIRCUMSPECT ABOUT HOW MANY
- 11 INDIVIDUAL PETITIONS WE PUT ON OUR AGENDA OBVIOUSLY
- 12 BECAUSE OF CONSTRAINTS OF THE TIME; BUT SINCE THEY HAVE A
- 13 MONUMENTAL INFLUENCE ON EDUCATION IN THE STATE AND AS A
- 14 RESOURCE FOR PERSONNEL DEDICATED TO THIS MISSION, AT
- 15 LEAST A POTENTIAL RESOURCE, IT APPEARED APPROPRIATE TO
- 16 AGENDIZE THAT AS A MATTER OF DISCRIMINATION.
- 17 SHERRY LANSING.
- DR. STEWARD: I WASN'T QUESTIONING IT. THAT'S
- 19 WHY I DIDN'T RAISE IT AT THE TIME. I'M REALLY RAISING IT
- 20 AS A GENERAL ISSUE FOR THE FUTURE.
- MS. LANSING: I THINK WHAT OS IS RAISING, WHICH
- 22 I THINK IS A GOOD QUESTION, I DON'T THINK ANYONE IS
- 23 QUESTIONING THIS. I THINK WHAT WE'RE SAYING, AND I THINK
- 24 WE CAN KICK IT BACK TO THE PRESIDENT, IS LET US ASSUME
- 25 THIS WILL NOT BE THE ONLY OTHER GOOD IDEA THAT COMES

- 1 FORWARD. I THINK IT WOULD BE GOOD IF YOU WOULD, WITH
- 2 YOUR TEAM, COME UP WITH A PROCESS BY WHICH SOMEBODY DOES
- 3 THAT, THAT IF SOME OTHER OUTSIDE PERSON HAS AN IDEA, DO
- 4 THEY GO TO YOU FIRST? WHO DO THEY GO TO? WHAT'S THE
- 5 PROCESS BEFORE IT BECOMES TO THE BOARD? IF ONE OF US
- 6 SHOULD HAVE AN IDEA, HOW DO WE DO IT BECAUSE NO ONE IS
- 7 QUESTIONING THIS. WE'RE ONLY SAYING LET'S ASSUME THIS
- 8 ISN'T THE ONLY GOOD IDEA IN THE NEXT TEN YEARS OR SEVEN
- 9 YEARS OR WHATEVER IT IS THAT WE'LL EXIST THAT WON'T HAVE
- 10 AN RFA.
- 11 CAN YOU COME UP WITH A PROCESS BY WHICH WE HAVE
- 12 AN EQUAL OPPORTUNITY FOR OTHER PEOPLE SHOULD THEY HAVE
- 13 THAT TO AT LEAST BE HEARD? THAT'S ALL WE'RE SAYING.
- DR. MURPHY: WE THINK WE CERTAINLY CAN. THANK
- 15 YOU.
- 16 CHAIRMAN KLEIN: DR. PIZZO.
- 17 DR. PIZZO: I'M ACTUALLY HONORED TO SAY THAT I
- 18 WAS GOING TO MAKE THE SAME SUGGESTION AS SHERRY LANSING,
- 19 SO I WILL NOT REPEAT THAT, BUT THANK HER.
- 20 CHAIRMAN KLEIN: ALL RIGHT. THIS IS AN
- 21 EXCELLENT REPORT. I'D LIKE TO ASK IF THERE IS PUBLIC
- 22 COMMENT. DR. SUSAN BAXTER, WHO IS THE EXECUTIVE DIRECTOR
- 23 OF THE CALIFORNIA STATE UNIVERSITY PROGRAM FOR EDUCATION
- 24 AND RESEARCH AND BIOTECHNOLOGY, IS HERE. DR. BAXTER,
- 25 WOULD YOU LIKE TO MAKE A COMMENT FROM THE PUBLIC?

1

1	DR. BAXTER: THANK YOU. NO. WE DID NOT COME
2	WITH ANY PREPARED COMMENTS, BUT I DID WANT TO SAY THAT
3	ALSO STANLEY MALLOY IS HERE FROM CSU, DEAN OF SCIENCES,
4	IN SUPPORT OF OUR PROPOSAL, AND ALSO BETH AMBOSE FROM THE
5	CHANCELLOR'S OFFICE, THE VICE PRESIDENT FOR RESEARCH
6	INITIATIVES AND PARTNERSHIPS, IS HERE WITH ME TODAY. AND
7	WE WERE SIMPLY HERE TO ANSWER ANY QUESTIONS THAT YOU MAY
8	HAVE OF US SPECIFICALLY.
9	CHAIRMAN KLEIN: THANK YOU FOR BRINGING SOME
10	GREAT IDEAS TO US, AND HOPEFULLY WE CAN HAVE A
11	PARTNERSHIP THAT IS PRODUCTIVE FOR CIRM AND THE CSU AND
12	COMMUNITY COLLEGE SYSTEMS. IT'S WONDERFUL TO HAVE SOME
13	GREAT IDEAS TO STIMULATE US.
14	OKAY. ANY ADDITIONAL COMMENTS FROM THE BOARD?
15	IF NOT, WE HAVE AN ADMINISTRATIVE ITEM TO COVER. WE HAVE
16	SOME ADMINISTRATIVE ITEMS THAT HAVE NOT REQUIRED A VOTE
17	AND DIDN'T REQUIRE A QUORUM. AND, DR. CHIU, WOULD YOU
18	LIKE TO REPORT ON THE STATUS OF PROCESSING OF GRANTS AND
19	OVERSIGHT?
20	DR. CHIU: THANK YOU, MR. CHAIRMAN. I'D LIKE
21	TO REPORT TO THE BOARD ON THE STATUS OF TWO APPLICATIONS
22	THAT WERE APPROVED FOR FUNDING BY THE ICOC. DURING
23	CAREFUL PRE-AWARD REVIEW THAT YOU'VE HEARD SO MUCH ABOUT,
24	CIRM HAS DETERMINED THAT APPLICATION NO. RS 1305-1 FROM
25	THE BURNHAM INSTITUTE ENTITLED "GENERATION OF HESC LINES

- 1 UNDER DEFINED CONDITIONS -- MODELING NORMAL AND DISEASE
- 2 STATES FOR MATERIALS STORED AT THE BURNHAM SHARED EMBRYO
- 3 BANK" DOES NOT MEET ALL THE ELIGIBILITY REQUIREMENTS OF
- 4 THE RFA AND WILL THEREFORE NOT BE FUNDED. THIS
- 5 DETERMINATION HAS BEEN COMMUNICATED WITH THE APPLICANT.
- A SECOND APPLICATION, NO. RC 123-1 FROM THE
- 7 CHAR REGENERATIVE MEDICINE INSTITUTE ENTITLED
- 8 "ESTABLISHMENT OF STEM CELL LINES FROM SOMATIC CELL
- 9 NUCLEAR TRANSFER EMBRYOS IN HUMANS" HAS BEEN WITHDRAWN BY
- 10 THE APPLICANT INSTITUTION.
- 11 WE WILL CONTINUE TO KEEP THE ICOC UPDATED WITH
- 12 SUCH ADMINISTRATIVE ACTIONS AS THEY TAKE PLACE. THANK
- 13 YOU. ARE THERE ANY QUESTIONS?
- 14 CHAIRMAN KLEIN: DR. PRICE.
- 15 DR. PRICE: I DON'T KNOW WHETHER IT'S
- 16 APPROPRIATE, BUT CAN WE KNOW WHAT CRITERIA THEY DIDN'T
- 17 MEET?
- DR. CHIU: WELL, THE SECOND ONE WAS WITHDRAWN,
- 19 AND EVERY APPLICANT INSTITUTION HAS THE RIGHT TO WITHDRAW
- 20 AN APPLICATION.
- DR. PRICE: NO, I UNDERSTAND THAT, BUT THE
- 22 FIRST ONE WHERE WE DISALLOWED IT.
- DR. CHIU: THE FIRST ONE, WE HAD CONDITIONS,
- 24 AND I BELIEVE I HAVE A SLIDE TO SHOW. ACTUALLY THAT'S
- 25 OKAY. YOU DON'T HAVE TO SHOW IT. THE RFA STATED A

						_	
1		TIIAT TIIC		THE DT	NOT	CO DIIC	\sim D
			1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	IHE DI	NIC 1 I	(1)-01 <	112
_	REOUIREMENT	IIIAI IIIL	ALLETCAM:		IVOI	COLT	OI.

- 2 ANYBODY ELSE, THE PI HAS TO BE AN ON-SITE, FULL TIME
- 3 EMPLOYEE OF THE APPLICANT INSTITUTION. AND THAT
- 4 REQUIREMENT WAS NOT MET.
- 5 CHAIRMAN KLEIN: OKAY. ANY ADDITIONAL
- 6 QUESTIONS FROM THE BOARD? ALL RIGHT. ON THIS ITEM ANY
- 7 PUBLIC COMMENT? JOHN SIMPSON.
- 8 MR. SIMPSON: JOHN SIMPSON FROM THE FOUNDATION
- 9 FOR TAXPAYER AND CONSUMER RIGHTS. IT'S PROBABLY NOT A
- 10 HAPPY DAY FOR THOSE TWO APPLICANTS, BUT I THINK THIS
- 11 SPEAKS VERY WELL OF THE STAFF AND THE DILIGENCE THAT
- 12 THEY'VE PUT INTO THIS. AND THOSE OF US WHO FROM TIME TO
- 13 TIME HAVE WONDERED ABOUT WHETHER THINGS MIGHT JUST END UP
- 14 BEING A RUBBER STAMP WILL CONTINUE TO HAVE THOSE WORRIES
- AND TO RAISE QUESTIONS, BUT THIS IS CLEARLY A CASE WHERE
- 16 THAT DID NOT HAPPEN. AND IT SHOWS, I THINK, TO ALL
- 17 RESEARCHERS THAT CIRM HAS STANDARDS AND IS SERIOUS ABOUT
- 18 THEM. AND I THINK THIS IS A VERY, VERY, VERY IMPORTANT
- 19 TIME FOR THE AGENCY. AND IT'S A VERY SIGNIFICANT THING.
- THE ONLY OTHER THING I WOULD ADD TO IT IS THAT
- 21 IT MIGHT HAVE SERVED THE STAFF A LITTLE BIT BETTER AND
- 22 MADE THEIR WORK A LITTLE BIT EASIER IF THE INITIAL REVIEW
- 23 PROCESS HAD BEEN A LITTLE BIT MORE TRANSPARENT TO THE
- 24 PUBLIC BECAUSE THEN MAYBE SOME OF THESE ISSUES WOULD HAVE
- 25 BEEN CAUGHT WAY BACK THEN. BUT THAT'S A POSITION THAT I

1	CONTINUE	TΩ	ARGUE	ΔND	TΩ	RFFFR	PFOPI F	TΩ	THE	$ST\Delta TF$	ΩF
_	CONTINUE								1111	J 1 A 1 L	O.

- 2 CONNECTICUT WHERE IT IS MORE OPEN.
- 3 ALL THAT ASIDE, THOUGH, THIS IS A MOMENTOUS
- 4 TIME THAT SHOWS THAT YOU TAKE YOUR RULES AND REGULATIONS
- 5 VERY SERIOUSLY AND ACT APPROPRIATELY. THANK YOU.
- 6 CHAIRMAN KLEIN: THANK YOU VERY MUCH.
- 7 ADDITIONAL PUBLIC COMMENT?
- 8 MR. ADAMS: VERY QUICKLY, I'M BILL ADAMS. I'M
- 9 FOUNDER AND THE CFO OF INTERNATIONAL STEM CELL
- 10 CORPORATION, WHICH IS AN OCEANSIDE-BASED COMPANY THAT IS
- 11 TRYING TO BE FOR-PROFIT IF WE CAN GET THERE. I JUST --
- 12 THIS IS ACTUALLY MY SECOND MEETING. I JUST WANT TO THANK
- 13 THE EMPHASIS THAT'S GOING ON TO WORK WITH FOR-PROFIT
- 14 COMPANIES, AND WE CERTAINLY HOPE TO BRING THINGS TO THE
- 15 CLINIC RATHER QUICKLY, AND WE'VE GOT A COUPLE PROJECTS
- 16 ALREADY GOING.
- 17 AND IF ANYONE WANTS TO KNOW A LITTLE BIT ABOUT
- 18 US, WE HAD A WONDERFUL WRITE-UP IN THE SAN DIEGO UNION
- 19 THIS LAST WEEK. SO THANK YOU.
- 20 CHAIRMAN KLEIN: THANK YOU FOR YOUR COMMENTS.
- 21 ADDITIONALLY, ADDITIONAL ITEM THAT'S NOT
- 22 CALENDARED. JUST AS AN ITEM OF INFORMATION, IN NOVEMBER
- 23 THERE WILL BE AN INDEPENDENT FINANCIAL ACCOUNTABILITY
- 24 OVERSIGHT COMMITTEE MEETING AS PROVIDED FOR UNDER THE
- 25 INITIATIVE. THAT COMMITTEE IS CHAIRED BY THE TREASURER

1	AND.	TF	WF	ΑΙΙ	RFCALL.	HAS	ΑN	APPOINTEE	FROM	THE

- 2 CONTROLLER, THE PRESIDENT PRO TEM OF THE SENATE, THE
- 3 SPEAKER, AS WELL AS I MAKE ONE APPOINTMENT TO THAT BOARD.
- 4 WE HAVE A GREAT DEAL TO REPORT IN THAT ONE OF
- 5 THE AREAS WHERE WE'RE GOING TO TRY AND REALLY FOCUS SOME
- 6 NEW TIME, AS REQUIRED BY THE INITIATIVE, IS ON EVALUATING
- 7 OUR CONTRIBUTION TO THE STATE ON AN ECONOMIC BASIS. THAT
- 8 WILL REQUIRE A STUDY FROM A THIRD-PARTY FIRM AS OUTLINED
- 9 IN OUR STRATEGIC PLAN, AND THE PRESIDENT HAS THE
- 10 AUTHORITY TO CONTRACT FOR STUDIES OF THAT TYPE. THIS
- 11 YEAR I WOULD DOUBT THAT WE HAVE THE TIME TO GET FAR
- 12 ENOUGH DOWNSTREAM TO HAVE THE IN-DEPTH STUDY THAT BY NEXT
- 13 YEAR WOULD BE POTENTIALLY VERY FEASIBLE, BUT IT IS
- 14 CERTAINLY A YEAR IN WHICH WE'VE HAD REMARKABLE PROGRESS.
- 15 SO WE HAVE SOME PHENOMENAL THINGS TO REPORT TO THE
- 16 OVERSIGHT COMMITTEE.
- 17 WITH THAT, I THINK THAT'S THE FINAL ITEM OF
- 18 INFORMATION TO BE BROUGHT UP TODAY. ANY ADDITIONAL ITEMS
- 19 BY MEMBERS OF THE BOARD? ANY ADDITIONAL COMMENTS FROM
- 20 THE PUBLIC? JOHN SIMPSON.
- MR. SIMPSON: JOHN SIMPSON AGAIN, FOUNDATION
- 22 FOR TAXPAYER AND CONSUMERS RIGHTS. I UNDERSTAND THAT
- 23 CIRM WILL BE REPRESENTED AT THE INTERSTATE ALLIANCE
- 24 MEETING IN BOSTON. I BELIEVE THAT'S CORRECT. SOME OF
- 25 YOU MAY RECALL THAT I HAD SOME INTERESTING ENCOUNTERS

WITH THEM WHEN THEY MET OUT HERE. THEY THREW ME OUT.

1

2	AND THEY NOW HAVE AGREED THAT THESE SHOULD BE OPEN
3	MEETINGS, AND THE BOSTON MEETING WILL BE OPEN, AND I
4	THINK THAT IT IS TREMENDOUS THAT CIRM WILL BE THERE AND
5	PLAYING A KEY LEADERSHIP ROLE. SO AS LONG AS THOSE
6	MEETINGS ARE OPEN TO THE PUBLIC, AND THESE, I'M SURE,
7	WILL BE, THIS IS A VERY GOOD THING. AND I THINK DR.
8	MURPHY AND THE STAFF ARE TO BE COMMENDED FOR TAKING PART
9	IN IT.
10	CHAIRMAN KLEIN: THANK YOU VERY MUCH. WHEN OUR
11	CRITICS END THE MEETING WITH POSITIVE COMMENTS, IT IS A
12	TIME TO END.
13	(APPLAUSE.)
14	CHAIRMAN KLEIN: MELISSA, DO YOU HAVE AN
15	ADMINISTRATIVE COMMENT?
16	MS. KING: JUST VERY QUICKLY. THERE IS A
17	SHUTTLE TO THE AIRPORT. JENNA HAS ARRANGED FOR IT TO BE
18	HERE MOMENTARILY. AND ALSO WE HAD AN AFTERNOON SNACK
19	BROUGHT OUT, AND SHE HAS IT BROUGHT OUT A BIT EARLY SO
20	THAT YOU CAN GRAB IT ON YOUR WAY OUT.
21	CHAIRMAN KLEIN: THANK YOU ALL FOR
22	PARTICIPATION IN WHAT IS A VERY HISTORIC DAY. THANK YOU.
23	(THE MEETING WAS THEN ADJOURNED AT 2:35 P.M.)
24	
25	

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE PROCEEDINGS BEFORE THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD AT THE LOCATION INDICATED BELOW

HILTON SAN DIEGO AIRPORT/HARBOR ISLAND
1960 HARBOR ISLAND DRIVE
SAN DIEGO, CALIFORNIA
ON
OCTOBER 3, 2007

WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152 BARRISTER'S REPORTING SERVICE 1072 S.E. BRISTOL STREET SUITE 100 SANTA ANA HEIGHTS, CALIFORNIA (714) 444-4100